Sentence,class,file
http://www.fish.wa.,Non-OADS,/arxiv_data1/oa_pdf/0a/30/srep07249.PMC5384193.pdf
http://www.fao.org/docrep/003/ V8400E/V8400E00.HTM Date of access: 25/08/2014.,Non-OADS,/arxiv_data1/oa_pdf/0a/30/srep07249.PMC5384193.pdf
http://www.fish.wa.gov.au/ Documents/research_reports/frr253.pdf Date of access: 25/08/2014.,Non-OADS,/arxiv_data1/oa_pdf/0a/30/srep07249.PMC5384193.pdf
http://www.fish.wa.gov.au/Documents/research_reports/frr192.,Non-OADS,/arxiv_data1/oa_pdf/0a/30/srep07249.PMC5384193.pdf
http://www.fish.wa.gov.au/Documents/research_reports/frr246.pdf Date of access: 02/04/2014.,OADS,/arxiv_data1/oa_pdf/0a/30/srep07249.PMC5384193.pdf
http://www.fish.wa.gov.au/ Documents/research_reports/frr248.pdf Date of access: 02/04/2014.,OADS,/arxiv_data1/oa_pdf/0a/30/srep07249.PMC5384193.pdf
http://researchrepository.murdoch.edu.au/47/ Date of access: 02/04/2014.,Non-OADS,/arxiv_data1/oa_pdf/0a/30/srep07249.PMC5384193.pdf
http://researchrepository.murdoch.edu.au/382/ Date of access: 02/04/ 2014.,Non-OADS,/arxiv_data1/oa_pdf/0a/30/srep07249.PMC5384193.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/0a/30/srep07249.PMC5384193.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/de/c4/srep07240.PMC5384195.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/ www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 7240 | DOI: 10.1038/srep07240 6",Non-OADS,/arxiv_data1/oa_pdf/de/c4/srep07240.PMC5384195.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/20/8e/srep07246.PMC5384205.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/ www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 7248 | DOI: 10.1038/srep07248 8",Non-OADS,/arxiv_data1/oa_pdf/93/ae/srep07248.PMC5384216.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/57/f3/srep07205.PMC5384251.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/ www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 7205 | DOI: 10.1038/srep07205 7",Non-OADS,/arxiv_data1/oa_pdf/57/f3/srep07205.PMC5384251.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/6e/77/srep07288.PMC5384281.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/ www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 7288 | DOI: 10.1038/srep07288 6",Non-OADS,/arxiv_data1/oa_pdf/6e/77/srep07288.PMC5384281.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/71/06/srep07344.PMC5384283.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/ www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 7344 | DOI: 10.1038/srep07344 9",Non-OADS,/arxiv_data1/oa_pdf/71/06/srep07344.PMC5384283.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by- nc-sa/4.0/ rThe Author(s) 2016Leukocyte migration in the liver HA McNamara and IA Cockburn 9 Clinical & Translational Immunology",Non-OADS,/arxiv_data1/oa_pdf/56/96/cti201684a.PMC5384287.pdf
Science 18.http://science.sciencemag.org/content/351/6279/1284.e-letters .,Non-OADS,/arxiv_data1/oa_pdf/c5/29/main.PMC5384288.pdf
Rep. 3 http://dx.doi.org/10.1038/ srep02106 .,Non-OADS,/arxiv_data1/oa_pdf/c5/29/main.PMC5384288.pdf
"a,c:https://www.youtube.com/watch?v ¼YWtmSoimhcM .",Non-OADS,/arxiv_data1/oa_pdf/c5/29/main.PMC5384288.pdf
Contents lists available at ScienceDirect International Journal for Parasitology: Parasites and Wildlife journal homepage: www.elsevier.com/locate/ijppaw International Journal for Parasitology: Parasites and Wildlife 6 (2017) 69 http://dx.doi.org/10.1016/j.ijppaw.2017.03.005 2213-2244/ ©2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/c5/29/main.PMC5384288.pdf
This  is  an  open access article under the CC BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/76/33/main.PMC5384289.pdf
She  had  previous  history  of  total  thyroidectomy http://dx.doi.org/10.1016/j.ijscr.2017.03.021 2210-2612/© 2017  The  Author(s).,Non-OADS,/arxiv_data1/oa_pdf/76/33/main.PMC5384289.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/c3/49/main.PMC5384290.pdf
Direct link to deposited data http://www.ncbi.nlm.nih.gov/sra/SRR5260688 2.,OADS,/arxiv_data1/oa_pdf/c3/49/main.PMC5384290.pdf
http://dx.doi.org/10.1016/j.gdata.2017.03.011 2213-5960/© 2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/c3/49/main.PMC5384290.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/c3/49/main.PMC5384290.pdf
http://dx.doi.org/10.1016/j.pmedr.2017.03.013 2211-3355/© 2017 Published by Elsevier Inc.,Non-OADS,/arxiv_data1/oa_pdf/e7/b5/main.PMC5384291.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/e7/b5/main.PMC5384291.pdf
Contents lists available at ScienceDirect Preventive Medicine Reports journal homepage: http://ees.elsevier.com/pmedr,Non-OADS,/arxiv_data1/oa_pdf/e7/b5/main.PMC5384291.pdf
http://dx.doi.org/10.1016/j.pec.2013.07.012 (Epub 2013 Aug 1.,OADS,/arxiv_data1/oa_pdf/e7/b5/main.PMC5384291.pdf
http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/e7/b5/main.PMC5384291.pdf
http://dx.doi.org/10.1017/S135246580001643X .,Non-OADS,/arxiv_data1/oa_pdf/e7/b5/main.PMC5384291.pdf
http://dx.doi.org/10.1093/ageing/afs027 (Epub 2012 Mar 16.,Non-OADS,/arxiv_data1/oa_pdf/e7/b5/main.PMC5384291.pdf
http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/e7/b5/main.PMC5384291.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/ 4.0/).,Non-OADS,/arxiv_data1/oa_pdf/75/2d/main.PMC5384293.pdf
E-mail address: p.p.de.deyn@umcg.nl http://dx.doi.org/10.1016/j.dadm.2017.02.006 2352-8729/ /C2112017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/75/2d/main.PMC5384293.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/75/2d/main.PMC5384293.pdf
This  is  an  open access article under the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/ae/39/main.PMC5384294.pdf
The  pain  pro- http://dx.doi.org/10.1016/j.ijscr.2017.03.013 2210-2612/© 2017  The  Authors.,Non-OADS,/arxiv_data1/oa_pdf/ae/39/main.PMC5384294.pdf
This  is  an  open access article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/4f/b1/main.PMC5384295.pdf
"Subsequent  PR  imaging  revealed  a  large,  radiolucent,  expanding http://dx.doi.org/10.1016/j.ijscr.2017.03.033 2210-2612/© 2017  The  Authors.",OADS,/arxiv_data1/oa_pdf/4f/b1/main.PMC5384295.pdf
"1  (2014)  1–4,  http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/4f/b1/main.PMC5384295.pdf
"11  (2015), http://dx.doi.org/10.1002/14651858.cd008464.pub3 ,  Art.",Non-OADS,/arxiv_data1/oa_pdf/4f/b1/main.PMC5384295.pdf
"Here, we described the development of ﬁrst microsatellite repeat database of the pea aphid (APMicroDB), accessible at “http://deepaklab.com/aphidmicrodb ”.W ei d e n t i ﬁed 3,40,233 SSRs using MI- croSAtellite (MISA) tool that was distributed in 14,067 (out of 23,924) scaffold of the pea aphid.",OADS,/arxiv_data1/oa_pdf/d3/58/main.PMC5384296.pdf
This i s an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/d3/58/main.PMC5384296.pdf
The complete genome was scaffold-wise scan for the occurrence of microsatellite repeats using MIcroSAtellite (MISA) tool ( http://pgrc.ipk-gatersleben.de/misa/ ).,OADS,/arxiv_data1/oa_pdf/d3/58/main.PMC5384296.pdf
http://dx.doi.org/10.1016/j.gdata.2017.03.014 2213-5960/© 2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/d3/58/main.PMC5384296.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/d3/58/main.PMC5384296.pdf
These data were used to calculate the standardized mean di ﬀerence in 8-iso-PGF 2α (Hedges' g) between groups (a ﬀected and control or exposed and http://dx.doi.org/10.1016/j.redox.2017.03.024 Received 23 January 2017; Received in revised form 23 March 2017; Accepted 24 March 2017⁎Corresponding author.,OADS,/arxiv_data1/oa_pdf/aa/ea/main.PMC5384299.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/BY-NC-ND/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/aa/ea/main.PMC5384299.pdf
1http://plotdigitizer.sourceforge.net .T.J.,Non-OADS,/arxiv_data1/oa_pdf/aa/ea/main.PMC5384299.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/21/86/main.PMC5384300.pdf
"So, most of the given methods take advantage of this additional information http://dx.doi.org/10.1016/j.jare.2017.03.005 2090-1232/ /C2112017 Production and hosting by Elsevier B.V. on behalf of Cairo University.",Non-OADS,/arxiv_data1/oa_pdf/21/86/main.PMC5384300.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Peer review under responsibility of Cairo University.,Non-OADS,/arxiv_data1/oa_pdf/21/86/main.PMC5384300.pdf
"This is an  Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/0f/87/biw180.PMC5384302.pdf
Data were acquired and analysed using R 3.0.1 software  (R Core Team 2015 https://www.R-project.org).,OADS,/arxiv_data1/oa_pdf/de/1c/0392-100X-37-38.PMC5384308.pdf
Criminal liability in endoscopic sinus surgery71tari (http://www.filodiritto.com/diritto-della-responsabilita- civile-e-del risarcimento-danni.,Non-OADS,/arxiv_data1/oa_pdf/1f/d7/0392-100X-37-65.PMC5384313.pdf
(In: http://www.vda.pt/xms/files/Publicacoes/Professional_Medi- cal_Responsibility_in_Portugal_The_Juridical_Perspective.,Non-OADS,/arxiv_data1/oa_pdf/1f/d7/0392-100X-37-65.PMC5384313.pdf
In: Diritto Penale Contemporaneo (http://www.penalecontemporaneo.,Non-OADS,/arxiv_data1/oa_pdf/1f/d7/0392-100X-37-65.PMC5384313.pdf
55 Girinelli F. Il Decreto Legge Balduzzi al vaglio della giuris-prudenza: luci e ombre sulla responsabilità civile dei sani-tari (http://www.filodiritto.com/articoli/2015/03/il-decreto- legge-balduzzi-al-vaglio-della-giurisprudenza-luci-ed-om-bre-sulla-responsabilit-civile-dei-sanitari.html (last access 12 June 2016).,Non-OADS,/arxiv_data1/oa_pdf/1f/d7/0392-100X-37-65.PMC5384313.pdf
"Magnetic resonance evaluation  V olumetric evaluation of primary tumours was performed using OsiriX Imaging Software (http://www.osirix-view-er.com): contours of primary lesions were manually out- lined by two different radiologists who are expert in HNC  imaging, in order to evaluate the impact of inter-observer differences in delineation.",OADS,/arxiv_data1/oa_pdf/c1/ae/0392-100X-37-9.PMC5384316.pdf
Statistical analysis Statistical analysis was performed using R Statistical Software (R Core Team 2013. http://www.R-project.org/).,OADS,/arxiv_data1/oa_pdf/c1/ae/0392-100X-37-9.PMC5384316.pdf
"It was delineated using  Pynomo, a program to create nomograms using Python  interpreter (http://www.pynomo.org).",OADS,/arxiv_data1/oa_pdf/c1/ae/0392-100X-37-9.PMC5384316.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/c0/ff/main.PMC5384322.pdf
Contents lists available at ScienceDirect Respiratory Medicine Case Reports journal homepage: www.elsevier.com/locate/rmcr http://dx.doi.org/10.1016/j.rmcr.2017.03.020 2213-0071/ ©2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/c0/ff/main.PMC5384322.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Respiratory Medicine Case Reports 21 (2017) 71 e73,Non-OADS,/arxiv_data1/oa_pdf/c0/ff/main.PMC5384322.pdf
"The mechanisms involved are thought to be related to its regulation on intracellular redox status and redox http://dx.doi.org/10.1016/j.redox.2017.03.030 Received 15 March 2017; Received in revised form 28 March 2017; Accepted 28 March 2017⁎Correspondence to: Department of the Advanced Biomedical Research, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Chuo, Yamanashi 409 –3898, Japan.",Non-OADS,/arxiv_data1/oa_pdf/9a/9c/main.PMC5384323.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/BY-NC-ND/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/9a/9c/main.PMC5384323.pdf
"The chemiluminescent signal iscaptured with a Fuji ﬁlm image LAS-1000 analyzer (Fuji ﬁlm, Tokyo, Japan) and quanti ﬁed with the NIH Image J software ( http://rsb.info.",OADS,/arxiv_data1/oa_pdf/9a/9c/main.PMC5384323.pdf
http://dx.doi.org/10.1016/j.redox.2017.03.029 Received 25 February 2017; Received in revised form 27 March 2017; Accepted 28 March 2017⁎Corresponding author.,Non-OADS,/arxiv_data1/oa_pdf/4f/bc/main.PMC5384325.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/BY-NC-ND/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/4f/bc/main.PMC5384325.pdf
"Sykiotis, M. Nishimura, R. Bodmer, D. Bohmann, Declining signal dependence of Nrf2-MafS-regulated gene expression correlates with agingphenotypes, Aging Cell 12 (2013) 554 –562, http://dx.doi.org/10.1111/acel.12078 .",OADS,/arxiv_data1/oa_pdf/4f/bc/main.PMC5384325.pdf
"26 (2016) 81 –95,http://dx.doi.org/10.1016/j.arr.2015.12.005 .",OADS,/arxiv_data1/oa_pdf/4f/bc/main.PMC5384325.pdf
"95 (2005) 1521 –1540, http://dx.doi.org/ 10.1111/j.1471-4159.2005.03515.x .",Non-OADS,/arxiv_data1/oa_pdf/4f/bc/main.PMC5384325.pdf
"63 (2013) 1 –29,http://dx.doi.org/10.1016/j.freeradbiomed.2013.03.018 .",OADS,/arxiv_data1/oa_pdf/4f/bc/main.PMC5384325.pdf
"[9] J. Burtscher, L. Zangrandi, C. Schwarzer, E. Gnaiger, Di ﬀerences in mitochondrial function in homogenated samples from healthy and epileptic speci ﬁc brain tissues revealed by high-resolution respirometry, Mitochondrion 25 (2015) 104 –112, http://dx.doi.org/10.1016/j.mito.2015.10.007 .",Non-OADS,/arxiv_data1/oa_pdf/4f/bc/main.PMC5384325.pdf
"Ali, J. Pedraza-Chaverrí, A. Santamaría, Early modulation of the transcription factor Nrf2 in rodent striatal slices by quinolinic acid, a toxic metabolite of the kynurenine pathway, Neuroscience 260 (2014) 130 –139, http://dx.doi.org/10.1016/j.neuroscience.",OADS,/arxiv_data1/oa_pdf/4f/bc/main.PMC5384325.pdf
"25 (2013) 2548 –2557, http://dx.doi.org/10.1016/j.cellsig.",OADS,/arxiv_data1/oa_pdf/4f/bc/main.PMC5384325.pdf
"USA 111 (2014) 3032 –3037, http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/4f/bc/main.PMC5384325.pdf
"255 (2011) 32 –39,http://dx.doi.org/10.1016/j.taap.2011.05.013 .",OADS,/arxiv_data1/oa_pdf/4f/bc/main.PMC5384325.pdf
"49 (2011)2631 –2637, http://dx.doi.org/10.1016/j.fct.2011.07.008 .",OADS,/arxiv_data1/oa_pdf/4f/bc/main.PMC5384325.pdf
"52(2012) 2038 –2046, http://dx.doi.org/10.1016/j.freeradbiomed.2012.02.042 .",OADS,/arxiv_data1/oa_pdf/4f/bc/main.PMC5384325.pdf
"Aging 35 (2014) 1901 –1912, http://dx.doi.org/10.1016/j.neurobiolaging.2014.01.143 .",Non-OADS,/arxiv_data1/oa_pdf/4f/bc/main.PMC5384325.pdf
"8 (2014) 323 –331, http://dx.doi.org/10.1007/s12079-014-0248-4 .",Non-OADS,/arxiv_data1/oa_pdf/4f/bc/main.PMC5384325.pdf
"282 (2007) 33412 –33420, http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/4f/bc/main.PMC5384325.pdf
"77 (2009) 1291 –1301, http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/4f/bc/main.PMC5384325.pdf
"46 (2012) 415 –425, http://dx.doi.org/10.1016/j.ejps.2012.03.004 .",OADS,/arxiv_data1/oa_pdf/4f/bc/main.PMC5384325.pdf
"24 (2013) 2040 –2050, http://dx.doi.org/10.1016/j.jnutbio.2013.07.005 .",OADS,/arxiv_data1/oa_pdf/4f/bc/main.PMC5384325.pdf
"[25] I. Túnez, I. Tasset, V. Pérez-De La Cruz, A. Santamaría, 3-Nitropropionic acid as a tool to study the mechanisms involved in Huntington's disease: past, present and future, Molecules 15 (2010) 878 –916, http://dx.doi.org/10.3390/ molecules15020878 .",Non-OADS,/arxiv_data1/oa_pdf/4f/bc/main.PMC5384325.pdf
"6 (2013)84–86,http://dx.doi.org/10.1016/j.brs.2012.03.015 .",OADS,/arxiv_data1/oa_pdf/4f/bc/main.PMC5384325.pdf
"135 (2015) 165 –172, http://dx.doi.org/10.1016/j.lfs.2015.06.",OADS,/arxiv_data1/oa_pdf/4f/bc/main.PMC5384325.pdf
"Rep. 65 (1978) 1123 –1128, http://dx.doi.org/10.2466/pr0.1978.43.3f.",Non-OADS,/arxiv_data1/oa_pdf/4f/bc/main.PMC5384325.pdf
"Maldonado, Heme oxygenase-1 (HO-1) upregulation delays morphological and oxidative damage induced in an excitotoxic/pro-oxidant model in the rat striatum, Neuroscience 23 (2013), http://dx.doi.org/10.1016/j.neuroscience.2012.11.031 .",OADS,/arxiv_data1/oa_pdf/4f/bc/main.PMC5384325.pdf
"66 (2011) 348 –354, http://dx.doi.org/10.1016/j.",Non-OADS,/arxiv_data1/oa_pdf/4f/bc/main.PMC5384325.pdf
"34 (2014) 127 –138, http://dx.doi.org/10.1002/jat.2841 .",Non-OADS,/arxiv_data1/oa_pdf/4f/bc/main.PMC5384325.pdf
"Acta 2015(1847) 143 –152, http://dx.doi.org/10.1016/j.bbabio.2014.10.002 .",Non-OADS,/arxiv_data1/oa_pdf/4f/bc/main.PMC5384325.pdf
"46 (2009) 492 –501, http://dx.doi.org/10.1016/j.freeradbiomed.2008.11.003 .",OADS,/arxiv_data1/oa_pdf/4f/bc/main.PMC5384325.pdf
"USA 110 (2013) 18291 –18296, http://dx.doi.org/ 10.1073/pnas.1208764110 .",Non-OADS,/arxiv_data1/oa_pdf/4f/bc/main.PMC5384325.pdf
"91 (2009) 327 –332, http://dx.doi.org/10.1016/j.pbb.2008.08.011 .",Non-OADS,/arxiv_data1/oa_pdf/4f/bc/main.PMC5384325.pdf
"USA 102 (2005) 244 –249, http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/4f/bc/main.PMC5384325.pdf
"159 (2001) 1507 –1520, http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/4f/bc/main.PMC5384325.pdf
"Rep. 67 (2015) 980 –985, http://dx.doi.org/10.1016/j.pharep.2015.03.003 .",Non-OADS,/arxiv_data1/oa_pdf/4f/bc/main.PMC5384325.pdf
"34 (2014) 990 –999, http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/4f/bc/main.PMC5384325.pdf
"[51] M. Eskandani, H. Hamishehkar, J. Ezzati Nazhad Dolatabadi, Cytotoxicity and DNA damage properties of tert-butylhydroquinone (TBHQ) food additive, Food Chem.153 (2014) 315 –320, http://dx.doi.org/10.1016/j.foodchem.2013.12.087 .",Non-OADS,/arxiv_data1/oa_pdf/4f/bc/main.PMC5384325.pdf
"86 (2012)1481 –1487, http://dx.doi.org/10.1007/s00204-012-0841-3 .",Non-OADS,/arxiv_data1/oa_pdf/4f/bc/main.PMC5384325.pdf
"8 (2009) 126 –136, http://dx.doi.org/10.1016/j.dnarep.2008.09.",OADS,/arxiv_data1/oa_pdf/4f/bc/main.PMC5384325.pdf
"Ríos, J. Vitorica, A. Castaño, D. Ruano, Dysfunction of the unfolded protein response increases neurodegenera- tion in aged rat hippocampus following proteasome inhibition, Aging Cell 8 (2009) 654 –665, http://dx.doi.org/10.1111/j.1474-9726.2009.00519.x .",Non-OADS,/arxiv_data1/oa_pdf/4f/bc/main.PMC5384325.pdf
"1352 (2010) 239 –247, http://dx.doi.org/10.1016/j.brainres.2010.07.011 .",OADS,/arxiv_data1/oa_pdf/4f/bc/main.PMC5384325.pdf
"48 (2015) 135 –143, http://dx.doi.org/10.1267/ahc.",Non-OADS,/arxiv_data1/oa_pdf/4f/bc/main.PMC5384325.pdf
"[58] Z. Wang, C. Ji, L. Wu, J. Qiu, Q. Li, Z. Shao, G. Chen, Tert-butylhydroquinone alleviates early brain injury and cognitive dysfunction after experimental subar- achnoid hemorrhage: role of Keap1/Nrf2/ARE pathway, PLoS One 9 (2014) e97685, http://dx.doi.org/10.1371/journal.pone.0097685 .",Non-OADS,/arxiv_data1/oa_pdf/4f/bc/main.PMC5384325.pdf
"58 (2016) 525 –531, http://dx.doi.org/10.1007/s12031- 016-0722-y .",Non-OADS,/arxiv_data1/oa_pdf/4f/bc/main.PMC5384325.pdf
"123 (2012) 182 –191, http://dx.doi.org/10.1111/j.1471-4159.2012.07877.x .",Non-OADS,/arxiv_data1/oa_pdf/4f/bc/main.PMC5384325.pdf
"31 (2010) 967 –977, http://dx.doi.org/10.1111/j.",Non-OADS,/arxiv_data1/oa_pdf/4f/bc/main.PMC5384325.pdf
"86 (2012) 1729 –1740, http://dx.doi.org/ 10.1007/s00204-012-0935-y .",Non-OADS,/arxiv_data1/oa_pdf/4f/bc/main.PMC5384325.pdf
"28 (2013) 1223– 1233, http://dx.doi.org/10.14670/HH-28.1223 .",Non-OADS,/arxiv_data1/oa_pdf/4f/bc/main.PMC5384325.pdf
"[64] H. Liu, X. Guo, Y. Chu, S. Lu, Heart protective e ﬀects and mechanism of quercetin preconditioning on anti-myocardial ischemia reperfusion (IR) injuries in rats, Gene545 (2014) 149 –155, http://dx.doi.org/10.1016/j.gene.2014.04.043 .",Non-OADS,/arxiv_data1/oa_pdf/4f/bc/main.PMC5384325.pdf
"Aging 11 (2016) 225 –236, http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/4f/bc/main.PMC5384325.pdf
"Ciriolo, Adipose triglycerides lipase decrement a ﬀects skeletal muscle homeostasis during aging through FAs-PPAR α-PGC-1 αantioxidant response, Oncotarget 7 (2016) 23019 –23032, http://dx.doi.org/10.18632/oncotarget.8552 .",Non-OADS,/arxiv_data1/oa_pdf/4f/bc/main.PMC5384325.pdf
"3 (2010) 2 –12,http://dx.doi.org/ 10.4161/oxim.3.1.10476 .",Non-OADS,/arxiv_data1/oa_pdf/4f/bc/main.PMC5384325.pdf
"88 (2015) 199 –204, http://dx.doi.org/10.1016/j.freeradbiomed.2015.06.014 .",OADS,/arxiv_data1/oa_pdf/4f/bc/main.PMC5384325.pdf
"12 (2010) 213 –223, http://dx.doi.org/10.1038/ncb2021 .",Non-OADS,/arxiv_data1/oa_pdf/4f/bc/main.PMC5384325.pdf
"Cell 51 (2013) 618 –631, http://dx.doi.org/10.1016/j.molcel.2013.08.",OADS,/arxiv_data1/oa_pdf/4f/bc/main.PMC5384325.pdf
"Acta 2014 (1841) 22 –33, http://dx.doi.org/10.1016/j.bbalip.2013.09.004 .",Non-OADS,/arxiv_data1/oa_pdf/4f/bc/main.PMC5384325.pdf
"6 (2013) 28 –33,http://dx.doi.org/10.14802/jmd.13007 .",Non-OADS,/arxiv_data1/oa_pdf/4f/bc/main.PMC5384325.pdf
"67 (2014) 1 –14,http://dx.doi.org/10.1002/0471142301.ns0948s67 .",Non-OADS,/arxiv_data1/oa_pdf/4f/bc/main.PMC5384325.pdf
"22 (2013) 3869 –3882, http://dx.doi.org/ 10.1093/hmg/ddt242 .",Non-OADS,/arxiv_data1/oa_pdf/4f/bc/main.PMC5384325.pdf
"Hort, M. Farina, Probucol increases striatal glutathione peroxidase activity and protects against 3-nitropropionic acid-induced pro-oxida- tive damage in rats, PLoS One 8 (2013) e67658, http://dx.doi.org/10.1371/journal.",Non-OADS,/arxiv_data1/oa_pdf/4f/bc/main.PMC5384325.pdf
"732 (2014) 111 –122, http://dx.doi.org/10.1016/j.",Non-OADS,/arxiv_data1/oa_pdf/4f/bc/main.PMC5384325.pdf
"16 (2009) 899 –909, http://dx.doi.org/10.1038/cdd.2009.22 .",Non-OADS,/arxiv_data1/oa_pdf/4f/bc/main.PMC5384325.pdf
"38 (2005) 796 –805, http://dx.doi.org/10.1016/j.freeradbiomed.2004.11.034 .",OADS,/arxiv_data1/oa_pdf/4f/bc/main.PMC5384325.pdf
"Guillemin, H. Mansour, T. Chan-Ling, A. Poljak, R. Grant, Age related changes in NAD+ metabolism oxidative stress and Sirt1 activity in Wistarrats, PLoS One 6 (2011) e19194, http://dx.doi.org/10.1371/journal.pone.0019194 .",OADS,/arxiv_data1/oa_pdf/4f/bc/main.PMC5384325.pdf
"136 (2016) 912 –919, http://dx.doi.org/10.1016/j.jid.2016.01.017 .",OADS,/arxiv_data1/oa_pdf/4f/bc/main.PMC5384325.pdf
"102 (2014) 57 –68,http://dx.doi.org/10.1016/j.",OADS,/arxiv_data1/oa_pdf/4f/bc/main.PMC5384325.pdf
"15 (2000) 31 –44,http://dx.doi.org/10.1385/JMN:15:1:31 .",Non-OADS,/arxiv_data1/oa_pdf/4f/bc/main.PMC5384325.pdf
"53 (2016) 2619 –2635, http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/4f/bc/main.PMC5384325.pdf
"Einstein, A. Poduval, D. Hwang, N. Barzilai, P. Cohen,Humanin: a novel central regulator of peripheral insulin action, PLoS One 4 (2009) e6334, http://dx.doi.org/10.1371/journal.pone.0006334 .",Non-OADS,/arxiv_data1/oa_pdf/4f/bc/main.PMC5384325.pdf
"65 (2010) 1028 –1041, http://dx.doi.org/10.1093/gerona/glq113 .A.",Non-OADS,/arxiv_data1/oa_pdf/4f/bc/main.PMC5384325.pdf
"Published with license by Taylor & Francis Group, LLC © Pilvi Maliniemia, Kirsi Laukkanen, Liisa V €akev€a, Katja Dettmerb, Tuomas Lipsanena, Leila Jeskanena, Alban Bessedec, Peter J. Oefnerb, Marshall E. Kadind, and Annamari Ranki.This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License ( http://creativecommons.org/licenses/by-nc/3.0/ ), which permits unre- stricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/22/46/koni-06-03-1273310.PMC5384345.pdf
"3, e1273310 (10 pages)http://dx.doi.org/10.1080/2162402X.2016.1273310",Non-OADS,/arxiv_data1/oa_pdf/22/46/koni-06-03-1273310.PMC5384345.pdf
ORCID Kirsi Laukkanen http://orcid.org/0000-0001-6243-9850 Liisa V €akev€a http://orcid.org/0000-0003-4828-1553 Annamari Ranki http://orcid.org/0000-0003-4335-0396References 1.,Non-OADS,/arxiv_data1/oa_pdf/22/46/koni-06-03-1273310.PMC5384345.pdf
Trends Immunol 2016; 37 (3):193-07; PMID:26839260; http://dx.doi.org/10.1016/j.it.2016.01.002 2.,OADS,/arxiv_data1/oa_pdf/22/46/koni-06-03-1273310.PMC5384345.pdf
Clin Cancer Res 2015 21(24):5427-33; PMID:26519060; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/22/46/koni-06-03-1273310.PMC5384345.pdf
Cancer Immunol Res 2015; 3:978-85; PMID:26269528; http://dx.doi.org/10.1158/2326-6066.CIR- 15-0095 4.,Non-OADS,/arxiv_data1/oa_pdf/22/46/koni-06-03-1273310.PMC5384345.pdf
Clin Cancer Res 2011; 17(22):6985-91;PMID:22068654; http://dx.doi.org/10.1158/1078-0432.CCR-11-1331 5.,Non-OADS,/arxiv_data1/oa_pdf/22/46/koni-06-03-1273310.PMC5384345.pdf
Cancer Immunol Res2015; 3(2):161-72; PMID:25271151; http://dx.doi.org/10.1158/2326- 6066.CIR-14-0137 6.,Non-OADS,/arxiv_data1/oa_pdf/22/46/koni-06-03-1273310.PMC5384345.pdf
BMC Cancer 2014; 14:335;PMID:24886161; http://dx.doi.org/10.1186/1471-2407-14-335 7.,Non-OADS,/arxiv_data1/oa_pdf/22/46/koni-06-03-1273310.PMC5384345.pdf
Leuk Lymphoma 2014; 55(2):405-14; PMID:23682557; http://dx.doi.org/10.3109/10428194.2013.804917 8.,Non-OADS,/arxiv_data1/oa_pdf/22/46/koni-06-03-1273310.PMC5384345.pdf
Clin CancerRes 2015; 21(12):2830-9; PMID:25788494; http://dx.doi.org/10.1158/ 1078-0432.CCR-14-2275 9.,OADS,/arxiv_data1/oa_pdf/22/46/koni-06-03-1273310.PMC5384345.pdf
Clin Sci 2015; 129(7): 601-72; PMID:26186743; http://dx.doi.org/10.1042/CS20140392 10.,Non-OADS,/arxiv_data1/oa_pdf/22/46/koni-06-03-1273310.PMC5384345.pdf
Blood 2014; 124(5):750- 60; PMID:24850760; http://dx.doi.org/10.1182/blood-2013-12-546416 11.,Non-OADS,/arxiv_data1/oa_pdf/22/46/koni-06-03-1273310.PMC5384345.pdf
Gene 2007; 396:203-13; PMID:17499941; http://dx.doi.org/ 10.1016/j.gene.2007.04.010 13.,OADS,/arxiv_data1/oa_pdf/22/46/koni-06-03-1273310.PMC5384345.pdf
Cancer Res 2007; 67:7082-7; PMID:17671174; http://dx.doi.org/10.1158/0008-5472.CAN-07-1872 14.,Non-OADS,/arxiv_data1/oa_pdf/22/46/koni-06-03-1273310.PMC5384345.pdf
PMID:24402311; http://dx.doi.org/10.1093/intimm/dxt073 15.,OADS,/arxiv_data1/oa_pdf/22/46/koni-06-03-1273310.PMC5384345.pdf
Front Immunol 2014 9; 5:485; PMID:25346733; http://dx.doi.org/10.3389/ ﬁmmu.2014.00485ONCOIMMUNOLOGY e1273310-9,Non-OADS,/arxiv_data1/oa_pdf/22/46/koni-06-03-1273310.PMC5384345.pdf
Orphanet J Rare Dis 2014; 9:160; PMID:25928531; http://dx.doi.org/10.1186/s13023-014-0160-2 17.,Non-OADS,/arxiv_data1/oa_pdf/22/46/koni-06-03-1273310.PMC5384345.pdf
Cyclosporine a as a primary treatment for pan- niculitis-like T cell lymphoma: a case with a long-term remission.Cancer Res Treat 2014; 46(3):312-6; PMID:25038767; http://dx.doi.org/10.4143/crt.2014.46.3.312 18.,Non-OADS,/arxiv_data1/oa_pdf/22/46/koni-06-03-1273310.PMC5384345.pdf
J Leukoc Biol 2016; 100(2):275-90; PMID:27256570; http://dx.doi.org/10.1189/jlb.5RI0116-013RR 20.,Non-OADS,/arxiv_data1/oa_pdf/22/46/koni-06-03-1273310.PMC5384345.pdf
"J Am Acad Dermatol 2012;66(6):928-37; PMID:21982062; http://dx.doi.org/10.1016/j.jaad.2011 .07.012 22. de la Garza Bravo MM, Patel KP, Loghavi S, Curry JL, Torres Cabala CA, Cason RC, Gangar P, Prieto VG, Medeiros LJ, Duvic M et al.Shared clonality in distinctive lesions of lymphomatoid papulosis and mycosis fungoides occurring in the same patients suggests a common origin.",Non-OADS,/arxiv_data1/oa_pdf/22/46/koni-06-03-1273310.PMC5384345.pdf
Hum Pathol 2015; 46(4):558-69; PMID:25666664; http://dx.doi.org/10.1016/j.humpath.2014.12.008 23.,OADS,/arxiv_data1/oa_pdf/22/46/koni-06-03-1273310.PMC5384345.pdf
Clin Exp Dermatol 2009; 34:576-81;PMID:19196298; http://dx.doi.org/10.1111/j.1365-2230.2008.03024.x 24.,Non-OADS,/arxiv_data1/oa_pdf/22/46/koni-06-03-1273310.PMC5384345.pdf
N Engl J Med 1992; 326(17):1115-22; PMID:1532439; http://dx.doi.org/10.1056/NEJM199204233261704 25.,OADS,/arxiv_data1/oa_pdf/22/46/koni-06-03-1273310.PMC5384345.pdf
Leuk Lymphoma 2015; 56(5):1398-405; PMID:25248875; http://dx.doi.org/10.3109/10428194.2014.953150 27.,Non-OADS,/arxiv_data1/oa_pdf/22/46/koni-06-03-1273310.PMC5384345.pdf
PLoS One 2013; 8(1):e53767 PMID:23372669; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/22/46/koni-06-03-1273310.PMC5384345.pdf
PMID:18331599; http://dx.doi.org/10.1111/j.1600- 0609.2008.01064.x 30.,Non-OADS,/arxiv_data1/oa_pdf/22/46/koni-06-03-1273310.PMC5384345.pdf
Front Immunol 2015; 5:673; PMID:25628622; http://dx.doi.org/ 10.3389/ ﬁmmu.2014.00673 31.,Non-OADS,/arxiv_data1/oa_pdf/22/46/koni-06-03-1273310.PMC5384345.pdf
Anal Bioanal Chem 2011; 401(10):3249-61; PMID:21983980; http://dx.doi.org/ 10.1007/s00216-011-5436-ye1273310-10 P. MALINIEMI ET AL.,OADS,/arxiv_data1/oa_pdf/22/46/koni-06-03-1273310.PMC5384345.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered , transformed, or built upon in any way.ONCOIMMUNOLOGY 2017, VOL.",Non-OADS,/arxiv_data1/oa_pdf/b3/5d/koni-06-03-1284719.PMC5384346.pdf
"3, e1284719 (11 pages)http://dx.doi.org/10.1080/2162402X.2017.1284719",Non-OADS,/arxiv_data1/oa_pdf/b3/5d/koni-06-03-1284719.PMC5384346.pdf
"26 In this study, we used a large set of pan-cancer tumor sam- ples (TCGA Research Network: http://cancergenome.nih.gov/ ) and a series of multivariate regression models to elucidate theoverall association between high levels of PD-1 ligand expres- sion and the mutation burden mechanisms mentioned above, especially as it pertains to anomalies correlated with the APO-BEC family of enzymes.",OADS,/arxiv_data1/oa_pdf/b3/5d/koni-06-03-1284719.PMC5384346.pdf
"Material and methods Data retrieval and processing Mutation, copy number variation, mRNA expression, protein expression, molecular phenotype (MSI and mutation burden estimates) data were downloaded from the community resourceproject TCGA, using the Broad GDAC Firehose website(https://gdac.broadinstitute.org/ —standardized data run release 2016_01_28).",OADS,/arxiv_data1/oa_pdf/b3/5d/koni-06-03-1284719.PMC5384346.pdf
All data used in this study respected the TCGA ’s Human Subjects Protection and Data Access Policies ( https://cancergenome.nih.gov/ abouttcga/policies/tcga-human-subjects-data-policies ).e1284719-8 A. BOICHARD ET AL.,OADS,/arxiv_data1/oa_pdf/b3/5d/koni-06-03-1284719.PMC5384346.pdf
"Whole-genome level 2 somatic mutation data were available for 9,103 tumor samples (all cohorts except mesothelioma),and lists of signi ﬁcant variants were generated using the Mut- Sig2CV algorithm ( http://www.broadinstitute.org/cancer/cga/ mutsig ), taking into account the somatic background mutation rate for each gene as well as neighbor genes.",OADS,/arxiv_data1/oa_pdf/b3/5d/koni-06-03-1284719.PMC5384346.pdf
"Focal CNV corresponding to level 3 genome-wide single nucleotide polymorphism (SNP) array data were normalizedand assessed at the gene-level using the GISTIC2 protocol 44 (http://www.broadinstitute.org/tcga/about ), where a “deep loss”was documented by the value ( ¡2), a “single-copy loss ” by the value ( ¡1), a “low-level gain ”by the value ( C1) and an “ampli ﬁcation ”by the value ( C2).",OADS,/arxiv_data1/oa_pdf/b3/5d/koni-06-03-1284719.PMC5384346.pdf
28 All statistical analyses were conducted by AB using SAS/C210 University Edition software ( http://support.sas.com/software/ products/university-edition/ ).,OADS,/arxiv_data1/oa_pdf/b3/5d/koni-06-03-1284719.PMC5384346.pdf
"Data and materials availability All the data used in this article were downloaded from the community resource project TCGA ( https://gdac.broadinstitute.org/ —standardized data run release 2016_01_28) and were available without restriction of useon the date of May 1, 2016.",OADS,/arxiv_data1/oa_pdf/b3/5d/koni-06-03-1284719.PMC5384346.pdf
Science 2002; 298:850-4; PMID:12242449; http://dx.doi.org/10.1126/science.1076514 2.,OADS,/arxiv_data1/oa_pdf/b3/5d/koni-06-03-1284719.PMC5384346.pdf
J Clin Oncol 2014; 32:1020-30; PMID:24590637; http://dx.doi.org/10.1200/JCO.2013.53.0105 4.,Non-OADS,/arxiv_data1/oa_pdf/b3/5d/koni-06-03-1284719.PMC5384346.pdf
N Engl J Med 2015; 372:311-9; PMID:25482239; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/b3/5d/koni-06-03-1284719.PMC5384346.pdf
N Engl J Med 2015; 373:123-35; PMID:26028407;http://dx.doi.org/10.1056/NEJMoa1504627 7.,OADS,/arxiv_data1/oa_pdf/b3/5d/koni-06-03-1284719.PMC5384346.pdf
Lancet 2016; 387:1909-20; PMID:26952546; http://dx.doi.org/10.1016/S0140-6736(16)00561-4 8.,Non-OADS,/arxiv_data1/oa_pdf/b3/5d/koni-06-03-1284719.PMC5384346.pdf
Nat Rev Clin Oncol 2016; advance online publication; PMID:27805626; http://dx.doi.org/10.1038/nrclinonc.2016.168 9.,OADS,/arxiv_data1/oa_pdf/b3/5d/koni-06-03-1284719.PMC5384346.pdf
Oral Oncol 2015; 51:221-8; PMID:25500094;http://dx.doi.org/10.1016/j.oraloncology.2014.11.014 10.,Non-OADS,/arxiv_data1/oa_pdf/b3/5d/koni-06-03-1284719.PMC5384346.pdf
Blood 2014; 123:2062-5; PMID:24497532; http://dx.doi.org/10.1182/blood-2013- 10-535443 11.,Non-OADS,/arxiv_data1/oa_pdf/b3/5d/koni-06-03-1284719.PMC5384346.pdf
Nature 2016; 534:402-6; PMID:27281199; http://dx.doi.org/10.1038/nature18294 12.,Non-OADS,/arxiv_data1/oa_pdf/b3/5d/koni-06-03-1284719.PMC5384346.pdf
Mol Cancer Ther 2015; 14:847-56; PMID:25695955; http://dx.doi.org/10.1158/1535-7163.MCT-14-0983 13.,Non-OADS,/arxiv_data1/oa_pdf/b3/5d/koni-06-03-1284719.PMC5384346.pdf
Clin Cancer Res 2014; 20:5064-74; PMID:24714771; http://dx.doi.org/10.11581078-0432.CCR-13-3271 14.,Non-OADS,/arxiv_data1/oa_pdf/b3/5d/koni-06-03-1284719.PMC5384346.pdf
J Clin Oncol 2016; 34:2690-7; PMID:27069084;http://dx.doi.org/10.1200/JCO.2016.66.4482 15.,Non-OADS,/arxiv_data1/oa_pdf/b3/5d/koni-06-03-1284719.PMC5384346.pdf
N Engl J Med 2015; 372:2509-20; PMID:26028255; http://dx.doi.org/10.1056/NEJMoa1500596 16.,OADS,/arxiv_data1/oa_pdf/b3/5d/koni-06-03-1284719.PMC5384346.pdf
Oncoimmunology 2015; 4(3):e976052;PMID:25949894; http://dx.doi.org/10.4161/2162402X.2014.976052 17.,Non-OADS,/arxiv_data1/oa_pdf/b3/5d/koni-06-03-1284719.PMC5384346.pdf
Clin Cancer Res 2016; 22:3915-23; PMID:26960397; http://dx.doi.org/ 10.1158/1078-0432.CCR-15-1714 18.,Non-OADS,/arxiv_data1/oa_pdf/b3/5d/koni-06-03-1284719.PMC5384346.pdf
Science 2015; 348:124-8; PMID:25765070; http://dx.doi.org/10.1126/science.aaa1348 19.,Non-OADS,/arxiv_data1/oa_pdf/b3/5d/koni-06-03-1284719.PMC5384346.pdf
JAMA Oncol 2015; 1:1319-23; PMID:26181000; http://dx.doi.org/10.1001/jamaoncol.2015.2151 20.,Non-OADS,/arxiv_data1/oa_pdf/b3/5d/koni-06-03-1284719.PMC5384346.pdf
Sci Rep2016; 6:27702; PMID:27283319; http://dx.doi.org/10.1038/srep27702 21.,OADS,/arxiv_data1/oa_pdf/b3/5d/koni-06-03-1284719.PMC5384346.pdf
Nature 2013;500:415-21; PMID:23945592; http://dx.doi.org/10.1038/nature12477 22.,OADS,/arxiv_data1/oa_pdf/b3/5d/koni-06-03-1284719.PMC5384346.pdf
Nat Genet 2013; 45:977-83; PMID:23852168; http://dx.doi.org/10.1038/ng.2701 23.,OADS,/arxiv_data1/oa_pdf/b3/5d/koni-06-03-1284719.PMC5384346.pdf
Science 1987; 238:363-6; PMID:3659919; http://dx.doi.org/10.1126/science.3659919 24.,Non-OADS,/arxiv_data1/oa_pdf/b3/5d/koni-06-03-1284719.PMC5384346.pdf
J Virol 2006; 80:1067-76;PMID:16414984; http://dx.doi.org/10.1128/JVI.80.3.1067-1076.2006 26.,Non-OADS,/arxiv_data1/oa_pdf/b3/5d/koni-06-03-1284719.PMC5384346.pdf
SeminCell Dev Biol 2012; 23:258-68; PMID:22001110; http://dx.doi.org/ 10.1016/j.semcdb.2011.10.004 27.,OADS,/arxiv_data1/oa_pdf/b3/5d/koni-06-03-1284719.PMC5384346.pdf
1973 [cited 2016 Sep 3]; Available from: https://elsa.berke ley.edu/reprints/mcfadden/zarembka.pdf 28.,Non-OADS,/arxiv_data1/oa_pdf/b3/5d/koni-06-03-1284719.PMC5384346.pdf
N Engl J Med 2012; 366:2455-65; PMID:22658128; http://dx.doi.org/10.1056/NEJMoa1200694e1284719-10 A. BOICHARD ET AL.,OADS,/arxiv_data1/oa_pdf/b3/5d/koni-06-03-1284719.PMC5384346.pdf
Virology 2007; 367:440-51; PMID:17631933; http://dx.doi.org/10.1016/j.virol.2007.06.010 31.,Non-OADS,/arxiv_data1/oa_pdf/b3/5d/koni-06-03-1284719.PMC5384346.pdf
Diabetes 2008; 57:1861-9; PMID:18420489; http://dx.doi.org/10.2337/db07-1260 34.,Non-OADS,/arxiv_data1/oa_pdf/b3/5d/koni-06-03-1284719.PMC5384346.pdf
J Invest Dermatol 1999;113:162-9; PMID:10469298; http://dx.doi.org/10.1046/j.1523- 1747.1999.00682.x 35.,Non-OADS,/arxiv_data1/oa_pdf/b3/5d/koni-06-03-1284719.PMC5384346.pdf
Int J Oncol 2007; 31:1439-47; PMID:17982670; http://dx.doi.org/10.3892/ ijo.31.6.1439 36.,OADS,/arxiv_data1/oa_pdf/b3/5d/koni-06-03-1284719.PMC5384346.pdf
Nature 1981; 293:144-6; PMID:7266668; http://dx.doi.org/10.1038/293144a0 37.,Non-OADS,/arxiv_data1/oa_pdf/b3/5d/koni-06-03-1284719.PMC5384346.pdf
Nat Med 2016; 22:105-13; PMID:26618723; http://dx.doi.org/10.1038/nm.3984 38.,OADS,/arxiv_data1/oa_pdf/b3/5d/koni-06-03-1284719.PMC5384346.pdf
Nature 2012; 481:306-13; PMID:22258609; http://dx.doi.org/10.1038/nature10762 39.,Non-OADS,/arxiv_data1/oa_pdf/b3/5d/koni-06-03-1284719.PMC5384346.pdf
Can-cer Discov 2015; 5:704-12; PMID:26091828; http://dx.doi.org/10.1158/2159-8290.CD-15-034440.,OADS,/arxiv_data1/oa_pdf/b3/5d/koni-06-03-1284719.PMC5384346.pdf
Nat Genet 2016; 48:1330-8; PMID:27643540; http://dx.doi.org/10.1038/ng.3670 41.,OADS,/arxiv_data1/oa_pdf/b3/5d/koni-06-03-1284719.PMC5384346.pdf
Cancer Metastasis Rev 2016; pp 1- 12; PMID:27873079; http://dx.doi.org/10.1007/s10555-016-9652-y 43.,Non-OADS,/arxiv_data1/oa_pdf/b3/5d/koni-06-03-1284719.PMC5384346.pdf
BMC Bioinform 2011;12:323; PMID:21816040; http://dx.doi.org/10.1186/1471-2105-12-323 46.,OADS,/arxiv_data1/oa_pdf/b3/5d/koni-06-03-1284719.PMC5384346.pdf
Nat Genet 2013; 45:970-6; PMID:23852170; http://dx.doi.org/10.1038/ng.2702 47.,OADS,/arxiv_data1/oa_pdf/b3/5d/koni-06-03-1284719.PMC5384346.pdf
Front Genet 2014; 5:187; PMID:24995013; http://dx.doi.org/10.3389/fgene.2014.00187 48.,OADS,/arxiv_data1/oa_pdf/b3/5d/koni-06-03-1284719.PMC5384346.pdf
Stat Med 2010;29:770-7; PMID:20213709; http://dx.doi.org/10.1002/sim.3794 49.,OADS,/arxiv_data1/oa_pdf/b3/5d/koni-06-03-1284719.PMC5384346.pdf
J Clin Epidemiol2001; 54:774-81; PMID:11470385; http://dx.doi.org/10.1016/S0895-4356(01)00341-9ONCOIMMUNOLOGY e1284719-11,Non-OADS,/arxiv_data1/oa_pdf/b3/5d/koni-06-03-1284719.PMC5384346.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered , transformed, or built upon in any way.ONCOIMMUNOLOGY 2017, VOL.",Non-OADS,/arxiv_data1/oa_pdf/11/67/koni-06-03-1277306.PMC5384349.pdf
"3, e1277306 (15 pages)http://dx.doi.org/10.1080/2162402X.2016.1277306",Non-OADS,/arxiv_data1/oa_pdf/11/67/koni-06-03-1277306.PMC5384349.pdf
ORCID David Wittig http://orcid.org/0000-0002-3296-6809 Maria Cristina de Vera Mudry http://orcid.org/0000-0003-1016-7480 Jose Saro http://orcid.org/0000-0003-0778-3864 Stefan Evers http://orcid.org/0000-0001-9587-5325 References 1.,Non-OADS,/arxiv_data1/oa_pdf/11/67/koni-06-03-1277306.PMC5384349.pdf
J Clin Immunol 2008; 28:635-9; PMID:18726679; http://dx.doi.org/ 10.1007/s10875-008-9235-y 2.,Non-OADS,/arxiv_data1/oa_pdf/11/67/koni-06-03-1277306.PMC5384349.pdf
Nat Rev Immunol 2006; 6:595-601; PMID:16868550; http://dx.doi.org/10.1038/nri1901 4.,Non-OADS,/arxiv_data1/oa_pdf/11/67/koni-06-03-1277306.PMC5384349.pdf
Nat Rev Immunol 2012; 12:180-90;PMID:22343569; http://dx.doi.org/10.1038/nri3156 5.,Non-OADS,/arxiv_data1/oa_pdf/11/67/koni-06-03-1277306.PMC5384349.pdf
Trends Immunol 2015; 36:763-77;PMID:26572555; http://dx.doi.org/10.1016/j.it.2015.10.003 6.,OADS,/arxiv_data1/oa_pdf/11/67/koni-06-03-1277306.PMC5384349.pdf
Cell Mol Life Sci 2012; 69:1597-608;PMID:22460580; http://dx.doi.org/10.1007/s00018-012-0968-7 7.,OADS,/arxiv_data1/oa_pdf/11/67/koni-06-03-1277306.PMC5384349.pdf
Nat Immunol 2005; 6:1142-51; PMID:16227984; http://dx.doi.org/10.1038/ni1263 8.,Non-OADS,/arxiv_data1/oa_pdf/11/67/koni-06-03-1277306.PMC5384349.pdf
Nat Immunol 2005; 6:1071-72; PMID:16239920; http://dx.doi.org/ 10.1038/ni1105-1071 10.,Non-OADS,/arxiv_data1/oa_pdf/11/67/koni-06-03-1277306.PMC5384349.pdf
J Immunol 2014; 192:5451-58; PMID:24907378; http://dx.doi.org/ 10.4049/jimmunol.1490019 11.,Non-OADS,/arxiv_data1/oa_pdf/11/67/koni-06-03-1277306.PMC5384349.pdf
Arch Biochem Biophys 2012; 526:194-205; PMID:22445675; http://dx.doi.org/10.1016/j.abb.2012.03.001 13.,OADS,/arxiv_data1/oa_pdf/11/67/koni-06-03-1277306.PMC5384349.pdf
Drug Discov Today 2012; 17:583-90; PMID:22289353;http://dx.doi.org/10.1016/j.drudis.2012.01.007 14.,Non-OADS,/arxiv_data1/oa_pdf/11/67/koni-06-03-1277306.PMC5384349.pdf
Expert Opin Biol Ther 2008; 8:609632; PMID:18407765; http://dx.doi.org/10.1517/14712598.8.5.609 15.,Non-OADS,/arxiv_data1/oa_pdf/11/67/koni-06-03-1277306.PMC5384349.pdf
Drugs Today (Barc) 2000; 36:321-36;PMID:12861355; http://dx.doi.org/10.1358/dot.2000.36.5.575044 16.,Non-OADS,/arxiv_data1/oa_pdf/11/67/koni-06-03-1277306.PMC5384349.pdf
Pharmacol Ther 1998; 80:277-92; PMID:9888698; http://dx.doi.org/10.1016/S0163-7258(98)00033-3 17.,Non-OADS,/arxiv_data1/oa_pdf/11/67/koni-06-03-1277306.PMC5384349.pdf
Cancer Cell 2015; 27:489-501; PMID:25873172; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/11/67/koni-06-03-1277306.PMC5384349.pdf
Nat Med 2016;22(12):1402-10; PMID:27775706; http://dx.doi.org/10.1038/nm.4200 20.,OADS,/arxiv_data1/oa_pdf/11/67/koni-06-03-1277306.PMC5384349.pdf
Br J Can- cer 2009; 101:1758-68; PMID:19904275; http://dx.doi.org/10.1038/sj.,OADS,/arxiv_data1/oa_pdf/11/67/koni-06-03-1277306.PMC5384349.pdf
Proc Natl Acad Sci U S A2001; 98:10256-260; PMID:11517330; http://dx.doi.org/10.1073/ pnas.181353498 23.,OADS,/arxiv_data1/oa_pdf/11/67/koni-06-03-1277306.PMC5384349.pdf
Oncoimmunology 2016; 5:e1203498; PMID:27622073; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/11/67/koni-06-03-1277306.PMC5384349.pdf
Res 2016; 22:4417-27; PMID:27117182; http://dx.doi.org/10.1158/ 1078-0432.CCR-15-2622 25.,Non-OADS,/arxiv_data1/oa_pdf/11/67/koni-06-03-1277306.PMC5384349.pdf
Clin Cancer Res 2016; 22:3286-97;PMID:26861458; http://dx.doi.org/10.1158/1078-0432.CCR-15-1696 26.,Non-OADS,/arxiv_data1/oa_pdf/11/67/koni-06-03-1277306.PMC5384349.pdf
Cancer Invest 2005;23:338-51; PMID:16100946; http://dx.doi.org/10.1081/CNV-58878 27.,Non-OADS,/arxiv_data1/oa_pdf/11/67/koni-06-03-1277306.PMC5384349.pdf
MAbs 2014; 6:1571-84; PMID:25484061; http://dx.doi.org/10.4161/19420862.2014.975660 28.,Non-OADS,/arxiv_data1/oa_pdf/11/67/koni-06-03-1277306.PMC5384349.pdf
PLoS One 2012; 7:e36412; PMID:22574157; http://dx.doi.org/10.1371/journal.pone.0036412 29.,Non-OADS,/arxiv_data1/oa_pdf/11/67/koni-06-03-1277306.PMC5384349.pdf
Clin Cancer Res 2016; 22(13):3286-97; PMID:26861458; http://dx.doi.org/10.1158/1078- 0432.CCR-15-1696 30.,Non-OADS,/arxiv_data1/oa_pdf/11/67/koni-06-03-1277306.PMC5384349.pdf
Hum Pathol 1996; 27:172-7; PMID:8617459; http://dx.doi.org/10.1016/S0046-8177(96)90371-8 32.,Non-OADS,/arxiv_data1/oa_pdf/11/67/koni-06-03-1277306.PMC5384349.pdf
J Clin Lab Anal 1991; 5:344-66; PMID:1941355; http://dx.doi.org/10.1002/ jcla.1860050510 33.,Non-OADS,/arxiv_data1/oa_pdf/11/67/koni-06-03-1277306.PMC5384349.pdf
Science2005; 308:1477-80; PMID:15933202; http://dx.doi.org/10.1126/science.1109745 35.,Non-OADS,/arxiv_data1/oa_pdf/11/67/koni-06-03-1277306.PMC5384349.pdf
Science 2005;310:1159-63; PMID:16293754; http://dx.doi.org/10.1126/science.1117893 36.,OADS,/arxiv_data1/oa_pdf/11/67/koni-06-03-1277306.PMC5384349.pdf
J Biol Chem1996; 271:4699-708; PMID:8617735; http://dx.doi.org/10.1074/jbc.271.23.13754 37.,OADS,/arxiv_data1/oa_pdf/11/67/koni-06-03-1277306.PMC5384349.pdf
Protein Eng Des Sel 2016; 29(10):457-66; PMID:27578889; http://dx.doi.org/10.1093/protein/gzw040 38.,OADS,/arxiv_data1/oa_pdf/11/67/koni-06-03-1277306.PMC5384349.pdf
Nat Biotechnol 1998; 16:677-81 PMID: 9661204; PMID:9661204; http://dx.doi.org/ 10.1038/nbt0798-677 39.,Non-OADS,/arxiv_data1/oa_pdf/11/67/koni-06-03-1277306.PMC5384349.pdf
Science 2006; 311:1924-27; PMID:16484453; http://dx.doi.org/10.1126/science.1122927 42.,OADS,/arxiv_data1/oa_pdf/11/67/koni-06-03-1277306.PMC5384349.pdf
Sci Transl Med 2016; 8:328rv324; PMID:26936508; http://dx.doi.org/10.1126/scitranslmed.aad7118 43.,OADS,/arxiv_data1/oa_pdf/11/67/koni-06-03-1277306.PMC5384349.pdf
Clin Cancer Res 2014; 20; 1055; PMID:24536075; http://dx.doi.org/10.1158/1078-0432.CCR-13-2699 44.,Non-OADS,/arxiv_data1/oa_pdf/11/67/koni-06-03-1277306.PMC5384349.pdf
Immunity 2015; 42:815-25; PMID:25992858; http://dx.doi.org/10.1016/j.immuni.2015.04.015 45.,OADS,/arxiv_data1/oa_pdf/11/67/koni-06-03-1277306.PMC5384349.pdf
Nature 2012; 484:529-33; PMID:22446627; http://dx.doi.org/10.1038/nature10975 46.,Non-OADS,/arxiv_data1/oa_pdf/11/67/koni-06-03-1277306.PMC5384349.pdf
Clinical Cancer Research 2016; 22:680-90; PMID:26832745; http://dx.doi.org/10.1158/1078-0432.CCR-15-1631 47.,Non-OADS,/arxiv_data1/oa_pdf/11/67/koni-06-03-1277306.PMC5384349.pdf
Clin Cancer Res 2011; 17:3673-85; PMID:21531812; http://dx.doi.org/10.1158/ 1078-0432.CCR-10-2921 48.,Non-OADS,/arxiv_data1/oa_pdf/11/67/koni-06-03-1277306.PMC5384349.pdf
Eur J Cancer 2013; 49:35-44;PMID:22918078; http://dx.doi.org/10.1016/j.ejca.2012.07.015 49.,Non-OADS,/arxiv_data1/oa_pdf/11/67/koni-06-03-1277306.PMC5384349.pdf
J Immunol 2013; 190:6230-38; PMID:23677467;http://dx.doi.org/10.4049/jimmunol.1201895 50.,Non-OADS,/arxiv_data1/oa_pdf/11/67/koni-06-03-1277306.PMC5384349.pdf
CancerImmunol Res 2016; PMID:27697858; http://dx.doi.org/10.1158/2326- 6066.CIR-15-0195 52.,Non-OADS,/arxiv_data1/oa_pdf/11/67/koni-06-03-1277306.PMC5384349.pdf
Nat Commun 2016; 7:12878; PMID:27650575; http://dx.doi.org/10.1038/ncomms12878 53.,OADS,/arxiv_data1/oa_pdf/11/67/koni-06-03-1277306.PMC5384349.pdf
Expert Opin Biol Ther 2006: 6:1323-1331; PMID:17223740;http://dx.doi.org/10.1517/14712598.6.12.1323 54.,OADS,/arxiv_data1/oa_pdf/11/67/koni-06-03-1277306.PMC5384349.pdf
Sci Transl Med 2016; 8:367ra166; PMID:27903862; http://dx.doi.org/10.1126/scitranslmed.aag3187 55.,Non-OADS,/arxiv_data1/oa_pdf/11/67/koni-06-03-1277306.PMC5384349.pdf
Cancer Immunol Res 2015; 3:219-227; PMID:25736261; http://dx.doi.org/10.1158/2326-6066.CIR-15-0009 58.,Non-OADS,/arxiv_data1/oa_pdf/11/67/koni-06-03-1277306.PMC5384349.pdf
Journal of clinical oncology: of ﬁcial journal of the American Society of Clinical Oncol- ogy 2015; 33:74-82; PMID:25403209; http://dx.doi.org/10.1200/JCO.2014.57.3329 59.,Non-OADS,/arxiv_data1/oa_pdf/11/67/koni-06-03-1277306.PMC5384349.pdf
2016; 22:596-608; PMID:26423796; http://dx.doi.org/10.1158/1078-0432.CCR-15-1419 61.,Non-OADS,/arxiv_data1/oa_pdf/11/67/koni-06-03-1277306.PMC5384349.pdf
The IL-15-based superagonist ALT- 803 promotes the antigen-independent conversion of memory CD8(C) T cells into innate-like effector cells with antitumor activity.Oncoimmunology 2013; 2:e26442; PMID:24404427; http://dx.doi.org/ 10.4161/onci.26442 62.,Non-OADS,/arxiv_data1/oa_pdf/11/67/koni-06-03-1277306.PMC5384349.pdf
Blood 2015; 126:1957; http://dx.doi.org/10.1182/blood-2015-02-625574 64.,Non-OADS,/arxiv_data1/oa_pdf/11/67/koni-06-03-1277306.PMC5384349.pdf
J Biol Chem 2016; 291(46):23869-881; PMID:27650494; http://dx.doi.org/10.1074/jbc.M116.733600 65.,OADS,/arxiv_data1/oa_pdf/11/67/koni-06-03-1277306.PMC5384349.pdf
Nature 2014; 515:572-6;PMID:25428506; http://dx.doi.org/10.1038/nature14001 66.,OADS,/arxiv_data1/oa_pdf/11/67/koni-06-03-1277306.PMC5384349.pdf
J Immunother2013; 36:477-89; PMID:24145359; http://dx.doi.org/10.1097/01.,Non-OADS,/arxiv_data1/oa_pdf/11/67/koni-06-03-1277306.PMC5384349.pdf
Blood 2009;113:2275-83; PMID:19005180; http://dx.doi.org/10.1182/blood-2008-05-160747ONCOIMMUNOLOGY e1277306-15,Non-OADS,/arxiv_data1/oa_pdf/11/67/koni-06-03-1277306.PMC5384349.pdf
"Autism and Animal Models   In the Diagnostic and Statistica l Manual of Mental  Disorders, 5th edition (http://www.dsm5.org/proposedre  vision/Pages/Neurodevelopment alDisorders.aspx; acc- essed April 11, 2014), soci al communication impair- ments and restricted repetiti ve patterns of behavior are  described as core symptom s of autism spectrum  disorder (ASD).",Non-OADS,/arxiv_data1/oa_pdf/27/07/CMM-15-193.PMC5384360.pdf
"3, e1219825 (11 pages)http://dx.doi.org/10.1080/2162402X.2016.1219825",Non-OADS,/arxiv_data1/oa_pdf/49/a7/koni-06-03-1219825.PMC5384368.pdf
"Search for homologous peptide sequences Screening sequence homology of MYD88L265Ppeptides with prokaryotic and virus proteins was performed for P1 (RPIPI- KYKAM), P2 (RPIPIKYKA), P3 (SPGAHQKRPI), and P4 (HQKRPIPIKY), using the Smith –Waterman protein searcher application (SSEARCH) on the European Molecular BiologyLaboratory server ( http://www.ebi.ac.uk/Tools/sss/fasta/ ), using default settings.",OADS,/arxiv_data1/oa_pdf/49/a7/koni-06-03-1219825.PMC5384368.pdf
Annu Rev Immunol1994; 12:337-65; PMID:8011285; http://dx.doi.org/10.1146/annurev.,Non-OADS,/arxiv_data1/oa_pdf/49/a7/koni-06-03-1219825.PMC5384368.pdf
Curr Opin Immunol 1994; 6:722-7;PMID:7826527; http://dx.doi.org/10.1016/0952-7915(94)90075-2 3.,Non-OADS,/arxiv_data1/oa_pdf/49/a7/koni-06-03-1219825.PMC5384368.pdf
Science 1993; 259:368-70; PMID:7678351; http://dx.doi.org/10.1126/ science.7678351 4.,Non-OADS,/arxiv_data1/oa_pdf/49/a7/koni-06-03-1219825.PMC5384368.pdf
Nat Med 2012; 18:1254-61; PMID:22842478; http://dx.doi.org/10.1038/nm.2883 5.,OADS,/arxiv_data1/oa_pdf/49/a7/koni-06-03-1219825.PMC5384368.pdf
Curr Opin Immunol 2014; 27:89- 97; PMID:24485523; http://dx.doi.org/10.1016/j.coi.2014.01.002 6.,OADS,/arxiv_data1/oa_pdf/49/a7/koni-06-03-1219825.PMC5384368.pdf
Curr Opin Hematol 2015; 22:337-42; PMID:26049755; http://dx.doi.org/10.1097/ MOH.0000000000000158 7.,OADS,/arxiv_data1/oa_pdf/49/a7/koni-06-03-1219825.PMC5384368.pdf
J Clin Oncol 2013; 31:e439-42;PMID:24043743; http://dx.doi.org/10.1200/JCO.2012.47.7521 9.,Non-OADS,/arxiv_data1/oa_pdf/49/a7/koni-06-03-1219825.PMC5384368.pdf
N Engl J Med 2012; 367:826-33; PMID:22931316; http://dx.doi.org/10.1056/ NEJMoa1200710 10.,OADS,/arxiv_data1/oa_pdf/49/a7/koni-06-03-1219825.PMC5384368.pdf
Blood 2013; 121:2522-8; PMID:23355535; http://dx.doi.org/10.1182/blood-2012-09-457101 11.,Non-OADS,/arxiv_data1/oa_pdf/49/a7/koni-06-03-1219825.PMC5384368.pdf
Blood 2013; 121:2051-8; PMID:23321251; http://dx.doi.org/10.1182/blood-2012-09-454355 12.,Non-OADS,/arxiv_data1/oa_pdf/49/a7/koni-06-03-1219825.PMC5384368.pdf
Nature 2011; 470:115-9;PMID:21179087; http://dx.doi.org/10.1038/nature09671 13.,Non-OADS,/arxiv_data1/oa_pdf/49/a7/koni-06-03-1219825.PMC5384368.pdf
Nat Genet 2011; 43:830-7;PMID:21804550; http://dx.doi.org/10.1038/ng.892 14.,OADS,/arxiv_data1/oa_pdf/49/a7/koni-06-03-1219825.PMC5384368.pdf
Nature 2011; 475:101-5; PMID:21642962; http://dx.doi.org/ 10.1038/nature10113 15.,Non-OADS,/arxiv_data1/oa_pdf/49/a7/koni-06-03-1219825.PMC5384368.pdf
Cell 2013; 152:714-26; PMID:23415222; http://dx.doi.org/ 10.1016/j.cell.2013.01.019 16.,OADS,/arxiv_data1/oa_pdf/49/a7/koni-06-03-1219825.PMC5384368.pdf
N Engl J Med 2008; 359:2313-23; PMID:19038878; http://dx.doi.org/10.1056/NEJMoa0802885 18.,OADS,/arxiv_data1/oa_pdf/49/a7/koni-06-03-1219825.PMC5384368.pdf
Leuk Lymphoma 2010; 51:1188-99; PMID:20545582; http://dx.doi.org/10.3109/10428194.2010.486089 19.,Non-OADS,/arxiv_data1/oa_pdf/49/a7/koni-06-03-1219825.PMC5384368.pdf
Blood 2008; 111:1357-65; PMID:17978170; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/49/a7/koni-06-03-1219825.PMC5384368.pdf
Blood 2006; 107:1325-31; PMID:16269610; http://dx.doi.org/10.1182/blood-2005-08-3373 21.,Non-OADS,/arxiv_data1/oa_pdf/49/a7/koni-06-03-1219825.PMC5384368.pdf
Clin Cancer Res 2011; 17:4550-7; PMID:21498393; http://dx.doi.org/10.1158/1078-0432.,Non-OADS,/arxiv_data1/oa_pdf/49/a7/koni-06-03-1219825.PMC5384368.pdf
Blood 2002; 99:1517-26; PMID:11861263;http://dx.doi.org/10.1182/blood.V99.5.1517 23.,Non-OADS,/arxiv_data1/oa_pdf/49/a7/koni-06-03-1219825.PMC5384368.pdf
Brit J Haematol 2008; 142:179-91; PMID:18422783; http://dx.doi.org/10.1111/j.1365-2141.2008.07143.x 24.,Non-OADS,/arxiv_data1/oa_pdf/49/a7/koni-06-03-1219825.PMC5384368.pdf
NatMed 2015; 21:922-6; PMID:26193343; http://dx.doi.org/10.1038/ nm.3884 25.,OADS,/arxiv_data1/oa_pdf/49/a7/koni-06-03-1219825.PMC5384368.pdf
Bioinformatics 2008; 24:1397-8; PMID:18413329; http://dx.doi.org/10.1093/bioinformatics/btn128 27.,OADS,/arxiv_data1/oa_pdf/49/a7/koni-06-03-1219825.PMC5384368.pdf
Improved prediction of MHC class Iand class II epitopes using a nove lG i b b ss a m p l i n ga p p r o a c h .B i o - informatics 2004; 20:1388-97; PMID:14962912; http://dx.doi.org/ 10.1093/bioinformatics/bth100 28.,Non-OADS,/arxiv_data1/oa_pdf/49/a7/koni-06-03-1219825.PMC5384368.pdf
Protein Sci 2003; 12:1007-17; PMID:12717023; http://dx.doi.org/10.1110/ps.0239403 29.,OADS,/arxiv_data1/oa_pdf/49/a7/koni-06-03-1219825.PMC5384368.pdf
Methods Mol Biol 2007; 409:75-93; PMID:18449993; http://dx.doi.org/10.1007/978-1-60327- 118-9_5 30.,Non-OADS,/arxiv_data1/oa_pdf/49/a7/koni-06-03-1219825.PMC5384368.pdf
J Exp Med 2014; 211:2231-48;PMID:25245761; http://dx.doi.org/10.1084/jem.20141308 31.,Non-OADS,/arxiv_data1/oa_pdf/49/a7/koni-06-03-1219825.PMC5384368.pdf
OncoImmunology 2016; 5(5):e1065369; PMID:27467910; http://dx.doi.org/10.1080/2162402X.,Non-OADS,/arxiv_data1/oa_pdf/49/a7/koni-06-03-1219825.PMC5384368.pdf
N Engl J Med 2013; 369:122- 33; PMID:23724867; http://dx.doi.org/10.1056/NEJMoa1302369 33.,OADS,/arxiv_data1/oa_pdf/49/a7/koni-06-03-1219825.PMC5384368.pdf
N Engl J Med 2012; 366:2443-54; PMID:22658127; http://dx.doi.org/10.1056/NEJMoa1200690 34.,OADS,/arxiv_data1/oa_pdf/49/a7/koni-06-03-1219825.PMC5384368.pdf
Lancet 2014; 384:1109-17; PMID:25034862; http://dx.doi.org/10.1016/S0140-6736(14)60958-2 35.,Non-OADS,/arxiv_data1/oa_pdf/49/a7/koni-06-03-1219825.PMC5384368.pdf
J Clin Oncol 2012; 30:2046-54; PMID:22547592; http://dx.doi.org/10.1200/JCO.2011.38.4032 36.,Non-OADS,/arxiv_data1/oa_pdf/49/a7/koni-06-03-1219825.PMC5384368.pdf
N Engl J Med 2015; 372:311-9; PMID:25482239; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/49/a7/koni-06-03-1219825.PMC5384368.pdf
Leuk Lymphoma 2015; 56(11):3065-70;PMID:25754579; http://dx.doi.org/10.3109/10428194.2015.1028052 3 8 .,Non-OADS,/arxiv_data1/oa_pdf/49/a7/koni-06-03-1219825.PMC5384368.pdf
NEngl J Med 2014; 371:2189-99; PMID:25409260; http://dx.doi.org/ 10.1056/NEJMoa1406498 39.,OADS,/arxiv_data1/oa_pdf/49/a7/koni-06-03-1219825.PMC5384368.pdf
Blood 2015; 126(10):1203-13;PMID:26138685; http://dx.doi.org/10.1182/blood-2015-04-640532 41.,Non-OADS,/arxiv_data1/oa_pdf/49/a7/koni-06-03-1219825.PMC5384368.pdf
"Leukemia 2015; 29, 647-59; PMID:25092142; http://dx.doi.org/10.1038/leu.2014.233 42.",Non-OADS,/arxiv_data1/oa_pdf/49/a7/koni-06-03-1219825.PMC5384368.pdf
Blood 2012; 120:1282-9; PMID:22592607; http://dx.doi.org/10.1182/blood-2011-11-394395 43.,Non-OADS,/arxiv_data1/oa_pdf/49/a7/koni-06-03-1219825.PMC5384368.pdf
Blood2013; 122:1087-8; PMID:23929838; http://dx.doi.org/10.1182/blood- 2013-04-496844 44.,Non-OADS,/arxiv_data1/oa_pdf/49/a7/koni-06-03-1219825.PMC5384368.pdf
Blood 2014; 123:3790-6; PMID:24782504; http://dx.doi.org/10.1182/blood-2013-12-543306 45.,Non-OADS,/arxiv_data1/oa_pdf/49/a7/koni-06-03-1219825.PMC5384368.pdf
J Immunological Methods 2010; 360:56-65; PMID:20558172;http://dx.doi.org/10.1016/j.jim.2010.06.005 46.,Non-OADS,/arxiv_data1/oa_pdf/49/a7/koni-06-03-1219825.PMC5384368.pdf
J Immunol 2005;175:2709-14; PMID:16081848; http://dx.doi.org/10.4049/jimmunol.175.4.2709 47.,Non-OADS,/arxiv_data1/oa_pdf/49/a7/koni-06-03-1219825.PMC5384368.pdf
Blood 2014; 124:3896-904; PMID:25359991; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/49/a7/koni-06-03-1219825.PMC5384368.pdf
Blood Cancer J 2014; 4:e183; PMID:24531446; http://dx.doi.org/10.1038/bcj.2014.4 49.,Non-OADS,/arxiv_data1/oa_pdf/49/a7/koni-06-03-1219825.PMC5384368.pdf
Nat Med 2015; 21:914-21; PMID:26193344; http://dx.doi.org/10.1038/nm.3910 51.,OADS,/arxiv_data1/oa_pdf/49/a7/koni-06-03-1219825.PMC5384368.pdf
Blood 2015; 126:76-9; PMID:25900979; http://dx.doi.org/ 10.1182/blood-2015-01-620518 52.,Non-OADS,/arxiv_data1/oa_pdf/49/a7/koni-06-03-1219825.PMC5384368.pdf
Brit J Haematol 2015; 169:795-803; PMID:25819228; http://dx.doi.org/10.1111/bjh.13361 53.,Non-OADS,/arxiv_data1/oa_pdf/49/a7/koni-06-03-1219825.PMC5384368.pdf
Nucleic Acids Res 2008; 1;36:W509-12; PMID:18463140; http://dx.doi.org/10.1093/nar/gkn202 54.,Non-OADS,/arxiv_data1/oa_pdf/49/a7/koni-06-03-1219825.PMC5384368.pdf
Science 1986; 232:341-7; PMID:3961484; http://dx.doi.org/10.1126/science.3961484 55.,Non-OADS,/arxiv_data1/oa_pdf/49/a7/koni-06-03-1219825.PMC5384368.pdf
J Chem Soc Chem Commun1978; 13:537-9; http://dx.doi.org/10.1039/c39780000537 56.,OADS,/arxiv_data1/oa_pdf/49/a7/koni-06-03-1219825.PMC5384368.pdf
Science 1996; 274:94-6; PMID:8810254; http://dx.doi.org/10.1126/science.274.5284.94 58.,Non-OADS,/arxiv_data1/oa_pdf/49/a7/koni-06-03-1219825.PMC5384368.pdf
Int J Can- cer 2012; 131:140-9; PMID:21858810; http://dx.doi.org/10.1002/ ijc.26365 60.,OADS,/arxiv_data1/oa_pdf/49/a7/koni-06-03-1219825.PMC5384368.pdf
Cancer Immunol Immunother2008; 57:289-302; PMID:17721783; http://dx.doi.org/10.1007/ s00262-007-0378-0 61.,Non-OADS,/arxiv_data1/oa_pdf/49/a7/koni-06-03-1219825.PMC5384368.pdf
Cancer Immunol Immunother 2008; 57:175-83; PMID:17657490; http://dx.doi.org/10.1007/s00262-007-0360-x 62.,Non-OADS,/arxiv_data1/oa_pdf/49/a7/koni-06-03-1219825.PMC5384368.pdf
"Neumann A, Horzer H, Hillen N, Klingel K, Schmid-Horch B, Buhr- ing HJ, Rammensee HG, Aebert H, Stevanovic S. Identi ﬁcation of HLA ligands and T-cell epitopes for immunotherapy of lung cancer.Cancer Immunol Immunother 2013; 62:1485-97; PMID:23817722; http://dx.doi.org/10.1007/s00262-013-1454-2 63.",OADS,/arxiv_data1/oa_pdf/49/a7/koni-06-03-1219825.PMC5384368.pdf
J Immunol Methods 2004; 285:25-40; PMID:14871532; http://dx.doi.org/10.1016/j.jim.2003.10.017ONCOIMMUNOLOGY e1219825-11,Non-OADS,/arxiv_data1/oa_pdf/49/a7/koni-06-03-1219825.PMC5384368.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License ( http://creativecommons.org/licenses/by-nc/3.0/ ), which permits unre- stricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/b6/a1/koni-06-03-1286436.PMC5384380.pdf
"3, e1286436 (10 pages)http://dx.doi.org/10.1080/2162402X.2017.1286436",Non-OADS,/arxiv_data1/oa_pdf/b6/a1/koni-06-03-1286436.PMC5384380.pdf
ORCID Nektarios A. Valous http://orcid.org/0000-0002-4014-2404 References 1.,Non-OADS,/arxiv_data1/oa_pdf/b6/a1/koni-06-03-1286436.PMC5384380.pdf
CA Cancer J Clin 2006; 56:106-30; PMID:16514137; http://dx.doi.org/10.3322/canjclin.56.2.106 2.,OADS,/arxiv_data1/oa_pdf/b6/a1/koni-06-03-1286436.PMC5384380.pdf
JNatl Cancer Inst 2004; 96:1420-5; PMID:15467030; http://dx.doi.org/ 10.1093/jnci/djh275 3.,Non-OADS,/arxiv_data1/oa_pdf/b6/a1/koni-06-03-1286436.PMC5384380.pdf
J Pathol 1997; 182(3):318-24; PMID:9349235; http://dx.doi.org/10.1002/(SICI)1096-9896(199707)182:3 <318::AID-PATH862 >3.0.CO;2-6 6.,Non-OADS,/arxiv_data1/oa_pdf/b6/a1/koni-06-03-1286436.PMC5384380.pdf
Science (80) 2006; 313:1960-4; PMID:17008531; http://dx.doi.org/10.1126/science.1129139 7.,Non-OADS,/arxiv_data1/oa_pdf/b6/a1/koni-06-03-1286436.PMC5384380.pdf
N Engl J Med 2005; 353:2654-66; PMID:16371631; http://dx.doi.org/10.1056/NEJMoa051424 8.,OADS,/arxiv_data1/oa_pdf/b6/a1/koni-06-03-1286436.PMC5384380.pdf
Hum Pathol 2004; 35(7):808-16; PMID:15257543; http://dx.doi.org/10.1016/j.humpath.2004.01.022 10.,OADS,/arxiv_data1/oa_pdf/b6/a1/koni-06-03-1286436.PMC5384380.pdf
Cancer Immunol Immunother 2003; 52:423-8; PMID:12695859; http://dx.doi.org/10.1007/s00262-003-0388-5 11.,Non-OADS,/arxiv_data1/oa_pdf/b6/a1/koni-06-03-1286436.PMC5384380.pdf
Lab Invest 2004; 84:493-501; PMID:14968119; http://dx.doi.org/ 10.1038/labinvest.3700055 12.,OADS,/arxiv_data1/oa_pdf/b6/a1/koni-06-03-1286436.PMC5384380.pdf
J Clin Oncol 2009; 27:186- 92; PMID:19064967; http://dx.doi.org/10.1200/JCO.2008.18.7229 13.,Non-OADS,/arxiv_data1/oa_pdf/b6/a1/koni-06-03-1286436.PMC5384380.pdf
Cancer Res 2011; 71:5670-7; PMID:21846824; http://dx.doi.org/10.1158/0008-5472.CAN-11-0268 14.,Non-OADS,/arxiv_data1/oa_pdf/b6/a1/koni-06-03-1286436.PMC5384380.pdf
Eur J Cancer 2015; 51(17):2708-17;PMID:26342674; http://dx.doi.org/10.1016/j.ejca.2015.08.014 15.,Non-OADS,/arxiv_data1/oa_pdf/b6/a1/koni-06-03-1286436.PMC5384380.pdf
Oncoimmunology 2013; 2:e24116; PMID:23734335; http://dx.doi.org/10.4161/onci.24116 17.,Non-OADS,/arxiv_data1/oa_pdf/b6/a1/koni-06-03-1286436.PMC5384380.pdf
Oncoimmunology 2015; 4:e1016700;PMID:26140242; http://dx.doi.org/10.1080/2162402X.2015.1016700 19.,Non-OADS,/arxiv_data1/oa_pdf/b6/a1/koni-06-03-1286436.PMC5384380.pdf
Cell 2016; 29:587-601; PMID:27070705; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/b6/a1/koni-06-03-1286436.PMC5384380.pdf
Science 2013; 339:286-91; PMID:23329041; http://dx.doi.org/10.1126/science.1232227 21.,OADS,/arxiv_data1/oa_pdf/b6/a1/koni-06-03-1286436.PMC5384380.pdf
Cancer Res 2005; 65:8072- 8; PMID:16166278; http://dx.do i.org/10.1158/0008-5472.CAN-04-4146 22.,Non-OADS,/arxiv_data1/oa_pdf/b6/a1/koni-06-03-1286436.PMC5384380.pdf
PLoS One 2009; 4:e7847; PMID:19924291; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/b6/a1/koni-06-03-1286436.PMC5384380.pdf
Vienna Austria 2015; Available from: http://www.r-project.org/ ; PMID:26321800 24.,Non-OADS,/arxiv_data1/oa_pdf/b6/a1/koni-06-03-1286436.PMC5384380.pdf
"Sci (New York, NY) 2006; 313:1960-4;PMID:17008531; http://dx.doi.org/10.1126/science.1129139 25.",Non-OADS,/arxiv_data1/oa_pdf/b6/a1/koni-06-03-1286436.PMC5384380.pdf
Cancer Lett2009; 273(1):80-5; PMID:18774635; http://dx.doi.org/10.1016/j.canlet.2008.07.032 26.,Non-OADS,/arxiv_data1/oa_pdf/b6/a1/koni-06-03-1286436.PMC5384380.pdf
Med Phys 2016; 43:2936;PMID:27277043; http://dx.doi.org/10.1118/1.4949003 27.,Non-OADS,/arxiv_data1/oa_pdf/b6/a1/koni-06-03-1286436.PMC5384380.pdf
Nat Rev Immunol2006; 6:715-27; PMID:16977338; http://dx.doi.org/10.1038/nri1936 28.,Non-OADS,/arxiv_data1/oa_pdf/b6/a1/koni-06-03-1286436.PMC5384380.pdf
Oncoimmunology 2012; 1:593-9; PMID:22934251; http://dx.doi.org/10.4161/onci.20179 29.,Non-OADS,/arxiv_data1/oa_pdf/b6/a1/koni-06-03-1286436.PMC5384380.pdf
The immune contexture in human tumours: impact on clinical outcome.Nat Publ Gr 2012; 12:298-306; PMID:22419253; http://dx.doi.org/ 10.1038/nrc3245 30.,Non-OADS,/arxiv_data1/oa_pdf/b6/a1/koni-06-03-1286436.PMC5384380.pdf
Clin Cancer Res 2011; 17:678-89; PMID:21325295; http://dx.doi.org/10.1158/1078-0432.CCR-10-2173 31.,Non-OADS,/arxiv_data1/oa_pdf/b6/a1/koni-06-03-1286436.PMC5384380.pdf
Cancer Cell 2015; 27:462-72; PMID:25858805; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/b6/a1/koni-06-03-1286436.PMC5384380.pdf
Cancer Sci 2014; 105:1-8; PMID:24168081; http://dx.doi.org/10.1111/cas.12314 33.,Non-OADS,/arxiv_data1/oa_pdf/b6/a1/koni-06-03-1286436.PMC5384380.pdf
Nat Rev Immunol 2008; 8:958-69; PMID:19029990; http://dx.doi.org/10.1038/nri2448 34.,Non-OADS,/arxiv_data1/oa_pdf/b6/a1/koni-06-03-1286436.PMC5384380.pdf
J Exp Med 2009; 206:1327-37; PMID:19451266; http://dx.doi.org/ 10.1084/jem.20082173 35.,Non-OADS,/arxiv_data1/oa_pdf/b6/a1/koni-06-03-1286436.PMC5384380.pdf
J Exp Med 2006; 203:871-81; PMID:16606666; http://dx.doi.org/10.1084/jem.20050930 36.,Non-OADS,/arxiv_data1/oa_pdf/b6/a1/koni-06-03-1286436.PMC5384380.pdf
J Immunother Cancer 2016; 4(40):1 –15; PMID:27437104; http://dx.doi.org/10.1186/s40425- 016-0145-x37.,Non-OADS,/arxiv_data1/oa_pdf/b6/a1/koni-06-03-1286436.PMC5384380.pdf
Int J Cancer 2016; 139:1129-39; PMID:27074317; http://dx.doi.org/10.1002/ijc.30138 38.,Non-OADS,/arxiv_data1/oa_pdf/b6/a1/koni-06-03-1286436.PMC5384380.pdf
Clin Cancer Res 2012; 18:3281- 92; PMID:22553348; http://dx.doi.org/10.1158/1078-0432.CCR-12-0234 39.,Non-OADS,/arxiv_data1/oa_pdf/b6/a1/koni-06-03-1286436.PMC5384380.pdf
Oncotarget 2014; 5:4651-64;PMID:25026291; http://dx.doi.org/10.18632/oncotarget.1701 40.,OADS,/arxiv_data1/oa_pdf/b6/a1/koni-06-03-1286436.PMC5384380.pdf
J Ovarian Res 2016; 9:21; PMID:27048364; http://dx.doi.org/10.1186/s13048-016-0232-0 41.,Non-OADS,/arxiv_data1/oa_pdf/b6/a1/koni-06-03-1286436.PMC5384380.pdf
Cancer Discov 2016; 6:270-85; PMID:26715645; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/b6/a1/koni-06-03-1286436.PMC5384380.pdf
J Immunol 2000; 165:15-9; PMID:10861029; http://dx.doi.org/10.4049/jimmunol.165.1.15 43.,Non-OADS,/arxiv_data1/oa_pdf/b6/a1/koni-06-03-1286436.PMC5384380.pdf
Nat Rev Mol Cell Biol 2001; 2:793-805; PMID:11715046; http://dx.doi.org/ 10.1038/35099066 44.,OADS,/arxiv_data1/oa_pdf/b6/a1/koni-06-03-1286436.PMC5384380.pdf
FASEB J 2008; 22(6):1649-59; PMID:18180334; http://dx.doi.org/10.1096/fj.07-090571 45.,Non-OADS,/arxiv_data1/oa_pdf/b6/a1/koni-06-03-1286436.PMC5384380.pdf
J Exp Med 2002; 196:1201-11; PMID:12417630; http://dx.doi.org/10.1084/jem.20020324 46.,Non-OADS,/arxiv_data1/oa_pdf/b6/a1/koni-06-03-1286436.PMC5384380.pdf
J Immunol 2010; 184:5485-92; PMID:20400708; http://dx.doi.org/10.4049/jimmunol.0902219 48.,Non-OADS,/arxiv_data1/oa_pdf/b6/a1/koni-06-03-1286436.PMC5384380.pdf
Int J Cancer 2008; 123:609-15; PMID:18498132; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/b6/a1/koni-06-03-1286436.PMC5384380.pdf
Cancer Immunol Immunother 2008; 57:97-106;PMID:17602225; http://dx.doi.org/10.1007/s00262-007-0353-9 50.,Non-OADS,/arxiv_data1/oa_pdf/b6/a1/koni-06-03-1286436.PMC5384380.pdf
PLoS One 2012; 7:e50946; PMID:23284651; http://dx.doi.org/10.1371/journal.pone.0050946 51.,Non-OADS,/arxiv_data1/oa_pdf/b6/a1/koni-06-03-1286436.PMC5384380.pdf
Cancer Immunol Immunother 2011; 60:909-18;PMID:21644034; http://dx.doi.org/10.1007/s00262-011-1046-ye1286436-10 A. BERTHEL ET AL.,Non-OADS,/arxiv_data1/oa_pdf/b6/a1/koni-06-03-1286436.PMC5384380.pdf
"Published with license by Taylor & Francis Group, LLC © Cristina Capuano, Chiara Pighi, Rosa Molfetta, Rossella Paolini, Simone Battella, Gabriella Palmieri, Giuseppe Giannini, Francesca Belardi- nilli, Angela Santoni, and Ricciarda Galandrini.This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered , transformed, or built upon in any way.ONCOIMMUNOLOGY 2017, VOL.",Non-OADS,/arxiv_data1/oa_pdf/2f/50/koni-06-03-1290037.PMC5384385.pdf
"3, e1290037 (13 pages)http://dx.doi.org/10.1080/2162402X.2017.1290037",Non-OADS,/arxiv_data1/oa_pdf/2f/50/koni-06-03-1290037.PMC5384385.pdf
ORCID Giuseppe Giannini http://orcid.org/0000-0003-0299-4056 Francesca Belardinilli http://orcid.org/0000-0003-4966-7044 References 1.,Non-OADS,/arxiv_data1/oa_pdf/2f/50/koni-06-03-1290037.PMC5384385.pdf
Haematologica 2010; 95(1):135-43; PMID:19773256; http://dx.doi.org/10.3324/haematol.2008.001628 2.,Non-OADS,/arxiv_data1/oa_pdf/2f/50/koni-06-03-1290037.PMC5384385.pdf
CancerTreat Rev 2015; 41(9):784-92; PMID:26190254; http://dx.doi.org/10.1016/j.ctrv.2015.07.003 3.,Non-OADS,/arxiv_data1/oa_pdf/2f/50/koni-06-03-1290037.PMC5384385.pdf
LancetOncol 2016; 17(8):1081-93; PMID:27345636; http://dx.doi.org/ 10.1016/S1470-2045(16)30097-3 5.,OADS,/arxiv_data1/oa_pdf/2f/50/koni-06-03-1290037.PMC5384385.pdf
MAbs 2013; 5(1):22-33; PMID:23211638; http://dx.doi.org/10.4161/mabs.22771 6.,Non-OADS,/arxiv_data1/oa_pdf/2f/50/koni-06-03-1290037.PMC5384385.pdf
J Immunol 2011; 186(6):3762-9; PMID:21296976; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/2f/50/koni-06-03-1290037.PMC5384385.pdf
Blood 2010; 115(22):4393-402;PMID:20194898; http://dx.doi.org/10.1182/blood-2009-06-225979 8.,Non-OADS,/arxiv_data1/oa_pdf/2f/50/koni-06-03-1290037.PMC5384385.pdf
J Immunol 2014; 192(5):2252- 60; PMID:24489098; http://dx.doi.org/10.4049/jimmunol.1301249 9.,Non-OADS,/arxiv_data1/oa_pdf/2f/50/koni-06-03-1290037.PMC5384385.pdf
Blood 2013; 122(20):3482-91; PMID:24106207; http://dx.doi.org/10.1182/blood-2013-05-504043 10.,Non-OADS,/arxiv_data1/oa_pdf/2f/50/koni-06-03-1290037.PMC5384385.pdf
"Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin- dependent, lysosome-mediated cell death in B-cell malignancies.Blood 2011; 117(17):4519-29; PMID:21378274; http://dx.doi.org/10.1182/blood-2010-07-296913 11.",Non-OADS,/arxiv_data1/oa_pdf/2f/50/koni-06-03-1290037.PMC5384385.pdf
Curr Opin Oncol 2014; 26(5):484-91;PMID:25014645; http://dx.doi.org/10.1097/CCO.0000000000000107 12.,Non-OADS,/arxiv_data1/oa_pdf/2f/50/koni-06-03-1290037.PMC5384385.pdf
J Clin Invest 2013; 123(12):5098-103;PMID:24177426; http://dx.doi.org/10.1172/JCI70972 13.,Non-OADS,/arxiv_data1/oa_pdf/2f/50/koni-06-03-1290037.PMC5384385.pdf
J Exp Med 2004; 199(12):1659- 69; PMID:15210744; http://dx.doi.org/10.1084/jem.20040119 14.,Non-OADS,/arxiv_data1/oa_pdf/2f/50/koni-06-03-1290037.PMC5384385.pdf
Sci Rep 2016; 6:34382; PMID:27698437; http://dx.doi.org/10.1038/srep34382 15.,OADS,/arxiv_data1/oa_pdf/2f/50/koni-06-03-1290037.PMC5384385.pdf
Leukemia 2015; 29(4):947-57; PMID:25231744; http://dx.doi.org/10.1038/leu.2014.275 16.,Non-OADS,/arxiv_data1/oa_pdf/2f/50/koni-06-03-1290037.PMC5384385.pdf
Leukemia 2017; PMID:27890931; http://dx.doi.org/ 10.1038/leu.2016.352 17.,Non-OADS,/arxiv_data1/oa_pdf/2f/50/koni-06-03-1290037.PMC5384385.pdf
Nat Immunol 2014; 15(8):707-16; PMID:25045879; http://dx.doi.org/10.1038/ni.2939 18.,Non-OADS,/arxiv_data1/oa_pdf/2f/50/koni-06-03-1290037.PMC5384385.pdf
Blood 2002; 99(3):754-8; PMID:11806974; http://dx.doi.org/10.1182/blood.V99.3.754 19.,Non-OADS,/arxiv_data1/oa_pdf/2f/50/koni-06-03-1290037.PMC5384385.pdf
Haematologica 2012; 97(6):937-42; PMID:22271896; http://dx.doi.org/10.3324/haematol.2011.050419 20.,Non-OADS,/arxiv_data1/oa_pdf/2f/50/koni-06-03-1290037.PMC5384385.pdf
Ann NY Acad Sci 1997; 815:282-95; PMID:9186665; http://dx.doi.org/10.1111/j.1749-6632.1997.tb52070.x 21.,OADS,/arxiv_data1/oa_pdf/2f/50/koni-06-03-1290037.PMC5384385.pdf
J Immunol 2014; 192(12):5618-24;PMID:24795454; http://dx.doi.org/10.4049/jimmunol.1400288 22.,Non-OADS,/arxiv_data1/oa_pdf/2f/50/koni-06-03-1290037.PMC5384385.pdf
Mol Cancer Ther 2013; 12(10):2031-42; PMID:23873847; http://dx.doi.org/10.1158/1535-7163.MCT-12-1182 23.,Non-OADS,/arxiv_data1/oa_pdf/2f/50/koni-06-03-1290037.PMC5384385.pdf
Annu Rev Immunol 2013; 31:227-58; PMID:23516982;http://dx.doi.org/10.1146/annurev-immunol-020711-075005 25.,Non-OADS,/arxiv_data1/oa_pdf/2f/50/koni-06-03-1290037.PMC5384385.pdf
Blood 2005; 106 (7):2252-8; PMID:15933055; http://dx.doi.org/10.1182/blood-2005- 03-1154 26.,Non-OADS,/arxiv_data1/oa_pdf/2f/50/koni-06-03-1290037.PMC5384385.pdf
Nat Immunol 2004; 5 (12):1260-5; PMID:15531883; http://dx.doi.org/10.1038/ni1138 27.,Non-OADS,/arxiv_data1/oa_pdf/2f/50/koni-06-03-1290037.PMC5384385.pdf
Trends Immunol 2015; 36(1):49-58; PMID:25432489; http://dx.doi.org/10.1016/j.it.2014.11.001 28.,OADS,/arxiv_data1/oa_pdf/2f/50/koni-06-03-1290037.PMC5384385.pdf
Immunol Cell Biol 2014; 92(3):221-9;PMID:24366519; http://dx.doi.org/10.1038/icb.2013.98 30.,Non-OADS,/arxiv_data1/oa_pdf/2f/50/koni-06-03-1290037.PMC5384385.pdf
Cancer Res 2015; 75(19):4097-108; PMID:26229120; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/2f/50/koni-06-03-1290037.PMC5384385.pdf
J Clin Invest 2012; 122(10):3769-80; PMID:23006327; http://dx.doi.org/10.1172/JCI64837 33.,Non-OADS,/arxiv_data1/oa_pdf/2f/50/koni-06-03-1290037.PMC5384385.pdf
J Immunol Methods2005; 306(1 –2):128-36; PMID:16181633; http://dx.doi.org/10.1016/ j.jim.2005.08.004 34.,OADS,/arxiv_data1/oa_pdf/2f/50/koni-06-03-1290037.PMC5384385.pdf
Ann Rheum Dis 2014; 73(4):716-21; PMID:23505228; http://dx.doi.org/10.1136/annrheumdis-2012-202435 35.,Non-OADS,/arxiv_data1/oa_pdf/2f/50/koni-06-03-1290037.PMC5384385.pdf
J Immu-nol Methods 2000; 242(1 –2):127-32; PMID:10986395; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/2f/50/koni-06-03-1290037.PMC5384385.pdf
Blood 2006; 107(1):159-66; PMID:16150947; http://dx.doi.org/10.1182/blood-2005-04-1351 38.,Non-OADS,/arxiv_data1/oa_pdf/2f/50/koni-06-03-1290037.PMC5384385.pdf
Nat Immunol 2013; 14 (11):1127-36; PMID:24036998; http://dx.doi.org/10.1038/ni.2708 39.,Non-OADS,/arxiv_data1/oa_pdf/2f/50/koni-06-03-1290037.PMC5384385.pdf
Immunity 2015; 42(3):431-42;PMID:25786175; http://dx.doi.org/10.1016/j.immuni.2015.02.013 40.,Non-OADS,/arxiv_data1/oa_pdf/2f/50/koni-06-03-1290037.PMC5384385.pdf
Blood 2015; 126 (24):2646-9; PMID:26447188; http://dx.doi.org/10.1182/blood-2015-09-670802 42.,Non-OADS,/arxiv_data1/oa_pdf/2f/50/koni-06-03-1290037.PMC5384385.pdf
Oncoim-munology 2015; 4(3):e990773; PMID:25949906; http://dx.doi.org/ 10.4161/2162402X.2014.990773 43.,Non-OADS,/arxiv_data1/oa_pdf/2f/50/koni-06-03-1290037.PMC5384385.pdf
Blood 2011; 118(12):3347-9; PMID:21768303; http://dx.doi.org/10.1182/blood-2011-05-351411 44.,Non-OADS,/arxiv_data1/oa_pdf/2f/50/koni-06-03-1290037.PMC5384385.pdf
J Immunol Methods 2005; 304(1 –2):88-99; PMID:16109421; http://dx.doi.org/ 10.1016/j.jim.2005.06.018 45.,Non-OADS,/arxiv_data1/oa_pdf/2f/50/koni-06-03-1290037.PMC5384385.pdf
Blood 2013; 121(18):3599-608; PMID:23487023; http://dx.doi.org/10.1182/blood-2012-04-425397 46.,Non-OADS,/arxiv_data1/oa_pdf/2f/50/koni-06-03-1290037.PMC5384385.pdf
Sci Signal 2015; 8(400):ra108; PMID:26508790; http://dx.doi.org/10.1126/scisignal.aab2724 47.,OADS,/arxiv_data1/oa_pdf/2f/50/koni-06-03-1290037.PMC5384385.pdf
Blood 2015; 125(5):762-6; PMID:25498911; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/2f/50/koni-06-03-1290037.PMC5384385.pdf
Immunity 2015; 42(3):443-56;PMID:25786176; http://dx.doi.org/10.1016/j.immuni.2015.02.008e1290037-12 C. CAPUANO ET AL.,OADS,/arxiv_data1/oa_pdf/2f/50/koni-06-03-1290037.PMC5384385.pdf
J Immu- nol 2013; 190(4):1402-6; PMID:23345329; http://dx.doi.org/10.4049/jimmunol.1203034 50.,Non-OADS,/arxiv_data1/oa_pdf/2f/50/koni-06-03-1290037.PMC5384385.pdf
Nat Rev Immunol 2016; 16(2):112-23; PMID:26806484; http://dx.doi.org/10.1038/nri.2015.9 51.,Non-OADS,/arxiv_data1/oa_pdf/2f/50/koni-06-03-1290037.PMC5384385.pdf
Nature 1995; 376(6539):435-8; PMID:7630421; http://dx.doi.org/10.1038/376435a0 53.,Non-OADS,/arxiv_data1/oa_pdf/2f/50/koni-06-03-1290037.PMC5384385.pdf
Blood 2011; 117(11):3087-95; PMID:21245479; http://dx.doi.org/10.1182/blood-2010-06-29221954.,Non-OADS,/arxiv_data1/oa_pdf/2f/50/koni-06-03-1290037.PMC5384385.pdf
PLoS One 2007; 2(3): e326; PMID:17389917; http://dx.doi.org/10.1371/journal.pone.0000326 55.,Non-OADS,/arxiv_data1/oa_pdf/2f/50/koni-06-03-1290037.PMC5384385.pdf
Cell 2015; 161(5):1035-45; PMID:25976835; http://dx.doi.org/10.1016/j.cell.2015.04.016 56.,OADS,/arxiv_data1/oa_pdf/2f/50/koni-06-03-1290037.PMC5384385.pdf
Blood 2010; 116(6):926-34; PMID:20439625; http://dx.doi.org/10.1182/blood-2009-10-248609 57.,Non-OADS,/arxiv_data1/oa_pdf/2f/50/koni-06-03-1290037.PMC5384385.pdf
Blood 2012; 119(10):2252-62;PMID:22271450; http://dx.doi.org/10.1182/blood-2010-12-324160 58.,Non-OADS,/arxiv_data1/oa_pdf/2f/50/koni-06-03-1290037.PMC5384385.pdf
Eur JImmunol 2014; 44(9):2761-70; PMID:24846123; http://dx.doi.org/10.1002/eji.201444512ONCOIMMUNOLOGY e1290037-13,Non-OADS,/arxiv_data1/oa_pdf/2f/50/koni-06-03-1290037.PMC5384385.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered , transformed, or built upon in any way.ONCOIMMUNOLOGY 2017, VOL.",Non-OADS,/arxiv_data1/oa_pdf/e8/24/koni-06-03-1280645.PMC5384396.pdf
"3, e1280645 (14 pages)http://dx.doi.org/10.1080/2162402X.2017.1280645",Non-OADS,/arxiv_data1/oa_pdf/e8/24/koni-06-03-1280645.PMC5384396.pdf
ORCID Emilie Solier http://orcid.org/0000-0002-4275-5191 Jennifer A. Cann http://orcid.org/0000-0002-7341-0620 Lolke de Haan http://orcid.org/0000-0002-2201-293Xe1280645-12 N. J. TIGUE ET AL.,Non-OADS,/arxiv_data1/oa_pdf/e8/24/koni-06-03-1280645.PMC5384396.pdf
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.N Engl J Med 2015; 373(17):1627-39; PMID:26412456; http://dx.doi.org/10.1056/NEJMoa1507643 2.,Non-OADS,/arxiv_data1/oa_pdf/e8/24/koni-06-03-1280645.PMC5384396.pdf
N Engl J Med 2015; 373(2):123-35; PMID:26028407; http://dx.doi.org/10.1056/NEJMoa1504627 3.,Non-OADS,/arxiv_data1/oa_pdf/e8/24/koni-06-03-1280645.PMC5384396.pdf
Drugs 2011; 71(8):1093-104; PMID:21668044; http://dx.doi.org/ 10.2165/11594010-000000000-00000 4.,Non-OADS,/arxiv_data1/oa_pdf/e8/24/koni-06-03-1280645.PMC5384396.pdf
Lancet 2015; 387(10027):1540-50; PMID:26712084; http://dx.doi.org/10.1016/S0140-6736(15)01281-7 5.,OADS,/arxiv_data1/oa_pdf/e8/24/koni-06-03-1280645.PMC5384396.pdf
N EnglJ Med 2015; 373(19):1803-13; PMID:26406148; http://dx.doi.org/ 10.1056/NEJMoa1510665 6.,OADS,/arxiv_data1/oa_pdf/e8/24/koni-06-03-1280645.PMC5384396.pdf
Lancet Oncol 2015; 16(8):908-18; PMID:26115796; http://dx.doi.org/10.1016/S1470-2045(15)00083-2 7.,Non-OADS,/arxiv_data1/oa_pdf/e8/24/koni-06-03-1280645.PMC5384396.pdf
Lancet Oncol 2015; 16 (3):257-65; PMID:25704439; http://dx.doi.org/10.1016/S1470-2045 (15)70054-9 8.,Non-OADS,/arxiv_data1/oa_pdf/e8/24/koni-06-03-1280645.PMC5384396.pdf
Lancet 2016; 387(10031):1909-20; PMID:26952546; http://dx.doi.org/10.1016/S0140-6736(16)00561-4 9.,Non-OADS,/arxiv_data1/oa_pdf/e8/24/koni-06-03-1280645.PMC5384396.pdf
Lancet Oncol 2015; 16(4):375-84; PMID:25795410; http://dx.doi.org/10.1016/S1470-2045(15)70076-8 10.,Non-OADS,/arxiv_data1/oa_pdf/e8/24/koni-06-03-1280645.PMC5384396.pdf
Cytokine GrowthFactor Rev 2014; 25(2):91-106; PMID:24484736; http://dx.doi.org/ 10.1016/j.cytogfr.2013.12.003 11.,OADS,/arxiv_data1/oa_pdf/e8/24/koni-06-03-1280645.PMC5384396.pdf
Cancer Immunol Res 2013; 1(5):320-31; PMID:24416730; http://dx.doi.org/10.1158/2326-6066.CIR-13-0086 12.,Non-OADS,/arxiv_data1/oa_pdf/e8/24/koni-06-03-1280645.PMC5384396.pdf
Curr Opin Immunol 2012; 24(2):217-24; PMID:22245556; http://dx.doi.org/10.1016/j.coi.2011.12.011 13.,Non-OADS,/arxiv_data1/oa_pdf/e8/24/koni-06-03-1280645.PMC5384396.pdf
J Exp Med 2013; 210(9):1685-93;PMID:23897982; http://dx.doi.org/10.1084/jem.2013057314.,Non-OADS,/arxiv_data1/oa_pdf/e8/24/koni-06-03-1280645.PMC5384396.pdf
Methods Enzymol 2004; 384:185-212; PMID:15081688; http://dx.doi.org/10.1016/S0076-6879(04)84012-6 15.,OADS,/arxiv_data1/oa_pdf/e8/24/koni-06-03-1280645.PMC5384396.pdf
J Biol Chem 2010; 285(17):13285-93; PMID:20181944; http://dx.doi.org/10.1074/jbc.M109.086058 19.,OADS,/arxiv_data1/oa_pdf/e8/24/koni-06-03-1280645.PMC5384396.pdf
FASEB J 2006; 20(8):1142-51; PMID:16770013; http://dx.doi.org/10.1096/fj.05-5262com 20.,Non-OADS,/arxiv_data1/oa_pdf/e8/24/koni-06-03-1280645.PMC5384396.pdf
Proc Natl Acad Sci US A 2005; 102(39):13891-6; PMID:16172398; http://dx.doi.org/ 10.1073/pnas.0502390102 21.,OADS,/arxiv_data1/oa_pdf/e8/24/koni-06-03-1280645.PMC5384396.pdf
NatStruct Biol 1998; 5(8):687-91; PMID:9699631; http://dx.doi.org/ 10.1038/90444 22.,OADS,/arxiv_data1/oa_pdf/e8/24/koni-06-03-1280645.PMC5384396.pdf
J Immu- nol 2004; 173(8):5008-20; PMID:15470044; http://dx.doi.org/10.4049/jimmunol.173.8.5008 23.,Non-OADS,/arxiv_data1/oa_pdf/e8/24/koni-06-03-1280645.PMC5384396.pdf
Eur J Immunol 2013; 43(9):2421-9;PMID:23722868; http://dx.doi.org/10.1002/eji.201343451 24.,Non-OADS,/arxiv_data1/oa_pdf/e8/24/koni-06-03-1280645.PMC5384396.pdf
J Immunol 2004; 172(10):5823-7; PMID:15128759; http://dx.doi.org/10.4049/jimmunol.172.10.5823 25.,Non-OADS,/arxiv_data1/oa_pdf/e8/24/koni-06-03-1280645.PMC5384396.pdf
Nat Immunol 2002; 3(2):135-42; PMID:11812990; http://dx.doi.org/10.1038/ni759 26.,Non-OADS,/arxiv_data1/oa_pdf/e8/24/koni-06-03-1280645.PMC5384396.pdf
Cancer Immunol Res 2013; 1(5):320-31;PMID:24416730; http://dx.doi.org/10.1158/2326-6066.CIR-13-0086 27.,Non-OADS,/arxiv_data1/oa_pdf/e8/24/koni-06-03-1280645.PMC5384396.pdf
Acta Crystallogr D Biol Crystallogr 2009; 65(Pt 5):434-9;PMID:19390148; http://dx.doi.org/10.1107/S0907444909005721 28.,OADS,/arxiv_data1/oa_pdf/e8/24/koni-06-03-1280645.PMC5384396.pdf
Mol Cell Proteomics 2011; 10(5):M110.004994; PMID:21311038; http://dx.doi.org/10.1074/mcp.M110.004994 30.,Non-OADS,/arxiv_data1/oa_pdf/e8/24/koni-06-03-1280645.PMC5384396.pdf
BioDrugs 2010; 24(1):9-21; PMID:20055529; http://dx.doi.org/10.2165/11530550-000000000-00000 31.,OADS,/arxiv_data1/oa_pdf/e8/24/koni-06-03-1280645.PMC5384396.pdf
Can-cer Res 2013; 73(24):7189-98; PMID:24177180; http://dx.doi.org/ 10.1158/0008-5472.CAN-12-4174 32.,Non-OADS,/arxiv_data1/oa_pdf/e8/24/koni-06-03-1280645.PMC5384396.pdf
Hepatology 2013; 57(1):183-94; PMID:22911397; http://dx.doi.org/10.1002/hep.26013 34.,Non-OADS,/arxiv_data1/oa_pdf/e8/24/koni-06-03-1280645.PMC5384396.pdf
Clin Cancer Res 2007; 13(15 Pt 1):4345-54; PMID:17671115; http://dx.doi.org/ 10.1158/1078-0432.CCR-07-0472 35.,Non-OADS,/arxiv_data1/oa_pdf/e8/24/koni-06-03-1280645.PMC5384396.pdf
2017 Jan 9; PMID:28069723; http://dx.doi.org/10.1158/1078-0432.CCR-16-2000e1280645-14 N. J. TIGUE ET AL.,OADS,/arxiv_data1/oa_pdf/e8/24/koni-06-03-1280645.PMC5384396.pdf
Available from: http://www.cdsco.nic.in/html/D&C_Rules_Schedule_Y.,Non-OADS,/arxiv_data1/oa_pdf/45/b7/PCR-8-63.PMC5384401.pdf
Available from: https://www.bps.ac.uk/news-events/news/society-news/ articles/improve‑early‑access‑to‑data‑from‑catastrophic‑cli.,Non-OADS,/arxiv_data1/oa_pdf/45/b7/PCR-8-63.PMC5384401.pdf
Available from: http://www.ncbi.nlm.,Non-OADS,/arxiv_data1/oa_pdf/45/b7/PCR-8-63.PMC5384401.pdf
Available from: https://www.socra.org/publications/past-socra- source‑articles/eres‑compliance‑and‑data‑integrity‑issues‑in‑e‑trials/.,OADS,/arxiv_data1/oa_pdf/45/b7/PCR-8-63.PMC5384401.pdf
Available from: http://www.phrma.org/sites/default/ files/pdf/042009_clinical_trial_principles_final_0.pdf.,Non-OADS,/arxiv_data1/oa_pdf/45/b7/PCR-8-63.PMC5384401.pdf
Available from: https://www.grants.nih.gov/grants/policy/data_sharing/ data_sharing_guidance.htm.,Non-OADS,/arxiv_data1/oa_pdf/45/b7/PCR-8-63.PMC5384401.pdf
Available from: https://www.oecd.org/sti/sci- tech/38500813.,Non-OADS,/arxiv_data1/oa_pdf/45/b7/PCR-8-63.PMC5384401.pdf
Available from: https://www.wellcome.ac.uk/sites/default/files/wtp053977.,Non-OADS,/arxiv_data1/oa_pdf/45/b7/PCR-8-63.PMC5384401.pdf
Available from:  http://www.humandbs.biosciencedbc.jp/en/guidelines/data-sharing- guidelines.,OADS,/arxiv_data1/oa_pdf/45/b7/PCR-8-63.PMC5384401.pdf
Available from: http://www.naco.gov.in/upload/2015%20MSLNS/ Data%20Sharing%20Guidelines_%2013%20July%202015.pdf.,OADS,/arxiv_data1/oa_pdf/45/b7/PCR-8-63.PMC5384401.pdf
Available  from: http://www.ogpl.gov.in/NDSAP/NDSAP‑30Jan2012.pdf.,Non-OADS,/arxiv_data1/oa_pdf/45/b7/PCR-8-63.PMC5384401.pdf
Available from: http://www.icmr.,Non-OADS,/arxiv_data1/oa_pdf/45/b7/PCR-8-63.PMC5384401.pdf
Available from: http://www.apps.who.int/medicinedocs/en/d/Jh2934e/3.,Non-OADS,/arxiv_data1/oa_pdf/49/67/PCR-8-68.PMC5384402.pdf
Available from: http://www.cdsco.nic.in/writereaddata/System%20of%20 Pre-screening%20for%20submission%20of%20reports%20of%20 SAEs%20to%20CDSCO.pdf.,Non-OADS,/arxiv_data1/oa_pdf/49/67/PCR-8-68.PMC5384402.pdf
Available from:  http://www.future‑science.com/doi/pdf/10.4155/cli.13.33.,Non-OADS,/arxiv_data1/oa_pdf/49/67/PCR-8-68.PMC5384402.pdf
Available from: http://www.fda.gov/ Safety/MedWatch/.,Non-OADS,/arxiv_data1/oa_pdf/49/67/PCR-8-68.PMC5384402.pdf
Available  from: http://www.cdsco.nic.in/writereaddata/Drugs&CosmeticAct.pdf.,Non-OADS,/arxiv_data1/oa_pdf/49/67/PCR-8-68.PMC5384402.pdf
Available from: http://www.cdsco.nic.in/writereaddata/GSR%2053(E).,Non-OADS,/arxiv_data1/oa_pdf/49/67/PCR-8-68.PMC5384402.pdf
Available from: http://www.cdsco.nic.in/writereaddata/Notificatiohn%20 on%20Compensation%20on%20clincial%20trial%20(1).pdf.,Non-OADS,/arxiv_data1/oa_pdf/49/67/PCR-8-68.PMC5384402.pdf
Available from:  http://www.ich.org/products/guidelines/efficacy/article/efficacy‑guidelines.,Non-OADS,/arxiv_data1/oa_pdf/49/67/PCR-8-68.PMC5384402.pdf
Available from: http://www.accessdata.fda.gov/scripts/ cder/rems/.,OADS,/arxiv_data1/oa_pdf/49/67/PCR-8-68.PMC5384402.pdf
Available  from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/ document_listing/document_listing_000360.jsp.,OADS,/arxiv_data1/oa_pdf/49/67/PCR-8-68.PMC5384402.pdf
Available from: http://www.medicalpracticeinsider.com/ best‑practices/healthcare‑social‑media‑whats‑it‑patients.,Non-OADS,/arxiv_data1/oa_pdf/44/7a/PCR-8-73.PMC5384403.pdf
Available from: http://www.statista.com/ statistics/346167/facebook‑global‑dau/.,Non-OADS,/arxiv_data1/oa_pdf/44/7a/PCR-8-73.PMC5384403.pdf
Available from: http://www.adweek.com/socialtimes/files/2012/12/ social‑media‑healthcare.png?red=at.,Non-OADS,/arxiv_data1/oa_pdf/44/7a/PCR-8-73.PMC5384403.pdf
Available from: http://www.mashable.com/social‑media/?utm_ cid=mash‑prod‑nav‑ch.,Non-OADS,/arxiv_data1/oa_pdf/44/7a/PCR-8-73.PMC5384403.pdf
Available from: http://www.clinicalleader.com/doc/social-media -the- new‑clinical‑research‑and‑marketing‑tool‑0001.,Non-OADS,/arxiv_data1/oa_pdf/44/7a/PCR-8-73.PMC5384403.pdf
Available from: http://www.fda.gov/AboutFDA/CentersOffices/ OfficeofMedicalProductsandTobacco/CDER/ucm397791.htm.,Non-OADS,/arxiv_data1/oa_pdf/44/7a/PCR-8-73.PMC5384403.pdf
Available from: http://www.csdd.tufts.edu/files/uploads/TCSDD_Social_ Media_Final.pdf.,Non-OADS,/arxiv_data1/oa_pdf/44/7a/PCR-8-73.PMC5384403.pdf
Available from: http://www.fiercepharmamarketing.,Non-OADS,/arxiv_data1/oa_pdf/44/7a/PCR-8-73.PMC5384403.pdf
Available from: http://www.wpp.com/wpp/press/2015/apr/21/ pharmas‑corporate‑participation‑in‑social‑media‑is‑rapidly‑evolving/.,Non-OADS,/arxiv_data1/oa_pdf/44/7a/PCR-8-73.PMC5384403.pdf
Available  from: http://www.hcltech.com/white-papers/life-sciences-and-healthcare/ way‑patient‑centricity‑through‑mobility‑and‑social‑media.,Non-OADS,/arxiv_data1/oa_pdf/44/7a/PCR-8-73.PMC5384403.pdf
Available from: http://www.mobihealthnews.,Non-OADS,/arxiv_data1/oa_pdf/44/7a/PCR-8-73.PMC5384403.pdf
Available from: http://www.searchcloudcomputing.,Non-OADS,/arxiv_data1/oa_pdf/44/7a/PCR-8-73.PMC5384403.pdf
How Big Data Can Revolutionize Pharmaceutical R and D. Available  from: http://www.mckinsey.com/insights/health_systems_and_services/ how_big_data_can_revolutionize_pharmaceutical_r_and_d.,OADS,/arxiv_data1/oa_pdf/44/7a/PCR-8-73.PMC5384403.pdf
Available from: http://www.bizjournals.com/philadelphia/blog/ guest ‑comment/2013/08/the ‑hidden‑ impact ‑of‑social‑ media.html.,Non-OADS,/arxiv_data1/oa_pdf/44/7a/PCR-8-73.PMC5384403.pdf
Available online at http:// www.tjpr.org http://dx.doi.org/10.4314/tjpr.v13i3.19 [Last accessed on 2015  Oct 15].,Non-OADS,/arxiv_data1/oa_pdf/46/bb/PCR-8-79.PMC5384404.pdf
Available from:  http://www.icmr.nic.in.,Non-OADS,/arxiv_data1/oa_pdf/63/2d/PCR-8-85.PMC5384405.pdf
Available from: http://www.nccr.gov.,Non-OADS,/arxiv_data1/oa_pdf/63/2d/PCR-8-85.PMC5384405.pdf
Available from: http://www.hindawi.,Non-OADS,/arxiv_data1/oa_pdf/8f/fb/PCR-8-95.PMC5384407.pdf
Available from: http://www.clinicaltrials.gov.,Non-OADS,/arxiv_data1/oa_pdf/8f/fb/PCR-8-95.PMC5384407.pdf
Available from: http://www.megabyte.utm.ro/articole/2010/info/sem1/ InfoStraini_Pdf/2_EVIDENCE%20BASED%20DENTISTRY.pdf.,OADS,/arxiv_data1/oa_pdf/8f/fb/PCR-8-95.PMC5384407.pdf
"3, e1283460 (14 pages)http://dx.doi.org/10.1080/2162402X.2017.1283460",Non-OADS,/arxiv_data1/oa_pdf/21/5e/koni-06-03-1283460.PMC5384408.pdf
Lancet 2015; 385(9967):517-28; PMID:25319501; http://dx.doi.org/10.1016/S0140-6736(14)61403-3 3.,Non-OADS,/arxiv_data1/oa_pdf/21/5e/koni-06-03-1283460.PMC5384408.pdf
N Engl JMed 2014; 371(16):1507-17; PMID:25317870; http://dx.doi.org/ 10.1056/NEJMoa1407222 4.,OADS,/arxiv_data1/oa_pdf/21/5e/koni-06-03-1283460.PMC5384408.pdf
Immunol Rev 2014; 257 (1):83-90; PMID:24329791; http://dx.doi.org/10.1111/imr.12125 5.,Non-OADS,/arxiv_data1/oa_pdf/21/5e/koni-06-03-1283460.PMC5384408.pdf
Nat Med 2015; 21(8):914-21; PMID:26193344; http://dx.doi.org/10.1038/nm.3910 7.,Non-OADS,/arxiv_data1/oa_pdf/21/5e/koni-06-03-1283460.PMC5384408.pdf
Cancer Res 2007; 67 (8):3898-903; PMID:17440104; http://dx.doi.org/10.1158/0008-5472.CAN-06-3986 9.,Non-OADS,/arxiv_data1/oa_pdf/21/5e/koni-06-03-1283460.PMC5384408.pdf
Cancer Res 2006; 66(17):8878-86; PMID:16951205;http://dx.doi.org/10.1158/0008-5472.CAN-06-1450 10.,Non-OADS,/arxiv_data1/oa_pdf/21/5e/koni-06-03-1283460.PMC5384408.pdf
Blood 2007; 109(6):2331-8; PMID:17082316; http://dx.doi.org/10.1182/blood-2006-05-023069 13.,Non-OADS,/arxiv_data1/oa_pdf/21/5e/koni-06-03-1283460.PMC5384408.pdf
"Nat Med 2010; 16(5):565-70, 1p following 70; PMID:20400962; http://dx.doi.org/10.1038/nm.2128 14.",Non-OADS,/arxiv_data1/oa_pdf/21/5e/koni-06-03-1283460.PMC5384408.pdf
J Immunol 2015; 194(3):1080-9; PMID:25539815; http://dx.doi.org/10.4049/ jimmunol.1401703 15.,Non-OADS,/arxiv_data1/oa_pdf/21/5e/koni-06-03-1283460.PMC5384408.pdf
Nat Med 2012; 18(5):807-15; PMID:22466705; http://dx.doi.org/10.1038/nm.2700 16.,OADS,/arxiv_data1/oa_pdf/21/5e/koni-06-03-1283460.PMC5384408.pdf
J Immunol 2008; 180(11):7736-46; PMID:18490778; http://dx.doi.org/10.4049/ jimmunol.180.11.7736 17.,Non-OADS,/arxiv_data1/oa_pdf/21/5e/koni-06-03-1283460.PMC5384408.pdf
J Immunol 2014; 193(10):5315-26; PMID: 25320284; http://dx.doi.org/10.4049/jimmunol.1302074 18.,Non-OADS,/arxiv_data1/oa_pdf/21/5e/koni-06-03-1283460.PMC5384408.pdf
J Immunother 2013; 36(2):133-51; PMID:23377668; http://dx.doi.org/10.1097/CJI.0b013e3182829903 19.,Non-OADS,/arxiv_data1/oa_pdf/21/5e/koni-06-03-1283460.PMC5384408.pdf
Blood 2013; 122(6):863-71;PMID:23770775; http://dx.doi.or g/10.1182/blood-2013-03-490565 20.,Non-OADS,/arxiv_data1/oa_pdf/21/5e/koni-06-03-1283460.PMC5384408.pdf
Hematol: Am Soc Hematol Educ Prog 2014; 2014 (1):559-64; http://dx.doi.org/10.1182/asheducation-2014.1.559 22.,Non-OADS,/arxiv_data1/oa_pdf/21/5e/koni-06-03-1283460.PMC5384408.pdf
Biochem Soc Trans 2016; 44 (3):951-9; PMID:27284065; http://dx.doi.org/10.1042/BST20160037 23.,OADS,/arxiv_data1/oa_pdf/21/5e/koni-06-03-1283460.PMC5384408.pdf
Blood 2013; 122(17):2965-73; PMID:24030379; http://dx.doi.org/10.1182/blood-2013-06-506741 24.,Non-OADS,/arxiv_data1/oa_pdf/21/5e/koni-06-03-1283460.PMC5384408.pdf
Blood 2013; 122(25):4129-39; PMID:24055823; http://dx.doi.org/10.1182/blood-2013-08-519413 25.,Non-OADS,/arxiv_data1/oa_pdf/21/5e/koni-06-03-1283460.PMC5384408.pdf
J Clin Oncol 2016; 34(10):1112-21; PMID:26811520; http://dx.doi.org/10.1200/JCO.2015.64.5929 26.,Non-OADS,/arxiv_data1/oa_pdf/21/5e/koni-06-03-1283460.PMC5384408.pdf
Leukemia 2014; 28(4):830-41; PMID:24091848; http://dx.doi.org/10.1038/leu.2013.285 28.,Non-OADS,/arxiv_data1/oa_pdf/21/5e/koni-06-03-1283460.PMC5384408.pdf
J Immunol 2009; 183(8):4859-70; PMID:19801512; http://dx.doi.org/ 10.4049/jimmunol.0900714 29.,Non-OADS,/arxiv_data1/oa_pdf/21/5e/koni-06-03-1283460.PMC5384408.pdf
Blood 2007; 110(7):2696-703; PMID:17630354; http://dx.doi.org/10.1182/blood-2007-03-082206 30.,Non-OADS,/arxiv_data1/oa_pdf/21/5e/koni-06-03-1283460.PMC5384408.pdf
Nature 1988; 335(6192):730-3; PMID:3262831; http://dx.doi.org/ 10.1038/335730a0 31.,Non-OADS,/arxiv_data1/oa_pdf/21/5e/koni-06-03-1283460.PMC5384408.pdf
Mol Ther 2013; 21(5):1055-63; PMID:23481324; http://dx.doi.org/10.1038/mt.2013.28 32.,Non-OADS,/arxiv_data1/oa_pdf/21/5e/koni-06-03-1283460.PMC5384408.pdf
Cell Stem Cell 2013; 12(1):114-26;PMID:23290140; http://dx.doi.org/10.1016/j.stem.2012.11.002 34.,OADS,/arxiv_data1/oa_pdf/21/5e/koni-06-03-1283460.PMC5384408.pdf
Cell Stem Cell 2013; 12(1):31-6; PMID:23290135; http://dx.doi.org/ 10.1016/j.stem.2012.12.006 35.,OADS,/arxiv_data1/oa_pdf/21/5e/koni-06-03-1283460.PMC5384408.pdf
Nat Biotechnol 2013; 31(10):928-33; PMID:23934177; http://dx.doi.org/10.1038/nbt.2678 36.,OADS,/arxiv_data1/oa_pdf/21/5e/koni-06-03-1283460.PMC5384408.pdf
Nat Biotechnol 2008; 26(4):453-61; PMID:18376399; http://dx.doi.org/10.1038/nbt1395 37.,Non-OADS,/arxiv_data1/oa_pdf/21/5e/koni-06-03-1283460.PMC5384408.pdf
Mol Ther 2015; 23(8):1358-67; PMID:26050990; http://dx.doi.org/10.1038/mt.2015.102 38.,Non-OADS,/arxiv_data1/oa_pdf/21/5e/koni-06-03-1283460.PMC5384408.pdf
Cell Stem Cell 2013; 12(1):6-8; PMID:23290132; http://dx.doi.org/10.1016/j.stem.2012.12.009 39.,OADS,/arxiv_data1/oa_pdf/21/5e/koni-06-03-1283460.PMC5384408.pdf
Biol Blood Marrow Transplant 2013; 19(5):725-34; PMID:23380344; http://dx.doi.org/10.1016/j.bbmt.2013.01.021 40.,Non-OADS,/arxiv_data1/oa_pdf/21/5e/koni-06-03-1283460.PMC5384408.pdf
J Immunol 2001; 167(11):6123-31;PMID:11714771; http://dx.doi.org /10.4049/jimmunol.167.11.6123 41.,Non-OADS,/arxiv_data1/oa_pdf/21/5e/koni-06-03-1283460.PMC5384408.pdf
J Immunol 2003; 170(4):2186-94; PMID:12574392;http://dx.doi.org/10.4049/jimmunol.170.4.2186 42.,Non-OADS,/arxiv_data1/oa_pdf/21/5e/koni-06-03-1283460.PMC5384408.pdf
Gene Ther- apy 2000; 7(16):1369-77; PMID:10981663; http://dx.doi.org/10.1038/ sj.gt.3301253 43.,OADS,/arxiv_data1/oa_pdf/21/5e/koni-06-03-1283460.PMC5384408.pdf
Blood Cells Mol Dis 2004; 33(3):227-32; PMID:15528136; http://dx.doi.org/10.1016/j.bcmd.2004.08.007 44.,OADS,/arxiv_data1/oa_pdf/21/5e/koni-06-03-1283460.PMC5384408.pdf
J Clin Invest 2014; 124(5):2246-59; PMID:24667641; http://dx.doi.org/10.1172/JCI73639 45.,Non-OADS,/arxiv_data1/oa_pdf/21/5e/koni-06-03-1283460.PMC5384408.pdf
Nat Methods 2015; 12(5):380-1; PMID:25924071; http://dx.doi.org/10.1038/nmeth.3364 46.,OADS,/arxiv_data1/oa_pdf/21/5e/koni-06-03-1283460.PMC5384408.pdf
PLoS Comput Biol 2015; 11(11):e1004503; PMID:26606115; http://dx.doi.org/10.1371/journal.pcbi.1004503e1283460-14 Y.,OADS,/arxiv_data1/oa_pdf/21/5e/koni-06-03-1283460.PMC5384408.pdf
"miR-450b which affects cellular proliferation and metabolic processes through RNF20 and SECB was predominanlty upregulated and correlated with poor outcome (ROC 0.958, p = 0.001).Received: 12 December 2016 Revised: 7 March 2017 Accepted: 28 March 2017 Heliyon 3 (2017) e00287 http://dx.doi.org/10.1016/j.heliyon.2017.e00287 2405-8440/© 2017 The Authors.",Non-OADS,/arxiv_data1/oa_pdf/d1/7e/main.PMC5384411.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/d1/7e/main.PMC5384411.pdf
After the initial Article No~e00287 2 http://dx.doi.org/10.1016/j.heliyon.2017.e00287 2405-8440/© 2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/d1/7e/main.PMC5384411.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/d1/7e/main.PMC5384411.pdf
Article No~e00287 3 http://dx.doi.org/10.1016/j.heliyon.2017.e00287 2405-8440/© 2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/d1/7e/main.PMC5384411.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/d1/7e/main.PMC5384411.pdf
Article No~e00287 4 http://dx.doi.org/10.1016/j.heliyon.2017.e00287 2405-8440/© 2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/d1/7e/main.PMC5384411.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/d1/7e/main.PMC5384411.pdf
Segmental analysis was done to understand miR mediated Article No~e00287 5 http://dx.doi.org/10.1016/j.heliyon.2017.e00287 2405-8440/© 2017 The Authors.,OADS,/arxiv_data1/oa_pdf/d1/7e/main.PMC5384411.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/d1/7e/main.PMC5384411.pdf
Gene Primer Sequence BIRC3 5 ′-GTTTCTGTGGCTTGCCTTCA-3 ′ 3′-TTTCCTCCCCTCACTTGGTC-5 ′ GDPD1 5 ′-AGAAGCAGCGATTCCTCAGT-3 ′ 3′-CAAGGTAAGGTGGGAGCTCA-5 ′ MAPK1 5 ′-CTAACGTTCTGCACCGTGAC-3 ′ 3′-AGAATGCAGCCTACAGACCA-5 ′ NFIB 5 ′-CCACCAAGCAGCAAAAGAC-3 ′ 3′-TGGAGATGCAGAGCTGAACA-5 ′ PDCD4 5 ′-TGGATTAACTGTGCCAACCA-3 ′ 3′-TCTCAAATGCCCTTTCATCC-5 ′ RNF20 5 ′-GAGCTCTTATCCCGGAAGCT-3 ′ 3′-TCCCACTGCAGGTCATCAAT-5 ′ Sptlc1 5 ′-AGTGGGTTCTGGTGGAGATG-3 ′ 3′-CAAGAGGTTCTGGTTGCCAC-5 ′ TNFSF15 5 ′-GCTGAGAAGGAATGCGACAG-3 ′ 3′-AAGCACATGGGGTTTGTCAC-5 ′ Article No~e00287 6 http://dx.doi.org/10.1016/j.heliyon.2017.e00287 2405-8440/© 2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/d1/7e/main.PMC5384411.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/d1/7e/main.PMC5384411.pdf
Article No~e00287 7 http://dx.doi.org/10.1016/j.heliyon.2017.e00287 2405-8440/© 2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/d1/7e/main.PMC5384411.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/d1/7e/main.PMC5384411.pdf
Parameters Median (Range) ALF-E(P) (N = 12) AVH-E(P) (N = 44) AVH-E(NP) (N = 10) HC(P) (N = 20) P Value Median Age (years; range) 25 24 25 24 NS (21–31) (18 –31) (20 –36) (19 –30) Median ALT (IU/L; range) 132 117 99 28*P<0.001 (115 –772) (55 –999) (58 –233) (20 –32) Median AST (IU/L; range) 147 134 112 24.5*P<0.001 (125 –1583) (60 –2639) (52 –1538) (20 –28) Median Bilirubin (mg/dl; range) 7.5 7 10 0.3*P<0.001 (3.9 –22) (2 –20) (2 –32) (0.1 –0.7) Median INR (range)3 1.2% 1.3% 1**a n d%P <0.001 (2.5 –4) (1.1 –1.3) (0.9 –1.4) (0.9 –1.3) Mortality 5/12 –– – – Median HEV RNA (Copies/mL) High Viral Load = 2.64 x 105(2.33 x 105–1.6 x 106) – 20% 16% –– Low Viral Load = 3.2 x 103(3.25 x 103–2.65 x 104) 82% 80% 34% Undetectable (less than 100 copies/ml) 18% 50% Serum Albumin (g/dl) 3.05 –– – – (2.8 –3.35) Arterial Ammonia ( μgm/dl) 155 –– – – (149 –724) Grade of Encephalopathy –– – – I–II 7(60%) III–IV 4(40%) Hemoglobin (g/dl) 11 –– – – (8.8 –11.5) Platelets (10 ∼9/l) 170 –– – – (94–330) Article No~e00287 8 http://dx.doi.org/10.1016/j.heliyon.2017.e00287 2405-8440/© 2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/d1/7e/main.PMC5384411.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/d1/7e/main.PMC5384411.pdf
Article No~e00287 9 http://dx.doi.org/10.1016/j.heliyon.2017.e00287 2405-8440/© 2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/d1/7e/main.PMC5384411.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/d1/7e/main.PMC5384411.pdf
Article No~e00287 10 http://dx.doi.org/10.1016/j.heliyon.2017.e00287 2405-8440/© 2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/d1/7e/main.PMC5384411.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/d1/7e/main.PMC5384411.pdf
Article No~e00287 11 http://dx.doi.org/10.1016/j.heliyon.2017.e00287 2405-8440/© 2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/d1/7e/main.PMC5384411.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/d1/7e/main.PMC5384411.pdf
"Genes related to miRs expressed in patients with self limiting HEV infection were associated mainly with T cells, B cells and plasmacytoid DCs and interferon Article No~e00287 12 http://dx.doi.org/10.1016/j.heliyon.2017.e00287 2405-8440/© 2017 The Authors.",Non-OADS,/arxiv_data1/oa_pdf/d1/7e/main.PMC5384411.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/d1/7e/main.PMC5384411.pdf
Article No~e00287 13 http://dx.doi.org/10.1016/j.heliyon.2017.e00287 2405-8440/© 2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/d1/7e/main.PMC5384411.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/d1/7e/main.PMC5384411.pdf
Article No~e00287 14 http://dx.doi.org/10.1016/j.heliyon.2017.e00287 2405-8440/© 2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/d1/7e/main.PMC5384411.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/d1/7e/main.PMC5384411.pdf
Article No~e00287 15 http://dx.doi.org/10.1016/j.heliyon.2017.e00287 2405-8440/© 2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/d1/7e/main.PMC5384411.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/d1/7e/main.PMC5384411.pdf
Article No~e00287 16 http://dx.doi.org/10.1016/j.heliyon.2017.e00287 2405-8440/© 2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/d1/7e/main.PMC5384411.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/d1/7e/main.PMC5384411.pdf
"Previously, also we have Article No~e00287 17 http://dx.doi.org/10.1016/j.heliyon.2017.e00287 2405-8440/© 2017 The Authors.",Non-OADS,/arxiv_data1/oa_pdf/d1/7e/main.PMC5384411.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/d1/7e/main.PMC5384411.pdf
Article No~e00287 18 http://dx.doi.org/10.1016/j.heliyon.2017.e00287 2405-8440/© 2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/d1/7e/main.PMC5384411.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/d1/7e/main.PMC5384411.pdf
Article No~e00287 19 http://dx.doi.org/10.1016/j.heliyon.2017.e00287 2405-8440/© 2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/d1/7e/main.PMC5384411.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/d1/7e/main.PMC5384411.pdf
Article No~e00287 20 http://dx.doi.org/10.1016/j.heliyon.2017.e00287 2405-8440/© 2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/d1/7e/main.PMC5384411.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/d1/7e/main.PMC5384411.pdf
Article No~e00287 21 http://dx.doi.org/10.1016/j.heliyon.2017.e00287 2405-8440/© 2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/d1/7e/main.PMC5384411.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/d1/7e/main.PMC5384411.pdf
"Ward, S. Uhlmann, et al., MicroRNA-200c represses migration and invasion of breast Article No~e00287 22 http://dx.doi.org/10.1016/j.heliyon.2017.e00287 2405-8440/© 2017 The Authors.",Non-OADS,/arxiv_data1/oa_pdf/d1/7e/main.PMC5384411.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/d1/7e/main.PMC5384411.pdf
Article No~e00287 23 http://dx.doi.org/10.1016/j.heliyon.2017.e00287 2405-8440/© 2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/d1/7e/main.PMC5384411.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/d1/7e/main.PMC5384411.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/df/11/main.PMC5384413.pdf
Contents lists available at ScienceDirect Respiratory Medicine Case Reports journal homepage: www.elsevier.c om/locate/rmcr http://dx.doi.org/10.1016/j.rmcr.2017.04.001 2213-0071/ ©2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/df/11/main.PMC5384413.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Respiratory Medicine Case Reports 21 (2017) 74 e77,Non-OADS,/arxiv_data1/oa_pdf/df/11/main.PMC5384413.pdf
"Hence, a higher level body like the Ministry of Forestry or Department of NationalReceived: 30 October 2016 Revised: 2 February 2017 Accepted: 29 March 2017 Heliyon 3 (2017) e00289 http://dx.doi.org/10.1016/j.heliyon.2017.e00289 2405-8440/© 2017 The Authors.",Non-OADS,/arxiv_data1/oa_pdf/6f/d9/main.PMC5384414.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/6f/d9/main.PMC5384414.pdf
The plant species studied to examine the Article No~e00289 2 http://dx.doi.org/10.1016/j.heliyon.2017.e00289 2405-8440/© 2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/6f/d9/main.PMC5384414.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/6f/d9/main.PMC5384414.pdf
There are 1750 households in the VDC and Article No~e00289 3 http://dx.doi.org/10.1016/j.heliyon.2017.e00289 2405-8440/© 2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/6f/d9/main.PMC5384414.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/6f/d9/main.PMC5384414.pdf
Attribute Area (km2) Forest 3.10 Agriculture 12.98 Grassland 3.66 Water bodies 0.94 Others 0.54 Article No~e00289 4 http://dx.doi.org/10.1016/j.heliyon.2017.e00289 2405-8440/© 2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/6f/d9/main.PMC5384414.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/6f/d9/main.PMC5384414.pdf
Respondents Gender N% Male 86 52.9 Female 79 47.1 EducationPrimary 49 29.70 Lower secondary 23 13.94 Secondary 11 6.67Higher secondary 19 11.52 Undergraduate 8 4.85 Uneducated 55 33.33 Income sourceAgriculture 131 79.39 Business 24 14.54 Others 10 9.06 Article No~e00289 5 http://dx.doi.org/10.1016/j.heliyon.2017.e00289 2405-8440/© 2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/6f/d9/main.PMC5384414.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/6f/d9/main.PMC5384414.pdf
"Respondents a) Date of arrival of Mikania N% After floods in 1992 93 54.7 Few years before 39 22.9 No idea 33 19.4 b) Effect of Mikania on daily life Negative 88 53.3 Can’t say 47 28.5 Nothing 30 18.2 c) Effects of Mikania on forest resources Negative on forest but positive on livelihood 2 1.21 Increased fuel wood and decreased fodder 24 14.5Decreased fuel wood and fodder 87 52.7 Decreased grass, fodder, fuel wood 5 3.03 No change 47 28.5 Article No~e00289 6 http://dx.doi.org/10.1016/j.heliyon.2017.e00289 2405-8440/© 2017 The Authors.",Non-OADS,/arxiv_data1/oa_pdf/6f/d9/main.PMC5384414.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/6f/d9/main.PMC5384414.pdf
Article No~e00289 7 http://dx.doi.org/10.1016/j.heliyon.2017.e00289 2405-8440/© 2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/6f/d9/main.PMC5384414.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/6f/d9/main.PMC5384414.pdf
Article No~e00289 8 http://dx.doi.org/10.1016/j.heliyon.2017.e00289 2405-8440/© 2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/6f/d9/main.PMC5384414.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/6f/d9/main.PMC5384414.pdf
Article No~e00289 9 http://dx.doi.org/10.1016/j.heliyon.2017.e00289 2405-8440/© 2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/6f/d9/main.PMC5384414.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/6f/d9/main.PMC5384414.pdf
Article No~e00289 10 http://dx.doi.org/10.1016/j.heliyon.2017.e00289 2405-8440/© 2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/6f/d9/main.PMC5384414.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/6f/d9/main.PMC5384414.pdf
It has been observed that manual cleaning is a never ending Article No~e00289 11 http://dx.doi.org/10.1016/j.heliyon.2017.e00289 2405-8440/© 2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/6f/d9/main.PMC5384414.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/6f/d9/main.PMC5384414.pdf
Article No~e00289 12 http://dx.doi.org/10.1016/j.heliyon.2017.e00289 2405-8440/© 2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/6f/d9/main.PMC5384414.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/6f/d9/main.PMC5384414.pdf
(accessed 20.10.11) http://www.gisp.org/ .,Non-OADS,/arxiv_data1/oa_pdf/6f/d9/main.PMC5384414.pdf
Article No~e00289 13 http://dx.doi.org/10.1016/j.heliyon.2017.e00289 2405-8440/© 2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/6f/d9/main.PMC5384414.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/6f/d9/main.PMC5384414.pdf
Article No~e00289 14 http://dx.doi.org/10.1016/j.heliyon.2017.e00289 2405-8440/© 2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/6f/d9/main.PMC5384414.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/6f/d9/main.PMC5384414.pdf
"Abstract Alzheimer ’s disease (AD), a progressive neurodegenerative disorder, is linked to oxidative stress, altered amyloid precursor protein (APP) proteolysis, tau hyperphosphorylation and the accumulation of amyloid- β(Aβ) plaques andReceived: 11 October 2016 Revised: 27 February 2017 Accepted: 23 March 2017 Heliyon 3 (2017) e00279 http://dx.doi.org/10.1016/j.heliyon.2017.e00279 2405-8440/© 2017 The Authors.",Non-OADS,/arxiv_data1/oa_pdf/a5/05/main.PMC5384415.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/a5/05/main.PMC5384415.pdf
"Our laboratory has screened 25 natural compounds for their ability to restore mitochondrial function in neuroblastoma cells expressing Swedish mutant APP and identified two compounds, epigallocatechin 3-gallate (EGCG) and luteolin, as top mitochondrial restorative compounds [10].A sa n in vivo confirmation, EGCG restored mitochondrial respiratory rates, mitochondrial membrane potential, ROS Article No~e00279 2 http://dx.doi.org/10.1016/j.heliyon.2017.e00279 2405-8440/© 2017 The Authors.",Non-OADS,/arxiv_data1/oa_pdf/a5/05/main.PMC5384415.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/a5/05/main.PMC5384415.pdf
"To enrich food with Nutra II, the contents of 1 capsule of NutraStem Cardio (NutraTherapeutics, Tampa, FL), containing 450 mg proprietary Article No~e00279 3 http://dx.doi.org/10.1016/j.heliyon.2017.e00279 2405-8440/© 2017 The Authors.",Non-OADS,/arxiv_data1/oa_pdf/a5/05/main.PMC5384415.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/a5/05/main.PMC5384415.pdf
Article No~e00279 4 http://dx.doi.org/10.1016/j.heliyon.2017.e00279 2405-8440/© 2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/a5/05/main.PMC5384415.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/a5/05/main.PMC5384415.pdf
The environment surrounding thepool was decorated with eye-catching visual cues to aid the mice in orientating Article No~e00279 5 http://dx.doi.org/10.1016/j.heliyon.2017.e00279 2405-8440/© 2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/a5/05/main.PMC5384415.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/a5/05/main.PMC5384415.pdf
"Briefly, brain regions of interest were quickly removed on ice and then placed in an ice cold glass Dounce homogenizer containing five volumes of isolation buffer(215 mM mannitol, 75 mM sucrose, 0.1% BSA, 1 mM EGTA, 20 mM HEPES (Na Article No~e00279 6 http://dx.doi.org/10.1016/j.heliyon.2017.e00279 2405-8440/© 2017 The Authors.",Non-OADS,/arxiv_data1/oa_pdf/a5/05/main.PMC5384415.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/a5/05/main.PMC5384415.pdf
The assaybuffer contained mitochondrial isolation buffer with the addition of 5 mM pyruvate Article No~e00279 7 http://dx.doi.org/10.1016/j.heliyon.2017.e00279 2405-8440/© 2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/a5/05/main.PMC5384415.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/a5/05/main.PMC5384415.pdf
Article No~e00279 8 http://dx.doi.org/10.1016/j.heliyon.2017.e00279 2405-8440/© 2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/a5/05/main.PMC5384415.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/a5/05/main.PMC5384415.pdf
Article No~e00279 9 http://dx.doi.org/10.1016/j.heliyon.2017.e00279 2405-8440/© 2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/a5/05/main.PMC5384415.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/a5/05/main.PMC5384415.pdf
Article No~e00279 10 http://dx.doi.org/10.1016/j.heliyon.2017.e00279 2405-8440/© 2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/a5/05/main.PMC5384415.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/a5/05/main.PMC5384415.pdf
Article No~e00279 11 http://dx.doi.org/10.1016/j.heliyon.2017.e00279 2405-8440/© 2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/a5/05/main.PMC5384415.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/a5/05/main.PMC5384415.pdf
Article No~e00279 12 http://dx.doi.org/10.1016/j.heliyon.2017.e00279 2405-8440/© 2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/a5/05/main.PMC5384415.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/a5/05/main.PMC5384415.pdf
Article No~e00279 13 http://dx.doi.org/10.1016/j.heliyon.2017.e00279 2405-8440/© 2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/a5/05/main.PMC5384415.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/a5/05/main.PMC5384415.pdf
Article No~e00279 14 http://dx.doi.org/10.1016/j.heliyon.2017.e00279 2405-8440/© 2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/a5/05/main.PMC5384415.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/a5/05/main.PMC5384415.pdf
Article No~e00279 15 http://dx.doi.org/10.1016/j.heliyon.2017.e00279 2405-8440/© 2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/a5/05/main.PMC5384415.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/a5/05/main.PMC5384415.pdf
Article No~e00279 16 http://dx.doi.org/10.1016/j.heliyon.2017.e00279 2405-8440/© 2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/a5/05/main.PMC5384415.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/a5/05/main.PMC5384415.pdf
"In addition, future studies should assess the effects of other compounds which enhance mitochondrial function on Article No~e00279 17 http://dx.doi.org/10.1016/j.heliyon.2017.e00279 2405-8440/© 2017 The Authors.",Non-OADS,/arxiv_data1/oa_pdf/a5/05/main.PMC5384415.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/a5/05/main.PMC5384415.pdf
Article No~e00279 18 http://dx.doi.org/10.1016/j.heliyon.2017.e00279 2405-8440/© 2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/a5/05/main.PMC5384415.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/a5/05/main.PMC5384415.pdf
"[12]K. Rezai-Zadeh, et al., Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral Article No~e00279 19 http://dx.doi.org/10.1016/j.heliyon.2017.e00279 2405-8440/© 2017 The Authors.",Non-OADS,/arxiv_data1/oa_pdf/a5/05/main.PMC5384415.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/a5/05/main.PMC5384415.pdf
Article No~e00279 20 http://dx.doi.org/10.1016/j.heliyon.2017.e00279 2405-8440/© 2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/a5/05/main.PMC5384415.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/a5/05/main.PMC5384415.pdf
Article No~e00279 21 http://dx.doi.org/10.1016/j.heliyon.2017.e00279 2405-8440/© 2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/a5/05/main.PMC5384415.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/a5/05/main.PMC5384415.pdf
Article No~e00279 22 http://dx.doi.org/10.1016/j.heliyon.2017.e00279 2405-8440/© 2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/a5/05/main.PMC5384415.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/a5/05/main.PMC5384415.pdf
A new cycle begins http://dx.doi.org/10.1016/j.redox.2017.03.026 Received 23 February 2017; Received in revised form 17 March 2017; Accepted 24 March 2017⁎Corresponding authors.,Non-OADS,/arxiv_data1/oa_pdf/8c/13/main.PMC5384416.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/BY-NC-ND/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/8c/13/main.PMC5384416.pdf
"60 (2004) 903 –911, http://dx.doi.org/10.1107/ S0907444904005013 .",Non-OADS,/arxiv_data1/oa_pdf/8c/13/main.PMC5384416.pdf
"278 (2003)11570 –11578, http://dx.doi.org/10.1074/jbc.M300252200 .",Non-OADS,/arxiv_data1/oa_pdf/8c/13/main.PMC5384416.pdf
"285 (2010) 21943 –21950, http://dx.doi.org/10.1074/ jbc.M110.117283 .",Non-OADS,/arxiv_data1/oa_pdf/8c/13/main.PMC5384416.pdf
"Helmann, S. Mongkolsuk, Bacterial Ohr and OsmC paralogues de ﬁne two protein families with distinct functions and patterns of expression, Microbiology 147 (2001) 1775 –1782, 〈http://www.ncbi.nlm.nih.gov/pubmed/11429455 〉.D.A.",OADS,/arxiv_data1/oa_pdf/8c/13/main.PMC5384416.pdf
"Dubbs, P. Vattanaviboon, S. Mongkolsuk, B. Prapagdee, ohrR and ohr are the Primary Sensor/Regulator and Protective Genes Against Organic Hydroperoxide Stress in Agrobacterium Tumefaciens ohrR and ohr are the Primary Sensor/Regulator and Protective Genes against Organic Hydroperoxide Stress in Agrobacteria, 2006. doi: 〈http://doi.org/10.1128/JB.188.",OADS,/arxiv_data1/oa_pdf/8c/13/main.PMC5384416.pdf
"152 (2001) 17 –26,〈http://www.ncbi.nlm.nih.gov/ pubmed/11281321 〉.",Non-OADS,/arxiv_data1/oa_pdf/8c/13/main.PMC5384416.pdf
"Netto, Analysis of the organic hydroper- oxide response of chromobacterium violaceum reveals that OhrR is a cys-basedredox sensor regulated by thioredoxin, PLoS One 7 (2012) e47090, http://dx.doi.",OADS,/arxiv_data1/oa_pdf/8c/13/main.PMC5384416.pdf
"Chaudhry, Y. Wang, X. Shen, Ohr protects corynebacterium glutamicum against organic hydroperoxideinduced oxidative stress, PLoS One 10 (2015) e0131634, http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/8c/13/main.PMC5384416.pdf
"278 (2003) 9203 –9211, http://dx.doi.org/10.1074/jbc.",Non-OADS,/arxiv_data1/oa_pdf/8c/13/main.PMC5384416.pdf
doi: 〈http://doi.org/10.1002/prot.22936.analysis 〉.,OADS,/arxiv_data1/oa_pdf/8c/13/main.PMC5384416.pdf
"359 (2006) 433 –445, http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/8c/13/main.PMC5384416.pdf
"39 (2011) 29 –37,http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/8c/13/main.PMC5384416.pdf
"[17] Y. Huang, B. Niu, Y. Gao, L. Fu, W. Li, CD-HIT Suite: a web server for clustering and comparing biological sequences, Bioinformatics 26 (2010) 680 –682, http://dx.doi.",OADS,/arxiv_data1/oa_pdf/8c/13/main.PMC5384416.pdf
"30 (2013) 772 –780, http://dx.doi.org/10.1093/molbev/mst010 .",Non-OADS,/arxiv_data1/oa_pdf/8c/13/main.PMC5384416.pdf
"33 (2016) msw054, http://dx.doi.",Non-OADS,/arxiv_data1/oa_pdf/8c/13/main.PMC5384416.pdf
"107 (1994) 2691 –2704, http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/8c/13/main.PMC5384416.pdf
"(2005) 571 –607, http://dx.doi.org/10.1385/1592598900 .",Non-OADS,/arxiv_data1/oa_pdf/8c/13/main.PMC5384416.pdf
"202 (1992) 384 –389, 〈http://www.ncbi.nlm.nih.gov/pubmed/ 1519766 〉.",Non-OADS,/arxiv_data1/oa_pdf/8c/13/main.PMC5384416.pdf
"385 (2009) 889 –901, http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/8c/13/main.PMC5384416.pdf
"(2002) 1073 –1077, http://dx.doi.org/ 10.1126/science.1067798 .",Non-OADS,/arxiv_data1/oa_pdf/8c/13/main.PMC5384416.pdf
"217 (1994) 220 –230, http://dx.doi.org/10.1016/0076-6879(95)60139-2 .",Non-OADS,/arxiv_data1/oa_pdf/8c/13/main.PMC5384416.pdf
"12 (2014) 87, http://dx.doi.org/10.1186/s12915-014-0087-z .",Non-OADS,/arxiv_data1/oa_pdf/8c/13/main.PMC5384416.pdf
"Jakobsen, T. Cavalier-Smith, Multigene phylogeny of Choanozoa and the origin of animals, PLoS One 3 (2008) http://dx.doi.org/10.1371/journal.pone.0002098 .",Non-OADS,/arxiv_data1/oa_pdf/8c/13/main.PMC5384416.pdf
"novicida(named FTN_1133), involved in the response to oxidative stress induced by organic peroxides, is not endowed with thiol-dependent peroxidase activity, PLoS One 9 (2014) e99492, http://dx.doi.org/10.1371/journal.pone.0099492 .",OADS,/arxiv_data1/oa_pdf/8c/13/main.PMC5384416.pdf
"14 (2015) 1113 –1126, http://dx.doi.org/10.1074/mcp.M114.043083 .",Non-OADS,/arxiv_data1/oa_pdf/8c/13/main.PMC5384416.pdf
"11 (2011) 100, http://dx.doi.org/10.1186/1471-2180-11-100 .",Non-OADS,/arxiv_data1/oa_pdf/8c/13/main.PMC5384416.pdf
"417 (2009) 1 –13,http://dx.doi.org/10.1042/BJ20081386 .",Non-OADS,/arxiv_data1/oa_pdf/8c/13/main.PMC5384416.pdf
"289 (2014) 8312 –8325, http://dx.doi.org/10.1074/jbc.M113.545301 .",Non-OADS,/arxiv_data1/oa_pdf/8c/13/main.PMC5384416.pdf
"12 (2016) 1 –27,http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/8c/13/main.PMC5384416.pdf
"Sasindran, C. Jagannath, S. Dhandayuthapani, OsmC proteins of Mycobacterium tuberculosis and Mycobacterium smegmatis protect against organic hydroperoxide stress, Tuberculosis 91 (Suppl 1) (2011) S119 –S127, http://dx.doi.org/10.1016/j.tube.2011.10.021 .",Non-OADS,/arxiv_data1/oa_pdf/8c/13/main.PMC5384416.pdf
"196 (2014)1012 –1019, http://dx.doi.org/10.1128/JB.00954-13 .",Non-OADS,/arxiv_data1/oa_pdf/8c/13/main.PMC5384416.pdf
"12 (2003)2838 –2843, http://dx.doi.org/10.1110/ps.03375603 .",Non-OADS,/arxiv_data1/oa_pdf/8c/13/main.PMC5384416.pdf
"Acta (2008) (1784) 783 –788, http://dx.doi.org/10.1016/j.bbapap.2008.",OADS,/arxiv_data1/oa_pdf/8c/13/main.PMC5384416.pdf
"Dear, A.A. Noegel, B. Barrell, A. Kuspa, The genome of the social amoeba Dictyostelium discoideum, Nature 435 (2005) 43 –57,http://dx.doi.org/10.1038/nature03481 .",OADS,/arxiv_data1/oa_pdf/8c/13/main.PMC5384416.pdf
"Martin, Endosymbiotic origin and di ﬀer- ential loss of eukaryotic genes, Nature 524 (2015) 427 –437, http://dx.doi.org/10.",Non-OADS,/arxiv_data1/oa_pdf/8c/13/main.PMC5384416.pdf
"Structural modelling Pentameric GABA Areceptor homology models were generated by combining human α1,β2 and γ2 structural models with the subunit arrangement β-α-β-α-γ2 implemented in the programme suite incorporated in SWISS-MODEL (http://swissmodel.expasy .org/SWISS-MODEL.html).",OADS,/arxiv_data1/oa_pdf/bb/b9/jmedgenet-2016-104083.PMC5384423.pdf
"Web resources The URLs for data presented herein are as follows:▸ANNOV AR, http://annovar.openbioinformatics.org/en/latest/ ▸1000 Genomes, http://www.1000genomes.org/ ▸ExAC browser, http://exac.broadinstitute.org/ ▸HGVD, http://www.genome.med.kyoto-u.ac.jp/SnpDB/index.html ▸ESP6500, http://evs.gs.washington.edu/EVS/ ▸dbSNP142, http://www.ncbi.nlm.nih.gov/snp/ ▸SIFT , http://sift.jcvi.org/ ▸PolyPhen2 hvar, http://genetics.bwh.harvard.edu/pph2/ ▸Mutation T aster, http://www.mutationtaster.org/Figure 6 Expression of mutant β2 (p.Thr287Pro) subunits reduces the peak current amplitudes of γ-aminobutyric acid-A (GABA A) channels.",OADS,/arxiv_data1/oa_pdf/bb/b9/jmedgenet-2016-104083.PMC5384423.pdf
"▸CADD, http://cadd.gs.washington.edu/ ▸PhyloP100way vertebrate, http://compgen.cshl.edu/phast/ ▸RefSeq, https://www.ncbi.nlm.nih.gov/refseq/ ▸STRING 10, http://string-db.org/ Acknowledgements The authors would like to thank the patients and their families who participated in this study for their cooperation.",Non-OADS,/arxiv_data1/oa_pdf/bb/b9/jmedgenet-2016-104083.PMC5384423.pdf
"See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1 Ohtahara S, Yamatogi Y. Ohtahara syndrome: with special reference to its developmental aspects for differentiating from early myoclonic encephalopathy.",Non-OADS,/arxiv_data1/oa_pdf/bb/b9/jmedgenet-2016-104083.PMC5384423.pdf
To view please visit the journal online(http://dx.doi.org/10.1136/ emermed-2015-205258).,Non-OADS,/arxiv_data1/oa_pdf/cb/8e/emermed-2015-205258.PMC5384429.pdf
To view please visit the journal online(http://dx.doi.org/10.1136/ emermed-2015-205258).,Non-OADS,/arxiv_data1/oa_pdf/cb/8e/emermed-2015-205258.PMC5384429.pdf
"2015. http://commons.wikimedia.org/wiki/ 16 van der Heijden JP, Thijssing L, Witkamp L, et al .",Non-OADS,/arxiv_data1/oa_pdf/cb/8e/emermed-2015-205258.PMC5384429.pdf
"2015. http://commons.wikimedia.org/wiki/ 16 van der Heijden JP, Thijssing L, Witkamp L, et al .",Non-OADS,/arxiv_data1/oa_pdf/cb/8e/emermed-2015-205258.PMC5384429.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).www.elsevier.com/locate/worlddev http://dx.doi.org/10.1016/j.worlddev.2017.02.008 465,Non-OADS,/arxiv_data1/oa_pdf/c5/64/main.PMC5384451.pdf
http://dx.doi.org/10.2135/cropsci2012.09.0545 .,Non-OADS,/arxiv_data1/oa_pdf/c5/64/main.PMC5384451.pdf
http://dx.doi.org/10.1111/j.1759- 5436.1989.mp20002001.x .,Non-OADS,/arxiv_data1/oa_pdf/c5/64/main.PMC5384451.pdf
http://dx.doi.org/10.1016/j.socscimed.2010.03.008 .,OADS,/arxiv_data1/oa_pdf/c5/64/main.PMC5384451.pdf
http://dx.doi.org/10.1198/016214504000000269 .,Non-OADS,/arxiv_data1/oa_pdf/c5/64/main.PMC5384451.pdf
http://dx.doi.org/ 10.1080/0376835x.2013.797232 .,Non-OADS,/arxiv_data1/oa_pdf/c5/64/main.PMC5384451.pdf
http://dx.doi.org/10.1080/ 03066150.2011.583642 .,Non-OADS,/arxiv_data1/oa_pdf/c5/64/main.PMC5384451.pdf
"http://dx.doi.org/10.1016/0306-9192(89) 90044-4 .Train, K. (2003).",OADS,/arxiv_data1/oa_pdf/c5/64/main.PMC5384451.pdf
E-mail: ejs@princeton.edu; Web: http://www.chemists.princeton.edu/sorensen †Electronic supplementary information (ESI) available.,OADS,/arxiv_data1/oa_pdf/e8/16/SC-008-C6SC04607J.PMC5384452.pdf
See: http://creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1.,Non-OADS,/arxiv_data1/oa_pdf/f3/7b/openhrt-2016-000523.PMC5384465.pdf
"creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use, reproduction and distribution of the work without further permiss ion provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).",Non-OADS,/arxiv_data1/oa_pdf/eb/4d/10.1177_2058460116684884.PMC5384491.pdf
Available at: http://www.drs.dk/guidelines/ct/quality/htmlindex.htm (accessed 18 April 2014).,Non-OADS,/arxiv_data1/oa_pdf/eb/4d/10.1177_2058460116684884.PMC5384491.pdf
Available at: http://medical.nema.org/dicom/2004/04_14PU.pdf (accessed 14 April 2014).,Non-OADS,/arxiv_data1/oa_pdf/eb/4d/10.1177_2058460116684884.PMC5384491.pdf
Availableat: http://www2.sas.com/proceedings/sugi29/193-29.pdf (accessed 22 November 2016).,OADS,/arxiv_data1/oa_pdf/eb/4d/10.1177_2058460116684884.PMC5384491.pdf
Supplemental Material The online supplemental figures are available at http://journals.sage pub.com/doi/suppl/10.1177/1559325816681320.,Non-OADS,/arxiv_data1/oa_pdf/34/fe/10.1177_1559325816681320.PMC5384492.pdf
"To view a copy of this li - cense, visit http://creativecommons.org/licenses/by-nc-nd/4.0/ Figure 2.",Non-OADS,/arxiv_data1/oa_pdf/88/63/10.2217_whe-2016-0001.PMC5384506.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/ Executive summary •	Female sexual dysfunction is a common and distressing condition with limited treatment options currently  available.",Non-OADS,/arxiv_data1/oa_pdf/e1/10/10.2217_whe-2016-0018.PMC5384512.pdf
THIS IS AN OPEN ACCESS ARTICLE UNDERTHE CC BY-NC-ND LICENSE ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).ISSN 2452-302X http://dx.doi.org/10.1016/j.jacbts.2016.11.004,Non-OADS,/arxiv_data1/oa_pdf/e4/72/main.PMC5384575.pdf
This is anopen access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/e4/72/main.PMC5384575.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered , transformed, or built upon in any way.CELL CYCLE 2017, VOL.",Non-OADS,/arxiv_data1/oa_pdf/fa/af/kccy-16-06-1282585.PMC5384577.pdf
"6, 515 –521 http://dx.doi.org/10.1080/15384101.2017.1282585",Non-OADS,/arxiv_data1/oa_pdf/fa/af/kccy-16-06-1282585.PMC5384577.pdf
"ORCID Masayuki Seki http://orcid.org/0000-0001-9824-0843 References [1] Yu CE, Oshima J, Fu YH, Wijsman EM, Hisama F, Alisch R, Matthews S, Nakura J, Miki T, Ouais S, Martin GM, Mulligan J,Schellenberg GD.",Non-OADS,/arxiv_data1/oa_pdf/fa/af/kccy-16-06-1282585.PMC5384577.pdf
"Science 1996; 272:258-262; PMID:8602509; http://dx.doi.org/ 10.1126/science.272.5259.258 [2] Kawabe Y, Branzei D, Hayashi T, Suzuki H, Masuko T, Onoda F, Heo SJ, Ikeda H, Shimamoto A, Furuichi Y, Seki M, Enomoto T. A novel protein interacts with the Werner ’s syndrome gene product physically and functionally.",OADS,/arxiv_data1/oa_pdf/fa/af/kccy-16-06-1282585.PMC5384577.pdf
"J Biol Chem 2001; 276:20364-20369;PMID:11301316; http://dx.doi.org/10.1074/jbc.C100035200 [3] Tsurimoto T, Shinozaki A, Yano M, Seki M, Enomoto T. Human Werner helicase interacting protein 1 (WRNIP1) functions as a novel modulator for DNA polymerase d. Genes Cells 2005; 10:13-22; PMID:15670210; http://dx.doi.org/10.1111/j.1365-2443.2004.00812.x [4] Hishida T, Iwasaki H, Ohno T, Morishita T, Shinagawa H. A yeast gene, MGS1 , encoding a DNA-dependent AAA CATPase is required to maintain genome stability.",OADS,/arxiv_data1/oa_pdf/fa/af/kccy-16-06-1282585.PMC5384577.pdf
"DNA Repair 2002; 1:671-682; PMID:12509289; http://dx.doi.org/10.1016/S1568-7864(02)00073-3 [6] Hishida T, Ohno T, Iwasaki H, Shinagawa H. Saccharomyces cerevi- siae MGS1 is essential in strains de ﬁcient in the RAD6 -dependent DNA damage tolerance pathway.",OADS,/arxiv_data1/oa_pdf/fa/af/kccy-16-06-1282585.PMC5384577.pdf
"EMBO J 2002; 21:2019-2029; PMID:11953321; http://dx.doi.org/10.1093/emboj/21.8.2019 [7] Hoege C, Pfander B, Moldovan GL, Pyrowolakis G, Jentsch S. RAD6 - dependent DNA repair is linked to modi ﬁcation of PCNA by ubiqui- tin and SUMO.",Non-OADS,/arxiv_data1/oa_pdf/fa/af/kccy-16-06-1282585.PMC5384577.pdf
"EMBO J 2009; 28:3657-3666; PMID:19851286; http://dx.doi.org/10.1038/emboj.2009.303 [9] Hishida T, Ohya T, Kubota Y, Kamada Y, Shinagawa H. Functional and physical interaction of yeast Mgs1 with PCNA: impact onRAD6 -dependent DNA damage tolerance.",OADS,/arxiv_data1/oa_pdf/fa/af/kccy-16-06-1282585.PMC5384577.pdf
"Mol Cell Biol 2006; 26:5509-5517; PMID:16809783; http://dx.doi.org/10.1128/ MCB.00307-06 [10] Saugar I, Parker JL, Zhao S, Ulrich HD.",OADS,/arxiv_data1/oa_pdf/fa/af/kccy-16-06-1282585.PMC5384577.pdf
"Nucleic Acids Res 2012; 40:245-257; PMID:21911365; http:// dx.doi.org/10.1093/nar/gkr738 [11] Branzei D, Seki M, Onoda F, Enomoto T. The product of Saccharo- myces cerevisiae WHIP/MGS1 , a gene related to replication factor C genes, interacts functionally with DNA polymerase d. Mol Genet Genomics 2002; 268:371-386; PMID:12436259; http://dx.doi.org/10.1007/s00438-002-0757-3 [12] Vijeh Motlagh ND, Seki M, Branzei D, Enomoto T. Mgs1 and Rad18/Rad5/Mms2 are required for survival of Saccharomyces cerevi- siae mutants with novel temperature/cold sensitive alleles of the DNA polymerase dsubunit, Pol31.",Non-OADS,/arxiv_data1/oa_pdf/fa/af/kccy-16-06-1282585.PMC5384577.pdf
"DNA Repair 2006; 5:1459-1474; PMID:16949354; http://dx.doi.org/10.1016/j.dnarep.2006.07.006 [13] Siebler HM, Lada AG, Baranovskiy AG, Tahirov TH, Pavlov YI.",OADS,/arxiv_data1/oa_pdf/fa/af/kccy-16-06-1282585.PMC5384577.pdf
"DNA Repair 2014; 24:138-149; PMID:24819597; http://dx.doi.org/10.1016/j.dnarep.2014.04.013 [14] Kim JH, Kang YH, Kang HJ, Kim DH, Ryu GH, Kang MJ, Seo YS.",OADS,/arxiv_data1/oa_pdf/fa/af/kccy-16-06-1282585.PMC5384577.pdf
"Nucleic Acids Res 2005; 33:6137-6150; http://dx.doi.org/10.1093/nar/gki900 [15] Barbour L, Xiao W. Regulation of altanative replication bypass path- ways at stalled replication forks and its effects on genome stability : a yeast model.",OADS,/arxiv_data1/oa_pdf/fa/af/kccy-16-06-1282585.PMC5384577.pdf
"Mutat Res 2003; 532:137-155; PMID:14643434; http://dx.doi.org/10.1016/j.mrfmmm.2003.08.014 [16] Crosetto N, Bienko M, Hibbert RG, Perica T, Ambrogio C, Kensche T, Hofmann K, Sixma TK, Dikic I.",OADS,/arxiv_data1/oa_pdf/fa/af/kccy-16-06-1282585.PMC5384577.pdf
"J Biol Chem 2008; 283:35173-35185; PMID:18842586;http://dx.doi.org/10.1074/jbc.M803219200 [17] Suzuki N, Rohaim A, Kato R, Dikic I, Wakatsuki S, Kawasaki M. A novel mode of ubiquitin recognition by ubiquitin-binding zinc ﬁnger domain of WRNIP1.",OADS,/arxiv_data1/oa_pdf/fa/af/kccy-16-06-1282585.PMC5384577.pdf
"FEBS J 2016; 283:2004-2017; PMID:27062441;http://dx.doi.org/10.1111/febs.13734 [18] Bish R, Myers MP.",OADS,/arxiv_data1/oa_pdf/fa/af/kccy-16-06-1282585.PMC5384577.pdf
"J Biol Chem 2007; 282:23184- 23193; PMID:17550899; http://dx.doi.org/10.1074/jbc.M701042200 [19] Bish RA, Fregoso OI, Piccini A, Myers MP.",OADS,/arxiv_data1/oa_pdf/fa/af/kccy-16-06-1282585.PMC5384577.pdf
"J Proteome Res 2008; 7:3481-3489;PMID:18613717; http://dx.doi.org/10.1021/pr800217q [20] Nomura H, Yashimura A, Edo T, Kanno S, Tada S, Seki M, Yasui A, Enomoto T. WRNIP1 accumulates at laser light irradiated sites rap- idly via its ubiquitin-binding zinc ﬁnger domain and independently from its ATPase domain.",OADS,/arxiv_data1/oa_pdf/fa/af/kccy-16-06-1282585.PMC5384577.pdf
Biochem Biophys Res Commun 2012;417:1145-1150; PMID:22209848; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/fa/af/kccy-16-06-1282585.PMC5384577.pdf
"Oncogene 2016;35:4009-4019; PMID:26549024; http://dx.doi.org/10.1038/onc.2015.427 [22] Yoshimura A, Seki M, Kanamori M, Tateishi S, Tsurimoto T, Tada S, Enomoto T. Physical and functional interaction between WRNIP1 and RAD18.",OADS,/arxiv_data1/oa_pdf/fa/af/kccy-16-06-1282585.PMC5384577.pdf
"Genes Genet Syst 2009; 84:171-178; PMID:19556710;http://dx.doi.org/10.1266/ggs.84.171 [23] Kawabe Y, Seki M, Yoshimura A, Nishino K, Hayashi T, Takeuchi T, Iguch S, Kusa Y, Ohtsuki M, Tsuyama T, Imamura O, Matsumoto T,Furuichi Y, Tada S, Enomoto T. Analyses of the interaction ofWRNIP1 with Werner syndrome protein (WRN) in vitro and in the cell.",OADS,/arxiv_data1/oa_pdf/fa/af/kccy-16-06-1282585.PMC5384577.pdf
DNA Repair 2006; 5:816-828; PMID:16769258; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/fa/af/kccy-16-06-1282585.PMC5384577.pdf
"org/10.1016/j.dnarep.2006.04.006 [24] Indig FE, Partridge JJ, von Kobbe C, Aladjem MI, Latterrich M, Bohr VA. Werner syndrome protein directly binds to the AAA A T P a s ep 9 7 / V C Pi na nA T P - d e p e n d e n tf a s h i o n .JS t r u c tB i o l 2004; 146:251-259; PMID:15037256; http://dx.doi.org/10.1016/j.jsb.2003.11.009 [25] Verma R, Oania R, Fang R, Smith GT, Deshaies RJ.",OADS,/arxiv_data1/oa_pdf/fa/af/kccy-16-06-1282585.PMC5384577.pdf
"Mol Cell 2011; 41:82-92; PMID:21211725; http://dx.doi.org/10.1016/j.molcel.2010.12.017 [26] Ghosal G, Leung JW, Nair BC, Fong KW, Chen J.",OADS,/arxiv_data1/oa_pdf/fa/af/kccy-16-06-1282585.PMC5384577.pdf
"J Biol Chem 2012; 287:34225-34233;PMID:22902628; http://dx.doi.org/10.1074/jbc.M112.400135 [27] Mosbech A, Gibbs-Seymour I, Kagias K, Thorslund T, Beli P, Povlsen L, Nielsen S V, Smedegaard S, Sedgwick G, Lukas C, Hartmann-Petersen R, Lukas J, Choudhary C, Pocock R, Bekker-Jen-sen S, Mailand N. DVC1(C1orf124) is a DNA damage-targeting p97adaptor that promotes ubiquitin-dependent responses to replication blocks.",OADS,/arxiv_data1/oa_pdf/fa/af/kccy-16-06-1282585.PMC5384577.pdf
"Nat Struct Mol Biol 2012; 19:1084-1092; PMID:23042605; http://dx.doi.org/10.1038/nsmb.2395 [28] Mano Y, Takahashi K, Ishikawa N, Takano A, Yasui W, Inai K, Nish- imura H, Tsuchiya E, Nakamura Y, Daigo Y. Fibroblast growth factor receptor 1 oncogene partner as a novel prognostic biomarker andtherapeutic target for lung cancer.",OADS,/arxiv_data1/oa_pdf/fa/af/kccy-16-06-1282585.PMC5384577.pdf
"Cancer Sci 2007; 98:1902-1913;PMID:17888034; http://dx.doi.org/10.1111/j.1349-7006.2007.00610.x [29] Kaur S, White TE, DiGuilio AL, Glavy JS.",Non-OADS,/arxiv_data1/oa_pdf/fa/af/kccy-16-06-1282585.PMC5384577.pdf
"Cell Cycle 2010; 9:3106-3111; PMID:20676042; http://dx.doi.org/10.4161/cc.9.15.12524 [30] Yu CC, Yang JC, Chang YC, Chuang JG, Lin CW, Wu MS, Chow LP.",OADS,/arxiv_data1/oa_pdf/fa/af/kccy-16-06-1282585.PMC5384577.pdf
"PLoS One 2013; 8:e55724; PMID:23383273; http://dx.doi.org/10.1371/ journal.pone.0055724 [31] Yuasa MS, Masutani C, Hirano A, Cohn MA, Yamaizumi M, Nakatani Y, Hanaoka F. A human DNA polymerase hcomplexcontaining Rad18, Rad6 and Rev1; proteomic analysis and targeting of the complex to the chromatin-bound fraction of cells undergoingreplication fork arrest.",OADS,/arxiv_data1/oa_pdf/fa/af/kccy-16-06-1282585.PMC5384577.pdf
"Genes Cells 2006; 11:731-744;PMID:16824193; http://dx.doi.org/10.1111/j.1365-2443.2006.00974.x [32] Yoshimura A, Kobayashi Y, Tada S, Seki M, Enomoto T. WRNIP1 functions upstream of DNA polymerase hin the UV-induced DNA damage response.",OADS,/arxiv_data1/oa_pdf/fa/af/kccy-16-06-1282585.PMC5384577.pdf
"Biochem Biophys Res Commun 2014; 452:48-52; PMID:25139235; http://dx.doi.org/10.1016/j.bbrc.2014.08.043 [33] Leuzzi G, Marabitti V, Pichierri P, Franchitto A. WRNIP1 protects stalled forks from degradation and promotes fork restart after repli-cation stress.",OADS,/arxiv_data1/oa_pdf/fa/af/kccy-16-06-1282585.PMC5384577.pdf
"Biol Pharm Bull 2006; 29:2192-2196; PMID:17077513;http://dx.doi.org/10.1248/bpb.29.2192 [37] Johnson RE, Klassen R, Prakash L, Prakash S. A major role of DNA- polymerase din replication of both the leading and lagging DNA strands.",OADS,/arxiv_data1/oa_pdf/fa/af/kccy-16-06-1282585.PMC5384577.pdf
"Mol Cell 2015; 59:163-175; PMID:26145172; http://dx.doi.org/10.1016/j.molcel.2015.05.038 [38] Schlacher K, Christ N, Siaud N, Egashira A, Wu H, Jasin M. Double-strand break repair-independent role for BRCA2 inblocking stalled replication fork degradation by MRE11.",OADS,/arxiv_data1/oa_pdf/fa/af/kccy-16-06-1282585.PMC5384577.pdf
Cell2011; 145:529-542; PMID:21565612; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/fa/af/kccy-16-06-1282585.PMC5384577.pdf
"DNA Repair 2011; 10:1060-1065; PMID:21900052; http://dx.doi.org/10.1016/j.dnarep.2011.07.009 [40] Derheimer FA, Kastan MB.",OADS,/arxiv_data1/oa_pdf/fa/af/kccy-16-06-1282585.PMC5384577.pdf
"FEBS Lett 2010; 584:3675-3681;PMID:20580718; http://dx.doi.org/10.1016/j.febslet.2010.05.031 [41] Lee JH, Paull TT.",OADS,/arxiv_data1/oa_pdf/fa/af/kccy-16-06-1282585.PMC5384577.pdf
"Oncogene 2007; 26:7741-7748; PMID:18066086; http://dx.doi.org/10.1038/sj.onc.1210872 [42] Kanu N, Behrens A. ATMIN de ﬁnes an NBS-independent pathway of ATM signalling.",OADS,/arxiv_data1/oa_pdf/fa/af/kccy-16-06-1282585.PMC5384577.pdf
"EMBO J 2007; 26:2933-2941; PMID:17525732; http://dx.doi.org/10.1038/sj.emboj.7601733 [43] Schmidt L, Wiedner M, Velimezi G, Prochazkova J, Owusu M, Bauer S, Loizou JI.",OADS,/arxiv_data1/oa_pdf/fa/af/kccy-16-06-1282585.PMC5384577.pdf
DNA Repair 2014; 24:122-130; PMID:25262557; http://dx.doi.org/10.1016/j.dnarep.2014.09.001CELL CYCLE 521,OADS,/arxiv_data1/oa_pdf/fa/af/kccy-16-06-1282585.PMC5384577.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered , transformed, or built upon in any way.CELL CYCLE 2017, VOL.",Non-OADS,/arxiv_data1/oa_pdf/2d/5f/kccy-16-06-1281486.PMC5384587.pdf
"6, 533 –535 http://dx.doi.org/10.1080/15384101.2017.1281486",Non-OADS,/arxiv_data1/oa_pdf/2d/5f/kccy-16-06-1281486.PMC5384587.pdf
"ORCID Eisuke Mekada http://orcid.org/0000-0001-8858-4781 References [1] Hanahan D, Coussens LM.",Non-OADS,/arxiv_data1/oa_pdf/2d/5f/kccy-16-06-1281486.PMC5384587.pdf
"Cancer Cell 2012; 21:309- 22; PMID: 22439926; http://dx.doi.org/10.1016/j.ccr.2012.02.022 [ 2 ] H o f f m a nR M ,B o u v e tM .I m a g i n gt h em icroenvironment of pancreatic cancer patient-derived orthotopic x enografts (PDOX) growing in trans- genic nude mice expressing GFP, RFP, or CFP.",Non-OADS,/arxiv_data1/oa_pdf/2d/5f/kccy-16-06-1281486.PMC5384587.pdf
"Cancer Lett 2016; 380:349- 55; PMID:26742463; http://dx.doi.org/10.1016/j.canlet.2015.12.021 [3] Garralda E, Paz K, L /C19opez-Casas PP, Jones S, Katz A, Kann LM, L/C19opez-Rios F, Sarno F, Al-Shahrour F, Vasquez D, et al.",OADS,/arxiv_data1/oa_pdf/2d/5f/kccy-16-06-1281486.PMC5384587.pdf
Clin Cancer Res 2014; 20:2476-84; PMID: 24634382; http://dx.doi.org/10.1158/1078-0432.CCR-13-3047 [4] Hoffman RM.,Non-OADS,/arxiv_data1/oa_pdf/2d/5f/kccy-16-06-1281486.PMC5384587.pdf
"Nat Rev Cancer 2015; 15:451-2; PMID: 26422835; http://dx.doi.org/10.1038/nrc3972 [5] Rygaard J, Povlsen CO. Heterotransplantation of a human malignant tumour to “Nude ”mice.",Non-OADS,/arxiv_data1/oa_pdf/2d/5f/kccy-16-06-1281486.PMC5384587.pdf
"Acta Pathol Microbiol Scand 1969; 77:758-60; PMID: 5383844; http://dx.doi.org/10.1111/j.1699-0463.1969.tb04520.x [6] Wang WR, Sordat B, Piguet D, Sordat M. Human Colon Tumors in Nude Mice: Implantation Site and Expression of the InvasivePhenotype 1.",OADS,/arxiv_data1/oa_pdf/2d/5f/kccy-16-06-1281486.PMC5384587.pdf
Cancer Res 2006;66:11293-7; PMID: 17145875; http://dx.doi.org/10.1158/0008-5472.,Non-OADS,/arxiv_data1/oa_pdf/2d/5f/kccy-16-06-1281486.PMC5384587.pdf
"Clin Exp Metastasis 2004; 21:275-81; PMID:15387378; http://dx.doi.org/10.1023/B:CLIN.0000037729.75981.9e [10] Murata T, Mizushima H, Chinen I, Moribe H, Yagi S, Hoffman RM, Kimura T, Yoshino K, Ueda Y, Enomoto T, Mekada E. HB-EGF andPDGF mediate reciprocal interactions of carcinoma cells with can-cer-associated ﬁbroblasts to support progression of uterine cervical cancers.",Non-OADS,/arxiv_data1/oa_pdf/2d/5f/kccy-16-06-1281486.PMC5384587.pdf
Drug Discov Today 2003; 8:1104-7; PMID: 14678733; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/2d/5f/kccy-16-06-1281486.PMC5384587.pdf
Cell Cycle 2005;4:1518-21; PMID: 16258270; http://dx.doi.org/10.4161/cc.4.11.,OADS,/arxiv_data1/oa_pdf/2d/5f/kccy-16-06-1281486.PMC5384587.pdf
Leukemia 2001; 15:936-41; PMID: 11417480; http://dx.doi.org/ 10.1038/sj.leu.2402127 [14] Blagosklonny MV.,Non-OADS,/arxiv_data1/oa_pdf/2d/5f/kccy-16-06-1281486.PMC5384587.pdf
Leukemia 2006;20:385-91; PMID: 16357832; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/2d/5f/kccy-16-06-1281486.PMC5384587.pdf
Oncotarget 2011;2:222-33; PMID: 21447859; http://dx.doi.org/10.18632/oncotarget.248 [16] Blagosklonny MV.,OADS,/arxiv_data1/oa_pdf/2d/5f/kccy-16-06-1281486.PMC5384587.pdf
Br J Cancer 2003;89:1147-51; PMID: 14520435; http://dx.doi.org/10.1038/sj.,Non-OADS,/arxiv_data1/oa_pdf/2d/5f/kccy-16-06-1281486.PMC5384587.pdf
"https://doi.org/10.1177/2333721416686019Gerontology & Geriatric Medicine Volume 3: 1 –12 © The Author(s) 2017Reprints and permissions: sagepub.com/journalsPermissions.nav DOI: 10.1177/2333721416686019 journals.sagepub.com/home/ggm Creative Commons CC-BY-NC: This article is distributed under the terms of the Creative Commons Attribution- NonCommercial 3.0 License (http://www.creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use,  reproduction and distribution of the work  without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).Article Introduction Low back pain is a major cause of functional limitation and  disability, particularly in the elderly (Eggermont et al., 2014).",Non-OADS,/arxiv_data1/oa_pdf/d1/c9/10.1177_2333721416686019.PMC5384601.pdf
Retrieved from https://www.aap.org/en-us/Documents/coding_2015_ rbrvs.pdf American Medical Association.,Non-OADS,/arxiv_data1/oa_pdf/d1/c9/10.1177_2333721416686019.PMC5384601.pdf
wrote and revised the paper.Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/b8/77/srep03891.PMC5384602.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0 www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 3891 | DOI: 10.1038/srep03891 8",Non-OADS,/arxiv_data1/oa_pdf/b8/77/srep03891.PMC5384602.pdf
"1, e1251873 (6 pages)http://dx.doi.org/10.1080/23262133.2016.1251873",Non-OADS,/arxiv_data1/oa_pdf/48/e3/kngs-03-01-1251873.PMC5384614.pdf
"Nucleic Acids Res 2014; 42:D68-73; PMID:24275495; http://dx.doi.org/10.1093/nar/gkt1181 [2] Han J, Kim HJ, Schafer ST, Paquola A, Clemenson GD, Toda T, Oh J, Pankonin AR, Lee BS, Johnston ST, et al.Functional Implications of miR-19 in the Migration ofNewborn Neurons in the Adult Brain.",OADS,/arxiv_data1/oa_pdf/48/e3/kngs-03-01-1251873.PMC5384614.pdf
"Neuron 2016;91:79-89; PMID:27387650; http://dx.doi.org/10.1016/j.neuron.2016.05.034 [3] He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S, Powers S, Cordon-Cardo C, LoweSW, Hannon GJ, et al.",OADS,/arxiv_data1/oa_pdf/48/e3/kngs-03-01-1251873.PMC5384614.pdf
"Nature 2005; 435:828-33;PMID:15944707; http://dx.doi.org/10.1038/nature03552 [4] Tanzer A, Stadler PF.",OADS,/arxiv_data1/oa_pdf/48/e3/kngs-03-01-1251873.PMC5384614.pdf
"J Mol Biol 2004; 339:327-35; PMID:15136036;http://dx.doi.org/10.1016/j.jmb.2004.03.065[5] Lewis BP, Burge CB, Bartel DP.",OADS,/arxiv_data1/oa_pdf/48/e3/kngs-03-01-1251873.PMC5384614.pdf
"Cell 2005; 120:15-20;PMID:15652477; http://dx.doi.org/10.1016/j.cell.2004.12.035 [6] de Pontual L, Yao E, Callier P, Faivre L, Drouin V, Cariou S, Van Haeringen A, Genevi /C18eve D, Goldenberg A, Oufadem M, et al.",OADS,/arxiv_data1/oa_pdf/48/e3/kngs-03-01-1251873.PMC5384614.pdf
"Nat Genet 2011; 43:1026-30;PMID:21892160; http://dx.doi.org/10.1038/ng.915 [7] Ganjavi H, Siu VM, Speevak M, MacDonald PA. A fourth case of Feingold syndrome type 2: psychiatricpresentation and management.",Non-OADS,/arxiv_data1/oa_pdf/48/e3/kngs-03-01-1251873.PMC5384614.pdf
"BMJ Case Rep 2014;2014; PMID:25391829; http://dx.doi.org/10.1136/bcr-2014-207501 [8] Celli J, van Bokhoven H, Brunner HG.",Non-OADS,/arxiv_data1/oa_pdf/48/e3/kngs-03-01-1251873.PMC5384614.pdf
"Am JMed Genet A 2003; 122A:294-300; PMID:14518066;http://dx.doi.org/10.1002/ajmg.a.20471 [9] Houbaviy HB, Murray MF, Sharp PA. Embryonic stem cell-speci ﬁc MicroRNAs.",OADS,/arxiv_data1/oa_pdf/48/e3/kngs-03-01-1251873.PMC5384614.pdf
"Dev Cell 2003; 5:351-8; PMID:12919684; http://dx.doi.org/10.1016/S1534-5807(03)00227-2 [10] Suh MR, Lee Y, Kim JY, Kim SK, Moon SH, Lee JY, Cha KY, Chung HM, Yoon HS, Moon SY, et al.",OADS,/arxiv_data1/oa_pdf/48/e3/kngs-03-01-1251873.PMC5384614.pdf
"Humanembryonic stem cells express a unique set of microRNAs.Dev Biol 2004; 270:488-98; PMID:15183728; http://dx.doi.org/10.1016/j.ydbio.2004.02.019 [11] Landgraf P, Rusu M, Sheridan R, Sewer A, Iovino N, Aravin A, Pfeffer S, Rice A, Kamphorst AO, LandthalerM, et al.",OADS,/arxiv_data1/oa_pdf/48/e3/kngs-03-01-1251873.PMC5384614.pdf
"Cell 2007; 129:1401-14; PMID:17604727; http://dx.doi.org/10.1016/j.cell.2007.04.040 [12] Ventura A, Young AG, Winslow MM, Lintault L, Meissner A, Erkeland SJ, Newman J, Bronson RT,Crowley D, Stone JR, et al.",OADS,/arxiv_data1/oa_pdf/48/e3/kngs-03-01-1251873.PMC5384614.pdf
Cell 2008; 132:875-86; PMID:18329372; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/48/e3/kngs-03-01-1251873.PMC5384614.pdf
"Development 2010; 137:2127-32;PMID:20504959; http://dx.doi.org/10.1242/dev.050633 [15] Bian S, Hong J, Li Q, Schebelle L, Pollock A, Knauss JL, Garg V, Sun T. MicroRNA cluster miR-17-92 regulatesneural stem cell expansion and transition to intermediateprogenitors in the developing mouse neocortex.",OADS,/arxiv_data1/oa_pdf/48/e3/kngs-03-01-1251873.PMC5384614.pdf
Cell Rep2013; 3:1398-406; PMID:23623502; http://dx.doi.org/ 10.1016/j.celrep.2013.03.037e1251873-4 J. HAN AND F. H. GAGE,OADS,/arxiv_data1/oa_pdf/48/e3/kngs-03-01-1251873.PMC5384614.pdf
"Aging 2011; 3:108-24; PMID:21386132;http://dx.doi.org/10.18632/aging.100285 [18] Gao Z, Ding P, Hsieh J.",OADS,/arxiv_data1/oa_pdf/48/e3/kngs-03-01-1251873.PMC5384614.pdf
"Pro ﬁling of REST-Dependent microRNAs Reveals Dynamic Modes of Expression.Front Neurosci 2012; 6:67; PMID:22590451; http://dx.doi.org/10.3389/fnins.2012.00067 [19] Liu XS, Chopp M, Wang XL, Zhang L, Hozeska-Solgot A, Tang T, Kassis H, Zhang RL, Chen C, Xu J, et al.MicroRNA-17-92 cluster mediates the proliferation andsurvival of neural progenitor cells after stroke.",OADS,/arxiv_data1/oa_pdf/48/e3/kngs-03-01-1251873.PMC5384614.pdf
"J BiolChem 2013; 288:12478-88; PMID:23511639; http://dx.doi.org/10.1074/jbc.M112.449025 [20] Jin J, Kim SN, Liu X, Zhang H, Zhang C, Seo JS, Kim Y, Sun T, et al.",OADS,/arxiv_data1/oa_pdf/48/e3/kngs-03-01-1251873.PMC5384614.pdf
"Cell Rep 2016; 16:1653-63; PMID:27477270; http://dx.doi.org/10.1016/j.celrep.2016.06.101 [21] Siomi H, Siomi MC.",OADS,/arxiv_data1/oa_pdf/48/e3/kngs-03-01-1251873.PMC5384614.pdf
"Front Neurol 2014; 5:132; PMID:25101050;http://dx.doi.org/10.3389/fneur.2014.00132 [23] Mao S, Li H, Sun Q, Zen K, Zhang CY, Li L. miR-17 regulates the proliferation and differentiation of theneural precursor cells during mouse corticogenesis.",Non-OADS,/arxiv_data1/oa_pdf/48/e3/kngs-03-01-1251873.PMC5384614.pdf
"FEBSJ 2014; 281:1144-58; PMID:24314167; http://dx.doi.org/ 10.1111/febs.12680 [24] Naka-Kaneda H, Nakamura S, Igarashi M, Aoi H, Kanki H, Tsuyama J, Tsutsumi S, Aburatani H, Shimazaki T,Okano H. The miR-17/106-p38 axis is a key regulator ofthe neurogenic-to-gliogenic transition in developing neu-ral stem/progenitor cells.",OADS,/arxiv_data1/oa_pdf/48/e3/kngs-03-01-1251873.PMC5384614.pdf
"EMBO Mol Med 2013; 5:1613-34; PMID:24014289; http://dx.doi.org/10.1002/emmm.201201974 [26] Beveridge NJ, Gardiner E, Carroll AP, Tooney PA, Cairns MJ.",Non-OADS,/arxiv_data1/oa_pdf/48/e3/kngs-03-01-1251873.PMC5384614.pdf
"Mol Psychiatry 2010; 15:1176-89; PMID:19721432; http://dx.doi.org/10.1038/ mp.2009.84[27] Wang J, Wang Y, Yang J, Huang Y. microRNAs as novel biomarkers of schizophrenia (Review).",OADS,/arxiv_data1/oa_pdf/48/e3/kngs-03-01-1251873.PMC5384614.pdf
"Mol Brain 2015; 8:5; PMID:25626686; http://dx.doi.org/10.1186/s13041-015-0095-0 [29] Mu P, Han YC, Betel D, Yao E, Squatrito M, Ogrodowski P, de Stanchina E, D ’Andrea A, Sander C, Ventura A.",OADS,/arxiv_data1/oa_pdf/48/e3/kngs-03-01-1251873.PMC5384614.pdf
"Genes Dev2009; 23:2806-11; PMID:20008931; http://dx.doi.org/10.1101/gad.1872909 [30] Olive V, Bennett MJ, Walker JC, Ma C, Jiang I, Cordon-Cardo C, Li QJ, Lowe SW, Hannon GJ, He L,et al.",OADS,/arxiv_data1/oa_pdf/48/e3/kngs-03-01-1251873.PMC5384614.pdf
"Genes Dev 2009; 23:2839-49; PMID:20008935; http://dx.doi.org/10.1101/gad.1861409 [31] Brown JP, Couillard-Despr /C19es S, Cooper-Kuhn CM, Winkler J, Aigner L, Kuhn HG.",OADS,/arxiv_data1/oa_pdf/48/e3/kngs-03-01-1251873.PMC5384614.pdf
"J Comp Neurol 2003; 467:1-10; PMID:14574675; http://dx.doi.org/ 10.1002/cne.10874 [32] Esposito MS, Piatti VC, Laplagne DA, Morgenstern NA, Ferrari CC, Pitossi FJ, Schinder AF.",Non-OADS,/arxiv_data1/oa_pdf/48/e3/kngs-03-01-1251873.PMC5384614.pdf
"J Neurosci 2005; 25:10074-86; PMID:16267214;http://dx.doi.org/10.1523/JNEUROSCI.3114-05.2005 [33] Liu C, Teng ZQ, Santistevan NJ, Szulwach KE, Guo W, Jin P, Zhao X. Epigenetic regulation of miR-184 by MBD1 governs neural stem cell proliferation and differentiation.Cell Stem Cell 2010; 6:433-44; PMID:20452318; http://dx.doi.org/10.1016/j.stem.2010.02.017 [34] Szulwach KE, Li X, Smrt RD, Li Y, Luo Y, Lin L, Santistevan NJ, Li W, Zhao X, Jin P. Cross talk betweenmicroRNA and epigenetic regulation in adult neurogene-sis.",OADS,/arxiv_data1/oa_pdf/48/e3/kngs-03-01-1251873.PMC5384614.pdf
"Nat Neurosci 2009; 12:399-408;PMID:19287386; http://dx.doi.org/10.1038/nn.2294 [36] Zhao C, Sun G, Li S, Shi Y.",OADS,/arxiv_data1/oa_pdf/48/e3/kngs-03-01-1251873.PMC5384614.pdf
"Nat Struct Mol Biol 2009; 16:365-71; PMID:19330006; http://dx.doi.org/ 10.1038/nsmb.1576 [37] Akerblom M, Sachdeva R, Barde I, Verp S, Gentner B, Trono D, Jakobsson J. MicroRNA-124 is a subventricularzone neuronal fate determinant.",OADS,/arxiv_data1/oa_pdf/48/e3/kngs-03-01-1251873.PMC5384614.pdf
"J Neurosci 2012;32:8879-89; PMID:22745489; http://dx.doi.org/10.1523/JNEUROSCI.0558-12.2012 [38] Smrt RD, Szulwach KE, Pfeiffer RL, Li X, Guo W, Pathania M, Teng ZQ, Luo Y, Peng J, Bordey A, et al.",OADS,/arxiv_data1/oa_pdf/48/e3/kngs-03-01-1251873.PMC5384614.pdf
"Stem Cells 2010; 28:1060- 70; PMID:20506192; http://dx.doi.org/10.1002/stem.431 [39] Magill ST, Cambronne XA, Luikart BW, Lioy DT, Leighton BH, Westbrook GL, Mandel G, Goodman RH.microRNA-132 regulates dendritic growth and arboriza-tion of newborn neurons in the adult hippocampus.",Non-OADS,/arxiv_data1/oa_pdf/48/e3/kngs-03-01-1251873.PMC5384614.pdf
"ProcNat Acad Sc U S A 2010; 107:20382-7; http://dx.doi.org/ 10.1073/pnas.1015691107 [40] Akerblom M, Petri R, Sachdeva R, Klussendorf T, Mattsson B, Gentner B, Jakobsson J. microRNA-125distinguishes developmentally generated and adult-bornolfactory bulb interneurons.",OADS,/arxiv_data1/oa_pdf/48/e3/kngs-03-01-1251873.PMC5384614.pdf
"Development 2014;141:1580-8; PMID:24598163; http://dx.doi.org/10.1242/dev.101659 [41] Gloerich M, Bos JL.",OADS,/arxiv_data1/oa_pdf/48/e3/kngs-03-01-1251873.PMC5384614.pdf
"Trends Cell Biol 2011; 21:615-23; PMID:21820312; http://dx.doi.org/10.1016/j.tcb.2011.07.001 [42] Kwon CH, Luikart BW, Powell CM, Zhou J, Matheny SA, Zhang W, Li Y, Baker SJ, Parada LF.",OADS,/arxiv_data1/oa_pdf/48/e3/kngs-03-01-1251873.PMC5384614.pdf
"Pten regulatesneuronal arborization and social interaction in mice.Neuron 2006; 50:377-88; PMID:16675393; http://dx.doi.org/10.1016/j.neuron.2006.03.023 [43] Amiri A, Cho W, Zhou J, Birnbaum SG, Sinton CM, McKay RM, Parada LF.",OADS,/arxiv_data1/oa_pdf/48/e3/kngs-03-01-1251873.PMC5384614.pdf
"J Neurosci 2012;32:5880-90; PMID:22539849; http://dx.doi.org/10.1523/JNEUROSCI.5462-11.2012 [44] Millar JK, Wilson-Annan JC, Anderson S, Christie S, Taylor MS, Semple CA, Devon RS, St Clair DM, MuirWJ, Blackwood DH, et al.",Non-OADS,/arxiv_data1/oa_pdf/48/e3/kngs-03-01-1251873.PMC5384614.pdf
"Hum Mol Genet 2000; 9:1415-23; PMID:10814723;http://dx.doi.org/10.1093/hmg/9.9.1415 [45] Duan X, Chang JH, Ge S, Faulkner RL, Kim JY, Kitabatake Y, Liu XB, Yang CH, Jordan JD, Ma DK, et al.Disrupted-In-Schizophrenia 1 regulates integration ofnewly generated neurons in the adult brain.",OADS,/arxiv_data1/oa_pdf/48/e3/kngs-03-01-1251873.PMC5384614.pdf
"Cell 2007;130:1146-58; PMID:17825401; http://dx.doi.org/10.1016/ j.cell.2007.07.010 [46] Lo Vasco VR, Cardinale G, Polonia P. Deletion of PLCB1 gene in schizophrenia-affected patients.",OADS,/arxiv_data1/oa_pdf/48/e3/kngs-03-01-1251873.PMC5384614.pdf
"J Cell Mol Med2012; 16:844-51; PMID:22507702; http://dx.doi.org/10.1111/j.1582-4934.2011.01363.x [47] Manning EE, Ransome MI, Burrows EL, Hannan AJ.",Non-OADS,/arxiv_data1/oa_pdf/48/e3/kngs-03-01-1251873.PMC5384614.pdf
"Hippocampus 2012;22:309-19; PMID:21080410; http://dx.doi.org/10.1002/hipo.20900 [48] Webster MJ, Knable MB, O ’Grady J, Orthmann J, Weickert CS.",OADS,/arxiv_data1/oa_pdf/48/e3/kngs-03-01-1251873.PMC5384614.pdf
"Mol Psychiatry 2002; 7:985-94, 924;PMID:12399952; http://dx.doi.org/10.1038/sj.mp.4001139 [49] Fitzsimons CP, van Hooijdonk LW, Schouten M, Zalachoras I, Brinks V, Zheng T, Schouten TG, SaaltinkDJ, Dijkmans T, Steindler DA, et al.",Non-OADS,/arxiv_data1/oa_pdf/48/e3/kngs-03-01-1251873.PMC5384614.pdf
"Mol Psychiatry 2013; 18:993-1005; PMID:22925833; http://dx.doi.org/10.1038/mp.2012.123 [50] Xu B, Woodroffe A, Rodriguez-Murillo L, Roos JL, van Rensburg EJ, Abecasis GR, Gogos JA, Karayiorgou M.Elucidating the genetic architecture of familial schizo-phrenia using rare copy number variant and linkage scans.",Non-OADS,/arxiv_data1/oa_pdf/48/e3/kngs-03-01-1251873.PMC5384614.pdf
"Mol Psychiatry2015; 20:361-368; http://dx.doi.org/10.1038/mp.2014.22 [52] Yu DX, Di Giorgio FP, Yao J, Marchetto MC, Brennand K, Wright R, Mei A, McHenry L, Lisuk D, Grasmick JM, et al.",OADS,/arxiv_data1/oa_pdf/48/e3/kngs-03-01-1251873.PMC5384614.pdf
"Stem cell reports 2014;2:295-310; PMID:24672753; http://dx.doi.org/10.1016/j.stemcr.2014.01.009 [53] Mulholland C, Cooper S. The symptom of depression in schizophrenia and its management.",Non-OADS,/arxiv_data1/oa_pdf/48/e3/kngs-03-01-1251873.PMC5384614.pdf
"Adv Psychiatric Treat2000; 6:169-77; http://dx.doi.org/10.1192/apt.6.3.169 [54] Parent JM, Yu TW, Leibowitz RT, Geschwind DH, Sloviter RS, Lowenstein DH.",Non-OADS,/arxiv_data1/oa_pdf/48/e3/kngs-03-01-1251873.PMC5384614.pdf
"Neurosci Res2009; 63:227-5; PMID:19367784; http://dx.doi.org/ 10.1016/j.neures.2009.01.002 [56] Chang YT, Chen PC, Tsai IJ, Sung FC, Chin ZN, Kuo HT, Tsai CH, Chou IC.",OADS,/arxiv_data1/oa_pdf/48/e3/kngs-03-01-1251873.PMC5384614.pdf
"Epilepsia 2011; 52:2036-42; PMID:21929680;http://dx.doi.org/10.1111/j.1528-1167.2011.03268.x [57] Brennand KJ, Simone A, Jou J, Gelboin-Burkhart C, Tran N, Sangar S, Li Y, Mu Y, Chen G, Yu D, et al.",OADS,/arxiv_data1/oa_pdf/48/e3/kngs-03-01-1251873.PMC5384614.pdf
Nature 2011; 473:221-5; PMID:21490598; http://dx.doi.org/10.1038/nature09915 [58] Mendell JT.,OADS,/arxiv_data1/oa_pdf/48/e3/kngs-03-01-1251873.PMC5384614.pdf
Cell 2008; 133:217-22;PMID:18423194; http://dx.doi.org/10.1016/j.cell.2008.04.001e1251873-6 J. HAN AND F. H. GAGE,OADS,/arxiv_data1/oa_pdf/48/e3/kngs-03-01-1251873.PMC5384614.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/07/b2/ccid-10-099.PMC5384684.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/07/b2/ccid-10-099.PMC5384684.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).Clinical, Cosmetic and Investigational Dermatology 2017:10 99–104Clinical, Cosmetic and Investigational Dermatology Dovepress submit your manuscript | www.dovepress.com Dovepress 99 ORIGINAL RESEARCH open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/CCID.S130126 A retrospective epidemiological study of skin  diseases among pediatric population attending a  tertiary dermatology referral center in Northern  Greece Efstratios Vakirlis Grigorios Theodosiou Zoe Apalla  Michael ArabatzisElizabeth LazaridouElena Sotiriou  Aimilios Lallas Demetrios Ioannides First Department of Dermatology,   Aristotle University Medical School,  Thessaloniki, GreeceBackground: The incidence of skin diseases in children is influenced by hereditary, social, and  environmental factors.",Non-OADS,/arxiv_data1/oa_pdf/07/b2/ccid-10-099.PMC5384684.pdf
"However, only few data extracted from few studies are cur - rently available about the epidemiology of pediatric dermatoses.2-6, 9-18 The aim of this study was to estimate the incidence rates of pediatric skin diseases  in our region that can subsequently serve as reference material for future comparative studies.Correspondence: Grigorios Theodosiou First Department of Dermatology Venereology, Aristotle University Medical School,124 Delfon street, 52440, Thessaloniki, GreeceEmail Grigorios.Theodosiou@skane.seJournal name: Clinical, Cosmetic and Investigational Dermatology Article Designation: ORIGINAL RESEARCH Y ear: 2017V olume: 10Running head verso: Vakirlis et alRunning head recto: Epidemiological study of pediatric skin diseasesDOI: http://dx.doi.org/10.2147/CCID.S130126",Non-OADS,/arxiv_data1/oa_pdf/07/b2/ccid-10-099.PMC5384684.pdf
Available from http://apps.who.int/iris/bitstream/10665/69229/1/WHO_FCH_CAH_05.12_eng.pdf.,OADS,/arxiv_data1/oa_pdf/07/b2/ccid-10-099.PMC5384684.pdf
"Clinical, Cosmetic and Investigational Dermatology 2017:10submit your manuscript | www.dovepress.com Dovepress Dovepress Clinical, Cosmetic and Investigational Dermatology Publish your work in this journal Submit your manuscript here:  https://www.dovepress.com/clinical-cosmetic-and-investigational-dermatology-journal Clinical, Cosmetic and Investigational Dermatology is an interna- tional, peer-reviewed, open access, online journal that focuses on   the latest clinical and experimental research in all aspects of skin   disease and cosmetic interventions.",Non-OADS,/arxiv_data1/oa_pdf/07/b2/ccid-10-099.PMC5384684.pdf
Visit http://www.dovepress.com/testimonials.php to read real quotes from published authorsDovepress 104 Vakirlis et al,Non-OADS,/arxiv_data1/oa_pdf/07/b2/ccid-10-099.PMC5384684.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/0e/f4/ott-10-1889.PMC5384685.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).OncoTargets and Therapy 2017:10 1889–1896OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  1889Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OTT .S12690 5 clinical course and outcome of patients with  high-level microsatellite instability cancers in  a real-life setting: a retrospective analysis naama halpern1 Yael goldberg2 luna Kadouri2 Morasha Duvdevani2 Tamar hamburger2 Tamar Peretz2 ayala hubert2 1institute of Oncology, The chaim  sheba Medical center, T el hashomer,   israel; 2sharett institute of Oncology,   hadassah Medical center, hebrew  University, Jerusalem, israelBackground:  The prognostic and predictive significance of the high-level microsatellite  instability (MSI-H) phenotype in various malignancies is unclear.",Non-OADS,/arxiv_data1/oa_pdf/0e/f4/ott-10-1889.PMC5384685.pdf
"Since the correspondence: naama halpern institute of Oncology, The chaim  sheba Medical center, Tel hashomer  5265601, israel Tel +972 3 530 5338 Fax +972 3 530 4958 email naama.halpern@sheba.health.gov.i l Journal name: OncoTargets and Therapy Article Designation: Original Research Y ear: 2017 Volume: 10 Running head verso: Halpern et al Running head recto: Clinical course of patients with high-level microsatellite instability cancers DOI: http://dx.doi.org/10.2147/OTT.S126905",Non-OADS,/arxiv_data1/oa_pdf/0e/f4/ott-10-1889.PMC5384685.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open  access journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/0e/f4/ott-10-1889.PMC5384685.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/0e/f4/ott-10-1889.PMC5384685.pdf
"Available  from: http://seer.cancer.gov/statfacts/html/colorect.htm l. Accessed  February 8, 2017.",Non-OADS,/arxiv_data1/oa_pdf/0e/f4/ott-10-1889.PMC5384685.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/7e/df/ndt-13-973.PMC5384686.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Neuropsychiatric Disease and Treatment 2017:13 973–980Neuropsychiatric Disease and Treatment Dove press submit your manuscript | www.dovepress.co m Dove press  973Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/NDT .S11900 4 Modulation of the activity of N-methyl- d- aspartate receptors as a novel treatment option  for depression: current clinical evidence and  therapeutic potential of rapastinel (GLYX-13) Andrei-Nicolae vasilescu1,* Nina Schweinfurth2,* Stefan Borgwardt2,* Peter Gass1 Undine e Lang2,* Dragos inta1,2,* Sarah eckart2,* 1Department of Psychiatry and  Psychotherapy, Central institute  of Mental Health, Medical Faculty  Mannheim, Heidelberg University,   Heidelberg, Germany; 2Department  of Psychiatry (Universitäre  Psychiatrische Kliniken), University  of Basel, Basel, Switzerland *These authors contributed equally  to this workAbstract:  Classical monoaminergic antidepressants show several disadvantages, such as  protracted onset of therapeutic action.",Non-OADS,/arxiv_data1/oa_pdf/7e/df/ndt-13-973.PMC5384686.pdf
"In addition,  these substances do not ameliorate key symptoms of depression, such as cognitive  impairment, symptoms that implicate synaptic dysfunction in the pathophysiology of  MDD.3 A growing body of evidence indicates that drugs targeting the glutamate system, Correspondence: Undine e Lang Department of Psychiatry, University  of Basel, wilhelm Klein-Strasse 27,  CH-4012 Basel, Switzerland email undine.lang@ukbs.c h Journal name: Neuropsychiatric Disease and Treatment Article Designation: Review Y ear: 2017 Volume: 13 Running head verso: Vasilescu et al Running head recto: Modulation of the activity of NMDARs DOI: http://dx.doi.org/10.2147/NDT.S119004",Non-OADS,/arxiv_data1/oa_pdf/7e/df/ndt-13-973.PMC5384686.pdf
"Neuropsychiatric Disease and Treatment Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journa lNeuropsychiatric Disease and Treatment is an international, peer- reviewed journal of clinical therapeutics and pharmacology focusing   on concise rapid reporting of clinical or pre-clinical studies on a   range of neuropsychiatric and neurological disorders.",Non-OADS,/arxiv_data1/oa_pdf/7e/df/ndt-13-973.PMC5384686.pdf
Visit http://www.dovepress.com/testimonials.ph p to  read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/7e/df/ndt-13-973.PMC5384686.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/52/01/dddt-11-1035.PMC5384687.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Drug Design, Development and Therapy 2017:11 1035–1041Drug Design, Development and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  1035Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/DDDT .S12574 3 Mirtazapine for symptom control in refractory  gastroparesis Mark Malamood1 aaron roberts2 rahul Kataria2 henry P Parkman2 ron schey2 1Department of internal Medicine,   2Department of gastroenterology,   T emple University hospital,   Philadelphia, P a, UsaIntroduction:  Gastroparesis symptoms can be severe and debilitating.",Non-OADS,/arxiv_data1/oa_pdf/52/01/dddt-11-1035.PMC5384687.pdf
"Mirtazapine (Remeron, Organon USA Inc., NJ, USA) is an antidepressant with  a multifactorial mechanism of action involving antagonism of central and peripheral correspondence: henry P Parkman section of gastroenterology, Department  of internal Medicine, Parkinson Pavilion,  8th Floor, Temple University school  of Medicine, 3401 n Broad street,  Philadelphia, Pa 19140, Usa Tel +1 215 707 7579 Fax +1 215 707 2684 email henry.parkman@tuhs.temple.ed u Journal name: Drug Design, Development and Therapy Article Designation: Original Research Y ear: 2017 Volume: 11 Running head verso: Malamood et al Running head recto: Mirtazapine for symptom control in refractory gastroparesis DOI: http://dx.doi.org/10.2147/DDDT.S125743",Non-OADS,/arxiv_data1/oa_pdf/52/01/dddt-11-1035.PMC5384687.pdf
"Available from: http://www.fda.gov/ ohrms/dockets/ac/04/briefing/2004-4065b1-26-tab11G-Remeron-Tabs- SLR016.pd f. Accessed June 3, 2016.",OADS,/arxiv_data1/oa_pdf/52/01/dddt-11-1035.PMC5384687.pdf
"Drug Design, Development and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/drug-design-development-and-therapy-journa lDrug Design, Development and Therapy is an international, peer- reviewed open-access journal that spans the spectrum of drug design  and development through to clinical applications.",Non-OADS,/arxiv_data1/oa_pdf/52/01/dddt-11-1035.PMC5384687.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/52/01/dddt-11-1035.PMC5384687.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/1c/db/dddt-11-1065.PMC5384688.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Drug Design, Development and Therapy 2017:11 1065–1079Drug Design, Development and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  1065Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/DDDT .S12497 1 effect of berberine on the renal tubular epithelial- to-mesenchymal transition by inhibition of the  notch/snail pathway in diabetic nephropathy  model KKa y mice guannan Yang Zongjiang Zhao Xinxue Zhang amin Wu Yawei huang Y onghui Miao Meijuan Yang school of Basic Medical science,   Beijing University of chinese  Medicine, Beijing, People’s  republic of chinaAbstract:  Renal tubular epithelial-to-mesenchymal transition (EMT) and renal tubular  interstitial fibrosis are the main pathological changes of diabetic nephropathy (DN), which is a  common cause of end-stage renal disease.",Non-OADS,/arxiv_data1/oa_pdf/1c/db/dddt-11-1065.PMC5384688.pdf
"To combat damage and avoid potential apoptosis, some renal tubular epithe - lial cells lose their epithelial cell markers, change their morphology, become muscle  fibroblasts, and produce the mesenchymal cell marker alpha-smooth muscle actin correspondence: Zongjiang Zhao school of Basic Medical science, Beijing  University of chinese Medicine, 11 Bei  san huan Dong lu, chaoyang, 100029  Beijing, People’s republic of china Tel +86 139 1050 7288 email zongjiangz@sina.co m Journal name: Drug Design, Development and Therapy Article Designation: Original Research Y ear: 2017 Volume: 11 Running head verso: Y ang et al Running head recto: Effect of berberine in DN model KKAy mice DOI: http://dx.doi.org/10.2147/DDDT.S124971",Non-OADS,/arxiv_data1/oa_pdf/1c/db/dddt-11-1065.PMC5384688.pdf
"Drug Design, Development and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/drug-design-development-and-therapy-journa lDrug Design, Development and Therapy is an international, peer- reviewed open-access journal that spans the spectrum of drug design  and development through to clinical applications.",Non-OADS,/arxiv_data1/oa_pdf/1c/db/dddt-11-1065.PMC5384688.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/1c/db/dddt-11-1065.PMC5384688.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/49/29/ccid-10-093.PMC5384689.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/49/29/ccid-10-093.PMC5384689.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).Clinical, Cosmetic and Investigational Dermatology 2017:10 93–98Clinical, Cosmetic and Investigational Dermatology Dovepress submit your manuscript | www.dovepress.com Dovepress 93 ORIGINAL RESEARCH open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/CCID.S129072 Ingenol mebutate in low amounts for the  treatment of actinic keratosis in Korean patients Hyun Jae Joe Byung Ho Oh Department of Dermatology,   Keimyung University, College of Medicine, Daegu, Republic of KoreaBackground: Ingenol mebutate (IM), a novel agent for field therapy of actinic keratosis (AK),  has a drawback of inducing local skin reactions (LSRs), which may cause discomfort in patients.",Non-OADS,/arxiv_data1/oa_pdf/49/29/ccid-10-093.PMC5384689.pdf
"In an attempt to reduce LSRs and patients’ complaints associated with Correspondence: Byung Ho Oh Department of Dermatology, Keimyung University, College of Medicine, 56 Dalseong-ro, Jung-gu, Daegu, Republic of KoreaEmail obh505@gmail.comJournal name: Clinical, Cosmetic and Investigational Dermatology Article Designation: ORIGINAL RESEARCHY ear: 2017V olume: 10Running head verso: Joe and OhRunning head recto: Application of ingenol mebutate for the treatment of actinic keratosisDOI: http://dx.doi.org/10.2147/CCID.S129072",Non-OADS,/arxiv_data1/oa_pdf/49/29/ccid-10-093.PMC5384689.pdf
"Clinical, Cosmetic and Investigational Dermatology 2017:10submit your manuscript | www.dovepress.com Dovepress Dovepress Clinical, Cosmetic and Investigational Dermatology Publish your work in this journal Submit your manuscript here:  https://www.dovepress.com/clinical-cosmetic-and-investigational-dermatology-journal Clinical, Cosmetic and Investigational Dermatology is an interna- tional, peer-reviewed, open access, online journal that focuses on   the latest clinical and experimental research in all aspects of skin   disease and cosmetic interventions.",Non-OADS,/arxiv_data1/oa_pdf/49/29/ccid-10-093.PMC5384689.pdf
Visit http://www.dovepress.com/testimonials.php to read real quotes from published authorsDovepress 98 Joe and Oh,Non-OADS,/arxiv_data1/oa_pdf/49/29/ccid-10-093.PMC5384689.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/33/5f/ott-10-1921.PMC5384690.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).OncoTargets and Therapy 2017:10 1921–1932OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  1921Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OTT .S12841 6 non-small-cell lung cancer cell lines a549  and nci-h460 express hypoxanthine guanine  phosphoribosyltransferase on the plasma  membrane Michelle h T ownsend Michael D anderson evita g Weagel edwin J Velazquez K scott Weber richard a robison Kim l O’n eill Department of Microbiology and  Molecular Biology, Brigham Young  University, Provo, UT, UsaAbstract:  In both males and females, lung cancer is one of the most lethal cancers worldwide  and accounts for .30% of cancer-related deaths.",Non-OADS,/arxiv_data1/oa_pdf/33/5f/ott-10-1921.PMC5384690.pdf
"In 2015, 221,200 individuals in the US were diagnosed with lung  cancer, while another 158,040 individuals were killed by the disease.1 Approximately  85% of lung cancer cases are diagnosed as non-small-cell lung cancer, which encom - passes squamous cell carcinoma, adenocarcinoma, and large cell carcinoma.2 Despite  advances in combinatorial therapy using both chemotherapy and radiotherapy, patient correspondence: Kim l O’neill Department of Microbiology and  Molecular Biology, Brigham Young  University, 3142 lsB, Provo,  UT 84602, Usa Tel +1 801 422 2449 Fax +1 801 422 0519 email kim_oneill@byu.ed u Journal name: OncoTargets and Therapy Article Designation: Original Research Y ear: 2017 Volume: 10 Running head verso: Townsend et al Running head recto: HPRT expression on the surface of lung cancer cells DOI: http://dx.doi.org/10.2147/OTT.S128416",Non-OADS,/arxiv_data1/oa_pdf/33/5f/ott-10-1921.PMC5384690.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open  access journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/33/5f/ott-10-1921.PMC5384690.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/33/5f/ott-10-1921.PMC5384690.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/2a/52/dddt-11-1043.PMC5384691.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Drug Design, Development and Therapy 2017:11 1043–1053Drug Design, Development and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  1043CliniC al Trial repor Topen access to scientific and medical research open access Full T ext article http: //dx.doi.org/10.2147/DDDT .S13179 7 Drug–drug interaction of microdose and  regular-dose omeprazole with a CYp2C19  inhibitor and inducer Gab-jin park1 Soo Hyeon Bae1 Wan-Su p ark1 Seunghoon Han1 Min-Ho park2 Seok-Ho Shin2 Y oung G Shin2 Dong-Seok Yim1,2 1Department of Clinical pharmacology  and Therapeutics, Seoul St Mary’s  Hospital, pipeT (pharmacometrics  institute for practical education  and Training), College of Medicine,   Catholic University of Korea, Seoul,   South Korea; 2College of pharmacy,   Chungnam national University,   Daejeon, South KoreaPurpose:  A microdose drug–drug interaction (DDI) study may be a valuable tool for anticipating  drug interaction at therapeutic doses.",Non-OADS,/arxiv_data1/oa_pdf/2a/52/dddt-11-1043.PMC5384691.pdf
"Microdose studies are a valuable tool for understanding the PKs of candidate  drugs in humans before the initiation of Phase I studies.2–5 A microdose is defined as  1% of the pharmacologically active dose, and must be no more than 100 μg for small Correspondence: Dong-Seok Yim Department of Clinical pharmacology  and Therapeutics, Seoul St Mary’s  Hospital, 222 Banpo-daero, Seocho-gu,  Seoul 06591, South Korea Tel +82 2 2258 7327 Fax +82 2 2258 7876 email yimds@catholic.ac.k r Journal name: Drug Design, Development and Therapy Article Designation: Clinical Trial Report Y ear: 2017 Volume: 11 Running head verso: Park et al Running head recto: Drug–drug interaction of microdoses and regular doses DOI: http://dx.doi.org/10.2147/DDDT.S131797",Non-OADS,/arxiv_data1/oa_pdf/2a/52/dddt-11-1043.PMC5384691.pdf
The  studies were registered on the Clinical Research Information  Service ( https://cris.nih.go.k r); KCT0002204 [inhibition  study] and KCT0002203 [induction study].,OADS,/arxiv_data1/oa_pdf/2a/52/dddt-11-1043.PMC5384691.pdf
"Available from: https://www.fda.gov/downloads/ drugs/guidances/ucm292362.pd f. Accessed March 16, 2017.2.",Non-OADS,/arxiv_data1/oa_pdf/2a/52/dddt-11-1043.PMC5384691.pdf
"Drug Design, Development and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/drug-design-development-and-therapy-journa lDrug Design, Development and Therapy is an international, peer- reviewed open-access journal that spans the spectrum of drug design  and development through to clinical applications.",Non-OADS,/arxiv_data1/oa_pdf/2a/52/dddt-11-1043.PMC5384691.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/2a/52/dddt-11-1043.PMC5384691.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/24/1d/amep-8-253.PMC5384692.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/24/1d/amep-8-253.PMC5384692.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).Advances in Medical Education and Practice 2017:8 253–256Advances in Medical Education and Practice Dovepress submit your manuscript | www.dovepress.com Dovepress 253 ORIGINAL RESEARCH   open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/AMEP .S128403 Writing skills enhancement for public health  professionals in Rwanda Raywat Deonandan1 Nodine Sangwa1 Steve Kanters2 Sabin Nsanzimana3 1Interdisciplinary School of Health  Sciences, University of Ottawa,   Ottawa, ON, Canada; 2University  of British Columbia, Vancouver, BC,  Canada;  3Rwanda Biomedical Center,   Kigali, RwandaAbstract:  In 2013, Canadian scholars delivered a 1-week workshop to 30 junior public health  professionals in Rwanda.",Non-OADS,/arxiv_data1/oa_pdf/24/1d/amep-8-253.PMC5384692.pdf
"5 And emerging research capacity  in low-income countries, particularly those in Africa, necessitates opportunities for Correspondence: Raywat Deonandan  Interdisciplinary School of Health Sciences, University of Ottawa, 25 University Pvt, Ottawa, ON, Canada K1N 6N5Tel +1 613 562 5800 Ext 8377Email ray@deonandan.c omJournal name: Advances in Medical Education and Practice Article Designation: ORIGINAL RESEARCH Y ear: 2017V olume: 8Running head verso: Deonandan et alRunning head recto: Medical writing in RwandaDOI: http://dx.doi.org/10.2147/AMEP .S128403",Non-OADS,/arxiv_data1/oa_pdf/24/1d/amep-8-253.PMC5384692.pdf
"Advances in Medical Education and Practice Publish your work in this journal Submit your manuscript here: http://www.dovepress.com/advances-in-medical-education-and-practice-journalAdvances in Medical Education and Practice is an international, peer-  reviewed, open access journal that aims to present and publish research on Medical Education covering medical, dental, nursing and allied   health care professional education.",Non-OADS,/arxiv_data1/oa_pdf/24/1d/amep-8-253.PMC5384692.pdf
"Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.Advances in Medical Education and Practice 2017:8submit your manuscript | www.dovepress.com Dovepress Dovepress Dovepress 256 Deonandan et al scholars, and dedicated programs to identify individuals in  countries best positioned to capitalize on dedicated training.",Non-OADS,/arxiv_data1/oa_pdf/24/1d/amep-8-253.PMC5384692.pdf
Available from: http://www.huffingtonpost.ca/dr-raywat-deonandan/1090-gap-rwanda_b_4203011.html.,Non-OADS,/arxiv_data1/oa_pdf/24/1d/amep-8-253.PMC5384692.pdf
Available from: http://mg.co.za/article/2015-03-06-dark-days-for-black-researchers.,Non-OADS,/arxiv_data1/oa_pdf/24/1d/amep-8-253.PMC5384692.pdf
Available from: http://www.moh.gov.rw/index.php?id=131.,OADS,/arxiv_data1/oa_pdf/24/1d/amep-8-253.PMC5384692.pdf
Available from: http://globalstudies.gu.se/english/cooperation/Rwanda.,Non-OADS,/arxiv_data1/oa_pdf/24/1d/amep-8-253.PMC5384692.pdf
Available from: http://www.acbf-pact.org/what-we-do/how-we-do-it/grants/projects-regions/eastern-southern-africa/rwanda/institute-policy.,Non-OADS,/arxiv_data1/oa_pdf/24/1d/amep-8-253.PMC5384692.pdf
Available from: https://www.fic.nih.gov/programs/pages/medical-education-africa.aspx.,Non-OADS,/arxiv_data1/oa_pdf/24/1d/amep-8-253.PMC5384692.pdf
Available from: https://www.pepfar.gov/partner - ships/initiatives/nepi/.,Non-OADS,/arxiv_data1/oa_pdf/24/1d/amep-8-253.PMC5384692.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/b2/24/ceg-10-067.PMC5384693.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/b2/24/ceg-10-067.PMC5384693.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).Clinical and Experimental Gastroenterology 2017:10 67–74Clinical and Experimental Gastroenterology Dovepress submit your manuscript | www.dovepress.com Dovepress  67 OriG inal rEsEarCh open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/CEG.S132004Endoscopic ultrasound-guided biliary drainage  versus percutaneous transhepatic biliary  drainage after failed endoscopic retrograde  cholangiopancreatography: a meta-analysis ramkaji Baniya sunil Upadhaya seetharamprasad Madala subash Chandra subedi Tabrez shaik Mohammed Ghassan Bachuwa hurley Medical Center, Michigan state  University, Flint, M i, UsaAbstract: The failure rate of endoscopic retrograde cholangiopancreatography for bili- ary cannulation is approximately 6%–7% in cases of obstructive jaundice.",Non-OADS,/arxiv_data1/oa_pdf/b2/24/ceg-10-067.PMC5384693.pdf
"11 It has the perceived benefits of being physiologic with anatomic internal  drainage, improved comfort and recovery with less adverse events, and low cost.12  However, there are few studies published, to date, comparing the EGBD with PTBD Correspondence: ramkaji Baniya Department of internal Medicine, hurley Medical Center, Michigan state University, One hurley Plaza, suite 212, Flint, Mi 48503, UsaTel +1 810 262 6887Email mail2ramkazi@gmail.comJournal name: Clinical and Experimental Gastroenterology Article Designation: Original ResearchY ear: 2017V olume: 10Running head verso: Baniya et alRunning head recto: EUS-guided vs percutaneous transhepatic biliary drainageDOI: http://dx.doi.org/10.2147/CEG.S132004",Non-OADS,/arxiv_data1/oa_pdf/b2/24/ceg-10-067.PMC5384693.pdf
"Clinical and Experimental Gastroenterology 2017:10submit your manuscript | www.dovepress.com Dovepress Dovepress Clinical and Experimental Gastroenterology Publish your work in this journal Submit your manuscript here: https://www.dovepress.com/clinical-and-experimental-gastroenterology-journalClinical and Experimental Gastroenterology is an international, peer- reviewed, open access, online journal publishing original research, reports, editorials, reviews and commentaries on all aspects of   gastroenterology in the clinic and laboratory.",Non-OADS,/arxiv_data1/oa_pdf/b2/24/ceg-10-067.PMC5384693.pdf
Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.Dovepress 74 Baniya et al  40.,Non-OADS,/arxiv_data1/oa_pdf/b2/24/ceg-10-067.PMC5384693.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/98/82/cia-12-593.PMC5384694.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Clinical Interventions in Aging 2017:12 593–602Clinical Interventions in Aging Dove press submit your manuscript | www.dovepress.co m Dove press  593OrIg InAl reseArChopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/CIA.S13227 7 Acute kidney injury and inflammatory response  of sepsis following cecal ligation and puncture  in d-galactose-induced aging rats Chao liu1,* Jie hu1,* Zhi Mao1,* hongjun Kang1 hui liu1 Wanlei Fu2 Yangfan lv2 Feihu Zhou1 1Department of Critical Care  Medicine, Chinese People’s  liberation Army general hospital,   Beijing, People’s republic of China;   2Department of Pathology, Xinqiao  hospital, Third Military Medical  University, Chongqing, People’s  republic of China *These authors contributed equally  to this workBackground:  Recently, the d-galactose ( d-gal)-induced mimetic aging rat model has been  widely used in studies of age-associated diseases, which have shown that chronic d-gal exposure  induces premature aging similar to natural aging in rats.",Non-OADS,/arxiv_data1/oa_pdf/98/82/cia-12-593.PMC5384694.pdf
"Keywords:  acute kidney injury, inflammatory response, cecal ligation and puncture, d-galactose,  aging rat Introduction Sepsis is a major health care concern, especially in the elderly population.1 Over 60%  of sepsis cases occur in patients older than 65 years, and both sepsis-related complica - tions and mortality rates significantly increase as age advances.2 Unfortunately, most  basic research on sepsis has been conducted using young animals, and these models  have not produced useful pharmacological therapies for clinical translation.3 This gap  in clinical applicability exists because most mice used in sepsis research are less than  3 months old, which is comparable to a person under 20 years of age and does not Correspondence: Feihu Zhou Department of Critical Care Medicine,  Chinese People’s liberation Army  general hospital, 28 Fu-Xing  road, Beijing 100853, People’s  republic of China Tel +86 10 6693 8148 Fax +86 10 8821 9862 email feihuzhou301@126.co m Journal name: Clinical Interventions in Aging Article Designation: Original Research Y ear: 2017 Volume: 12 Running head verso: Liu et al Running head recto: Acute kidney injury and inflammatory response of sepsis DOI: http://dx.doi.org/10.2147/CIA.S132277",Non-OADS,/arxiv_data1/oa_pdf/98/82/cia-12-593.PMC5384694.pdf
"Clinical Interventions in Aging Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-interventions-in-aging-journa lClinical Interventions in Aging is an international, peer-reviewed journal  focusing on evidence-based reports on the value or lack thereof of treatments  intended to prevent or delay the onset of maladaptive correlates of aging  in human beings.",Non-OADS,/arxiv_data1/oa_pdf/98/82/cia-12-593.PMC5384694.pdf
Visit http://www.dovepress.,Non-OADS,/arxiv_data1/oa_pdf/98/82/cia-12-593.PMC5384694.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/fc/0f/cia-12-603.PMC5384695.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Clinical Interventions in Aging 2017:12 603–610Clinical Interventions in Aging Dove press submit your manuscript | www.dovepress.co m Dove press  603OrIg InAl reseArChopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/CIA.S13239 9 Assessment of effects of differences in trunk  posture during Fowler’s position on hemodynamics  and cardiovascular regulation in older and  younger subjects satoshi Kubota1 Yutaka endo1 Mitsue Kubota1 T omohiko shigemasa2 1school of nursing and rehabilitation  sciences at Odawara, International  University of health and Welfare,   Odawara, Kanagawa, Japan;   2Department of Cardiology,   International University of health  and Welfare Atami hospital, Atami,   shizuoka, JapanBackground:  Downward shifts in blood volume with changing position generally cause  tachycardic responses.",Non-OADS,/arxiv_data1/oa_pdf/fc/0f/cia-12-603.PMC5384695.pdf
"Keywords:  aging, cardiovascular regulation, hemodynamics, Fowler’s position, stroke volume Introduction Bed rest, heart failure, depletion of intravascular volume, and aging often induce  hypotension when the body or trunk is upright.1–5 Generally, a tachycardic response  occurs due to vagal withdrawal according to the downward blood shift that occurs  under orthostatic stress in healthy humans,6 although orthostatic hypotension presents  as an excessive drop in cardiac output (Q) and lower tachycardic response in frail and  elderly patients as a consequence of inadequate vascular contraction or autonomic Correspondence: satoshi Kubota Department of Occupational Therapy,  school of nursing and rehabilitation  sciences at Odawara, International  University of health and Welfare,  1-2-25 shiroyama, Odawara, Kanagawa  250-8588, Japan Tel +81 465 21 6626 Fax +81 465 21 6744 email satoshi@iuhw.ac.j p Journal name: Clinical Interventions in Aging Article Designation: Original Research Y ear: 2017 Volume: 12 Running head verso: Kubota et al Running head recto: Hemodynamics in Fowler’s position in older and younger adults DOI: http://dx.doi.org/10.2147/CIA.S132399",Non-OADS,/arxiv_data1/oa_pdf/fc/0f/cia-12-603.PMC5384695.pdf
"Clinical Interventions in Aging Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-interventions-in-aging-journa lClinical Interventions in Aging is an international, peer-reviewed journal  focusing on evidence-based reports on the value or lack thereof of treatments  intended to prevent or delay the onset of maladaptive correlates of aging  in human beings.",Non-OADS,/arxiv_data1/oa_pdf/fc/0f/cia-12-603.PMC5384695.pdf
Visit http://www.dovepress.,Non-OADS,/arxiv_data1/oa_pdf/fc/0f/cia-12-603.PMC5384695.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/d5/cd/ott-10-1865.PMC5384697.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).OncoTargets and Therapy 2017:10 1865–1873OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  1865Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OTT .S13002 2 DnMT1 regulates human endometrial carcinoma  cell proliferation Xinjing Wang Bilan li Department of gynecology, shanghai  First Maternity and infant hospital,   T ongji University school of Medicine,   shanghai, People’s republic of chinaAbstract:  Endometrial carcinoma (EC) is the most common gynecologic malignancy, but the  molecular events involved in the development and progression of EC remain unclear.",Non-OADS,/arxiv_data1/oa_pdf/d5/cd/ott-10-1865.PMC5384697.pdf
"Meanwhile, inhibition of DNMT1  activity could reduce the hypermethylation of repressive genes and reverse phenotypes of  malignant tumor.9 Global DNA hypomethylation is associated with chromosomal instability  and is an early event in the neoplastic progression of most human and animal cancers.10correspondence: Bilan li Department of gynecology, shanghai  First Maternity and infant hospital,   Tongji University school of Medicine,   2699 West gaoke road, shanghai  201204, People’s republic of china Tel +86 137 6161 0432 email libilan@51mch.co m Journal name: OncoTargets and Therapy Article Designation: Original Research Y ear: 2017 Volume: 10 Running head verso: Wang and Li Running head recto: DNMT1 promotes endometrial carcinoma DOI: http://dx.doi.org/10.2147/OTT.S130022",Non-OADS,/arxiv_data1/oa_pdf/d5/cd/ott-10-1865.PMC5384697.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open  access journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/d5/cd/ott-10-1865.PMC5384697.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/d5/cd/ott-10-1865.PMC5384697.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/17/fc/dddt-11-1055.PMC5384698.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Drug Design, Development and Therapy 2017:11 1055–1063Drug Design, Development and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  1055Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/DDDT .S11319 1 Spotlight on romiplostim in the treatment of  children with chronic immune thrombocytopenia:  design, development, and potential place in therapy David Buchbinder Diane Nugent Loan Hsieh Division of Hematology, CHOC  Children’s Hospital and UC irvine  Medical Center, CA, USAAbstract:  Primary immune thrombocytopenia (ITP) is an autoimmune disorder characterized by  isolated thrombocytopenia.",Non-OADS,/arxiv_data1/oa_pdf/17/fc/dddt-11-1055.PMC5384698.pdf
"Keywords:  thrombocytopenia, chronic, thrombopoietin, childhood Introduction Primary immune thrombocytopenia (ITP) in children is defined as an autoimmune  disorder characterized by isolated thrombocytopenia in the absence of other causes  or disorders that are associated with thrombocytopenia.1 Current estimates suggest  that the incidence of newly diagnosed ITP in children is between 1.9 and 6.4 per 105  children/year.2 Newly diagnosed, “acute” ITP is defined as lasting ,3 months, “per - sistent” lasting up to 12 months, and “chronic” lasting beyond 12 months in which a  spontaneous remission is not achieved or in which patients do not achieve a response  off therapy.1 Despite the fact that the vast majority of children with ITP will experi - ence resolution, estimates suggest that one-third of children will demonstrate throm - bocytopenia at 12 months post-diagnosis consistent with chronic ITP.3 Risk factors  associated with the development of chronic ITP in children are numerous such as  female gender, older age at presentation, a lack of preceding infection or vaccination,  insidious onset, higher platelet counts at presentation, and the presence of antinuclear  antibodies.4 Other biomarkers such as cytokines and gene expression profiles are  currently being explored to better differentiate chronic ITP from those newly diag - nosed cases that will not become chronic.5,6 As an example, genes involved in B-cell Correspondence: David Buchbinder Division of Hematology, CHOC  Children’s Hospital and UC irvine  Medical Center, 1201 w. La veta  Avenue, Orange, CA 92868, USA Tel +1 714 509 8459 Fax +1 714 509 8771 email dbuchbinder@choc.or g Journal name: Drug Design, Development and Therapy Article Designation: Review Y ear: 2017 Volume: 11 Running head verso: Buchbinder et al Running head recto: Usage of romiplostim in the treatment of chronic ITP in children DOI: http://dx.doi.org/10.2147/DDDT.S113191",Non-OADS,/arxiv_data1/oa_pdf/17/fc/dddt-11-1055.PMC5384698.pdf
"Drug Design, Development and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/drug-design-development-and-therapy-journa lDrug Design, Development and Therapy is an international, peer- reviewed open-access journal that spans the spectrum of drug design  and development through to clinical applications.",Non-OADS,/arxiv_data1/oa_pdf/17/fc/dddt-11-1055.PMC5384698.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/17/fc/dddt-11-1055.PMC5384698.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/6d/ff/ahmt-8-041.PMC5384699.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/6d/ff/ahmt-8-041.PMC5384699.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).Adolescent Health, Medicine and Therapeutics 2017:8 41–55Adolescent Health, Medicine and Therapeutics Dovepress submit your manuscript | www.dovepress.com Dovepress  41 REVIEW open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/AHMT .S70377Targeted therapy for soft tissue sarcomas in  adolescents and young adults Diana A Steppan   Christine A Pratilas   David M Loeb Division of Pediatric Oncology,   The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine,  Baltimore, MD, USAAbstract: Soft tissue sarcomas (STSs) are a heterogeneous group of tumors originating from the  mesenchyme.",Non-OADS,/arxiv_data1/oa_pdf/6d/ff/ahmt-8-041.PMC5384699.pdf
"Keywords: synovial sarcoma, MPNST, soft tissue sarcoma, targeted therapy Abbreviations AJCC, American Joint Committee on Cancer; ASPS, alveolar soft part sarcoma;  A YAs, adolescent and young adults; CAR, chimeric antigen receptor; COG, Children’ s Oncology Group; CR, complete remission; DSRCT, desmoplastic small round cell tumor; EGFR, endothelial growth factor receptor; EORTC, European Organization for Research and Treatment of Cancer; FDA, Food and Drug Administration; FDG-PET, fludeoxyglucose - positron emission tomography; FNCLCC, Federation Nationales des Centres de Lutte Contre le Cancer; GIST, gastrointestinal stromal tumor; HDAC, histone deacetylase; Hsp90, heat-shock protein 90; IGF-1R, insulin-like growth factor-1 receptor; MPNST, malignant peripheral nerve sheath tumor; mTOR, mechanistic target of rapamycin; mTORC1, mTOR complex 1; mTORC2, mTOR complex 2; MTP-PE, liposomal muramyl tripeptide phosphatidylethanolamine; NRSTSs, nonrhabdomyo-sarcoma soft tissue sarcomas; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; Ph+, Philadelphia chromosome-positive; PPTP , Pediatric Preclinical Testing Program; PR, partial response; RECIST, Response Evaluation Criteria in Solid Tumors; RMS, rhabdomyosarcoma; SARC, Sarcoma Alliance for Research through Collaboration; SD, stable disease; SEER, Surveillance, Epidemiol-ogy, and End Results; SINE, selective inhibitors of nuclear export; STSs, soft tissue sarcomas; SUVmax, standardized uptake value; TIL, tumor-infiltrating lymphocyte;  Correspondence: David M Loeb   Division of Pediatric Oncology,   The Sidney Kimmel Comprehensive  Cancer Center, Johns Hopkins University School of Medicine, Bunting-Blaustein Cancer Research Building,   Room 2M-51, 1650 Orleans Street, Baltimore, MD 21231, USA Tel +1 410 502 7247   Fax +1 410 502 6902   Email loebda@jhmi.eduJournal name: Adolescent Health, Medicine and Therapeutics Article Designation: REVIEWY ear: 2017V olume: 8Running head verso: Steppan et alRunning head recto: Targeted therapy in STSDOI: http://dx.doi.org/10.2147/AHMT.S70377",Non-OADS,/arxiv_data1/oa_pdf/6d/ff/ahmt-8-041.PMC5384699.pdf
Available from: http://www.cancer.gov/about-cancer/treatment/types/targeted-therapies/targeted-therapies-fact-sheet.,Non-OADS,/arxiv_data1/oa_pdf/6d/ff/ahmt-8-041.PMC5384699.pdf
"Adolescent Health, Medicine and Therapeutics 2017:8submit your manuscript | www.dovepress.com Dovepress Dovepress Adolescent Health, Medicine and Therapeutics Publish your work in this journal Submit your manuscript here: http://www.dovepress.com/adolescent-health-medicine-and-therapeutics-journalAdolescent Health, Medicine and Therapeutics is an international,   peer-reviewed, open access journal focusing on health, pathology, and  treatment issues specific to the adolescent age group.",Non-OADS,/arxiv_data1/oa_pdf/6d/ff/ahmt-8-041.PMC5384699.pdf
Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/6d/ff/ahmt-8-041.PMC5384699.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/2a/5a/ott-10-1915.PMC5384700.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).OncoTargets and Therapy 2017:10 1915–1920OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  1915Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OTT .S13153 7 expression of shP-1 and sOcs6 in patients with  acute leukemia and their clinical implication Jinmei liu1 Yurong Zheng1 Ju gao1 guimei Zhu1 Kun gao2 Wenzhen Zhang3 Fangyan shi4 Qing Zhang5 1Department of hematology, Kailuan  general hospital, 2Department of  emergency, Tangshan Union Medical  college hospital, 3Department of  clinical laboratory, Tangshan People’s  hospital, 4Department of Blood  Dialysis, linxi hospital, 5Department  of Ultrasonography, Tangshan, People’s  republic of chinaBackground:  To investigate the expression and clinical relevance of Src homology region 2  domain-containing phosphatase-1 (SHP-1) and suppressor of cytokine signaling 6 (SOCS6) in  acute leukemia (AL).",Non-OADS,/arxiv_data1/oa_pdf/2a/5a/ott-10-1915.PMC5384700.pdf
"SHP-1, a member of the protein  tyrosine phosphatase (PTP) family, plays an important role in suppressing the growth- promoting and oncogenic potentials of tyrosine kinases.3 SHP-1 is primarily expressed  in hematopoietic cells and functions as a negative regulator of p-STAT3Tyr705 signal correspondence: Jinmei liu Department of hematology, Kailuan  general hospital, no 57, Xinhua east  road, lubei District, Tangshan 063000,   People’s republic of china Tel/fax +86 315 302 7152 email drmei2015@sina.co m Journal name: OncoTargets and Therapy Article Designation: Original Research Y ear: 2017 Volume: 10 Running head verso: Liu et al Running head recto: SHP-1 and SOCS6 in acute leukemia DOI: http://dx.doi.org/10.2147/OTT.S131537",Non-OADS,/arxiv_data1/oa_pdf/2a/5a/ott-10-1915.PMC5384700.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open  access journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/2a/5a/ott-10-1915.PMC5384700.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/2a/5a/ott-10-1915.PMC5384700.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/ba/bf/ndt-13-987.PMC5384701.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Neuropsychiatric Disease and Treatment 2017:13 987–1006Neuropsychiatric Disease and Treatment Dove press submit your manuscript | www.dovepress.co m Dove press  987CliNiC al Trial repor Topen access to scientific and medical research open access Full T ext article http: //dx.doi.org/10.2147/NDT .S13099 4 an internet-based program for depressive  symptoms using human and automated support:  a randomized controlled trial adriana Mira1 Juana Bretón-lópez1,2 azucena García-p alacios1,2 Soledad Quero1,2 rosa María Baños2,3 Cristina Botella1,2 1Department of Basic, Clinical  psychology and psychobiology,   labpsitec, Universitat Jaume i,   Castellón de la plana, Spain; 2CiBer of  physiopathology of obesity and  Nutrition C iBerobn, CB06/03  instituto de Salud Carlos iii, Santiago  de Compostela, Spain; 3Department  of personality, evaluation and  psychological Treatment, Universidad  de Valencia, Valencia, SpainPurpose:  The purpose of this study was to analyze the efficacy of an Internet-based program  for depressive symptoms using automated support by information and communication technolo - gies (ICTs) and human support.",Non-OADS,/arxiv_data1/oa_pdf/ba/bf/ndt-13-987.PMC5384701.pdf
"Thus, if people feel tense too often or the tension goes on for too long, they become Correspondence: adriana Mira  Department of Basic, Clinical psychology  and psychobiology, labpsitec, Universitat  Jaume i, av Sos Baynat s/n, 12071  Castellón de la plana, Spain Tel +34 964 387 651 email miraa@uji.e s Journal name: Neuropsychiatric Disease and Treatment Article Designation: Clinical Trial Report Y ear: 2017 Volume: 13 Running head verso: Mira et al Running head recto: Types of support in an Internet-based intervention DOI: http://dx.doi.org/10.2147/NDT.S130994",Non-OADS,/arxiv_data1/oa_pdf/ba/bf/ndt-13-987.PMC5384701.pdf
"It is designed  for optimal use on a personal computer, but it can also be  used on a tablet ( https://www.sonreiresdivertido.com /).",Non-OADS,/arxiv_data1/oa_pdf/ba/bf/ndt-13-987.PMC5384701.pdf
"Neuropsychiatric Disease and Treatment Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journa lNeuropsychiatric Disease and Treatment is an international, peer- reviewed journal of clinical therapeutics and pharmacology focusing   on concise rapid reporting of clinical or pre-clinical studies on a   range of neuropsychiatric and neurological disorders.",Non-OADS,/arxiv_data1/oa_pdf/ba/bf/ndt-13-987.PMC5384701.pdf
Visit http://www.dovepress.com/testimonials.ph p to  read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/ba/bf/ndt-13-987.PMC5384701.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/d0/14/bctt-9-227.PMC5384703.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/d0/14/bctt-9-227.PMC5384703.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).Breast Cancer - Targets and Therapy 2017:9 227–236Breast Cancer - Targets and Therapy Dovepress submit your manuscript | www.dovepress.com Dovepress 227 ORIGINAL RESEARCH open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/BCTT .S126184 The role of the chemokine receptor XCR1 in  breast cancer cells Xiao Li Yang1,* Li Guo Qi2,* Feng Juan Lin1 Zhou Luo Ou1 1Department of Oncology, Breast  Cancer Institute, Fudan University,   Shanghai Cancer Center, Shanghai,   2Department of Neurosurgery,   Taian City Central Hospital, Taian,  Shangdong, People’s Republic of China *These authors contributed equally to  this workAbstract: Considerable attention has recently been paid to the application of chemokines to  cancer immunotherapy due to their complex role in cell proliferation, invasion, metastasis, and  tumorigenesis, which extends beyond the regulation of lymphocyte migration during immune  responses.",Non-OADS,/arxiv_data1/oa_pdf/d0/14/bctt-9-227.PMC5384703.pdf
"4 X-C motif chemokine recep- tor 1 (XCR1), as the receptor of XCL1, is the only chemokine receptor selectively expressed in “Batf3-IRF-8-Id2-dependent dendritic cells (DCs)” or as “CD8 alpha (+ ) Correspondence: Zhou Luo Ou Department of Oncology, Breast Cancer Institute, Fudan University Shanghai Cancer Center, 270 DongAn Road, Shanghai 200032, People’s Republic of ChinaTel +86 21 6417 5590Fax +86 21 6417 4774Email ouzhouluo@163.comJournal name: Breast Cancer - Targets and Therapy Article Designation: ORIGINAL RESEARCHY ear: 2017V olume: 9Running head verso: Y ang et alRunning head recto: Role of the chemokine receptor XCR1 in breast cancer cellsDOI: http://dx.doi.org/10.2147/BCTT.S126184",Non-OADS,/arxiv_data1/oa_pdf/d0/14/bctt-9-227.PMC5384703.pdf
"Breast Cancer - Targets and Therapy 2017:9submit your manuscript | www.dovepress.com Dovepress Dovepress Breast Cancer - Targets and Therapy Publish your work in this journal Submit your manuscript here: https://www.dovepress.com/breast-cancer---targets-and-therapy-journal Breast Cancer - Targets and Therapy is an international, peer-   reviewed open access journal focusing on breast cancer research,  identification of therapeutic targets and the optimal use of preven-tative and integrated treatment interventions to achieve improved  outcomes, enhanced survival and quality of life for the cancer patient.",Non-OADS,/arxiv_data1/oa_pdf/d0/14/bctt-9-227.PMC5384703.pdf
Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.Dovepress 236 Yang et al  22.,Non-OADS,/arxiv_data1/oa_pdf/d0/14/bctt-9-227.PMC5384703.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/6e/1f/ceor-9-201.PMC5384707.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/6e/1f/ceor-9-201.PMC5384707.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).ClinicoEconomics and Outcomes Research 2017:9 201–206ClinicoEconomics and Outcomes Research Dovepress submit your manuscript | www.dovepress.com Dovepress  201 ORIGINAL RESEARCH open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/CEOR.S115322Cost analysis of pulmonary lobectomy procedure:  comparison of stapler versus precision dissection  and sealant Andrea Droghetti1  Giuseppe Marulli2  Jacopo Vannucci3  Michele Giovanardi1  Maria Caterina Bottoli1  Mark Ragusa3  Giovanni Muriana1 1Thoracic Surgery Division, Carlo  Poma Hospital, Mantova, 2Thoracic  Surgery Division, University of  Padova, Padova, 3Thoracic Surgery  Division, University of Perugia,  Perugia, ItalyObjective: We aimed to evaluate the direct costs of pulmonary lobectomy hospitalization,  comparing surgical techniques for the division of interlobar fissures: stapler (ST) versus elec- trocautery and hemostatic sealant patch (ES).",Non-OADS,/arxiv_data1/oa_pdf/6e/1f/ceor-9-201.PMC5384707.pdf
"1,2Correspondence: Andrea Droghetti Thoracic Surgery Division, Carlo Poma Hospital, Via Lago Paiolo 10, 46100 Mantova, Italy   Tel/fax +39 0376 201959 Email ADroghetti@libero.itJournal name: ClinicoEconomics and Outcomes Research Article Designation: ORIGINAL RESEARCHY ear: 2017V olume: 9Running head verso: Droghetti et alRunning head recto: Cost analysis of pulmonary lobectomy procedureDOI: http://dx.doi.org/10.2147/CEOR.S115322",Non-OADS,/arxiv_data1/oa_pdf/6e/1f/ceor-9-201.PMC5384707.pdf
Available from: http://www.agenziafarmaco.gov.it/it/content/negoziazione-e-rimborsabilit%C3%A0.,Non-OADS,/arxiv_data1/oa_pdf/6e/1f/ceor-9-201.PMC5384707.pdf
Available from: http://www.istat.it/it/archivio/30440.,Non-OADS,/arxiv_data1/oa_pdf/6e/1f/ceor-9-201.PMC5384707.pdf
"ClinicoEconomics and Outcomes Research 2017:9submit your manuscript | www.dovepress.com Dovepress Dovepress ClinicoEconomics and Outcomes Research Publish your work in this journal Submit your manuscript here: https://www.dovepress.com/clinicoeconomics-and-outcomes-research-journalClinicoEconomics and Outcomes Research is an international, peer- reviewed open-access journal focusing on health technology assess-ment, pharmacoeconomics and outcomes research in the areas of   diagnosis, medical devices, and clinical, surgical and pharmacological intervention.",Non-OADS,/arxiv_data1/oa_pdf/6e/1f/ceor-9-201.PMC5384707.pdf
Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.Dovepress 206 Droghetti et al  7.,Non-OADS,/arxiv_data1/oa_pdf/6e/1f/ceor-9-201.PMC5384707.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/5d/12/bctt-9-237.PMC5384708.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/5d/12/bctt-9-237.PMC5384708.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).Breast Cancer - Targets and Therapy 2017:9 237–243Breast Cancer - Targets and Therapy Dovepress submit your manuscript | www.dovepress.com Dovepress 237 ORIGINAL RESEARCH open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/BCTT .S131398 T umescent mastectomy: the current indications  and operative tips and tricks Ashraf Khater1 Alaa Mazy2 Mona Gad2 Ola Taha Abd Eldayem2 Mohamed Hegazy1 1Department of Surgical Oncology,   Mansoura Oncology Center (OCMU),   2Anesthesia and Surgical Intensive  Care Department, Mansoura  University Hospital, Faculty of Medicine, Mansoura University,  Mansoura, EgyptBackground: Tumescent mastectomy refers to usage of a mixture of lidocaine and epinephrine in  a diluting saline solution that makes flaps firm and tense, thus minimizing systemic drugs toxicity  and making surgery possible with minimal bleeding.",Non-OADS,/arxiv_data1/oa_pdf/5d/12/bctt-9-237.PMC5384708.pdf
"3,4 The use of this technique in mastectomy with or without  reconstruction Correspondence:  Ashraf Khater  Department of Surgical Oncology,  Mansoura Oncology Center (OCMU), Faculty of Medicine, Mansoura University, 60 Gomhoria Street, Mansoura, 35511, EgyptTel +20 50 235 8021Email dr.ashrafkhater@yahoo.com Journal name: Breast Cancer - Targets and Therapy Article Designation: ORIGINAL RESEARCHY ear: 2017V olume: 9Running head verso: Khater et alRunning head recto: Tumescent mastectomy; indications and techniqueDOI: http://dx.doi.org/10.2147/BCTT.S131398",Non-OADS,/arxiv_data1/oa_pdf/5d/12/bctt-9-237.PMC5384708.pdf
"Breast Cancer - Targets and Therapy 2017:9submit your manuscript | www.dovepress.com Dovepress Dovepress Breast Cancer - Targets and Therapy Publish your work in this journal Submit your manuscript here: https://www.dovepress.com/breast-cancer---targets-and-therapy-journal Breast Cancer - Targets and Therapy is an international, peer-   reviewed open access journal focusing on breast cancer research,  identification of therapeutic targets and the optimal use of preven-tative and integrated treatment interventions to achieve improved  outcomes, enhanced survival and quality of life for the cancer patient.",Non-OADS,/arxiv_data1/oa_pdf/5d/12/bctt-9-237.PMC5384708.pdf
Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.Dovepress 243 T umescent mastectomy; indications and technique  23.,Non-OADS,/arxiv_data1/oa_pdf/5d/12/bctt-9-237.PMC5384708.pdf
"3, 498 –505 http://dx.doi.org/10.1080/19420862.2017.1279773",Non-OADS,/arxiv_data1/oa_pdf/55/02/kmab-09-03-1279773.PMC5384710.pdf
mAbs 2016; 8:1525-35; PMID:27612038; http://dx.doi.org/ 10.1080/19420862.2016.1231277 2.,OADS,/arxiv_data1/oa_pdf/55/02/kmab-09-03-1279773.PMC5384710.pdf
Anal Chem 2016; 88:9495-502; PMID:27575380; http://dx.doi.org/ 10.1021/acs.analchem.6b01958 3.,OADS,/arxiv_data1/oa_pdf/55/02/kmab-09-03-1279773.PMC5384710.pdf
Biochemistry 2008; 47:5088-100; PMID:18407665; http://dx.doi.org/10.1021/bi702238b 4.,Non-OADS,/arxiv_data1/oa_pdf/55/02/kmab-09-03-1279773.PMC5384710.pdf
Protein Sci 2009; 18:424-33; PMID:19165723; http://dx.doi.org/10.1002/pro.45 5.,Non-OADS,/arxiv_data1/oa_pdf/55/02/kmab-09-03-1279773.PMC5384710.pdf
"Gaza-Bulseco G, Faldu S, Hurkmans K, Chumsae C, Liu H. Effect of methionine oxidation of a recombinant monoclonal antibody on the binding af ﬁnity to protein A and protein G. J Chromatogr B Analyt Technol Biomed Life Sci 2008; 870:55-62; PMID:18567545; http://dx.doi.org/10.1016/j.jchromb.2008.05.045 6.",OADS,/arxiv_data1/oa_pdf/55/02/kmab-09-03-1279773.PMC5384710.pdf
Mol Immunol 2009; 46:1878-82; PMID:19269032; http://dx.doi.org/10.1016/j.molimm.2009.02.002 7.,Non-OADS,/arxiv_data1/oa_pdf/55/02/kmab-09-03-1279773.PMC5384710.pdf
Analyt Chem 2014; 86:3468-75; PMID:24597564;http://dx.doi.org/10.1021/ac404130a 8.,OADS,/arxiv_data1/oa_pdf/55/02/kmab-09-03-1279773.PMC5384710.pdf
J Pharm Sci 2015; 104:368- 77; PMID:25175600; http://dx.doi.org/10.1002/jps.24136 9.,Non-OADS,/arxiv_data1/oa_pdf/55/02/kmab-09-03-1279773.PMC5384710.pdf
Mol Immunol 2011; 48:860-6; PMID:21256596; http://dx.doi.org/10.1016/j.molimm.2010.12.009 10.,Non-OADS,/arxiv_data1/oa_pdf/55/02/kmab-09-03-1279773.PMC5384710.pdf
Analyt Chem 2013; 85:715-36; PMID:23134362; http://dx.doi.org/10.1021/ac3032355 11.,OADS,/arxiv_data1/oa_pdf/55/02/kmab-09-03-1279773.PMC5384710.pdf
J Chromatog A 2016; 1460:51-60; PMID:27432793; http://dx.doi.org/10.1016/j.chroma.2016.06.085 12.,OADS,/arxiv_data1/oa_pdf/55/02/kmab-09-03-1279773.PMC5384710.pdf
mAbs 2015; 7:881-90; PMID:26186204; http://dx.doi.org/10.1080/19420862.2015.1069454 13.,Non-OADS,/arxiv_data1/oa_pdf/55/02/kmab-09-03-1279773.PMC5384710.pdf
mAbs 2016; 8:1477-86; PMID:27598507; http://dx.doi.org/10.1080/19420862.2016.1226715 14.,Non-OADS,/arxiv_data1/oa_pdf/55/02/kmab-09-03-1279773.PMC5384710.pdf
J Chromatogr A 2006; 1123:189-98; PMID:16716331;http://dx.doi.org/10.1016/j.chroma.2006.04.046 15.,OADS,/arxiv_data1/oa_pdf/55/02/kmab-09-03-1279773.PMC5384710.pdf
mAbs 2014; 6:879-93; PMID:24927271; http://dx.doi.org/10.4161/mabs.28762 16.,OADS,/arxiv_data1/oa_pdf/55/02/kmab-09-03-1279773.PMC5384710.pdf
J Chromatogr B Analyt Technol Biomed Life Sci 2014; 961:1-4;PMID:24837162; http://dx.doi.org/10.1016/j.jchromb.2014.04.053 17.,OADS,/arxiv_data1/oa_pdf/55/02/kmab-09-03-1279773.PMC5384710.pdf
J Chromatogr A 2007; 1156:174-82; PMID:17379231; http://dx.doi.org/10.1016/j.chroma.2007.01.140 19.,OADS,/arxiv_data1/oa_pdf/55/02/kmab-09-03-1279773.PMC5384710.pdf
J Chromatog A 2008; 1214:81-9; PMID:19012891; http://dx.doi.org/10.1016/j.chroma.2008.10.078 20.,OADS,/arxiv_data1/oa_pdf/55/02/kmab-09-03-1279773.PMC5384710.pdf
J Chromatogr BAnalyt Technol Biomed Life Sci 2011; 879:955-60; PMID:21440514;http://dx.doi.org/10.1016/j.jchromb.2011.03.006 21.,OADS,/arxiv_data1/oa_pdf/55/02/kmab-09-03-1279773.PMC5384710.pdf
mAbs 2014; 6:852-8;PMID:24751784; http://dx.doi.org/10.4161/mabs.28693 22.,Non-OADS,/arxiv_data1/oa_pdf/55/02/kmab-09-03-1279773.PMC5384710.pdf
J Pharm Sci 2012; 101:4248-57; PMID:22899501; http://dx.doi.org/10.1002/jps.23286 23.,Non-OADS,/arxiv_data1/oa_pdf/55/02/kmab-09-03-1279773.PMC5384710.pdf
J Chromatogr A 2016; 1431:154-65; PMID:26774436; http://dx.doi.org/10.1016/j.chroma.2015.12.068 2 4 .,OADS,/arxiv_data1/oa_pdf/55/02/kmab-09-03-1279773.PMC5384710.pdf
J Chromatogr A 2011; 1218:2091-7; PMID:21145555; http://dx.doi.org/10.1016/j.chroma.2010.10.107 25.,OADS,/arxiv_data1/oa_pdf/55/02/kmab-09-03-1279773.PMC5384710.pdf
E xp Rev Proteomics 2016; 13:157-83; PMID:26653789; http://dx.doi.org/10.1586/14789450.2016.1132167 26.,Non-OADS,/arxiv_data1/oa_pdf/55/02/kmab-09-03-1279773.PMC5384710.pdf
Analyt Biochem 2011; 415:212-4; PMID:21596014; http://dx.doi.org/10.1016/j.ab.2011.04.030 27.,OADS,/arxiv_data1/oa_pdf/55/02/kmab-09-03-1279773.PMC5384710.pdf
"Analyst 2016; 141:3114-25; PMID:27156477; http://dx.doi.org/10.1039/C6AN00071A 2 9 .F e k e t eS ,G u i l l a r m eD ,S a n d r aP ,S a n d r aK .C h r o m a t o g r a p h i c , electrophoretic, and mass spectrometric methods for the analytical characterization of protein biopharmaceuticals.",OADS,/arxiv_data1/oa_pdf/55/02/kmab-09-03-1279773.PMC5384710.pdf
mAbs 2016; 8:1224-34; PMID:27362833; http://dx.doi.org/10.1080/ 19420862.2016.1203497 31.,OADS,/arxiv_data1/oa_pdf/55/02/kmab-09-03-1279773.PMC5384710.pdf
mAbs 2016; 8:318-30;PMID:26760197; http://dx.doi.org/10.1080/19420862.2015.1128607 32.,OADS,/arxiv_data1/oa_pdf/55/02/kmab-09-03-1279773.PMC5384710.pdf
mAbs 2013; 5:699-710; PMID:23924801; http://dx.doi.org/10.4161/mabs.25423 33.,OADS,/arxiv_data1/oa_pdf/55/02/kmab-09-03-1279773.PMC5384710.pdf
Acs Sym Ser 2015; 1201:1-62; http://dx.doi.org/ 10.1021/bk-2015-1201.ch001 34.,Non-OADS,/arxiv_data1/oa_pdf/55/02/kmab-09-03-1279773.PMC5384710.pdf
Biochem Biophys Res Commun 2016; 477:363-8;PMID:27342663; http://dx.doi.org/10.1016/j.bbrc.2016.06.099 36.,OADS,/arxiv_data1/oa_pdf/55/02/kmab-09-03-1279773.PMC5384710.pdf
J Proteom 2016; 134:93-101; PMID:26485299; http://dx.doi.org/10.1016/j.jprot.2015.10.021 37.,OADS,/arxiv_data1/oa_pdf/55/02/kmab-09-03-1279773.PMC5384710.pdf
mAbs 2015; 7:719-31; PMID:26030340; http://dx.doi.org/10.1080/19420862.2015.104666339.,OADS,/arxiv_data1/oa_pdf/55/02/kmab-09-03-1279773.PMC5384710.pdf
Analyst 2013; 138:3058-65; PMID:23579346; http://dx.doi.org/10.1039/c3an36524g 40.,Non-OADS,/arxiv_data1/oa_pdf/55/02/kmab-09-03-1279773.PMC5384710.pdf
Ana- lyt Chem 2016; 88:5430-7; PMID:27115984; http://dx.doi.org/10.1021/ acs.analchem.6b00822 41.,OADS,/arxiv_data1/oa_pdf/55/02/kmab-09-03-1279773.PMC5384710.pdf
Analyt Chim Acta 2016;918:50-9; PMID:27046210; http://dx.doi.org/10.1016/j.aca.2016.03.006 42.,OADS,/arxiv_data1/oa_pdf/55/02/kmab-09-03-1279773.PMC5384710.pdf
"mAbs 2014; 6:273-85; PMID:24135617; http://dx.doi.org/10.4161/mabs.26773 43. von Pawel-Rammingen U, Johansson BP, Bjorck L. IdeS, a novel streptococcal cysteine proteinase with unique speci ﬁcity for immuno- globulin G. The EMBO journal 2002; 21:1607-15; PMID:11927545; http://dx.doi.org/10.1093/emboj/21.7.1607 44.",Non-OADS,/arxiv_data1/oa_pdf/55/02/kmab-09-03-1279773.PMC5384710.pdf
BMC microbiology 2011; 11:120; PMID:21619648; http://dx.doi.org/10.1186/1471-2180-11-120 45.,Non-OADS,/arxiv_data1/oa_pdf/55/02/kmab-09-03-1279773.PMC5384710.pdf
J Chromatogrphy B Analyt Tech-nol Biomed Life Sci 2007; 850:285-94; PMID:17182291; http://dx.doi.org/10.1016/j.jchromb.2006.11.050 47.,OADS,/arxiv_data1/oa_pdf/55/02/kmab-09-03-1279773.PMC5384710.pdf
mAbs 2014; 6:1229-42; PMID:25517308; http://dx.doi.org/10.4161/mabs.29601 48.,Non-OADS,/arxiv_data1/oa_pdf/55/02/kmab-09-03-1279773.PMC5384710.pdf
Analyt Chem 2016; 88:8673-9; PMID:27487007; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/55/02/kmab-09-03-1279773.PMC5384710.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/d6/5e/ndt-13-959.PMC5384714.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Neuropsychiatric Disease and Treatment 2017:13 959–965Neuropsychiatric Disease and Treatment Dove press submit your manuscript | www.dovepress.co m Dove press  959OrigiNal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/NDT .S13431 1 sleep apnea and the subsequent risk of Parkinson’s  disease: a 3-year nationwide population-based  study Ping-song chou1 chiou-lian lai1–3 Yii-her chou4,5,* Wei-Pin chang6,* 1Department of Neurology, Kaohsiung  Medical University hospital,   2Department of Neurology, Faculty  of Medicine, college of Medicine,   3Department of Neurology, Kaohsiung  Municipal hsiao-Kang hospital,   4Department of Urology, Faculty  of Medicine, college of Medicine,   5Department of Urology, Kaohsiung  Medical University hospital,   Kaohsiung Medical University,   Kaohsiung, 6school of health care  administration, Taipei Medical  University, Taipei city, Taiwan *These authors contributed equally  to this workPurpose:  Sleep apnea (SA)-induced chronic intermittent hypoxia increases oxidative stress  and inflammation, which may contribute to the pathophysiology of Parkinson’s disease (PD).",Non-OADS,/arxiv_data1/oa_pdf/d6/5e/ndt-13-959.PMC5384714.pdf
"Insomnia, day - time sleepiness with sleep attacks, restless legs syndrome, and rapid eye move - ment sleep behavior disorder  are the most frequent sleep disorders associated with  PD.8 Furthermore, snoring was observed in up to 70% of patients with PD,9 and  14.5%–60% of patients with PD were estimated to have an apnea–hypopnea index  of .15.10 Therefore, a close association between sleep-disordered breathing and PD  can be considered.correspondence: Wei-Pin chang school of health care administration,  Taipei Medical University, No 250  Wuxing street, Taipei 110, Taiwan Tel +886 2 6638 2736 ext 1008 Fax +886 2 2378 9788 email wpchang@tmu.edu.t w Journal name: Neuropsychiatric Disease and Treatment Article Designation: Original Research Y ear: 2017 Volume: 13 Running head verso: Chou et al Running head recto: Risk of Parkinson’s disease in sleep apnea DOI: http://dx.doi.org/10.2147/NDT.S134311",Non-OADS,/arxiv_data1/oa_pdf/d6/5e/ndt-13-959.PMC5384714.pdf
"Neuropsychiatric Disease and Treatment Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journa lNeuropsychiatric Disease and Treatment is an international, peer- reviewed journal of clinical therapeutics and pharmacology focusing   on concise rapid reporting of clinical or pre-clinical studies on a   range of neuropsychiatric and neurological disorders.",Non-OADS,/arxiv_data1/oa_pdf/d6/5e/ndt-13-959.PMC5384714.pdf
Visit http://www.dovepress.com/testimonials.ph p to  read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/d6/5e/ndt-13-959.PMC5384714.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/ae/57/dddt-11-1027.PMC5384716.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Drug Design, Development and Therapy 2017:11 1027–1033Drug Design, Development and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  1027Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/DDDT .S12941 9 effects of β-d-mannuronic acid, as a novel non- steroidal anti-inflammatory medication within  immunosuppressive properties, on IL17, RORγ  t,  IL4 and GATA3  gene expressions in rheumatoid  arthritis patients anis Barati1 ahmad reza Jamshidi2,* hossein ahmadi1 Zahra aghazadeh1 abbas Mirshafiey1,* 1Department of immunology, school  of Public health, 2iranian institute  for health sciences research,   rheumatology research center,   shariati hospital, Tehran University  of Medical sciences, T ehran, iran *These authors contributed equally  to this workAbstract:  Rheumatoid arthritis (RA) is the most common form of chronic inflammatory  arthritis characterized by pain, swelling and destruction of joints, with a resultant disability.",Non-OADS,/arxiv_data1/oa_pdf/ae/57/dddt-11-1027.PMC5384716.pdf
"Keywords:  M2000, IL17 , RORγ t, rheumatoid arthritis, inflammation, immunosuppressive Introduction Alginic acid as a biomaterial has been successfully used in biomedical science,  bioengineering and especially pharmaceutical application for over 40  years without any  significant side effects.1 It has been applied in drug delivery systems such as controlled  release, disintegrant, film former, thickening and stabilization.2 Moreover, the positive  effect, safety and efficacy of sodium alginate on gastric reflux control and wound care  have been completely proved.3 Accordingly, its comonomer β-d-mannuronic acid  (M2000), patented (DEU: 102016113018.4), has been shown to have significant thera - peutic and anti-inflammatory properties in several experimental models.4 Since sodium  alginate comes from a natural polysaccharide (brown seaweeds), its comonomers have Correspondence: Abbas Mirshafiey Department of immunology, school  of Public health, Tehran University  of Medical sciences, Box 14155-6446,  Tehran, iran Tel +98 21 8895 4913 Fax +98 21 8895 4913 email mirshafiey@tums.ac.i rJournal name: Drug Design, Development and Therapy Article Designation: Original Research Y ear: 2017 Volume: 11 Running head verso: Barati et al Running head recto: Effects of M2000 on rheumatoid arthritis patients DOI: http://dx.doi.org/10.2147/DDDT.S129419",Non-OADS,/arxiv_data1/oa_pdf/ae/57/dddt-11-1027.PMC5384716.pdf
"Drug Design, Development and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/drug-design-development-and-therapy-journa lDrug Design, Development and Therapy is an international, peer- reviewed open-access journal that spans the spectrum of drug design  and development through to clinical applications.",Non-OADS,/arxiv_data1/oa_pdf/ae/57/dddt-11-1027.PMC5384716.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/ae/57/dddt-11-1027.PMC5384716.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/5b/e4/ndt-13-967.PMC5384718.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Neuropsychiatric Disease and Treatment 2017:13 967–972Neuropsychiatric Disease and Treatment Dove press submit your manuscript | www.dovepress.co m Dove press  967OrigiNal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/NDT .S13174 6 T welve-week physical exercise does not have a  long-lasting effect on kynurenines in plasma of  depressed patients Vincent Millischer1,2 sophie erhardt3 Örjan ekblom4 Yvonne Forsell5 catharina lavebratt1,2 1Department of Molecular Medicine  and surgery, Karolinska institutet,   2center for Molecular Medicine,   Karolinska University hospital,   3Department of Physiology and  Pharmacology, Karolinska institutet,   4Department of sport sciences, The  swedish school of sport and health  sciences, gih, 5Department of Public  health sciences, Karolinska institutet,   stockholm, swedenBackground:  Physical exercise has well-characterized positive effects on depressive symptoms.",Non-OADS,/arxiv_data1/oa_pdf/5b/e4/ndt-13-967.PMC5384718.pdf
"Its products include kynurenine, a metabolite able to cross correspondence: Vincent Millischer Neurogenetics Unit, center for  Molecular Medicine, Karolinska  University hospital, l8:00, 171 76  stockholm, sweden Tel +46 8 5177 5541 email vincent.millischer@ki.s eJournal name: Neuropsychiatric Disease and Treatment Article Designation: Original Research Y ear: 2017 Volume: 13 Running head verso: Millischer et al Running head recto: Physical exercise and plasma kynurenines DOI: http://dx.doi.org/10.2147/NDT.S131746",Non-OADS,/arxiv_data1/oa_pdf/5b/e4/ndt-13-967.PMC5384718.pdf
"Neuropsychiatric Disease and Treatment Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journa lNeuropsychiatric Disease and Treatment is an international, peer- reviewed journal of clinical therapeutics and pharmacology focusing   on concise rapid reporting of clinical or pre-clinical studies on a   range of neuropsychiatric and neurological disorders.",Non-OADS,/arxiv_data1/oa_pdf/5b/e4/ndt-13-967.PMC5384718.pdf
Visit http://www.dovepress.com/testimonials.ph p to  read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/5b/e4/ndt-13-967.PMC5384718.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/3c/22/cia-12-611.PMC5384721.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Clinical Interventions in Aging 2017:12 611–617Clinical Interventions in Aging Dove press submit your manuscript | www.dovepress.co m Dove press  611OrIg InAl reseArChopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/CIA.S12981 8 Prevalence and pattern of the elongated  styloid process among geriatric patients in saudi  Arabia Bader K AlZarea Department of Prosthodontics,   College of Dentistry, AlJouf University,   sakaka, Kingdom of saudi ArabiaObjective:  The objectives of this study were to assess the elongation of the styloid process  on digital panoramic radiographs and to evaluate the prevalence of the elongation according  to age, sex and types.",Non-OADS,/arxiv_data1/oa_pdf/3c/22/cia-12-611.PMC5384721.pdf
"It is proposed that these features  are manifested due to the pressure of the styloid process on the neural and vascular  structures, which are in its vicinity.15 Differential diagnoses in these patients include  cranial nerve neuralgias, unerupted or impacted tooth, temporal arthritis, diseases of  the temporomandibular joint, migraine headaches, pharyngotonsillitis and head and Correspondence: Bader K AlZarea Department of Prosthodontics, College  of Dentistry, AlJouf University, sakaka,  Kingdom of saudi Arabia email bkzarea@ju.edu.s a Journal name: Clinical Interventions in Aging Article Designation: Original Research Y ear: 2017 Volume: 12 Running head verso: AlZarea Running head recto: Length of styloid process among the Saudi Arabian population DOI: http://dx.doi.org/10.2147/CIA.S129818",Non-OADS,/arxiv_data1/oa_pdf/3c/22/cia-12-611.PMC5384721.pdf
"Clinical Interventions in Aging Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-interventions-in-aging-journa lClinical Interventions in Aging is an international, peer-reviewed journal  focusing on evidence-based reports on the value or lack thereof of treatments  intended to prevent or delay the onset of maladaptive correlates of aging  in human beings.",Non-OADS,/arxiv_data1/oa_pdf/3c/22/cia-12-611.PMC5384721.pdf
Visit http://www.dovepress.,Non-OADS,/arxiv_data1/oa_pdf/3c/22/cia-12-611.PMC5384721.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/22/39/ott-10-1897.PMC5384723.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).OncoTargets and Therapy 2017:10 1897–1908OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  1897Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OTT .S13250 7 cytokine-induced killer cells/dendritic cells and  cytokine-induced killer cells immunotherapy for  the treatment of esophageal cancer in china:  a meta-analysis Yan liu1,* Ying Mu2,* anqi Zhang3 shaoda ren3 Weihua Wang3 Jiaping Xie2 Yingxin Zhang3 changhui Zhou3 1Department of gastroenterology,   Weifang People’s hospital, Weifang,   2Department of gastroenterology,   3central laboratory, liaocheng  People’s hospital, liaocheng clinical  school of Taishan Medical University,   liaocheng, shandong Province,   People’s republic of china *These authors contributed equally  to this workBackground:  Immunotherapy based on cytokine-induced killer cells or combination of dendritic  cells and cytokine-induced killer cells (CIK/DC-CIK) showed promising clinical outcomes for  treating esophageal cancer (EC).",Non-OADS,/arxiv_data1/oa_pdf/22/39/ott-10-1897.PMC5384723.pdf
"Keywords:  cytokine-induced killer cells, dendritic cells, esophageal cancer, immunotherapy,  meta-analysis Introduction Esophageal cancer (EC) is a global common cancer, with 450,000 new cases and  400,000 estimated deaths per year.1,2 The incidence of EC has increased exponentially  over the past few decades and the 5-year survival rate remains bleak.3 At present,  surgery, radiotherapy and chemotherapy are most widely used for EC.4 However, their correspondence: changhui Zhou;  Yingxin Zhang central laboratory, liaocheng People’s  hospital, liaocheng clinical school of  Taishan Medical University, Dongchang  West road, no 67, liaocheng 252000,  shandong Province, People’s republic  of china Tel +86 135 6207 8772;  +86 139 6351 0009 email zhouch2006@163.co m;  zhangyingxin77@163.co m Journal name: OncoTargets and Therapy Article Designation: Original Research Y ear: 2017 Volume: 10 Running head verso: Liu et al Running head recto: Cytokine-induced killer cells for the treatment of esophageal cancer DOI: http://dx.doi.org/10.2147/OTT.S132507",Non-OADS,/arxiv_data1/oa_pdf/22/39/ott-10-1897.PMC5384723.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open  access journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/22/39/ott-10-1897.PMC5384723.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/22/39/ott-10-1897.PMC5384723.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/d4/4a/cia-12-619.PMC5384725.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Clinical Interventions in Aging 2017:12 619–628Clinical Interventions in Aging Dove press submit your manuscript | www.dovepress.co m Dove press  619RevIewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/CIA.S13190 3 Systematic review on strength training in  Parkinson’s disease: an unsolved question Ileana Ramazzina1 Benedetta Bernazzoli2 Cosimo Costantino1 1Department of Biomedical,   Biotechnological and Translational  Sciences, 2Department of Clinical  and experimental Medicine, Graduate  School of Rehabilitation and Physical  Medicine, University of Parma,   Parma,  ItalyAbstract:  The purpose of this study was to investigate the effectiveness of strength training,  performed against a different resistance from body weight, in improving motor and nonmotor  symptoms in patients with Parkinson’s disease (PD).",Non-OADS,/arxiv_data1/oa_pdf/d4/4a/cia-12-619.PMC5384725.pdf
"The loss of functions of  native alpha-synuclein and the gain of toxic functions following the misfolding or  oligomerization process play a pivotal role in the pathogenesis of PD.5,6Correspondence: Cosimo Costantino Department of Biomedical,  Biotechnological and Translational  Sciences, University of Parma,  via Gramsci, 14, 43126 Parma, Italy Tel +39 521 703 517 Fax +39 521 702 893 email cosimo.costantino@unipr.i t Journal name: Clinical Interventions in Aging Article Designation: Review Y ear: 2017 Volume: 12 Running head verso: Ramazzina et al Running head recto: Different types of strength training in PD DOI: http://dx.doi.org/10.2147/CIA.S131903",Non-OADS,/arxiv_data1/oa_pdf/d4/4a/cia-12-619.PMC5384725.pdf
"Clinical Interventions in Aging Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-interventions-in-aging-journa lClinical Interventions in Aging is an international, peer-reviewed journal  focusing on evidence-based reports on the value or lack thereof of treatments  intended to prevent or delay the onset of maladaptive correlates of aging  in human beings.",Non-OADS,/arxiv_data1/oa_pdf/d4/4a/cia-12-619.PMC5384725.pdf
Visit http://www.dovepress.,Non-OADS,/arxiv_data1/oa_pdf/d4/4a/cia-12-619.PMC5384725.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered , transformed, or built upon in any way.MABS 2017, VOL.",Non-OADS,/arxiv_data1/oa_pdf/fb/39/kmab-09-03-1276683.PMC5384726.pdf
"3, 536 –549 http://dx.doi.org/10.1080/19420862.2016.1276683",Non-OADS,/arxiv_data1/oa_pdf/fb/39/kmab-09-03-1276683.PMC5384726.pdf
ORCID Shreya Pramanick http://orcid.org/0000-0002-9487-0212 References 1.,Non-OADS,/arxiv_data1/oa_pdf/fb/39/kmab-09-03-1276683.PMC5384726.pdf
Gastro- enterology 2007; 132:2131-57; PMID:17498508; http://dx.doi.org/ 10.1053/j.gastro.2007.03.054MABS 547,Non-OADS,/arxiv_data1/oa_pdf/fb/39/kmab-09-03-1276683.PMC5384726.pdf
VitamHorm 2009; 80:409-71; PMID:19251046; http://dx.doi.org/10.1016/S0083-6729(08)00615-8 3.,Non-OADS,/arxiv_data1/oa_pdf/fb/39/kmab-09-03-1276683.PMC5384726.pdf
Diabetes 2011; 60:3103-9; PMID:21984584; http://dx.doi.org/10.2337/db11- 0979 4.,Non-OADS,/arxiv_data1/oa_pdf/fb/39/kmab-09-03-1276683.PMC5384726.pdf
Expert Opin Investig Drugs 2010; 19:1039-48; PMID:20698813; http://dx.doi.org/10.1517/13543784.2010.513381 5.,Non-OADS,/arxiv_data1/oa_pdf/fb/39/kmab-09-03-1276683.PMC5384726.pdf
Diabet Med 2008; 25:759-64.; PMID: 18513308; http://dx.doi.org/10.1111/j.1464-5491.2008.02455.x 6.,Non-OADS,/arxiv_data1/oa_pdf/fb/39/kmab-09-03-1276683.PMC5384726.pdf
Regul Pept 2002; 107:1- 13; PMID:12137960; http://dx.doi.org/10.1016/S0167-0115(02)00039-3 7.,OADS,/arxiv_data1/oa_pdf/fb/39/kmab-09-03-1276683.PMC5384726.pdf
Diabetes2004; 53(Suppl 3):S190-6; PMID:15561910; http://dx.doi.org/10.2337/diabetes.53.suppl_3.S190 8.,Non-OADS,/arxiv_data1/oa_pdf/fb/39/kmab-09-03-1276683.PMC5384726.pdf
Endocrinology 1993; 133:2861-70; PMID:8243312; http://dx.doi.org/10.1210/endo.133.6.8243312 9.,Non-OADS,/arxiv_data1/oa_pdf/fb/39/kmab-09-03-1276683.PMC5384726.pdf
Biochem Pharmacol 2015; 96:237-46; PMID:26043830; http://dx.doi.org/10.1016/j.bcp.2015.05.015 10.,Non-OADS,/arxiv_data1/oa_pdf/fb/39/kmab-09-03-1276683.PMC5384726.pdf
Biochem Soc Trans 2007; 35:709-12; PMID:17635130;http://dx.doi.org/10.1042/BST0350709 11.,OADS,/arxiv_data1/oa_pdf/fb/39/kmab-09-03-1276683.PMC5384726.pdf
Trends Phar- macol Sci 2014; 35:12-22; PMID:24359917; http://dx.doi.org/10.1016/j.tips.2013.11.001 12.,OADS,/arxiv_data1/oa_pdf/fb/39/kmab-09-03-1276683.PMC5384726.pdf
Nat Med 2002; 8:738-42;PMID:12068290; http://dx.doi.org/10.1038/nm727 13.,OADS,/arxiv_data1/oa_pdf/fb/39/kmab-09-03-1276683.PMC5384726.pdf
Biochem Biophys Res Commun 2007; 364:175-80; PMID:17937928; http://dx.doi.org/10.1016/j.bbrc.2007.09.128 14.,OADS,/arxiv_data1/oa_pdf/fb/39/kmab-09-03-1276683.PMC5384726.pdf
Mol Cell Endocrinol 2015; 401:120-9; PMID:25449420; http://dx.doi.org/10.1016/j.mce.2014.10.025 15.,OADS,/arxiv_data1/oa_pdf/fb/39/kmab-09-03-1276683.PMC5384726.pdf
Diabetologia2007; 50:1752-62; PMID:17558485; http://dx.doi.org/10.1007/s00125- 007-0710-4 16.,Non-OADS,/arxiv_data1/oa_pdf/fb/39/kmab-09-03-1276683.PMC5384726.pdf
J Biol Chem 2013; 288:19760-72; PMID: 23689510; http://dx.doi.org/10.1074/jbc.M112.426288 18.,OADS,/arxiv_data1/oa_pdf/fb/39/kmab-09-03-1276683.PMC5384726.pdf
mAbs 2010; 2:594-606; PMID: 20864805; http://dx.doi.org/10.4161/mabs.2.6.13420 19.,Non-OADS,/arxiv_data1/oa_pdf/fb/39/kmab-09-03-1276683.PMC5384726.pdf
mAbs 2016; 8:264-77; PMID: 26652308; http://dx.doi.org/10.1080/19420862.2015.1118596 20.,OADS,/arxiv_data1/oa_pdf/fb/39/kmab-09-03-1276683.PMC5384726.pdf
J Immunol 2012; 188:322-33; PMID:22131336; http://dx.doi.org/10.4049/jimmunol.1102466 21.,Non-OADS,/arxiv_data1/oa_pdf/fb/39/kmab-09-03-1276683.PMC5384726.pdf
J Immunol Methods 2014; 405:1-14; PMID: 24380699; http://dx.doi.org/10.1016/j.jim.2013.12.007 22.,Non-OADS,/arxiv_data1/oa_pdf/fb/39/kmab-09-03-1276683.PMC5384726.pdf
Bioinformatics 2006; 22:1540-2;PMID: 16595560; http://dx.doi.org/10.1093/bioinformatics/btl117 23.,OADS,/arxiv_data1/oa_pdf/fb/39/kmab-09-03-1276683.PMC5384726.pdf
Bioinformatics 2007; 23:2947-8; PMID: 17846036; http://dx.doi.org/10.1093/bioinformatics/btm404 25.,OADS,/arxiv_data1/oa_pdf/fb/39/kmab-09-03-1276683.PMC5384726.pdf
"Microscopy(Oxford, England) 2016; 65:341-52; PMID:27107009; http://dx.doi.org/10.1093/jmicro/dfw014 26.",Non-OADS,/arxiv_data1/oa_pdf/fb/39/kmab-09-03-1276683.PMC5384726.pdf
Biochem Biophys Res Commun 2015;463:414-20; PMID: 26036575; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/fb/39/kmab-09-03-1276683.PMC5384726.pdf
mAbs 2012; 4:17-23; PMID: 22327427; http://dx.doi.org/10.4161/ mabs.4.1.18347 29.,Non-OADS,/arxiv_data1/oa_pdf/fb/39/kmab-09-03-1276683.PMC5384726.pdf
Anal Chem 2010; 82:5219-26; PMID: 20491447; http://dx.doi.org/10.1021/ac100575n 30.,Non-OADS,/arxiv_data1/oa_pdf/fb/39/kmab-09-03-1276683.PMC5384726.pdf
J Pharm Sci 2010; 99:764-81; PMID:19691118; http://dx.doi.org/10.1002/jps.21868 31.,Non-OADS,/arxiv_data1/oa_pdf/fb/39/kmab-09-03-1276683.PMC5384726.pdf
mAbs 2013; 5:608-13; PMID: 23751615; http://dx.doi.org/ 10.4161/mabs.24725 32.,Non-OADS,/arxiv_data1/oa_pdf/fb/39/kmab-09-03-1276683.PMC5384726.pdf
Arthritis Res Ther 2015; 17:135; PMID:25994180; http://dx.doi.org/10.1186/s13075-015-0651-0548 J. D. K €ONITZER ET AL.,Non-OADS,/arxiv_data1/oa_pdf/fb/39/kmab-09-03-1276683.PMC5384726.pdf
Pharmacology & Therapeutics 2017; 169:47-56;PMID:27373507; http://dx.doi.org/10.1016/j.pharmthera.2016.06.012 3 4 .,Non-OADS,/arxiv_data1/oa_pdf/fb/39/kmab-09-03-1276683.PMC5384726.pdf
Front Immunol 2015; 6; PMID: 25852694; http://dx.doi.org/10.3389/ ﬁmmu.2015.00126 36.,Non-OADS,/arxiv_data1/oa_pdf/fb/39/kmab-09-03-1276683.PMC5384726.pdf
PLoS One 2013; 8:e80108;PMID: 24278246; http://dx.doi.org/10.1371/journal.pone.0080108 37.,Non-OADS,/arxiv_data1/oa_pdf/fb/39/kmab-09-03-1276683.PMC5384726.pdf
Immunity 2000; 13:37-45; PMID: 10933393; http://dx.doi.org/10.1016/S1074-7613(00)00006-6 38.,OADS,/arxiv_data1/oa_pdf/fb/39/kmab-09-03-1276683.PMC5384726.pdf
PLoS One 2014; 9:e92451; PMID: 24651868; http://dx.doi.org/10.1371/journal.pone.0092451 39.,Non-OADS,/arxiv_data1/oa_pdf/fb/39/kmab-09-03-1276683.PMC5384726.pdf
Anal Biochem 2009; 386:172-80; PMID: 19111520; http://dx.doi.org/10.1016/j.ab.2008.11.038 40.,OADS,/arxiv_data1/oa_pdf/fb/39/kmab-09-03-1276683.PMC5384726.pdf
J Immunol Methods 2012; 382:101-16; PMID: 22609372; http://dx.doi.org/10.1016/j.jim.2012.05.010 41.,Non-OADS,/arxiv_data1/oa_pdf/fb/39/kmab-09-03-1276683.PMC5384726.pdf
J Immunol Methods2004; 292:141-55; PMID: 15350519; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/fb/39/kmab-09-03-1276683.PMC5384726.pdf
J Immunol Methods2011; 365:118-25; PMID: 21223970; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/fb/39/kmab-09-03-1276683.PMC5384726.pdf
Biochim Biophys Acta 2011; 1814:882-8; PMID: 21539943; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/fb/39/kmab-09-03-1276683.PMC5384726.pdf
Vitam Horm 2010; 84:251-78; PMID:21094903; http://dx.doi.org/10.1016/B978-0-12-381517-0.00009-6 45.,Non-OADS,/arxiv_data1/oa_pdf/fb/39/kmab-09-03-1276683.PMC5384726.pdf
J Pept Sci 2010; 16:383-91; PMID:20607844; http://dx.doi.org/10.1002/psc.1250 46.,Non-OADS,/arxiv_data1/oa_pdf/fb/39/kmab-09-03-1276683.PMC5384726.pdf
Acta Phar- macol Sin 2012; 33:300-11; PMID: 22266723; http://dx.doi.org/ 10.1038/aps.2011.170 47.,Non-OADS,/arxiv_data1/oa_pdf/fb/39/kmab-09-03-1276683.PMC5384726.pdf
The full terms of this license are available at https://www.dovepress.com/terms.,Non-OADS,/arxiv_data1/oa_pdf/be/55/clep-9-195.PMC5384727.pdf
"php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/).",OADS,/arxiv_data1/oa_pdf/be/55/clep-9-195.PMC5384727.pdf
"For  permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).Clinical Epidemiology 2017:9 195–204Clinical Epidemiology Dovepress submit your manuscript | www.dovepress.com Dovepress 195 METHODOLOGY open access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/CLEP .S129886 Control of confounding in the analysis phase – an  overview for clinicians Johnny Kahlert1  Sigrid Bjerge Gribsholt1,2  Henrik Gammelager1,3  Olaf M Dekkers1,4,5  George Luta1,6 1Department of Clinical Epidemiology,   Institute of Clinical Medicine,   2Department of Endocrinology and  Internal Medicine, 3Department of  Anaesthesiology and Intensive Care  Medicine, Aarhus University Hospital,  Aarhus, Denmark;  4Department of  Clinical Epidemiology, 5Department  of Medicine, Section Endocrinology,  Leiden University Medical Center,  Leiden, the Netherlands;  6Department  of Biostatistics, Bioinformatics,  and Biomathematics, Georgetown University Medical Center,  Washington, DC, USAAbstract:  In observational studies, control of confounding can be done in the design and  analysis phases.",Non-OADS,/arxiv_data1/oa_pdf/be/55/clep-9-195.PMC5384727.pdf
"Hence, if we study the effect of hypertension on the risk of stroke, we cannot just compare hypertensive people Correspondence: Johnny Kahlert Department of Clinical Epidemiology, Institute of Clinical Medicine, Aarhus University Hospital, Olof Palmes Allé 43-45, 8200 Aarhus N, Denmark   Tel +45 8716 8517 Fax +45 8716 7215 Email jok@clin.au.dkJournal name: Clinical Epidemiology Article Designation: METHODOLOGYY ear: 2017V olume: 9Running head verso: Kahlert et alRunning head recto: Confounding in the analysis phaseDOI: http://dx.doi.org/10.2147/CLEP .S129886",Non-OADS,/arxiv_data1/oa_pdf/be/55/clep-9-195.PMC5384727.pdf
"Clinical Epidemiology 2017:9submit your manuscript | www.dovepress.com Dovepress Dovepress Clinical Epidemiology Publish your work in this journal Submit your manuscript here: https://www.dovepress.com/clinical-epidemiology-journalClinical Epidemiology is an international, peer-reviewed, open access,  online journal focusing on disease and drug epidemiology, identifica-tion of risk factors and screening procedures to develop optimal pre-ventative initiatives and programs.",Non-OADS,/arxiv_data1/oa_pdf/be/55/clep-9-195.PMC5384727.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/4e/ad/tcrm-13-407.PMC5384729.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Therapeutics and Clinical Risk Management 2017:13 407–419Therapeutics and Clinical Risk Management Dove press submit your manuscript | www.dovepress.co m Dove press  407ORiginal ReseaRChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/TCRM.S11801 0 Drug-related problems in patients with erectile  dysfunctions and multiple comorbidities hasniza Zaman huri1,2 Chui Fang ling1 azad hassan abdul Razack3 1Department of Pharmacy, Faculty  of Medicine, University of Malaya,   2Clinical investigation Centre,   University Malaya Medical Centre,   3Department of surgery, Faculty of  Medicine, University of Malaya, Kuala  lumpur, MalaysiaAbstract:  This study was conducted in a tertiary medical center in Kuala Lumpur, Malaysia.",Non-OADS,/arxiv_data1/oa_pdf/4e/ad/tcrm-13-407.PMC5384729.pdf
"Second-line treatment includes intracavern - ous or transurethral prostaglandin E1 injection and vacuum erection device, whereas  penile prosthesis and revascularization surgery are third-line therapies.8 In addition to  pharmacotherapy, lifestyle, risk factor modification, proper education and counseling  to both patients and their partners play a crucial role in ED treatment.9 Certain drug-related problems (DRPs), defined as events or circumstances involv - ing drug therapy, may actually or potentially interfere with desired health outcomes.10 Correspondence: hasniza Zaman huri Department of Pharmacy, Faculty of  Medicine, University of Malaya, 50603  Kuala lumpur, Malaysia Tel +60 3 7967 6659 Fax +60 3 7967 4964 email hasnizazh@um.edu.m y Journal name: Therapeutics and Clinical Risk Management Article Designation: Original Research Y ear: 2017 Volume: 13 Running head verso: Huri et al Running head recto: Drug-related problems in erectile dysfunction patients DOI: http://dx.doi.org/10.2147/TCRM.S118010",Non-OADS,/arxiv_data1/oa_pdf/4e/ad/tcrm-13-407.PMC5384729.pdf
Available from: https://uroweb.org/wp-content/ uploads/14-Male-Sexual-Dysfunction_LR.pdf.,Non-OADS,/arxiv_data1/oa_pdf/4e/ad/tcrm-13-407.PMC5384729.pdf
Available from:  http://www.who.int/healthinfo/survey/ageingdefnolder/en/.,Non-OADS,/arxiv_data1/oa_pdf/4e/ad/tcrm-13-407.PMC5384729.pdf
Available from:  http://reference.medscape.com/drug/caverject-edex-alprostadil-34284 6.,Non-OADS,/arxiv_data1/oa_pdf/4e/ad/tcrm-13-407.PMC5384729.pdf
"Therapeutics and Clinical Risk Management Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/therapeutics-and-clinical-risk-management-journa lTherapeutics and Clinical Risk Management is an international, peer- reviewed journal of clinical therapeutics and risk management, focusing  on concise rapid reporting of clinical studies in all therapeutic areas,  outcomes, safety, and programs for the effective, safe, and sustained  use of medicines.",Non-OADS,/arxiv_data1/oa_pdf/4e/ad/tcrm-13-407.PMC5384729.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/4e/ad/tcrm-13-407.PMC5384729.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/68/2e/ott-10-1933.PMC5384730.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).OncoTargets and Therapy 2017:10 1933–1939OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  1933Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OTT .S11834 6 FaM172a expression in circulating tumor cells  for prediction of high-risk subgroups of colorectal  cancer chang Xu1 chunhong Zhang2 haowen Wang3 han Yang3 gang li3 Zhenghua Fei3 Wenfeng li1,3,4 1Department of colorectal  surgery, 2Department of Pharmacy,   3Department of chemoradiotherapy,   4laboratory for interdisciplinary  research, institution for Translational  Medicine, The First affiliated hospital  of Wenzhou Medical University,   Wenzhou, People’s republic of chinaObjectives:  Previous studies used enumerated circulating tumor cells (CTCs) to predict  prognosis and therapeutic effect in several types of cancers.",Non-OADS,/arxiv_data1/oa_pdf/68/2e/ott-10-1933.PMC5384730.pdf
"Therefore, there is an urgent need to  develop a reliable and versatile method for discriminating high-risk factors of recurrent  patients and continuous surveillance of antitumor treatment response.2 The spread of circulating tumor cells (CTCs) in the blood plays a major role in the  initiation of metastases and tumor recurrence after surgery.3 The clinical relevance correspondence: Wenfeng li Department of chemoradiotherapy,  The First Affiliated Hospital of Wenzhou  Medical University, shangcai village,  nanbaixiang, Ouhai District, Wenzhou,  People’s republic of china Tel +86 577 8800 2215 email wflee_wmu@163.co m Journal name: OncoTargets and Therapy Article Designation: Original Research Y ear: 2017 Volume: 10 Running head verso: Xu et al Running head recto: FAM172A expression in circulating tumor cells DOI: http://dx.doi.org/10.2147/OTT.S118346",Non-OADS,/arxiv_data1/oa_pdf/68/2e/ott-10-1933.PMC5384730.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open  access journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/68/2e/ott-10-1933.PMC5384730.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/68/2e/ott-10-1933.PMC5384730.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/e9/8b/dddt-11-985.PMC5384731.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Drug Design, Development and Therapy 2017:11 985–994Drug Design, Development and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  985Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/DDDT .S11829 8 an open randomized active-controlled clinical  trial with low-dose sKa cytokines versus  DMarDs evaluating low disease activity  maintenance in patients with rheumatoid arthritis ls Martin-Martin1 F giovannangeli2 e Bizzi2 U Massafra2 e Ballanti2 M cassol3 a Migliore2 1Department of internal Medicine,   regina apostolorum hospital,   2Operative Unit of rheumatology,   3Department of internal Medicine,   san Pietro Fatebenefratelli hospital,   rome, italyBackground:  Biologic agents are currently the strongest immunosuppressive drugs able to  induce remission in rheumatoid arthritis (RA).",Non-OADS,/arxiv_data1/oa_pdf/e9/8b/dddt-11-985.PMC5384731.pdf
"Preliminary evidence of correspondence: e Bizzi Operative Unit of rheumatology,  san Pietro Fatebenefratelli hospital,  Via cassia 600, rome 00189, italy Tel +39 063 358 5802 email bizzi.emanuele@gmail.co m Journal name: Drug Design, Development and Therapy Article Designation: Original Research Y ear: 2017 Volume: 11 Running head verso: Martin-Martin et al Running head recto: Low-dose SKA cytokines versus DMARDs DOI: http://dx.doi.org/10.2147/DDDT.S118298",Non-OADS,/arxiv_data1/oa_pdf/e9/8b/dddt-11-985.PMC5384731.pdf
"Drug Design, Development and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/drug-design-development-and-therapy-journa lDrug Design, Development and Therapy is an international, peer- reviewed open-access journal that spans the spectrum of drug design  and development through to clinical applications.",Non-OADS,/arxiv_data1/oa_pdf/e9/8b/dddt-11-985.PMC5384731.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/e9/8b/dddt-11-985.PMC5384731.pdf
"Published with license by Taylor & Francis Group, LLC © Sarah-Jane Kellmann, Stefan D €ubel, and Holger Thie This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered , transformed, or built upon in any way.MABS 2017, VOL.",Non-OADS,/arxiv_data1/oa_pdf/b1/0f/kmab-09-03-1277302.PMC5384732.pdf
"3, 404 –418 http://dx.doi.org/10.1080/19420862.2016.1277302",Non-OADS,/arxiv_data1/oa_pdf/b1/0f/kmab-09-03-1277302.PMC5384732.pdf
ORCID Sarah-Jane Kellmann http://orcid.org/0000-0001-7259-4264 Stefan D €ubel http://orcid.org/0000-0001-8811-7390 References 1.,Non-OADS,/arxiv_data1/oa_pdf/b1/0f/kmab-09-03-1277302.PMC5384732.pdf
Gene Ther 2012; 19:365-74; PMID: 21753797; http://dx.doi.org/10.1038/gt.2011.104 2.,OADS,/arxiv_data1/oa_pdf/b1/0f/kmab-09-03-1277302.PMC5384732.pdf
BMC Biotechnol 2007; 7:14; PMID: 17346344; http://dx.doi.org/ 10.1186/1472-6750-7-14 3.,Non-OADS,/arxiv_data1/oa_pdf/b1/0f/kmab-09-03-1277302.PMC5384732.pdf
"Science 1988; 242:423-6; PMID: 3140379; http://dx.doi.org/10.1126/science.3140379 5. van Wezenbeek P, Schoenmakers JGG.",OADS,/arxiv_data1/oa_pdf/b1/0f/kmab-09-03-1277302.PMC5384732.pdf
Nucleic Acids Res 1979;6:2799-818; PMID:379830; http://dx.doi.org/10.1093/nar/6.8.2799 6.,Non-OADS,/arxiv_data1/oa_pdf/b1/0f/kmab-09-03-1277302.PMC5384732.pdf
Trends Biotechnol 2010; 28:333-9; PMID:20538360; http://dx.doi.org/10.1016/j.tibtech.2010.05.001 7.,OADS,/arxiv_data1/oa_pdf/b1/0f/kmab-09-03-1277302.PMC5384732.pdf
Front Immunol 2015; 6:440; PMID: 26388868; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/b1/0f/kmab-09-03-1277302.PMC5384732.pdf
Nature 1989;339:394-7; PMID: 2498664; http://dx.doi.org/10.1038/339394a0 9.,Non-OADS,/arxiv_data1/oa_pdf/b1/0f/kmab-09-03-1277302.PMC5384732.pdf
Drug Dis- cov Today 2005; 10:1237-44; PMID: 16213416; http://dx.doi.org/ 10.1016/S1359-6446(05)03554-3 11.,Non-OADS,/arxiv_data1/oa_pdf/b1/0f/kmab-09-03-1277302.PMC5384732.pdf
N Engl J Med 2011; 365:725-33; PMID: 21830940; http://dx.doi.org/10.1056/ NEJMoa1103849 12.,OADS,/arxiv_data1/oa_pdf/b1/0f/kmab-09-03-1277302.PMC5384732.pdf
Sc i Transl Med 2013; 5:177ra38; PMID: 23515080; http://dx.doi.org/10.1126/scitranslmed.3005930 13.,Non-OADS,/arxiv_data1/oa_pdf/b1/0f/kmab-09-03-1277302.PMC5384732.pdf
Bioanalysis 2010; 2:769- 90; PMID: 20640220; http://dx.doi.org/10.4155/bio.10.31 14.,Non-OADS,/arxiv_data1/oa_pdf/b1/0f/kmab-09-03-1277302.PMC5384732.pdf
"Kobatake E, Kosaku C, Hanzawa S, Mie M. Construction of af ﬁnity changeable antibody in response to Ca2 C. Biotechnol Lett 2012; 34:1019- 23; PMID: 22350334; http://dx.doi.org/10.1007/s10529-012-0881-z 15.",OADS,/arxiv_data1/oa_pdf/b1/0f/kmab-09-03-1277302.PMC5384732.pdf
Cytometry 1990; 11:231-8; PMID:1690625; http://dx.doi.org/10.1002/cyto.990110203 16.,Non-OADS,/arxiv_data1/oa_pdf/b1/0f/kmab-09-03-1277302.PMC5384732.pdf
Cancer Lett 2013; 328:191-7; PMID:23022475; http://dx.doi.org/10.1016/j.canlet.2012.09.015 17.,Non-OADS,/arxiv_data1/oa_pdf/b1/0f/kmab-09-03-1277302.PMC5384732.pdf
"Hironiwa N, Ishii S, Kadono S, Iwayanagi Y, Mimoto F, Habu K, Igawa T, Hattori K. Calcium-dependent antigen binding as a novelmodality for antibody recycling by endosomal antigen dissociation.MAbs 2016; 8:65-73; PMID: 26496237; http://dx.doi.org/10.1080/ 19420862.2015.1110660 18.",OADS,/arxiv_data1/oa_pdf/b1/0f/kmab-09-03-1277302.PMC5384732.pdf
Protein Sci 2011; 20:1619-31; PMID: 21766385; http://dx.doi.org/10.1002/pro.696 19.,OADS,/arxiv_data1/oa_pdf/b1/0f/kmab-09-03-1277302.PMC5384732.pdf
Biomacromolecules 2006; 7:999-1004; PMID:16602713; http://dx.doi.org/10.1021/bm0507002 21.,OADS,/arxiv_data1/oa_pdf/b1/0f/kmab-09-03-1277302.PMC5384732.pdf
ChemBioChem 2013; 14:1460-7; PMID:23825049; http://dx.doi.org/10.1002/cbic.201300168 22.,Non-OADS,/arxiv_data1/oa_pdf/b1/0f/kmab-09-03-1277302.PMC5384732.pdf
Nat Struct Biol 1995; 2:768-76; PMID: 7552748; http://dx.doi.org/10.1038/nsb0995-768 23.,Non-OADS,/arxiv_data1/oa_pdf/b1/0f/kmab-09-03-1277302.PMC5384732.pdf
J Mol Biol 1992; 228:1177-92; PMID: 1474585; http://dx.doi.org/10.1016/0022-2836(92)90324-D 24.,OADS,/arxiv_data1/oa_pdf/b1/0f/kmab-09-03-1277302.PMC5384732.pdf
Science 1992; 256:632-8; PMID: 1585175; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/b1/0f/kmab-09-03-1277302.PMC5384732.pdf
Nature 1997; 388:882-7; PMID: 9278050; http://dx.doi.org/10.1038/42264 26.,Non-OADS,/arxiv_data1/oa_pdf/b1/0f/kmab-09-03-1277302.PMC5384732.pdf
"Nagai T, Sawano A, Park ES, Miyawaki A. Circularly permuted green ﬂuorescent proteins engineered to sense Ca2 C. Proc Natl Acad Sci 2001; 98:3197-202; PMID: 11248055; http://dx.doi.org/10.1073/ pnas.051636098MABS 417",OADS,/arxiv_data1/oa_pdf/b1/0f/kmab-09-03-1277302.PMC5384732.pdf
Chem Biol 2004; 11:1483-7; PMID: 15555998; http://dx.doi.org/10.1016/j.chembiol.2004.08.020 28.,OADS,/arxiv_data1/oa_pdf/b1/0f/kmab-09-03-1277302.PMC5384732.pdf
J Mol Biol 2004; 336:263-73; PMID: 14741221; http://dx.doi.org/10.1016/j.jmb.2003.12.016 29.,OADS,/arxiv_data1/oa_pdf/b1/0f/kmab-09-03-1277302.PMC5384732.pdf
Cell Biophys 1992; 21:69-79; PMID:1285332; http://dx.doi.org/10.1007/BF02789479 30.,OADS,/arxiv_data1/oa_pdf/b1/0f/kmab-09-03-1277302.PMC5384732.pdf
J Mol Biol 1996; 258:6-13; PMID: 8613992; http://dx.doi.org/ 10.1006/jmbi.1996.0229 31.,Non-OADS,/arxiv_data1/oa_pdf/b1/0f/kmab-09-03-1277302.PMC5384732.pdf
J Mol Biol 2004; 343:559-68; PMID: 15465045; http://dx.doi.org/10.1016/j.jmb.2004.08.012 32.,OADS,/arxiv_data1/oa_pdf/b1/0f/kmab-09-03-1277302.PMC5384732.pdf
"Matsubara M, Titani K, Taniguchi H. Interaction of Calmodulin- Binding Domain Peptides of Nitric Oxide Synthase with Membrane Phospholipids: Regulation by Protein Phosphorylation and Ca2 C -Calmodulin y. Biochemistry 1996; 35:14651-8; PMID: 8931564; http://dx.doi.org/10.1021/bi9613988 35.",OADS,/arxiv_data1/oa_pdf/b1/0f/kmab-09-03-1277302.PMC5384732.pdf
Cell 1996; 84:745-55; PMID: 8625412; http://dx.doi.org/10.1016/S0092-8674(00)81052-1 36.,OADS,/arxiv_data1/oa_pdf/b1/0f/kmab-09-03-1277302.PMC5384732.pdf
Factors In ﬂuencing the Dimer to Monomer Transition of an Antibody Single-Chain Fv Fragment y. Biochemistry 1998; 37:12918-26; PMID: 9737871; http://dx.doi.org/10.1021/bi9810407 38.,Non-OADS,/arxiv_data1/oa_pdf/b1/0f/kmab-09-03-1277302.PMC5384732.pdf
Nat Protoc 2006; 1:755-68; PMID: 17406305; http://dx.doi.org/10.1038/nprot.2006.94 40.,OADS,/arxiv_data1/oa_pdf/b1/0f/kmab-09-03-1277302.PMC5384732.pdf
Sci- ence 1986; 233:747-53; PMID: 2426778; http://dx.doi.org/10.1126/science.2426778 41.,OADS,/arxiv_data1/oa_pdf/b1/0f/kmab-09-03-1277302.PMC5384732.pdf
J Mol Biol 2004; 343:685-701; PMID: 15465055; http://dx.doi.org/10.1016/j.jmb.2004.08.019 43.,OADS,/arxiv_data1/oa_pdf/b1/0f/kmab-09-03-1277302.PMC5384732.pdf
Protein Eng Des Sel 2010; 23:689-97; PMID: 20591902; http://dx.doi.org/10.1093/protein/gzq043 44.,OADS,/arxiv_data1/oa_pdf/b1/0f/kmab-09-03-1277302.PMC5384732.pdf
Biochemistry 1999; 38:12320-32; PMID: 10493800; http://dx.doi.org/10.1021/bi9908235 45.,Non-OADS,/arxiv_data1/oa_pdf/b1/0f/kmab-09-03-1277302.PMC5384732.pdf
J Biol Chem 2002; 277:21630-8; PMID:11901148; http://dx.doi.org/10.1074/jbc.M110803200 47.,OADS,/arxiv_data1/oa_pdf/b1/0f/kmab-09-03-1277302.PMC5384732.pdf
J Mol Biol 2009; 385:1470-80; PMID:18845160; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/b1/0f/kmab-09-03-1277302.PMC5384732.pdf
Nat Commun 2016; 7:11844; PMID: 27296868; http://dx.doi.org/10.1038/ncomms11844 49.,OADS,/arxiv_data1/oa_pdf/b1/0f/kmab-09-03-1277302.PMC5384732.pdf
Arch Toxicol 1983; 54:61-70; PMID: 6314931; http://dx.doi.org/10.1007/BF00277816 50.,Non-OADS,/arxiv_data1/oa_pdf/b1/0f/kmab-09-03-1277302.PMC5384732.pdf
J Mol Biol 1983; 170:1055-8; PMID:6644814; http://dx.doi.org/10.1016/S0022-2836(83)80206-X 52.,OADS,/arxiv_data1/oa_pdf/b1/0f/kmab-09-03-1277302.PMC5384732.pdf
J Exp Med 1990; 172:1233-42; PMID: 1698911; http://dx.doi.org/10.1084/ jem.172.4.1233 54.,Non-OADS,/arxiv_data1/oa_pdf/b1/0f/kmab-09-03-1277302.PMC5384732.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/65/ba/ott-10-1909.PMC5384733.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).OncoTargets and Therapy 2017:10 1909–1914OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  1909Reviewopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/OTT .S9868 9 Spotlight on ibrutinib and its potential in frontline  treatment of chronic lymphocytic leukemia Maliha Khan Jamie L Gibbons Alessandra Ferrajoli Department of Leukemia, The  University of Texas MD Anderson  Cancer Center, Houston, TX, USAAbstract:  Chronic lymphocytic leukemia (CLL) is the most prevalent leukemia in the adult  population.",Non-OADS,/arxiv_data1/oa_pdf/65/ba/ott-10-1909.PMC5384733.pdf
"Unit 428, Houston,  TX 77030, USA email aferrajo@mdanderson.or g Journal name: OncoTargets and Therapy Article Designation: Review Y ear: 2017 Volume: 10 Running head verso: Khan et al Running head recto: Ibrutinib as frontline treatment for CLL DOI: http://dx.doi.org/10.2147/OTT.S98689",Non-OADS,/arxiv_data1/oa_pdf/65/ba/ott-10-1909.PMC5384733.pdf
"Available from: http://emedicine.medscape.com/article/199313- overvie w. Accessed August 12, 2016.",OADS,/arxiv_data1/oa_pdf/65/ba/ott-10-1909.PMC5384733.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets­and­therapy­journa lOncoTargets and Therapy is an international, peer-reviewed, open  access journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/65/ba/ott-10-1909.PMC5384733.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/65/ba/ott-10-1909.PMC5384733.pdf
"[updated September 15, 2015] Available from:  https://medlineplus.gov/druginfo/meds/a614007.htm l. Accessed  August 12, 2016.",Non-OADS,/arxiv_data1/oa_pdf/65/ba/ott-10-1909.PMC5384733.pdf
Available from: https://www.imbruvica.com/docs/ librariesprovider7 /default-document-library/prescribing_information.,Non-OADS,/arxiv_data1/oa_pdf/65/ba/ott-10-1909.PMC5384733.pdf
"[Updated July 28, 2014] Available from:  http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ ucm406916.ht m. Accessed August 12, 2016.",Non-OADS,/arxiv_data1/oa_pdf/65/ba/ott-10-1909.PMC5384733.pdf
Available from:  https://clinicaltrials.gov/ct2/show/NCT02315768?term =NCT+023157 68&rank=1.,Non-OADS,/arxiv_data1/oa_pdf/65/ba/ott-10-1909.PMC5384733.pdf
Available from: https://clinicaltrials.gov/ct2/show/ NCT0262980 9.,Non-OADS,/arxiv_data1/oa_pdf/65/ba/ott-10-1909.PMC5384733.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/ac/b5/dddt-11-1011.PMC5384734.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Drug Design, Development and Therapy 2017:11 1011–1026Drug Design, Development and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  1011Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/DDDT .S10351 1 rutin protects against neuronal damage in vitro  and ameliorates doxorubicin-induced memory  deficits in vivo  in Wistar rats grandhi Venkata  ramalingayya sri Pragnya cheruku Pawan g nayak anoop Kishore rekha shenoy chamallamudi  Mallikarjuna  rao nandakumar Krishnadas Department of Pharmacology,   Manipal college of Pharmaceutical  sciences, Manipal University, Manipal,   Karnataka,  indiaAbstract:  Doxorubicin (DOX) is the most widely used broad-spectrum anticancer agent,  either alone or in combination, for most cancers including breast cancer.",Non-OADS,/arxiv_data1/oa_pdf/ac/b5/dddt-11-1011.PMC5384734.pdf
"Furthermore, the 10- and 15-year survival rates (for  all stages of breast cancer combined) are currently at 83% and 78%, respectively, in  the United States.2 Despite this prolonged survival, chemotherapy-induced cognitive correspondence: nandakumar  Krishnadas Department of Pharmacology, Manipal  college of Pharmaceutical sciences,  Manipal University, Madhav nagar,  Manipal 576104, Karnataka, india email mailnandakumar77@gmail.co mJournal name: Drug Design, Development and Therapy Article Designation: Original Research Y ear: 2017 Volume: 11 Running head verso: Ramalingayya et al Running head recto: Rutin ameliorates chemobrain through neuroprotection DOI: http://dx.doi.org/10.2147/DDDT.S103511",Non-OADS,/arxiv_data1/oa_pdf/ac/b5/dddt-11-1011.PMC5384734.pdf
"Available from: http://www.cancer.or g. Accessed May 5, 2016.",Non-OADS,/arxiv_data1/oa_pdf/ac/b5/dddt-11-1011.PMC5384734.pdf
"Drug Design, Development and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/drug-design-development-and-therapy-journa lDrug Design, Development and Therapy is an international, peer- reviewed open-access journal that spans the spectrum of drug design  and development through to clinical applications.",Non-OADS,/arxiv_data1/oa_pdf/ac/b5/dddt-11-1011.PMC5384734.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/ac/b5/dddt-11-1011.PMC5384734.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/9c/53/ndt-13-981.PMC5384735.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Neuropsychiatric Disease and Treatment 2017:13 981–985Neuropsychiatric Disease and Treatment Dove press submit your manuscript | www.dovepress.co m Dove press  981Case repor Topen access to scientific and medical research open access Full T ext article http: //dx.doi.org/10.2147/NDT .S13277 5 punding following posterior cerebral artery  infarction: a case report and literature review Cho-I Lin1 Yu-Ching Lin1–3 Wei-Chih Lien1 pei-Chun Hsieh1 sheng-Han Lin1 Ta-shen Kuan1,2 1Department of physical Medicine  and rehabilitation, National Cheng  Kung University Hospital, College  of Medicine, National Cheng  Kung University, Tainan, Taiwan;   2Department of p hysical Medicine and  rehabilitation, College of Medicine,   National Cheng Kung University,   Tainan, Taiwan; 3Medical Device  Innovation Center, National Cheng  Kung University, Tainan, TaiwanIntroduction:  Punding is a complex stereotyped behavior, characterized by excessiveness,  non-goal orientation, and repetitiveness.",Non-OADS,/arxiv_data1/oa_pdf/9c/53/ndt-13-981.PMC5384735.pdf
"Unenhanced computed tomography (CT) upon his arrival to the ER and magnetic  resonance imaging (MRI) of the brain (Figure 1) 2 days later confirmed the diagnosis Correspondence: Ta-shen Kuan Department of physical Medicine and  rehabilitation, National Cheng Kung  University Hospital, College of Medicine,  National Cheng Kung University,  138 sheng-Li road, Tainan 704, Taiwan Tel +886 6 235 3535 ext 5242 Fax +886 6 276 6106 email kuan@mail.ncku.edu.t w Journal name: Neuropsychiatric Disease and Treatment Article Designation: Case report Y ear: 2017 Volume: 13 Running head verso: Lin et al Running head recto: Poststroke punding DOI: http://dx.doi.org/10.2147/NDT.S132775",Non-OADS,/arxiv_data1/oa_pdf/9c/53/ndt-13-981.PMC5384735.pdf
"Neuropsychiatric Disease and Treatment Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journa lNeuropsychiatric Disease and Treatment is an international, peer- reviewed journal of clinical therapeutics and pharmacology focusing   on concise rapid reporting of clinical or pre-clinical studies on a   range of neuropsychiatric and neurological disorders.",Non-OADS,/arxiv_data1/oa_pdf/9c/53/ndt-13-981.PMC5384735.pdf
Visit http://www.dovepress.com/testimonials.ph p to  read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/9c/53/ndt-13-981.PMC5384735.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/29/4a/cia-12-629.PMC5384736.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Clinical Interventions in Aging 2017:12 629–634Clinical Interventions in Aging Dove press submit your manuscript | www.dovepress.co m Dove press  629OrIg InAl reseArChopen access to scientific and medical research Open Access Full T ext Article http: //dx.doi.org/10.2147/CIA.S13094 6 relationship between jaw opening force and hyoid  bone dynamics in healthy elderly subjects hiromichi shinozaki haruka T ohara Mariko Matsubara nobuhiro Inokuchi Yasuhiro Yamazaki Ayako n akane Y oko Wakasugi shunsuke Minakuchi Department of gerodontology,   T okyo Medical and Dental University,   T okyo, JapanPurpose:  This study aimed to examine the relationship between jaw opening force and hyoid  bone dynamics and resting position in elderly individuals based on gender.",Non-OADS,/arxiv_data1/oa_pdf/29/4a/cia-12-629.PMC5384736.pdf
"Meanwhile, in the superior displacement of the hyoid bone,  the mylohyoid is the primary muscle and the posterior belly of the digastric muscle Correspondence: haruka Tohara Department of gerodontology, Tokyo  Medical and Dental University, 1-5-45  Yushima, Bunkyo-ku, Tokyo, Japan Tel/fax +81 3 5803 5559 email haruka-t@rd5.so-net.ne.j p Journal name: Clinical Interventions in Aging Article Designation: Original Research Y ear: 2017 Volume: 12 Running head verso: Shinozaki et al Running head recto: Jaw opening force and hyoid dynamics DOI: http://dx.doi.org/10.2147/CIA.S130946",Non-OADS,/arxiv_data1/oa_pdf/29/4a/cia-12-629.PMC5384736.pdf
"Clinical Interventions in Aging Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/clinical-interventions-in-aging-journa lClinical Interventions in Aging is an international, peer-reviewed journal  focusing on evidence-based reports on the value or lack thereof of treatments  intended to prevent or delay the onset of maladaptive correlates of aging  in human beings.",Non-OADS,/arxiv_data1/oa_pdf/29/4a/cia-12-629.PMC5384736.pdf
Visit http://www.dovepress.,Non-OADS,/arxiv_data1/oa_pdf/29/4a/cia-12-629.PMC5384736.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/9d/1c/tcrm-13-401.PMC5384737.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Therapeutics and Clinical Risk Management 2017:13 401–406Therapeutics and Clinical Risk Management Dove press submit your manuscript | www.dovepress.co m Dove press  401ORiginal ReseaRChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/TCRM.S13062 4 Predictors of common femoral artery access site  complications in patients on oral anticoagulants  and undergoing a coronary procedure nicolas W shammas1,2 gail a shammas1 susan Jones-Miller1,2 Mileah Rose gumpert1 Miranda Jade gumpert1 Christine harb1 Majid Z Chammas1 W John shammas1 Rommy a Khalafallah1 amy Barzgari1 Bassel Bou Dargham1 ghassan e Daher1 Rayan Jo Rachwan1 andrew n shammas1 1Midwest Cardiovascular Research  Foundation, 2Cardiology Division,   genesis heart institute, Davenport,   ia, UsaBackground:  It is unclear whether patients on oral anticoagulants (OAC) undergoing a  procedure using common femoral artery access have higher adverse events when compared to  patients who are not anticoagulated at the time of the procedure.",Non-OADS,/arxiv_data1/oa_pdf/9d/1c/tcrm-13-401.PMC5384737.pdf
"Keywords:  access site, common femoral artery, complications, oral anticoagulant Introduction Femoral artery access remains the most commonly used arterial access during  coronary angiography and intervention despite an increase in radial procedures.1,2 Femo - ral access complications remain infrequent, ranging from ,1% to 17% of procedures.3–7  It is not uncommon to see patients presenting to the cardiac catheterization laboratory  on oral anticoagulant (OAC) fully or partially anticoagulated and undergoing com - mon femoral artery (CFA) access.8 Several new OAC (NOACs; oral Xa and thrombin  inhibitors) have emerged within the past 3–6 years and are now an alternative to war - farin in treating patients with nonvalvular atrial fibrillation or venous thromboembolic Correspondence: nicolas W shammas Midwest Cardiovascular Research  Foundation, 1622 e lombard street,  Davenport, ia 52803, Usa Tel +1 563 320 0263 email shammas@mchsi.co m Journal name: Therapeutics and Clinical Risk Management Article Designation: Original Research Y ear: 2017 Volume: 13 Running head verso: Shammas et al Running head recto: Predictors of CFA access site complications DOI: http://dx.doi.org/10.2147/TCRM.S130624",Non-OADS,/arxiv_data1/oa_pdf/9d/1c/tcrm-13-401.PMC5384737.pdf
"Therapeutics and Clinical Risk Management Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/therapeutics-and-clinical-risk-management-journa lTherapeutics and Clinical Risk Management is an international, peer- reviewed journal of clinical therapeutics and risk management, focusing  on concise rapid reporting of clinical studies in all therapeutic areas,  outcomes, safety, and programs for the effective, safe, and sustained  use of medicines.",Non-OADS,/arxiv_data1/oa_pdf/9d/1c/tcrm-13-401.PMC5384737.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/9d/1c/tcrm-13-401.PMC5384737.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/f9/af/ott-10-1941.PMC5384738.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).OncoTargets and Therapy 2017:10 1941–1946OncoTargets and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  1941Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/OTT .S13531 5 apoptotic and genomic effects of corilagin  on sKOV3 ovarian cancer cell line rukset attar1 Zeynep Birsu cincin2 elif sinem Bireller3 Bedia cakmakoglu2 1Department of Obstetrics and  gynecology, Yeditepe University  hospital, 2Department of Molecular  Medicine, aziz sancar institute of  experimental Medicine, istanbul  University, 3Department of  Pharmaceutical Microbiology, Faculty  of Pharmacy, istanbul Yeni Yuzyil  University, istanbul, T urkeyAbstract:  Corilagin is a member of the tannin family and has been isolated from traditional  Chinese medicinal plants, such as Phyllanthus  spp.",Non-OADS,/arxiv_data1/oa_pdf/f9/af/ott-10-1941.PMC5384738.pdf
"Keywords:  epithelial ovarian cancer, corilagin, apoptotic effects, gene ontology Introduction Ovarian cancer is one of the leading causes of cancer-related deaths in women around  the world.1,2 Epithelial ovarian cancer accounts for ~90% of ovarian cancer cases, with  four major subtypes: endometrioid, clear, mucinous, and serous cell.3,4 According to  recent Globocan (2012) statistical data, 238,700 people were diagnosed as having  epithelial ovarian cancer and there were 151,900 deaths worldwide.5 Despite various  current surgical and therapeutic methods, the 5-year survival ratio of ovarian cancer  is nearly 30%–40%, because of the absence of significant symptoms at earlier stages  and late diagnosis at advanced or metastatic stages.6–10 In order to improve the overall  survival ratio of patients with ovarian cancer, recent studies have targeted the find - ing of novel, effective, and nontoxic treatment strategies, as well as nutraceuticals,  which are physiologically bioavailable and also cost-effective.11 Corilagin belongs to the tannin family, which is extracted from different  medicinal plants, including Phyllanthus amarus , P. urinaria , Geranium thunbergii ,  G. carolinianum , and Dimocarpus longan .12–15 Recent studies have reported that corilagin  has beneficial properties in cardiovascular diseases with its antihypertensive, throm - bolytic, and antiatherogenic features.16–18 It has also been demonstrated that corilagin can correspondence: Bedia cakmakoglu Department of Molecular Medicine,  aziz sancar institute of experimental  Medicine, istanbul University, capa, Fatih,  istanbul 34093, Turkey email bedia@istanbul.edu.t r Journal name: OncoTargets and Therapy Article Designation: Original Research Y ear: 2017 Volume: 10 Running head verso: Attar et al Running head recto: Corilagin and SKOV3 cells DOI: http://dx.doi.org/10.2147/OTT.S135315",Non-OADS,/arxiv_data1/oa_pdf/f9/af/ott-10-1941.PMC5384738.pdf
"OncoTargets and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/oncotargets-and-therapy-journa lOncoTargets and Therapy is an international, peer-reviewed, open  access journal focusing on the pathological basis of all cancers, potential  targets for therapy and treatment protocols employed to improve the  management of cancer patients.",Non-OADS,/arxiv_data1/oa_pdf/f9/af/ott-10-1941.PMC5384738.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/f9/af/ott-10-1941.PMC5384738.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/87/df/tcrm-13-393.PMC5384739.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Therapeutics and Clinical Risk Management 2017:13 393–400Therapeutics and Clinical Risk Management Dove press submit your manuscript | www.dovepress.co m Dove press  393ORiginal ReseaRChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/TCRM.S12479 4 Predictive values of D-dimer assay, gRa Ce scores  and TiMi scores for adverse outcome in patients  with non-sT -segment elevation myocardial  infarction Muhammet hulusi  satilmisoglu1 sinem Ozbay Ozyilmaz1 Mehmet gul1 hayriye ak Yildirim2 Osman Kayapinar3 Kadir gokturk4 huseyin aksu1 Korhan erkanli5 abdurrahman eksik1 1Department of Cardiology,   2Department of Biochemistry,   Mehmet akif ersoy Thoracic and  Cardiovascular surgery Training  and Research hospital, istanbul,   3Department of Cardiology, Duzce  University Faculty of Medicine, Duzce,   4Department of infectious Diseases,   5Department of Thoracic and  Cardiovascular surgery, Mehmet akif  ersoy Thoracic and Cardiovascular  surgery Training and Research  hospital, istanbul, T urkeyPurpose:  To determine the predictive values of D-dimer assay, Global Registry of Acute Coronary  Events (GRACE) and Thrombolysis in Myocardial Infarction (TIMI) risk scores for adverse  outcome in patients with non-ST-segment elevation myocardial infarction (NSTEMI).",Non-OADS,/arxiv_data1/oa_pdf/87/df/tcrm-13-393.PMC5384739.pdf
"Keywords:  acute coronary syndrome, non-ST-segment elevation myocardial infarction, GRACE  score, D-dimer assay, TIMI score Introduction Acute coronary syndrome (ACS) is characterized by a spectrum of distinct clinical  entities with a common etiology that ranges from unstable angina (UA) to non- ST-segment elevation myocardial infarction (NSTEMI) and ST-segment elevation  myocardial infarction depending on the severity.1,2 Despite advances in coronary inter - vention techniques and equipment, ACS has still been associated with high morbidity  and mortality rates.3 This necessitates the use of guideline-recommended clinical risk  score calculations for identifying life-threatening adverse cardiac outcomes, particu - larly in NSTEMI and UA patients, and for determining appropriate treatment and  follow-up strategies.4–6  The term “NSTEMI patients” refers to a heterogeneous population of ACS  with varying short- and long-term mortality and recurrent adverse cardiac events, Correspondence: Muhammet hulusi  satilmisoglu Department of Cardiology, Mehmet  akif ersoy Thoracic and Cardiovascular  surgery Training and Research  hospital, Turgut Ozal Bulvari no 11,  Kucukcekmece, istanbul 34303, Turkey Tel +90 53 2598 2318 email hulusim@gmail.co m Journal name: Therapeutics and Clinical Risk Management Article Designation: Original Research Y ear: 2017 Volume: 13 Running head verso: Satilmisoglu et al Running head recto: Clinical risk scores in non-ST-segment elevation myocardial infarction DOI: http://dx.doi.org/10.2147/TCRM.S124794",Non-OADS,/arxiv_data1/oa_pdf/87/df/tcrm-13-393.PMC5384739.pdf
"Therapeutics and Clinical Risk Management Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/therapeutics-and-clinical-risk-management-journa lTherapeutics and Clinical Risk Management is an international, peer- reviewed journal of clinical therapeutics and risk management, focusing  on concise rapid reporting of clinical studies in all therapeutic areas,  outcomes, safety, and programs for the effective, safe, and sustained  use of medicines.",Non-OADS,/arxiv_data1/oa_pdf/87/df/tcrm-13-393.PMC5384739.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/87/df/tcrm-13-393.PMC5384739.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/3f/93/ndt-13-947.PMC5384740.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Neuropsychiatric Disease and Treatment 2017:13 947–958Neuropsychiatric Disease and Treatment Dove press submit your manuscript | www.dovepress.co m Dove press  947OrigiNal researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/NDT .S12875 2 access to diagnosis, treatment, and supportive  services among pharmacotherapy-treated children/ adolescents with aDhD in europe: data from the  caregiver Perspective on Pediatric aDhD survey Moshe Fridman1 T obias Banaschewski2 Vanja sikirica3 Javier Quintero4 Kristina s chen5 1aMF consulting, inc., los angeles,   ca, Usa; 2Department of child  and adolescent Psychiatry and  Psychotherapy, central institute  of Mental health, Medical Faculty  Mannheim of the University of  heidelberg, Mannheim, germany;   3global health economics Outcomes  research and epidemiology, shire,   Wayne, P a, Usa; 4Psychiatry  Department, hospital Universitario  infanta leonor, complutense  University, Madrid, spain; 5global  health economics Outcomes  research and epidemiology, shire,   lexington, M a, UsaBackground:  Attention-deficit/hyperactivity disorder (ADHD) is one of the most common  childhood psychiatric disorders and negatively impacts caregivers’ lives.",Non-OADS,/arxiv_data1/oa_pdf/3f/93/ndt-13-947.PMC5384740.pdf
"Keywords:  attention-deficit/hyperactivity disorder, burden of illness, caregivers, diagnosis,  treatment Introduction Attention-deficit/hyperactivity disorder (ADHD) is one of the most common psychiatric  disorders of childhood, affecting 3%–5% of children and adolescents worldwide,1,2 and correspondence: Moshe Fridman aMF consulting, inc., 846 s citrus  avenue, los angeles, ca 90036, Usa Tel +1 323 857 6618 Fax +1 323 857 6656 email fmoshe@amf-consulting.co m Journal name: Neuropsychiatric Disease and Treatment Article Designation: Original Research Y ear: 2017 Volume: 13 Running head verso: Fridman et al Running head recto: Diagnosis, treatment, and support in the CAPPA survey DOI: http://dx.doi.org/10.2147/NDT.S128752",Non-OADS,/arxiv_data1/oa_pdf/3f/93/ndt-13-947.PMC5384740.pdf
"Available from:  http://www.guiasalud.es/GPC/GPC_477_TDAH_AIAQS_compl.pd f.  Accessed July 21, 2016.",Non-OADS,/arxiv_data1/oa_pdf/3f/93/ndt-13-947.PMC5384740.pdf
Available from: https://www.nice.org.uk/guidance/cg7 2.,Non-OADS,/arxiv_data1/oa_pdf/3f/93/ndt-13-947.PMC5384740.pdf
Available from: http://www.aidaiassociazione.com/documents/ Linee_guida_SINPIA_Diagnosi.pdf.,Non-OADS,/arxiv_data1/oa_pdf/3f/93/ndt-13-947.PMC5384740.pdf
Available from:  http://www.wma.net/en/30publications/10policies/b3 /.,Non-OADS,/arxiv_data1/oa_pdf/3f/93/ndt-13-947.PMC5384740.pdf
"Available from: http://www.adhdeurope.eu/ images/files/20090513_Survey.pd f. Accessed July 21, 2016.",OADS,/arxiv_data1/oa_pdf/3f/93/ndt-13-947.PMC5384740.pdf
"Neuropsychiatric Disease and Treatment Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journa lNeuropsychiatric Disease and Treatment is an international, peer- reviewed journal of clinical therapeutics and pharmacology focusing   on concise rapid reporting of clinical or pre-clinical studies on a   range of neuropsychiatric and neurological disorders.",Non-OADS,/arxiv_data1/oa_pdf/3f/93/ndt-13-947.PMC5384740.pdf
Visit http://www.dovepress.com/testimonials.ph p to  read real quotes from published authors.,Non-OADS,/arxiv_data1/oa_pdf/3f/93/ndt-13-947.PMC5384740.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/5b/4c/tcrm-13-421.PMC5384741.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Therapeutics and Clinical Risk Management 2017:13 421–425Therapeutics and Clinical Risk Management Dove press submit your manuscript | www.dovepress.co m Dove press  421ORiginal ReseaRChopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/TCRM.S13019 8 Polymorphisms of VKORC1 and CYP2C9 are  associated with warfarin sensitivity in Chinese  population liQun Jia1 Zanxin Wang1,2 Jianlong Men3 heng Cai4 Minxin Wei2 1Department of Cardiovascular  surgery, Tianjin Medical University  general hospital, Tianjin,   2Department of Cardiac surgery,   shenzhen sun Yat-sen Cardiovascular  hospital, shenzhen, 3Department of  Clinical laboratory, 4Department of  Cardiology, Tianjin Medical University  general hospital, Tianjin, People’s  Republic of ChinaObjective:  Warfarin is a commonly prescribed anticoagulant for prevention of thromboembolic  events.",Non-OADS,/arxiv_data1/oa_pdf/5b/4c/tcrm-13-421.PMC5384741.pdf
"This cannot be explained simply  by a lower mean body weight among the Chinese.3 The vitamin K epoxide reductase complex 1 (VKORC1) recycles vitamin K  2, 3-epoxide back to active vitamin K hydroquinone, an important cofactor involved Correspondence: Zanxin Wang Department of Cardiac surgery,  shenzhen sun Yat-sen Cardiovascular  hospital, #1021 Dongmen north Road,  luohu District, shenzhen 518112,  guangdong Province, People’s Republic  of China email zanxinwang@126.co m Journal name: Therapeutics and Clinical Risk Management Article Designation: Original Research Y ear: 2017 Volume: 13 Running head verso: Jia et al Running head recto: Polymorphisms of VKORC1 and CYP2C9 with warfarin DOI: http://dx.doi.org/10.2147/TCRM.S130198",Non-OADS,/arxiv_data1/oa_pdf/5b/4c/tcrm-13-421.PMC5384741.pdf
"Therapeutics and Clinical Risk Management Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/therapeutics-and-clinical-risk-management-journa lTherapeutics and Clinical Risk Management is an international, peer- reviewed journal of clinical therapeutics and risk management, focusing  on concise rapid reporting of clinical studies in all therapeutic areas,  outcomes, safety, and programs for the effective, safe, and sustained  use of medicines.",Non-OADS,/arxiv_data1/oa_pdf/5b/4c/tcrm-13-421.PMC5384741.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/5b/4c/tcrm-13-421.PMC5384741.pdf
"The full terms of this license are available at https://www.dovepress.com/terms.ph p   and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 /).",Non-OADS,/arxiv_data1/oa_pdf/1d/bf/dddt-11-995.PMC5384742.pdf
"For permission  for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.ph p).Drug Design, Development and Therapy 2017:11 995–1009Drug Design, Development and Therapy Dove press submit your manuscript | www.dovepress.co m Dove press  995Original researchopen access to scientific and medical research Open access Full T ext article http: //dx.doi.org/10.2147/DDDT .S10701 8 The antiulcer effect of Cibotium barometz  leaves  in rats with experimentally induced acute  gastric ulcer nahla saeed al-Wajeeh1 Maryam hajrezaie1 nawal al-henhena1 sareh Kamran1 elham Bagheri1 Maryam Zahedifard1 Kamelia saremi1 suzita Mohd noor1 hapipah Mohd ali2 Mahmood ameen abdulla1 1Department of Biomedical science,   Faculty of Medicine, 2Department  of chemistry, Faculty of science,   University of Malaya, Kuala lumpur,   MalaysiaAbstract:  Cibotium barometz is a pharmaceutical plant customarily used in traditional medicine  in Malaysia for the treatment of different diseases, such as gastric ulcer.",Non-OADS,/arxiv_data1/oa_pdf/1d/bf/dddt-11-995.PMC5384742.pdf
"The most benign  injuries in the stomach that are known as gastric ulcers affect many people around the  world.1 An imbalance between destructive factors and mucosal defence mechanisms  in the mucosal epithelium causes gastric ulcer.2 Many destructive factors enhance  the occurrence of acute gastrointestinal disorders such as a higher secretion of acid– pepsin, a lower secretion of mucus and bicarbonate, severe psychological or physical  stress, smoking, imbalanced bile salt secretion, Helicobacter pylori  infection, ingestion  of ethanol, aspirin, and other nonsteroidal anti-inflammatory drugs, and hereditary  factors.3,4 Several investigations have concerned the production of oxygen-derived  free radicals in the pathogenesis of stomach ulcers.5 Additionally, the higher level of lipid peroxidation has a destroying effect on stomach  glandular epithelial, which causes injury provoked by consuming ethanol.6 Antioxidants  are well known to restrain lipid peroxidation in addition to scavenging free radicals.7 correspondence: Mahmood ameen  abdulla Department of Biomedical science,  Faculty of Medicine, University of Malaya,  Jalan University, 50603 Kuala lumpur,  Malaysia Tel +603 7967 6604 Fax +603 7967 6600 email ammeen@um.edu.m y Journal name: Drug Design, Development and Therapy Article Designation: Original Research Y ear: 2017 Volume: 11 Running head verso: AL-Wajeeh et al Running head recto: Gastroprotective effect of Cibotium barometz DOI: http://dx.doi.org/10.2147/DDDT.S107018",Non-OADS,/arxiv_data1/oa_pdf/1d/bf/dddt-11-995.PMC5384742.pdf
"Drug Design, Development and Therapy Publish your work in this journal Submit your manuscript here:  http://www.dovepress.com/drug-design-development-and-therapy-journa lDrug Design, Development and Therapy is an international, peer- reviewed open-access journal that spans the spectrum of drug design  and development through to clinical applications.",Non-OADS,/arxiv_data1/oa_pdf/1d/bf/dddt-11-995.PMC5384742.pdf
Visit  http://www.dovepress.com/testimonials.ph p to read real quotes from  published authors.,Non-OADS,/arxiv_data1/oa_pdf/1d/bf/dddt-11-995.PMC5384742.pdf
"Center, Jonathan Bebbington, Jack Cuthbertson, Christopher Gonelli , Georges Khoury, Charlene Mackenzie, Marit Lichtfuss, Grant Rawlin, Brian Muller, and Damian PurcellThis is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered , transformed, or built upon in any way.MABS 2017, VOL.",Non-OADS,/arxiv_data1/oa_pdf/25/28/kmab-09-03-1270491.PMC5384801.pdf
"3, 550 –566 http://dx.doi.org/10.1080/19420862.2016.1270491",Non-OADS,/arxiv_data1/oa_pdf/25/28/kmab-09-03-1270491.PMC5384801.pdf
"87 Structure- based modeling of VH region To de ﬁne the location of aromatic, His and Cys residues in both 6A and 8C antibodies, and the structure changes following Alasubstitution, the VH region was modeled using a fully auto-mated protein structure homology-modeling server (SWISS-MODEL, http://swissmodel.expasy.org ).",OADS,/arxiv_data1/oa_pdf/25/28/kmab-09-03-1270491.PMC5384801.pdf
ORCID Behnaz Heydarchi http://orcid.org/0000-0003-3043-1322 Christopher Gonelli http://orcid.org/0000-0002-7521-8528 Charlene Mackenzie http://orcid.org/0000-0002-9448-0951 Brian Muller http://orcid.org/0000-0002-7425-2644 References 1.,Non-OADS,/arxiv_data1/oa_pdf/25/28/kmab-09-03-1270491.PMC5384801.pdf
JAMA2016; 316(2):191-210; PMID:27404187; http://dx.doi.org/10.1001/ jama.2016.8900 2.,Non-OADS,/arxiv_data1/oa_pdf/25/28/kmab-09-03-1270491.PMC5384801.pdf
Science2013; 341(6151):1199-204; PMID:24031012; http://dx.doi.org/10.1126/ science.1241144 3.,Non-OADS,/arxiv_data1/oa_pdf/25/28/kmab-09-03-1270491.PMC5384801.pdf
PLoS One 2011; 6(3):e18207; PMID:21483815; http://dx.doi.org/10.1371/journal.pone.0018207 4.,Non-OADS,/arxiv_data1/oa_pdf/25/28/kmab-09-03-1270491.PMC5384801.pdf
Annu Rev Immunol 2010; 28:413-44; PMID:20192810; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/25/28/kmab-09-03-1270491.PMC5384801.pdf
Curr HIV Res 2007; 5(6):642-55; PMID:18045119; http://dx.doi.org/10.2174/157016207782418506MABS 563,Non-OADS,/arxiv_data1/oa_pdf/25/28/kmab-09-03-1270491.PMC5384801.pdf
Nat Rev Microbiol 2004; 2(9):695-703;PMID:15372080; http://dx.doi.org/10.1038/nrmicro974 7.,Non-OADS,/arxiv_data1/oa_pdf/25/28/kmab-09-03-1270491.PMC5384801.pdf
J Virol 2012; 86(5):2488-500; PMID:22205734; http://dx.doi.org/10.1128/JVI.06259-11 8 .,Non-OADS,/arxiv_data1/oa_pdf/25/28/kmab-09-03-1270491.PMC5384801.pdf
Virology 2007; 360(2):329-40;PMID:17126869; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/25/28/kmab-09-03-1270491.PMC5384801.pdf
N Engl J Med 2009; 361(23):2209-20; PMID:19843557;http://dx.doi.org/10.1056/NEJMoa0908492 10.,Non-OADS,/arxiv_data1/oa_pdf/25/28/kmab-09-03-1270491.PMC5384801.pdf
Nat Immunol 2004; 5(3):233- 6; PMID:14985706; http://dx.doi.org/10.1038/ni0304-233 11.,Non-OADS,/arxiv_data1/oa_pdf/25/28/kmab-09-03-1270491.PMC5384801.pdf
Vaccine 2009; 27(37):5120-32; PMID:19567243;http://dx.doi.org/10.1016/j.vaccine.2009.06.037 13.,Non-OADS,/arxiv_data1/oa_pdf/25/28/kmab-09-03-1270491.PMC5384801.pdf
J Exp Med 2012; 209(6):1091-103; PMID:22641382; http://dx.doi.org/10.1084/jem.20112655 14.,Non-OADS,/arxiv_data1/oa_pdf/25/28/kmab-09-03-1270491.PMC5384801.pdf
Antimicrob Agents Chemother 2012; 56(8):4310-9; PMID:22664963; http://dx.doi.org/10.1128/AAC.00453-12 15.,Non-OADS,/arxiv_data1/oa_pdf/25/28/kmab-09-03-1270491.PMC5384801.pdf
Proc Natl Acad Sci U S A 1985; 82(9):2945-9; PMID:3921967; http://dx.doi.org/ 10.1073/pnas.82.9.2945 17.,OADS,/arxiv_data1/oa_pdf/25/28/kmab-09-03-1270491.PMC5384801.pdf
Semin Immunol 1997; 9(3):189-97; PMID:9200330; http://dx.doi.org/ 10.1006/smim.1997.0070 19.,Non-OADS,/arxiv_data1/oa_pdf/25/28/kmab-09-03-1270491.PMC5384801.pdf
Immunol Rev 1998; 162:55-66; PMID:9602352; http://dx.doi.org/10.1111/j.1600-065X.1998.tb01429.x 21.,Non-OADS,/arxiv_data1/oa_pdf/25/28/kmab-09-03-1270491.PMC5384801.pdf
Annu Rev Biochem 2007; 76:1-22; PMID:17328676;http://dx.doi.org/10.1146/annurev.biochem.76.061705.09074022.,Non-OADS,/arxiv_data1/oa_pdf/25/28/kmab-09-03-1270491.PMC5384801.pdf
J Exp Med 2011; 208 (1):181-93; PMID:21220454; http://dx.doi.org/10.1084/jem.20101352 23.,Non-OADS,/arxiv_data1/oa_pdf/25/28/kmab-09-03-1270491.PMC5384801.pdf
Nature 2009; 458(7238):636-40; PMID:19287373;http://dx.doi.org/10.1038/nature07930 24.,Non-OADS,/arxiv_data1/oa_pdf/25/28/kmab-09-03-1270491.PMC5384801.pdf
Immunity 2007;26(2):205-13; PMID:17306569; http://dx.doi.org/10.1016/j.immuni.2007.01.009 25.,OADS,/arxiv_data1/oa_pdf/25/28/kmab-09-03-1270491.PMC5384801.pdf
Front Microbiol 2012;3:277; PMID:22876240; http://dx.doi.org/10.3389/fmicb.2012.00277 26.,OADS,/arxiv_data1/oa_pdf/25/28/kmab-09-03-1270491.PMC5384801.pdf
Nature 2010; 467(7315):591-5; PMID:20882016; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/25/28/kmab-09-03-1270491.PMC5384801.pdf
Nature 2007; 445 (7129):732-7; PMID:17301785; http://dx.doi.org/10.1038/nature05580 28.,Non-OADS,/arxiv_data1/oa_pdf/25/28/kmab-09-03-1270491.PMC5384801.pdf
J Mol Biol 2003; 325(2):337-54; PMID:12488099; http://dx.doi.org/10.1016/S0022- 2836(02)01222-6 31.,OADS,/arxiv_data1/oa_pdf/25/28/kmab-09-03-1270491.PMC5384801.pdf
J Virol 2010; 84(6):2955- 62; PMID:20042512; http://dx.doi.org/10.1128/JVI.02257-09 33.,Non-OADS,/arxiv_data1/oa_pdf/25/28/kmab-09-03-1270491.PMC5384801.pdf
J Virol 2010; 84(9):4136-47; PMID:20147404; http://dx.doi.org/10.1128/JVI.02357-09 35.,Non-OADS,/arxiv_data1/oa_pdf/25/28/kmab-09-03-1270491.PMC5384801.pdf
J Virol 2004; 78(19):10724-37; PMID:15367639; http://dx.doi.org/ 10.1128/JVI.78.19.10724-10737.2004 36.,Non-OADS,/arxiv_data1/oa_pdf/25/28/kmab-09-03-1270491.PMC5384801.pdf
AIDS Res Hum Retroviruses1994; 10(4):359-69; PMID:7520721; http://dx.doi.org/10.1089/ aid.1994.10.359 37.,Non-OADS,/arxiv_data1/oa_pdf/25/28/kmab-09-03-1270491.PMC5384801.pdf
AIDS Res Hum Retroviruses 1994; 10(12):1651-8;PMID:7888224; http://dx.doi.org/10.1089/aid.1994.10.1651 38.,Non-OADS,/arxiv_data1/oa_pdf/25/28/kmab-09-03-1270491.PMC5384801.pdf
Supersite of immune vulnerabil- ity on the glycosylated face of HIV-1 envelope glycoprotein gp120.Nat Struct Mol Biol 2013; 20(7):796-803; PMID:23708606; http://dx.doi.org/10.1038/nsmb.2594 39.,Non-OADS,/arxiv_data1/oa_pdf/25/28/kmab-09-03-1270491.PMC5384801.pdf
Immunity 2012; 37(3):412- 25; PMID:22999947; http://dx.doi.org/10.1016/j.immuni.2012.08.012 40.,Non-OADS,/arxiv_data1/oa_pdf/25/28/kmab-09-03-1270491.PMC5384801.pdf
J Mol Biol2003; 334(4):733-49; PMID:14636599; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/25/28/kmab-09-03-1270491.PMC5384801.pdf
Proteins 1993; 16(1):1-7; PMID:8497480; http://dx.doi.org/10.1002/prot.340160102 44.,OADS,/arxiv_data1/oa_pdf/25/28/kmab-09-03-1270491.PMC5384801.pdf
J Immunol 2005; 174(12):7773-80; PMID:15944280; http://dx.doi.org/ 10.4049/jimmunol.174.12.7773 45.,Non-OADS,/arxiv_data1/oa_pdf/25/28/kmab-09-03-1270491.PMC5384801.pdf
Cell 2013; 153(6):1379-93; PMID:23746848; http://dx.doi.org/10.1016/j.cell.2013.04.049 46.,OADS,/arxiv_data1/oa_pdf/25/28/kmab-09-03-1270491.PMC5384801.pdf
Dev Comp Immunol 2006; 30(1-2):175-86; PMID:16054212; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/25/28/kmab-09-03-1270491.PMC5384801.pdf
Vet Immunol Immunopathol 2009; 127(1-2):106-13; PMID:19012969; http://dx.doi.org/10.1016/j.vetimm.2008.09.024 50.,Non-OADS,/arxiv_data1/oa_pdf/25/28/kmab-09-03-1270491.PMC5384801.pdf
J Virol 2009; 83(2):757-69; PMID:18987148; http://dx.doi.org/10.1128/JVI.02036-08 51.,Non-OADS,/arxiv_data1/oa_pdf/25/28/kmab-09-03-1270491.PMC5384801.pdf
J Virol 2014; 88 (5):2426-41; PMID:24335316; http://dx.doi.org/10.1128/JVI.02837-13 52.,Non-OADS,/arxiv_data1/oa_pdf/25/28/kmab-09-03-1270491.PMC5384801.pdf
Euro J Immunol 2012; 42(10):2771-81; PMID:22730083; http://dx.doi.org/ 10.1002/eji.201242469 55.,Non-OADS,/arxiv_data1/oa_pdf/25/28/kmab-09-03-1270491.PMC5384801.pdf
BMC Immunol 2009; 10(22);PMID:19405939; http://dx.doi.org/10.1186/1471-2172-10-22 57.,Non-OADS,/arxiv_data1/oa_pdf/25/28/kmab-09-03-1270491.PMC5384801.pdf
Mol Immunol 2010; 47:2119-28; PMID:20435350; http://dx.doi.org/10.1016/j.molimm.2010.02.014 59.,Non-OADS,/arxiv_data1/oa_pdf/25/28/kmab-09-03-1270491.PMC5384801.pdf
Nucleic Acids Res 2014; 42 (Web Server issue):W252-8; PMID:24782522; http://dx.doi.org/10.1093/nar/gku340 60.,OADS,/arxiv_data1/oa_pdf/25/28/kmab-09-03-1270491.PMC5384801.pdf
Electrophoresis 2009; 30(Suppl 1):S162-73;PMID:19517507; http://dx.doi.org/10.1002/elps.200900140 61.,OADS,/arxiv_data1/oa_pdf/25/28/kmab-09-03-1270491.PMC5384801.pdf
"Kiefer F, Arnold K, Kunzli M, Bordoli L, Schwede T. The SWISS-MODEL Repository and associated resource s. Nucleic Acids Res 2009; 37(Database issue):D387-92; PMID:18931379; http://dx.doi.org/10.1093/nar/gkn750 62.",OADS,/arxiv_data1/oa_pdf/25/28/kmab-09-03-1270491.PMC5384801.pdf
Bioinformatics 2006; 22(2):195-201; PMID:16301204;http://dx.doi.org/10.1093/bioinformatics/bti770 63.,OADS,/arxiv_data1/oa_pdf/25/28/kmab-09-03-1270491.PMC5384801.pdf
J Virol 2009; 83(1):188-99; PMID:18922865; http://dx.doi.org/ 10.1128/JVI.01583-08 64.,Non-OADS,/arxiv_data1/oa_pdf/25/28/kmab-09-03-1270491.PMC5384801.pdf
AIDS 2003; 17(16):2323-30; PMID:14571183; http://dx.doi.org/10.1097/00002030-200311070-00006 65.,Non-OADS,/arxiv_data1/oa_pdf/25/28/kmab-09-03-1270491.PMC5384801.pdf
J Infect Dis 2013; 207(3):426-31; PMID:23162135; http://dx.doi.org/10.1093/infdis/jis696 66.,OADS,/arxiv_data1/oa_pdf/25/28/kmab-09-03-1270491.PMC5384801.pdf
J Exp Med 2010; 207(9):2003-17; PMID:20679401; http://dx.doi.org/10.1084/jem.20100025 67.,Non-OADS,/arxiv_data1/oa_pdf/25/28/kmab-09-03-1270491.PMC5384801.pdf
J Virol 2012; 86(20):11231-41; PMID:22875963; http://dx.doi.org/ 10.1128/JVI.01543-12 68.,Non-OADS,/arxiv_data1/oa_pdf/25/28/kmab-09-03-1270491.PMC5384801.pdf
PLoS One 2011; 6(9):e24078; PMID:21931643; http://dx.doi.org/10.1371/journal.pone.0024078 69.,Non-OADS,/arxiv_data1/oa_pdf/25/28/kmab-09-03-1270491.PMC5384801.pdf
J Immunol Methods 2009; 343(2):65-7; PMID:19100741;http://dx.doi.org/10.1016/j.jim.2008.11.012 70.,Non-OADS,/arxiv_data1/oa_pdf/25/28/kmab-09-03-1270491.PMC5384801.pdf
Sci Transl Med 2012; 4(142): 142ra96; PMID:22786681; http://dx.doi.org/10.1126/scitranslmed.3003752 71.,Non-OADS,/arxiv_data1/oa_pdf/25/28/kmab-09-03-1270491.PMC5384801.pdf
J Immunol 2014; 192(8):3637-44;PMID:24623130; http://dx.doi.org/10.4049/jimmunol.1303334 72.,Non-OADS,/arxiv_data1/oa_pdf/25/28/kmab-09-03-1270491.PMC5384801.pdf
Sci- ence 2010; 329(5993):856-61; PMID:20616233; http://dx.doi.org/ 10.1126/science.1187659 73.,OADS,/arxiv_data1/oa_pdf/25/28/kmab-09-03-1270491.PMC5384801.pdf
Construction and characterization of chimeric and human-ized forms of a broadly neutralizing monoclonal antibody to HIV-1.Hum Antibodies Hybridomas 1994; 5(1-2):9-17; PMID:7858187; http://dx.doi.org/10.3233/HAB-1994-51-202 75.,Non-OADS,/arxiv_data1/oa_pdf/25/28/kmab-09-03-1270491.PMC5384801.pdf
Vaccines (Basel) 2013; 1(4):497-512; PMID:26344344; http://dx.doi.org/10.3390/vaccines1040497 76.,Non-OADS,/arxiv_data1/oa_pdf/25/28/kmab-09-03-1270491.PMC5384801.pdf
Cell 2003; 114(2):161-70; PMID:12887918;http://dx.doi.org/10.1016/S0092-8674(03)00508-7 78.,OADS,/arxiv_data1/oa_pdf/25/28/kmab-09-03-1270491.PMC5384801.pdf
J Immunol 2004; 172(9):5154-7; PMID:15100251; http://dx.doi.org/10.4049/ jimmunol.172.9.5154 81.,Non-OADS,/arxiv_data1/oa_pdf/25/28/kmab-09-03-1270491.PMC5384801.pdf
Virology 2009; 385(1):275-81; PMID:19135223; http://dx.doi.org/10.1016/j.virol.2008.12.009 82.,Non-OADS,/arxiv_data1/oa_pdf/25/28/kmab-09-03-1270491.PMC5384801.pdf
BioMed Central 2012; 5:93; PMID:22333045; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/25/28/kmab-09-03-1270491.PMC5384801.pdf
Vet Res 2009; 40(1):3; PMID:18828984; http://dx.doi.org/10.1051/vetres:2008041 85.,Non-OADS,/arxiv_data1/oa_pdf/25/28/kmab-09-03-1270491.PMC5384801.pdf
J Immunol Methods2008; 329(1 –2):112-124; PMID:17996249; http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/25/28/kmab-09-03-1270491.PMC5384801.pdf
Vaccine 2009; 27(47):6605-12; PMID:19712773; http://dx.doi.org/10.1016/j.vaccine.2009.08.016 87.,Non-OADS,/arxiv_data1/oa_pdf/25/28/kmab-09-03-1270491.PMC5384801.pdf
Methods Mol Biol 2009; 485:395-405; PMID:19020839; http://dx.doi.org/10.1007/978-1-59745-170-3_26 88.,Non-OADS,/arxiv_data1/oa_pdf/25/28/kmab-09-03-1270491.PMC5384801.pdf
SUPPLEMENTARY MATERIALS Supplementary material for this article is available at http://advances.sciencemag.org/cgi/ content/full/3/4/e1600663/DC1 fig.,Non-OADS,/arxiv_data1/oa_pdf/2d/ea/1600663.PMC5384802.pdf
SUPPLEMENTARY MATERIALS Supplementary material for this article is available at http://advances.sciencemag.org/cgi/ content/full/3/4/e1601614/DC1 section S1.,Non-OADS,/arxiv_data1/oa_pdf/04/15/1601614.PMC5384803.pdf
Literature data from the GEOROC database (http://georoc.mpch -mainz.gwdg.de/ georoc/) and only recent subaerial extrusive lavas with <62% SiO 2have been included to avoid effects from fractional crys tallization and assimilation (see the Supplementary Materials for details).,OADS,/arxiv_data1/oa_pdf/4c/00/1602402.PMC5384804.pdf
(A) Literature data are from the GEOROC database (http://georoc.mpch-mainz.gwdg.,OADS,/arxiv_data1/oa_pdf/4c/00/1602402.PMC5384804.pdf
"Mélange rocks are rich in volatile elements; may act as a temporary storage of H 2O, CO 2, and sulfur near or at the slab surface; and control the volatile transport into the mantle w e d g ea n di n t ot h ed e e pm a n t l e .T h ed i f f e r e n c e si nt h ep a t h w a y sa n dbudgets of volatiles between the two contrasting models for the gener-ation of arc magmas are drastic and call for a reevaluation of further published data sets and revision of concepts and conclusions on subduction zone processes.MATERIALS AND METHODS We used data for arc lavas compiled from the GEOROC database(http://georoc.mpch-mainz.gwdg.de/georoc/) for eight well-studiedisland arcs.",Non-OADS,/arxiv_data1/oa_pdf/4c/00/1602402.PMC5384804.pdf
SUPPLEMENTARY MATERIALS Supplementary material for this article is available at http://advances.sciencemag.org/cgi/ content/full/3/4/e1602402/DC1Supplementary Textfig.,Non-OADS,/arxiv_data1/oa_pdf/4c/00/1602402.PMC5384804.pdf
SUPPLEMENTARY MATERIALS Supplementary material for this article is available at http://advances.sciencemag.org/cgi/ content/full/3/4/e1601721/DC1Supplementary Resultstable S1.,Non-OADS,/arxiv_data1/oa_pdf/b5/04/1601721.PMC5384805.pdf
SUPPLEMENTARY MATERIALS Supplementary material for this article is available at http://advances.sciencemag.org/cgi/ content/full/3/4/e1601589/DC1 table S1.,Non-OADS,/arxiv_data1/oa_pdf/d2/2b/1601589.PMC5384806.pdf
SUPPLEMENTARY MATERIALS Supplementary material for this article is available at http://advances.sciencemag.org/cgi/ content/full/3/4/e1601659/DC1fig.,Non-OADS,/arxiv_data1/oa_pdf/a1/29/1601659.PMC5384807.pdf
SUPPLEMENTARY MATERIALS Supplementary material for this article is available at http://advances.sciencemag.org/cgi/ content/full/3/4/e1602273/DC1 section S1.,Non-OADS,/arxiv_data1/oa_pdf/bf/4b/1602273.PMC5384808.pdf
SUPPLEMENTARY MATERIALS Supplementary material for this article is available at http://advances.sciencemag.org/cgi/ content/full/3/4/e1601601/DC1fig.,Non-OADS,/arxiv_data1/oa_pdf/0b/19/1601601.PMC5384809.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/c8/a6/main.PMC5384885.pdf
Contents lists available at ScienceDirect Respiratory Medicine Case Reports journal homepage: www.elsevier.c om/locate/rmcr http://dx.doi.org/10.1016/j.rmcr.2017.03.022 2213-0071/ ©2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/c8/a6/main.PMC5384885.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).Respiratory Medicine Case Reports 21 (2017) 78 e81,Non-OADS,/arxiv_data1/oa_pdf/c8/a6/main.PMC5384885.pdf
https://www.cdc.gov/pneumonia/ atypical/mycoplasma/ .,Non-OADS,/arxiv_data1/oa_pdf/c8/a6/main.PMC5384885.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/57/e4/main.PMC5384886.pdf
Contents lists available at ScienceDirect International Journal for Parasitology: Drugs and Drug Resistance journal homepage: www.elsevier.c om/locate/ijpddr http://dx.doi.org/10.1016/j.ijpddr.2017.03.007 2211-3207/ ©2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/57/e4/main.PMC5384886.pdf
http://www.who.int/malaria/publications/ world_malaria_report_2013/report/en/ .,Non-OADS,/arxiv_data1/oa_pdf/57/e4/main.PMC5384886.pdf
"Recently, a number of studies on additional fracture related risk factors, new treatment options as well as real world studies demonstrating a much higher fracture rate than suggested by randomized clinical controlled trials (RCTs).Therefore, this updated algorithm was developed to better assess fracture risk and direct treatment as a position http://dx.doi.org/10.1016/j.jbo.2017.03.001 Received 9 March 2017; Accepted 10 March 2017⁎Correspondence to: Prof. Dr. med.",Non-OADS,/arxiv_data1/oa_pdf/ff/40/main.PMC5384888.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/BY-NC-ND/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/ff/40/main.PMC5384888.pdf
"In the past years, we have accumulated an expanded understanding offracture risk factors other than BMD [5,45] , resulting in several national and international bone health guidelines being updated toprovide more comprehensive insights into fracture risk assessment and clinical decision making regarding antiresorptive therapy ( Table 1 ) [5,6,11,46 –53]A key advance in this ﬁeld has been the development of the FRAX algorithm developed by the former WHO CollaboratingCenter at She ﬃeld, UK ( http://www.she ﬃeld.ac.uk/FRAX/ ), an easy- to-use online tool for assessing fracture risk in postmenopausal womenwith or without BMD data.",Non-OADS,/arxiv_data1/oa_pdf/ff/40/main.PMC5384888.pdf
"In addition, the Cochrane Register of Controlled Trials and databases of ongoing and unpublished trials http://www.clinicaltrials.gov were searched.",OADS,/arxiv_data1/oa_pdf/ff/40/main.PMC5384888.pdf
Available at: 〈http://www.posters2view.com/sabcs09/viewp.php?Nu=4083 〉.,Non-OADS,/arxiv_data1/oa_pdf/ff/40/main.PMC5384888.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/0f/f7/main.PMC5384889.pdf
1476-5586http://dx.doi.org/10.1016/j.neo.2017.02.011,OADS,/arxiv_data1/oa_pdf/0f/f7/main.PMC5384889.pdf
Available online 18 March 2017; http://dx.doi.org/10.1016/j.simyco.2017.03.001 .,OADS,/arxiv_data1/oa_pdf/12/c5/main.PMC5384890.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by- nc-nd/4.0/ ).available online at www.studiesinmycology.org STUDIES IN MYCOLOGY 88: 1 –35 (2017).,Non-OADS,/arxiv_data1/oa_pdf/12/c5/main.PMC5384890.pdf
With Findmodel ( http://www.hiv.lanl.gov/content/ sequence/ ﬁndmodel/ ﬁndmodel.html ) the best nucleotide substi- tution models were determined.,OADS,/arxiv_data1/oa_pdf/12/c5/main.PMC5384890.pdf
"The resulting trees were printed with TreeView v. 1.6.6 ( Page 1996 ) and, together with the alignments, deposited into TreeBASE ( http://www.treebase.org ).Table 1.",OADS,/arxiv_data1/oa_pdf/12/c5/main.PMC5384890.pdf
Available from: http://tree.bio.,OADS,/arxiv_data1/oa_pdf/12/c5/main.PMC5384890.pdf
"Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which per-mits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commonslicense, and indicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/df/01/40264_2017_Article_506.PMC5384950.pdf
"Open Access This article is distributed under the terms of the Creative Commons Attribu‑tion‑NonCommercial 4.0 International License (http://creativecommons.org/licenses/by‑nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/98/8d/134_2017_Article_4743.PMC5384959.pdf
http://www.eucast.org .,Non-OADS,/arxiv_data1/oa_pdf/98/8d/134_2017_Article_4743.PMC5384959.pdf
"European Committee on Antibiotic Susceptibility Testing (2013) Flucona‑zole: rationale for the clinical breakpoints, version 2.0. http://www.eucast.org.",Non-OADS,/arxiv_data1/oa_pdf/98/8d/134_2017_Article_4743.PMC5384959.pdf
Funding The Web-RADR project has received support from the Innovative Medicine Initiative Joint Undertaking ( http://www.imi.,Non-OADS,/arxiv_data1/oa_pdf/a7/c2/40264_2016_Article_494.PMC5384960.pdf
"115632—resources of which are composed of ﬁnancial contributions from the European Union’sSeventh Framework Programme FP7/2007–2013 and EFPIA com- panies in kind contribution, http://www.imi.europa.eu , UK.",Non-OADS,/arxiv_data1/oa_pdf/a7/c2/40264_2016_Article_494.PMC5384960.pdf
"Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 InternationalLicense (http://creativecommons.org/licenses/by-nc/4.0/), which per-mits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commonslicense, and indicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/a7/c2/40264_2016_Article_494.PMC5384960.pdf
Available from: http://www.ema.europa.eu/docs/en_GB/ document_library/Scientiﬁc_guideline/2013/01/WC500137666.,Non-OADS,/arxiv_data1/oa_pdf/a7/c2/40264_2016_Article_494.PMC5384960.pdf
Available from: http://www.medscape.org/viewarticle/581013_2 .,Non-OADS,/arxiv_data1/oa_pdf/a7/c2/40264_2016_Article_494.PMC5384960.pdf
"2.5 Ethical Aspects All ADR reporters agreed to the Lareb privacy statement (http://www.lareb.nl/Footer/Privacy ), and the ADR reports were anonymously forwarded to students by Lareb staff.The Institutional Review Board (IRB) of the VUmc reviewed the research protocol and concluded that the study did not fall under the scope of the Dutch MedicalResearch Involving Human Subjects Act (WMO) [refer- ence 15348).",Non-OADS,/arxiv_data1/oa_pdf/4b/42/40264_2016_Article_502.PMC5384963.pdf
"Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which per-mits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commonslicense, and indicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/4b/42/40264_2016_Article_502.PMC5384963.pdf
"http://www.who.int/medicines/areas/quality_safety/safety_efﬁcacy/collab-centres-netherlands/ ,http:// www.lareb.nl/whocc?lang=en-GB .",Non-OADS,/arxiv_data1/oa_pdf/4b/42/40264_2016_Article_502.PMC5384963.pdf
"In this trial (registered as number 4895 in the Netherlands TrialRegister; http://www.trialregister.nl ), after providing informed consent patients were randomised into an inter- vention group and a control group (unpublished data).",Non-OADS,/arxiv_data1/oa_pdf/db/f3/40264_2017_Article_504.PMC5384965.pdf
"Informed consent Informed consent was obtained from all individ- ual participants included in the study.Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which per-mits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commonslicense, and indicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/db/f3/40264_2017_Article_504.PMC5384965.pdf
Utrecht: Nederlands Huisartsen Genootschap; 2012. https://www.nhg.org/sites/Evaluation of Potentially Drug-Related Patient-Reported Common Symptoms 429,Non-OADS,/arxiv_data1/oa_pdf/db/f3/40264_2017_Article_504.PMC5384965.pdf
The Hague: Dutch Foundation for Pharma-ceutical Statistics (SFK); 2013. http://www.sfk.nl/nieuws- publicaties/PW/2013/meer-ur-omzet-niet-vergoed .,Non-OADS,/arxiv_data1/oa_pdf/db/f3/40264_2017_Article_504.PMC5384965.pdf
Oslo: World Health Organization; 2013. http://www.whocc.no/atc_ ddd_index/ .,Non-OADS,/arxiv_data1/oa_pdf/db/f3/40264_2017_Article_504.PMC5384965.pdf
http://www.apotheek.nl/Medische_informatie/Medicijnen/Medicijnen/default.aspx?mId= 10698&rId= .,Non-OADS,/arxiv_data1/oa_pdf/db/f3/40264_2017_Article_504.PMC5384965.pdf
https://kennisbank.knmp.nl/ .,Non-OADS,/arxiv_data1/oa_pdf/db/f3/40264_2017_Article_504.PMC5384965.pdf
"This is an Open Access artic le distributed under the terms  of the Creative Commons Attribution-Non-Commercial License (https://creativecommons.org/licenses/by-nc/3.0)DOI 10.1080/17453674.2017.1289326Classiﬁ  cation systems have been introduced for a variety  of orthopedic conditions over the years, and for many of them—including fractures—several systems have been sug-gested.",Non-OADS,/arxiv_data1/oa_pdf/8b/25/iort-88-121.PMC5385103.pdf
"This is an Open Access artic le distributed under the terms  of the Creative Commons Attribution-Non-Commercial License (https://creativecommons.org/licenses/by-nc/3.0)DOI 10.1080/17453674.2016.1258532Background and purpose —  To achieve a common understanding  when dealing with long bone fractures in children, the AO Pedi-atric Comprehensive Classiﬁ  cation of Long Bone Fractures (AO  PCCF) was introduced in 2007.",Non-OADS,/arxiv_data1/oa_pdf/b1/22/iort-88-123.PMC5385104.pdf
Supplementary data Tables 3–7 are available as supplementary data in the online  version of this article http://dx.doi.org/10.1080/17453674.2016.1258532.,OADS,/arxiv_data1/oa_pdf/b1/22/iort-88-123.PMC5385104.pdf
"This is an Open Access artic le distributed under the terms  of the Creative Commons Attribution-Non-Commercial License (https://creativecommons.org/licenses/by-nc/3.0)DOI 10.1080/17453674.2016.1258533Background and purpose —  To achieve a common understanding  when dealing with long bone fractures in children, the AO Pedi-atric Comprehensive Classiﬁ  cation of Long Bone Fractures (AO  PCCF) was introduced in 2007.",Non-OADS,/arxiv_data1/oa_pdf/7a/b4/iort-88-129.PMC5385105.pdf
Supplementary data Tables 3–7 are available as supplementary data in the online  version of this article http://dx.doi.org/10.1080/17453674.2016.1258533.,OADS,/arxiv_data1/oa_pdf/7a/b4/iort-88-129.PMC5385105.pdf
"This is an Open Access artic le distributed under the terms  of the Creative Commons Attribution-Non-Commercial License (https://creativecommons.org/licenses/by-nc/3.0)DOI 10.1080/17453674.2016.1258534Background and purpose —  The AO Pediatric Comprehensive  Classiﬁ  cation of Long Bone Fractures (PCCF) describes the local- ization and morphology of fractures, and considers severity in 2 categories: (1) simple, and (2) multifragmentary.",Non-OADS,/arxiv_data1/oa_pdf/1f/c0/iort-88-133.PMC5385106.pdf
This is an Open Access artic le distributed under the terms  of the Creative Commons Attribution-Non-Commercial License (https://creativecommons.org/licenses/by-nc/3.0)DOI 10.1080/17453674.2016.1274865Background and purpose —  Fast-track protocols have been intro- duced worldwide to improve the recovery after total hip arthro-plasty (THA).,Non-OADS,/arxiv_data1/oa_pdf/d9/ca/iort-88-140.PMC5385107.pdf
Supplementary data Tables 1 and 2 and Figures 2–7 are available as supplementary  data in the online version of this article http://dx.doi.org/10.1080/17453674.2016.1274865.,OADS,/arxiv_data1/oa_pdf/d9/ca/iort-88-140.PMC5385107.pdf
This is an Open Access artic le distributed under the terms  of the Creative Commons Attribution-Non-Commercial License (https://creativecommons.org/licenses/by-nc/3.0)DOI 10.1080/17453674.2016.1262687Background and purpose —  Total hip replacement (THR) is the  preferred method for the active and lucid elderly patient with a displaced femoral neck fracture (FNF).,Non-OADS,/arxiv_data1/oa_pdf/9d/98/iort-88-145.PMC5385108.pdf
"Supplementary data Tables 4–6 are available as supplementary data in the online  version of this article http://dx.doi.org/10.1080/17453674.2016.1262687.GC and OS initiated the study, followed patients, and wrote the manuscript.",Non-OADS,/arxiv_data1/oa_pdf/9d/98/iort-88-145.PMC5385108.pdf
This is an Open Access artic le distributed under the terms  of the Creative Commons Attribution-Non-Commercial License (https://creativecommons.org/licenses/by-nc/3.0)DOI 10.1080/17453674.2016.1269051Background and purpose —  Little is know about patterns of sick  leave in connection with total hip and knee joint replacement (THR and TKR) in patients with osteoarthritis (OA).,Non-OADS,/arxiv_data1/oa_pdf/22/68/iort-88-152.PMC5385109.pdf
Avail- able at: http://www.oecd.org/els/health-systems/Health-at-a-Glance-2013.pdf.,Non-OADS,/arxiv_data1/oa_pdf/22/68/iort-88-152.PMC5385109.pdf
Available at: http://www.who.int/classiﬁ  cations/icd/en/index.html.,Non-OADS,/arxiv_data1/oa_pdf/22/68/iort-88-152.PMC5385109.pdf
This is an Open Access artic le distributed under the terms  of the Creative Commons Attribution-Non-Commercial License (https://creativecommons.org/licenses/by-nc/3.0)DOI 10.1080/17453674.2016.1250059Background and purpose —  There are concerns that mental  health (MH) may inﬂ  uence outcomes of total knee arthroplasty  (TKA) or total hip arthroplasty (THA).,Non-OADS,/arxiv_data1/oa_pdf/fb/09/iort-88-158.PMC5385110.pdf
"This is an Open Access artic le distributed under the terms  of the Creative Commons Attribution-Non-Commercial License (https://creativecommons.org/licenses/by-nc/3.0)DOI 10.1080/17453674.2016.1267835Background and purpose —  Computer-assisted surgery (CAS) in  total knee arthroplasty (TKA) has been used in recent years in the hope of improving the alignment and positioning of the implant, thereby achieving a better functional outcome and durability.",Non-OADS,/arxiv_data1/oa_pdf/5d/1b/iort-88-166.PMC5385111.pdf
"Helse Bergen HF, Department of Ortho-paedic Surgery, Haukeland University Hospital 2015: http://nrlweb.ihelse.net.",Non-OADS,/arxiv_data1/oa_pdf/5d/1b/iort-88-166.PMC5385111.pdf
This is an Open Access artic le distributed under the terms  of the Creative Commons Attribution-Non-Commercial License (https://creativecommons.org/licenses/by-nc/3.0)DOI 10.1080/17453674.2016.1275200Background and purpose —  The annual number of total knee  arthroplasties (TKAs) has increased worldwide in recent years.,Non-OADS,/arxiv_data1/oa_pdf/f2/12/iort-88-173.PMC5385112.pdf
This is an Open Access artic le distributed under the terms  of the Creative Commons Attribution-Non-Commercial License (https://creativecommons.org/licenses/by-nc/3.0)DOI 10.1080/17453674.2016.1262678Background and purpose —  Femoral lengthening may result in  decrease in knee range of motion (ROM) and quadriceps and hamstring muscle weakness.,Non-OADS,/arxiv_data1/oa_pdf/d4/06/iort-88-179.PMC5385113.pdf
"This is an Open Access artic le distributed under the terms  of the Creative Commons Attribution-Non-Commercial License (https://creativecommons.org/licenses/by-nc/3.0)DOI 10.1080/17453674.2016.1265876Background and purpose —  When children with irregular body  proportions or asymmetric limbs present, it may be unclear where the pathology is located.",Non-OADS,/arxiv_data1/oa_pdf/4b/e1/iort-88-185.PMC5385114.pdf
An online body proportions calculator is available:  www.pedslimbdeformity.com Supplementary data Figures 4 and 6 and Tables 1–5 are available as supplementary  data in the online version of this article http://dx.doi.org/10.1080/17453674.2016.1265876.,OADS,/arxiv_data1/oa_pdf/4b/e1/iort-88-185.PMC5385114.pdf
This is an Open Access artic le distributed under the terms  of the Creative Commons Attribution-Non-Commercial License (https://creativecommons.org/licenses/by-nc/3.0)DOI 10.1080/17453674.2016.1273644Background and purpose —  Patients with osteoporosis who pres- ent with an acute onset of back pain often have multiple fractures on plain radiographs.,Non-OADS,/arxiv_data1/oa_pdf/7f/90/iort-88-192.PMC5385115.pdf
Supplementary data Supplementary data is available in the online version of this  article http://dx.doi.org/10.1080/17453674.2016.1273644.,OADS,/arxiv_data1/oa_pdf/7f/90/iort-88-192.PMC5385115.pdf
Available from https://www.laekb.de/ﬁ  les/14BC112BB91/ DVO_Leitlinie_18092014.pdf.,Non-OADS,/arxiv_data1/oa_pdf/7f/90/iort-88-192.PMC5385115.pdf
This is an Open Access artic le distributed under the terms  of the Creative Commons Attribution-Non-Commercial License (https://creativecommons.org/licenses/by-nc/3.0)DOI 10.1080/17453674.2016.1263110Background and purpose —  Studies have indicated that one-third  of children with cerebral palsy (CP) develop dislocation of the hip that needs surgical intervention.,Non-OADS,/arxiv_data1/oa_pdf/ca/40/iort-88-198.PMC5385116.pdf
"This is an Open Access artic le distributed under the terms  of the Creative Commons Attribution-Non-Commercial License (https://creativecommons.org/licenses/by-nc/3.0)DOI 10.1080/17453674.2016.1262685Background and purpose —  Hip displacement is common in  children with severe cerebral palsy (CP) and can cause problems such as pain, contractures, and nursing difﬁ  culties.",Non-OADS,/arxiv_data1/oa_pdf/1f/a2/iort-88-205.PMC5385117.pdf
"http://www.sickkids.ca/Research/CPCHILD-Questionaire/Manual-interpretation-guide/index.html: The Hospital for Sick Children; 555 University Avenue,Toronto, Ontario, Canada [Accessed April 29th 2016].",Non-OADS,/arxiv_data1/oa_pdf/1f/a2/iort-88-205.PMC5385117.pdf
http://www.who.in/classiﬁ  cations/icd10/browse/2010/en.,Non-OADS,/arxiv_data1/oa_pdf/1f/a2/iort-88-205.PMC5385117.pdf
"This is an Open Access artic le distributed under the terms  of the Creative Commons Attribution-Non-Commercial License (https://creativecommons.org/licenses/by-nc/3.0)DOI 10.1080/17453674.2016.1278113Background and purpose —  The use of point-of-care or local  investigations before referral to specialist sarcoma centers as part of a fast-track diagnostic pathway varies, and may affect the time to diagnosis.",Non-OADS,/arxiv_data1/oa_pdf/9a/72/iort-88-211.PMC5385118.pdf
This is an Open Access artic le distributed under the terms  of the Creative Commons Attribution-Non-Commercial License (https://creativecommons.org/licenses/by-nc/3.0)DOI 10.1080/17453674.2016.1256940Background and purpose —  Constant ﬁ  xator stiffness for the  duration of healing may not provide suitable mechanical condi-tions for all stages of bone repair.,Non-OADS,/arxiv_data1/oa_pdf/9d/73/iort-88-217.PMC5385119.pdf
"This is an Open Access artic le distributed under the terms  of the Creative Commons Attribution-Non-Commercial License (https://creativecommons.org/licenses/by-nc/3.0)DOI 10.1080/17453674.2016.1274587Background and purpose —  Fracture healing involves different  inﬂ ammatory cells, some of which are not part of the traditional  bone ﬁ  eld, such as B-cells and cytotoxic T-cells.",Non-OADS,/arxiv_data1/oa_pdf/22/38/iort-88-223.PMC5385120.pdf
Supplementary data  The Table and Figures S1–S5 are available as supplementary  data in the online version of this article http://dx.doi.org/10.1080/17453674.2016.1274587.,OADS,/arxiv_data1/oa_pdf/22/38/iort-88-223.PMC5385120.pdf
"Available from: http://www.ors.org/Transactions/60/1511.pdf Könnecke I, Serra A, Khassawna El T, Schlundt C, Schell H, Hauser A, et al.",OADS,/arxiv_data1/oa_pdf/22/38/iort-88-223.PMC5385120.pdf
This is an Open Access artic le distributed under the terms  of the Creative Commons Attribution-Non-Commercial License (https://creativecommons.org/licenses/by-nc/3.0)DOI 10.1080/17453674.2016.1260403A 72-year-old man with a history of hypertension and hypo- thyroidism underwent ulnar nerve decompressive surgery at the elbow.,Non-OADS,/arxiv_data1/oa_pdf/05/d3/iort-88-231.PMC5385121.pdf
"This is an Open Access artic le distributed under the terms  of the Creative Commons Attribution-Non-Commercial License (https://creativecommons.org/licenses/by-nc/3.0)DOI 10.1080/17453674.2017.1283473Sir,— The efforts of the Norwegian Hip Fracture Register  (NHFR) to track hip fractures and gain patient-reported out-come data from a national cohort is praiseworthy.",Non-OADS,/arxiv_data1/oa_pdf/28/62/iort-88-234.PMC5385122.pdf
"According to the Annual Report of the NHFR (http://nrlweb.ihelse.net/Rapporter/Rapport2016.pdf), 356 reoperations due to dislocation were reported after approxi-mately 31,000 primary fracture arthroplasties, i.e.",OADS,/arxiv_data1/oa_pdf/28/62/iort-88-234.PMC5385122.pdf
"This is an Open Access artic le distributed under the terms  of the Creative Commons Attribution-Non-Commercial License (https://creativecommons.org/licenses/by-nc/3.0)DOI 10.1080/17453674.2016.1274591Sir,—I read with interest the study by Leer-Salvesen et al.",Non-OADS,/arxiv_data1/oa_pdf/10/86/iort-88-236.PMC5385123.pdf
"Lars Erichsen and Hanne Haahr are employees and shareholders of Novo Nordisk.Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which per-mits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commonslicense, and indicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/70/7b/40262_2017_Article_514.PMC5385193.pdf
http://www.accessdata.fda.gov/scripts/ cder/iig/index.cfm .,OADS,/arxiv_data1/oa_pdf/70/7b/40262_2017_Article_514.PMC5385193.pdf
"Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 InternationalLicense (http://creativecommons.org/licenses/by-nc/4.0/), which per-mits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commonslicense, and indicate if changes were made.",Non-OADS,/arxiv_data1/oa_pdf/59/7b/40262_2016_Article_452.PMC5385201.pdf
Available from: http://boris.unibe.ch/48827/1/mayer_workshop_final-1.pdf.,Non-OADS,/arxiv_data1/oa_pdf/9f/86/IJCBNM-5-123.PMC5385235.pdf
"Available from  http://www.diabetesatlas.org/ 5 Knowler WC, Barrett-Connor E, Fowler  SE, et al.",Non-OADS,/arxiv_data1/oa_pdf/49/48/IJCBNM-5-153.PMC5385238.pdf
[Cited 5 August 2014] Available  from: http://www.chcf.org/~/media/ MEDIA%20LIBRARY%20Files/ PDF/PDF%20H/PDF%20Helping  PatientsManageTheirChronicConditions.,Non-OADS,/arxiv_data1/oa_pdf/49/48/IJCBNM-5-153.PMC5385238.pdf
https://deepblue.lib.umich.edu/bitstream/ handle/2027.42/85350/HEALTH_ PROMOTION_MANUAL_Rev_5-2011.,Non-OADS,/arxiv_data1/oa_pdf/b6/68/IJCBNM-5-165.PMC5385239.pdf
Available from: http://thenetcommunity.org/wp-content/ uploads/2013/05/The-Monograph.pdf.,Non-OADS,/arxiv_data1/oa_pdf/5b/e2/IJCBNM-5-175.PMC5385240.pdf
Available  from: http://ird.behdasht.gov.ir/index.,OADS,/arxiv_data1/oa_pdf/5b/e2/IJCBNM-5-175.PMC5385240.pdf
Available  from: http://op.mdar.behdasht.gov.ir/ uploads/naghshe-jameh.pdf.,Non-OADS,/arxiv_data1/oa_pdf/5b/e2/IJCBNM-5-175.PMC5385240.pdf
Available from: http://www.who.int/patientsafety/events/05/cairo/,Non-OADS,/arxiv_data1/oa_pdf/5b/e2/IJCBNM-5-175.PMC5385240.pdf
Available from: http://apps.who.,Non-OADS,/arxiv_data1/oa_pdf/c9/eb/IJCBNM-5-188.PMC5385241.pdf
"1 Lab Anim Res 2017: 33(1), 1-7 https://doi.org/10.5625/lar.2017.33.1.1ISSN 1738-6055 (Print) ISSN 2233-7660 (Online) Over-expression of myosin7A in cochlea r hair cells of circling mice Yoo Yeon Kim, Hajin Nam, Harry Jung, Boyoung Kim, Jun Gyo Suh* Department of Medical Genetics, College of Medicine, Hallym University, Chuncheon, Korea Circling mouse (C57BL/6J- cir/cir ) deleted the transmembrane inner ear ( Tmie ) gene is an animal model for human non-syndromic recessive deafness, DFNB6.",Non-OADS,/arxiv_data1/oa_pdf/02/a4/lar-33-1.PMC5385277.pdf
"15 Lab Anim Res 2017: 33(1), 15-23 https://doi.org/10.5625/lar.2017.33.1.15ISSN 1738-6055 (Print) ISSN 2233-7660 (Online) The effects of pentoxifylline adminstration on fracture healing in a postmenopausal osteoporotic rat model Mohammad Mahdi Vashghani Farahani1, Reza Ahadi2, Mohammadamin Abdollahifar3, Mohammad Bayat4,* 1Basic Sciences Department, Paramedical School, Shahid Beheshti University of Medical Sciences , Tehran, Iran 2Department of Anatomy, School of medicine, Iran University of Medical Sciences, Tehran, Iran 3Department of Anatomical sciences and Biology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran 4Cellular and Molecular Biology Research Centre, Department of Anatomical Sciences and Biology, Medical School, Shahid Beheshti University of Medical Sciences, Tehran, Iran Previous studies report positive effects of pentoxifylline (PTX) alone or in combination with other drugs on some pathologic bone diseases as well as an ability to accelerate osteogensis and fracture healing in both animal models and human patients.",Non-OADS,/arxiv_data1/oa_pdf/6a/ac/lar-33-15.PMC5385278.pdf
"24 Lab Anim Res 2017: 33(1), 24-31 https://doi.org/10.5625/lar.2017.33.1.24ISSN 1738-6055 (Print) ISSN 2233-7660 (Online) Effects of coenzyme Q10 on the antioxidant system in SD rats  exposed to lipopolysaccharide-induced toxicity Min-Hae Song1, Ha-Na Kim1, Yong Lim2, In-Surk Jang1,* 1Department of Animal Science and Biotechnology, and the Regional Animal Research Center, Gyeongnam National University of Science and Technology, Jinju, Korea 2Department of Clinical Laboratory Science, Dong-Eui Univerisity, Busan, Korea The study was performed to see the effects of coenzyme Q10 (CoQ10) on blood biochemical components and hepatic antioxidant system in rats exposed to lipopolysaccharide (LPS)-induced toxicity.",OADS,/arxiv_data1/oa_pdf/8f/2c/lar-33-24.PMC5385279.pdf
"32 Lab Anim Res 2017: 33(1), 32-39 https://doi.org/10.5625/lar.2017.33.1.32ISSN 1738-6055 (Print) ISSN 2233-7660 (Online) Immunomodulatory effects of ethanol extract of germinated ice  plant (Mesembryanthemum crystallinum) Joo-Hee Choi1,#, Sung-Gang Jo1,#, Seoung-Ki Jung2#, Woo-Tae Park2, Keun-Young Kim2, Yong-Wook Park3, Jong-Hwan Park1,* 1Laboratory Animal Medicine, College of Veterinary Medicine and BK 21 PLUS Project Team, Chonnam National University, Gwangju, Korea 2Institute of Biotechnology, Bioresource Inc., Cheomdan venture, Gwangju, Korea 3Department of Rheumatology, Chonnam National University Medical School, Chonnam National University Hospital,  Gwangju, Korea The purpose of this study was to investigate the immunomodulatory activity of ice plant ( Mesem- bryanthemum crystallinum ) extract (IPE) in vitro  and in vivo .",OADS,/arxiv_data1/oa_pdf/6d/29/lar-33-32.PMC5385280.pdf
"40 Lab Anim Res 2017: 33(1), 40-47 https://doi.org/10.5625/lar.2017.33.1.40ISSN 1738-6055 (Print) ISSN 2233-7660 (Online) HemoHIM, a herbal preparation, alleviates airway inflammation  caused by cigarette smoke  and lipopolysaccharide Na-Rae Shin1,#, Sung-Ho Kim1,#, Je-Won Ko1, Sung-Hyeuk Park1, In-Chul Lee2, Jung-Min Ryu1, Jong-Choon Kim1, In-Sik Shin1,* 1College of Veterinary Medicine (BK21 Plus Project Team), Chonnam National University, Gwangju, Korea 2Natural Product Research Center, Korea Research Institute of Bioscience and Biotechnology, Jeongeup, Korea HemoHIM, herbal preparation has designed for immune system recovery.",Non-OADS,/arxiv_data1/oa_pdf/b1/c5/lar-33-40.PMC5385281.pdf
"8 Lab Anim Res 2017: 33(1), 8-14 https://doi.org/10.5625/lar.2017.33.1.8ISSN 1738-6055 (Print) ISSN 2233-7660 (Online) Comparison of commonly used ICR stocks and the characterization of Korl:ICR Hye-Jun Shin1, Young Min Cho1, Hee Jung Shin1, Hae Deun Kim1, Kyung Min Choi1, Mi Gyeong Kim1, Hyoung Doo Shin2, Myeon-Woo Chung1,* 1Laboratory Animal Resources Division, Toxicological Evaluation and Research Department, National Institute of Food and Drug Safety Evaluation, Cheongju, Korea 2Department of Life Sciences, Sogang University, Seoul 04107, Korea Mouse is a commonly used animal in life science studies and is classified as outbred if genetically diverse and inbred if genetically homogeneous.",Non-OADS,/arxiv_data1/oa_pdf/9e/a2/lar-33-8.PMC5385282.pdf
Phylogenetic analysis Phylogenetic trees were constructed using the dnapars program of phylip (phylogeny inference package) Version 3.695 (http://evolution.genetics.washington.edu/phylip.html)based on alignment of SNPs.,OADS,/arxiv_data1/oa_pdf/9e/a2/lar-33-8.PMC5385282.pdf
"pISSN: 2234-8646 eISSN: 2234-8840 https://doi.org/10.5223/pghn.2017.20.1.1 Pediatr Gastroenterol Hepatol Nutr 2017 March 20(1):1-13PGHN Review Article PEDIATRIC GASTROENTEROLOGY, HEPATOLOGY & NUTRITION The New Rome IV Criteria for Functional Gastrointestinal  Disorders in Infants and Toddlers  Judith Zeevenhooven, Ilan J.N.",Non-OADS,/arxiv_data1/oa_pdf/b8/a6/pghn-20-1.PMC5385301.pdf
"Tel: +31-20-5662906, Fax: +31-20-5669478, E-mail:  j.zeevenhooven@amc.uva.nl Copyright ⓒ 2017 by The Korean Society of Pediatric Gastroenterology, Hepatology and Nutrition This is an open ­access article distributed under the terms of the Creative Commons Attribution Non ­Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits  unrestricted non ­commercial use, distribution, and reproduction in any medium, provided the original  work is properly cited.INTRODUCTION Functional gastrointestinal disorders (FGIDs) in  infants and toddlers are common worldwide and  cover a variety of disorders associated with chronic,  recurrent symptoms attribut able to the gastrointes- tinal tract, but not explai ned by structural or bio- chemical abnormalities [1].",Non-OADS,/arxiv_data1/oa_pdf/b8/a6/pghn-20-1.PMC5385301.pdf
"pISSN: 2234-8646 eISSN: 2234-8840 https://doi.org/10.5223/pghn.2017.20.1.14 Pediatr Gastroenterol Hepatol Nutr 2017 March 20(1):14-21PGHN Review Article PEDIATRIC GASTROENTEROLOGY, HEPATOLOGY & NUTRITION Surgery in Pediatric Crohn’s Disease: Indications, Timing  and Post-Operative Management Seung Kim Department of Pediatrics, Severance Ch ildren’s Hospital, Yonsei  University College of Medicine, Seoul, Korea Pediatric onset Crohn’s disease (CD) tends to have complicate d behavior (stricture or penetration) than elderly onset  CD at diagnosis.",Non-OADS,/arxiv_data1/oa_pdf/9e/ae/pghn-20-14.PMC5385302.pdf
"Tel: +82-2-2228-84 72, Fax: +82-2-393-9118, E-mail: PEDKS@yuhs.ac Copyright ⓒ 2017 by The Korean Society of Pediatric Gastroenterology, Hepatology and Nutrition This is an open ­access article distributed under the terms of the Creative Commons Attribution Non ­Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits  unrestricted non ­commercial use, distribution, and reproduction in any medium, provided the original  work is properly cited.INTRODUCTION Crohn’s disease (CD) is a chronic relapsing in- flammatory disease that ma inly affects the gastro- intestinal tract.",Non-OADS,/arxiv_data1/oa_pdf/9e/ae/pghn-20-14.PMC5385302.pdf
"pISSN: 2234-8646 eISSN: 2234-8840 https://doi.org/10.5223/pghn.2017.20.1.22 Pediatr Gastroenterol Hepatol Nutr 2017 March 20(1):22-26PGHN Original Article PEDIATRIC GASTROENTEROLOGY, HEPATOLOGY & NUTRITION Pooled Analysis of the Cow ’s Milk-related-Symptom-Score  (CoMiSSTM) as a Predictor for Cow ’s Milk Related Symptoms Yvan Vandenplas, Philippe Steenhout *, Anette Järvi *, Anne-Sophie Garreau†,  and Rajat Mukherjee‡ Department of Pediatrics, Universitair Ziekenhuis Brus sel, Vrije Universiteit Br ussel, Brussels, Belgium, *Nestlé Health  Science, Vevey, Switzerland, †United Pharmaceuticals/Novalac, Paris, France, ‡Cytel, Cambridge, MA, USA Purpose: The diagnosis of cow’s milk (CM) allergy is a challenge.",Non-OADS,/arxiv_data1/oa_pdf/52/e7/pghn-20-22.PMC5385303.pdf
"Tel: +32-2-477-57-80, Fax: +32-2-477-57 -83, E-mail: yvan.vandenplas@uzbrussel.be Copyright ⓒ 2017 by The Korean Society of Pediatric Gastroenterology, Hepatology and Nutrition This is an open ­access article distributed under the terms of the Creative Commons Attribution Non ­Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits  unrestricted non ­commercial use, distribution, and reproduction in any medium, provided the original  work is properly cited.INTRODUCTION Primary health care physicians are insufficiently  aware of symptoms caused  by cow milk because there is no pathognomonic symptom and no reliable  diagnostic test, which results in repeated con- sultations and inaccurate management.",Non-OADS,/arxiv_data1/oa_pdf/52/e7/pghn-20-22.PMC5385303.pdf
"pISSN: 2234-8646 eISSN: 2234-8840 https://doi.org/10.5223/pghn.2017.20.1.27 Pediatr Gastroenterol Hepatol Nutr 2017 March 20(1):27-33PGHN Original Article PEDIATRIC GASTROENTEROLOGY, HEPATOLOGY & NUTRITION Comparison of Percutaneous Endoscopic Gastrostomy and  Surgical Gastrostomy in Se verely Handicapped Children June Kim *,†, Min Lee *,†, Soon Chul Kim *,†, Chan Uhng Joo *,†, and Sun Jun Kim *,† *Department of Pediatrics, Chonbuk National University Hospital, Chonbuk National University Medical School,  †Research Institute of Clinical Medicine of Chonbuk Nati onal University-Biomedical Re search Institute of Chonbuk  National University H ospital, Jeonju, Korea Purpose:  Gastrostomy is commonly used procedures to provide enteral nutrition support for severely handicapped  patients.",Non-OADS,/arxiv_data1/oa_pdf/1a/4a/pghn-20-27.PMC5385304.pdf
"Tel: +82 -63-250-1460, Fax: +82-63-250-1464, E -mail: kimsc@jbnu.ac.kr Copyright ⓒ 2017 by The Korean Society of Pediatric Gastroenterology, Hepatology and Nutrition This is an open ­access article distributed under the terms of the Creative Commons Attribution Non ­Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits  unrestricted non ­commercial use, distribution, and reproduction in any medium, provided the original  work is properly cited.INTRODUCTION Severely handicapped patients who cannot meet their nutritional requirements by oral food intake  alone require long-term enteral access with a gastro- stomy tube.",Non-OADS,/arxiv_data1/oa_pdf/1a/4a/pghn-20-27.PMC5385304.pdf
"pISSN: 2234-8646 eISSN: 2234-8840 https://doi.org/10.5223/pghn.2017.20.1.34 Pediatr Gastroenterol Hepatol Nutr 2017 March 20(1):34-40PGHN Original Article PEDIATRIC GASTROENTEROLOGY, HEPATOLOGY & NUTRITION Single Center Experience with Gastrostomy Insertion  in Pediatric Patients: A 10-Year Review Jiyoung Kim, Hong Koh, Eun Young Ch ang, Sun Yeong Pa rk, and Seung Kim  Department of Pediatrics, Severance Ch ildren’s Hospital, Yonsei  University College of Medicine, Seoul, Korea Purpose:  This study was performed to review the outcomes of gastrostomy insertion in children at our institute during  10 years.Methods:  A retrospective chart review was performed on 236 patients who underwent gastrostomy insertion from  October 2005 to March 2015.",Non-OADS,/arxiv_data1/oa_pdf/b1/40/pghn-20-34.PMC5385305.pdf
"Tel: +82-2-2228-84 72, Fax: +82-2-393-9118, E-mail: PEDKS@yuhs.ac Copyright ⓒ 2017 by The Korean Society of Pediatric Gastroenterology, Hepatology and Nutrition This is an open ­access article distributed under the terms of the Creative Commons Attribution Non ­Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits  unrestricted non ­commercial use, distribution, and reproduction in any medium, provided the original  work is properly cited.INTRODUCTION Enteral nutrition is recomme nded in patients with  at least a partially-functioning gastrointestinal (GI) tract when oral intake is no longer possible or adequate.",Non-OADS,/arxiv_data1/oa_pdf/b1/40/pghn-20-34.PMC5385305.pdf
"pISSN: 2234-8646 eISSN: 2234-8840 https://doi.org/10.5223/pghn.2017.20.1.41 Pediatr Gastroenterol Hepatol Nutr 2017 March 20(1):41-46PGHN Original Article PEDIATRIC GASTROENTEROLOGY, HEPATOLOGY & NUTRITION Effect of the Baseline Vitamin D Level on Growth Outcome  in Pediatric Crohn Disease Eun Joo Lee, Jin Soo Moon, Jae Sung Ko, Hye Ran Yang, Ju Young Jang, Ju Whi Kim, and Kyung Jae Lee Department of Pediatrics, Seoul National Un iversity College of Medicine, Seoul, Korea Purpose:  Vitamin D deficiency is common in Crohn disease (CD) .",Non-OADS,/arxiv_data1/oa_pdf/7e/0a/pghn-20-41.PMC5385306.pdf
"Tel: +82-2-2072-3627, Fax: +82-2-743-3455, E-mail: mjschj@s nu.ac.kr Copyright ⓒ 2017 by The Korean Society of Pediatric Gastroenterology, Hepatology and Nutrition This is an open ­access article distributed under the terms of the Creative Commons Attribution Non ­Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits  unrestricted non ­commercial use, distribution, and reproduction in any medium, provided the original  work is properly cited.INTRODUCTION Crohn disease (CD) is a chronic inflammatory dis- ease of the gastrointestinal tract.",Non-OADS,/arxiv_data1/oa_pdf/7e/0a/pghn-20-41.PMC5385306.pdf
"pISSN: 2234-8646 eISSN: 2234-8840 https://doi.org/10.5223/pghn.2017.20.1.47 Pediatr Gastroenterol Hepatol Nutr 2017 March 20(1):47-54PGHN Original Article PEDIATRIC GASTROENTEROLOGY, HEPATOLOGY & NUTRITION Effect of Metronidazole in Infants with Bowel Habit Change:  Irrelative to the Clostridium difficile  Colonization Eun Jin Kim, Sung Hyun Lee,  Hann Tchah, and Eell Ryoo Department of Pediatrics, Gachon Univer sity Gil Medical Center, Incheon, Korea Purpose:  Clinical symptoms associated with Clostridium difficile  infection (CDI) can vary widely.",Non-OADS,/arxiv_data1/oa_pdf/69/59/pghn-20-47.PMC5385307.pdf
"Tel: +82-32-460-3223, Fax: +8 2-32-460-3224, E-mail: ryoo518@gilhospital.com Copyright ⓒ 2017 by The Korean Society of Pediatric Gastroenterology, Hepatology and Nutrition This is an open ­access article distributed under the terms of the Creative Commons Attribution Non ­Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits  unrestricted non ­commercial use, distribution, and reproduction in any medium, provided the original  work is properly cited.INTRODUCTION Chronic diarrhea in children shows age related  spectrum.",Non-OADS,/arxiv_data1/oa_pdf/69/59/pghn-20-47.PMC5385307.pdf
"pISSN: 2234-8646 eISSN: 2234-8840 https://doi.org/10.5223/pghn.2017.20.1.55 Pediatr Gastroenterol Hepatol Nutr 2017 March 20(1):55-60PGHN Case Report PEDIATRIC GASTROENTEROLOGY, HEPATOLOGY & NUTRITION Intestinal Hypoganglionosis Leading to Intestinal Failure and  the Compassionate Use of OmegavenTM Racha Khalaf, Sara Karjoo *, Paul Danielson†, Michael Wilsey *, and Fauzia Shakeel‡ Departments of Medical Education, *Gatroenterology, Hepatology and Nutrition, †Surgery, and ‡Neonatology, Johns  Hopkins All Children’s Hospital, St. Petersburg, FL, USA  Intestinal hypoganglionosis is a rare innervation disorder t hat provides numerous nutritional, medical and surgical  challenges.",Non-OADS,/arxiv_data1/oa_pdf/55/6b/pghn-20-55.PMC5385308.pdf
"Tel: +1-727-767-4106, Fax: +1-72 7-767-8634, E-mail: rkhalaf1@jhmi.edu Copyright ⓒ 2017 by The Korean Society of Pediatric Gastroenterology, Hepatology and Nutrition This is an open ­access article distributed under the terms of the Creative Commons Attribution Non ­Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits  unrestricted non ­commercial use, distribution, and reproduction in any medium, provided the original  work is properly cited.INTRODUCTION Intestinal hypoganglionosis  is an innervation dis- order that provides diagnostic and management  challenges secondary to i ll-defined diagnostic cri- teria [1].",Non-OADS,/arxiv_data1/oa_pdf/55/6b/pghn-20-55.PMC5385308.pdf
"pISSN: 2234-8646 eISSN: 2234-8840 https://doi.org/10.5223/pghn.2017.20.1.61 Pediatr Gastroenterol Hepatol Nutr 2017 March 20(1):61-64PGHN Case Report PEDIATRIC GASTROENTEROLOGY, HEPATOLOGY & NUTRITION A Rare Cause of Recurrent Acute Pancreatitis in a Child:  Isovaleric Acidemia with Novel Mutation Elif Sag, Alper Han Cebi *, Gulay Kaya†, Gulay Karaguzel‡, and Murat Cakir Departments of Pediatric Gastroenterology Hepatology and Nutrition, *Genetics, †Pediatrics, and ‡Pediatric  Endocrinology and Metabolism, Karadeniz Technical University, Faculty of Medicine, Trabzon, Turkey Recurrent acute pancreatic attacks is a rare clinical condit ion (2-5% of all acute pancreat is) in children and is mainly  idiopathic in most cases.",Non-OADS,/arxiv_data1/oa_pdf/42/f3/pghn-20-61.PMC5385309.pdf
"Tel: +90-532681-03- 18, Fax: +90-462-377-5890, E-mail: muratcak@hotmail.com Copyright ⓒ 2017 by The Korean Society of Pediatric Gastroenterology, Hepatology and Nutrition This is an open ­access article distributed under the terms of the Creative Commons Attribution Non ­Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits  unrestricted non ­commercial use, distribution, and reproduction in any medium, provided the original  work is properly cited.INTRODUCTION Acute pancreatitis (AP) is an inflammatory dis- ease characterized by sudden onset abdominal pain together with elevation of pancreatic enzymes in se- rum and/or urine and radiographic changes in the  pancreas [1].",Non-OADS,/arxiv_data1/oa_pdf/42/f3/pghn-20-61.PMC5385309.pdf
Available from: http://www.hgmd.cf.ac.uk/ac/ index.php.,Non-OADS,/arxiv_data1/oa_pdf/42/f3/pghn-20-61.PMC5385309.pdf
"pISSN: 2234-8646 eISSN: 2234-8840 https://doi.org/10.5223/pghn.2017.20.1.65 Pediatr Gastroenterol Hepatol Nutr 2017 March 20(1):65-70PGHN Case Report PEDIATRIC GASTROENTEROLOGY, HEPATOLOGY & NUTRITION Bannayan-Riley-Ruvalcaba Synd rome in a Patient with a PTEN  Mutation Identified by Chromosomal Microarray Analysis:  A Case Report Sun Hwa Lee, Eell Ryoo, and Hann Tchah Department of Pediatrics, Gachon Univer sity Gil Medical Center, Incheon, Korea Bannayan-Riley-Ruvalcaba syndrome (BRRS) is one of the phosphatase and tensin homolog hamartoma tumor  syndrome with a PTEN  gene mutation.",Non-OADS,/arxiv_data1/oa_pdf/dd/16/pghn-20-65.PMC5385310.pdf
"Tel: +82-32-460-2362, Fax: +8 2-32-460-3224, E-mail: ryoo518@gilhospital.com Copyright ⓒ 2017 by The Korean Society of Pediatric Gastroenterology, Hepatology and Nutrition This is an open ­access article distributed under the terms of the Creative Commons Attribution Non ­Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits  unrestricted non ­commercial use, distribution, and reproduction in any medium, provided the original  work is properly cited.INTRODUCTION Bannayan-Riley-Ruvalcaba syndrome (BRRS) is  one of the phosphatase and tensin homolog ha- martoma tumor syndromes (PHT S).",Non-OADS,/arxiv_data1/oa_pdf/dd/16/pghn-20-65.PMC5385310.pdf
Available from: https://ghr.nlm.nih.gov/con dition/bannayan-riley-  ruvalcaba-syndrome.,Non-OADS,/arxiv_data1/oa_pdf/dd/16/pghn-20-65.PMC5385310.pdf
Available from: https://ghr.nlm.nih.gov/ condition/cowden-syndrome.,Non-OADS,/arxiv_data1/oa_pdf/dd/16/pghn-20-65.PMC5385310.pdf
Available from: http://www.ncbi.nlm.nih.gov/  books/NBK1488/.,Non-OADS,/arxiv_data1/oa_pdf/dd/16/pghn-20-65.PMC5385310.pdf
"The majority of differences re- garding LV diastolic function between two groups were result-ed from the mitral inflow Doppler parameters, which are de-pISSN 1975-4612 / eISSN 2005-9655  Copyright © 2017 Korean Society of Echocardiography  www.kse-jcu.org https://doi.org/10.4250/jcu.2017.25.1.1 pendent on LV preloads.",Non-OADS,/arxiv_data1/oa_pdf/68/75/jcu-25-1.PMC5385311.pdf
"•	Received: February 26, 2017  •	Revised: February 27, 2017  •	Accepted: February 27, 2017 •		Address for Correspondence: Chi Young Shim, Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, 50-1 Yonsei-ro,  Seodaemun-gu, Seoul 03722, Korea   Tel: +82-2-2228-8453, Fax: +82-2-2227-7732, E-mail: cysprs@yuhs.ac •	This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0)    which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.EDITORIAL COMMENT J Cardiovasc Ultrasound  2017;25(1):1-2 REFER TO THE PAGE 12-19Progeria of the Heart in Type 1 Diabetic  Children?",Non-OADS,/arxiv_data1/oa_pdf/68/75/jcu-25-1.PMC5385311.pdf
"By definition,  DCM is a distinct primary disease process which develops sec-pISSN 1975-4612 / eISSN 2005-9655  Copyright © 2017 Korean Society of Echocardiography  www.kse-jcu.org https://doi.org/10.4250/jcu.2017.25.1.12 ORIGINAL ARTICLE J Cardiovasc Ultrasound  2017;25(1):12-19 •	Received: September 20, 2016  •	Revised: January 12, 2017  •	Accepted: February 21, 2017 •		Address for Correspondence: Aya M Fattouh, Department of Pediatrics, Faculty of Medicine, Cairo University, 9157 Adel Ghonaim Street, 8th District, Elhadabah  Elwosta, Mokattam, Cairo 11439, Egypt   Tel: +20-1001572630, Fax: +20-23646718, E-mail: aya.fattouh@gmail.com •	This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0)    which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.ondary to a metabolic insult, resulting in structural and func- tional abnormalities of the myocardium leading to heart fail - ure.6) The most frequent and earliest detectable functional  abnormality in DCM is impaired diastolic function.7) The ear - ly reductions in diastolic performance have been found to be followed by progressive reductions in systolic function during  the later stages of DCM.",Non-OADS,/arxiv_data1/oa_pdf/4a/c8/jcu-25-12.PMC5385312.pdf
"Diagnostic protocols to rule out coronary artery disease (CAD) are based on risk factors, mul- tiple electrocardiographic (ECG) assessments, repeated cardiac pISSN 1975-4612 / eISSN 2005-9655  Copyright © 2017 Korean Society of Echocardiography  www.kse-jcu.org https://doi.org/10.4250/jcu.2017.25.1.20 ORIGINAL ARTICLE J Cardiovasc Ultrasound  2017;25(1):20-27 •	Received: October 20, 2016  •	Revised: February 6, 2017  •	Accepted: February 21, 2017 •		Address for Correspondence: Sang-Hoon Na, Division of Cardiology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul  National University Hospital,101 Daehak-ro, Jongno-gu, Seoul 03080, Korea     Tel: +82-2-2072-0855, Fax: +82-2-3674-0805, E-mail: imnash70@snu.ac.kr •	This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0)    which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.biomarker assessments, noninvasive stress testing, and, if indi- cated, invasive coronary angiography (CAG).",Non-OADS,/arxiv_data1/oa_pdf/c1/d3/jcu-25-20.PMC5385313.pdf
28pISSN 1975-4612 / eISSN 2005-9655  Copyright © 2017 Korean Society of Echocardiography  www.kse-jcu.org https://doi.org/10.4250/jcu.2017.25.1.28 ORIGINAL ARTICLE J Cardiovasc Ultrasound  2017;25(1):28-33 •	*Doo-Youp Kim and Jung-Hyun Choi contributed equally to this work.,Non-OADS,/arxiv_data1/oa_pdf/e3/bd/jcu-25-28.PMC5385314.pdf
"•	Received: October 29, 2016  •	Revised: March 21, 2017  •	Accepted: March 21, 2017 •		Address for Correspondence: Geu-Ru Hong, Division of Cardiology, Department of Internal Medicine, Yonsei University College of Medicine, 50-1 Yonsei-ro,  Seodaemun-gu, Seoul 03722, Korea   Tel: +82-2-2228-8460, Fax: +82-2-2227-7732, E-mail: grhong@yuhs.ac •	This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0)    which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.Impact of Contrast Echocardiography   on Assessment of Ventricular Function  and Clinical Diagnosis in Routine   Clinical Echocardiography:   Korean Multicenter Study Doo-Youp Kim, MD1*, Jung-Hyun Choi, MD2*, Geu-Ru Hong, MD3, Se-Joong Rim, MD3,   Jang-Young Kim, MD4, Sang-Chol Lee, MD5, Il-Suk Sohn, MD6,   Wook-Jin Chung, MD7, Hye-Sun Seo, MD8, Se-Jung Yoon, MD9,   Kyoung-Im Cho, MD10, Si-Wan Choi, MD11, and Kyung-Jin Lee, MD12 1Department of Internal Medicine, Bongseng Memorial Hospital, Busan, Korea  2Division of Cardiology, Department of Internal Medicine, Pusan National University School of Medicine, Busan, Korea  3Division of Cardiology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea  4Division of Cardiology, Department of Internal Medicine, Wonju College of Medicine, Yonsei University, Wonju, Korea  5Division of Cardiology, Department of Internal Medicine, Samsung Medical Center,   Sungkyunkwan University School of Medicine, Seoul, Korea  6Department of Cardiology, Kyung Hee University School of Medicine, Seoul, Korea  7Division of Cardiology, Heart Center, Gachon University Gil Hospital, Gachon University School of Medicine,  Incheon, Korea  8Division of Cardiology, Department of Internal Medicine, Soonchunhyang University Hospital, Bucheon, Korea  9Division of Cardiology, Department of Internal Medicine, National Health Insurance Service Ilsan Hospital,  Goyang, Korea  10Division of Cardiology, Department of Internal Medicine, Kosin University Gospel Hospital, Busan, Korea  11Division of Cardiology, Department of Internal Medicine, Chungnam National University Hospital, Daejeon, Korea  12Division of Cardiology, Department of Internal Medicine, Eulji University Hospital, Daejeon, Korea Background:  Fundamental echocardiography has some drawbacks in patients with difficult-to-image echocardiograms.",Non-OADS,/arxiv_data1/oa_pdf/e3/bd/jcu-25-28.PMC5385314.pdf
"With the introduction of tissue Doppler imaging (TDI), pISSN 1975-4612 / eISSN 2005-9655  Copyright © 2017 Korean Society of Echocardiography  www.kse-jcu.org https://doi.org/10.4250/jcu.2017.25.1.3 it has also become possible to determine segmental velocities  at a sampling rate of more than 140 samples per second by us-ing standard echo views.",Non-OADS,/arxiv_data1/oa_pdf/29/35/jcu-25-3.PMC5385315.pdf
"•	Received: February 27, 2017  •	Revised: February 27, 2017  •	Accepted: February 27, 2017 •		Address for Correspondence: Kyoung Im Cho, Division of Cardiology, Department of Internal Medicine, Kosin University College of Medicine, 262 Gamcheon-ro,  Seo-gu, Busan 49267, Korea   Tel: +82-51-990-6105, Fax: +82-51-990-3047, E-mail: kyoungim74@gmail.com •	This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0)    which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.EDITORIAL COMMENT J Cardiovasc Ultrasound  2017;25(1):3-4 REFER TO THE PAGE 20-27Role of Echocardiography in Diagnosing  Myocardial Ischemia at Emergency Department Kyoung Im Cho, MD, PhD Division of Cardiology, Department of Internal Medicine, Kosin University College of Medicine, Busan, Korea",Non-OADS,/arxiv_data1/oa_pdf/29/35/jcu-25-3.PMC5385315.pdf
"Coronary angiography showed a severe stenosis in the distal segment of the pISSN 1975-4612 / eISSN 2005-9655  Copyright © 2017 Korean Society of Echocardiography  www.kse-jcu.org https://doi.org/10.4250/jcu.2017.25.1.34 •	Received: December 4, 2016  •	Revised: March 2, 2017  •	Accepted: March 2, 2017 •		Address for Correspondence: Jun Shiraishi, Department of Cardiology, Kyoto First Red Cross Hospital, Honmachi, Higashiyama-ku, Kyoto 605-0981, Japan     Tel: +81-75-561-1121, Fax: +81-75-561-6308, E-mail: risa11221998@yahoo.co.jp •	This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0)    which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.right coronary artery (Fig.",Non-OADS,/arxiv_data1/oa_pdf/97/45/jcu-25-34.PMC5385316.pdf
"5)6) In obesity, diastolic function is correlated with fat mass,  serum leptin levels, waist-to-hip ratio, LV mass, and LV end-di-pISSN 1975-4612 / eISSN 2005-9655  Copyright © 2017 Korean Society of Echocardiography  www.kse-jcu.org https://doi.org/10.4250/jcu.2017.25.1.5 ORIGINAL ARTICLE J Cardiovasc Ultrasound  2017;25(1):5-11 •	Received: August 28, 2015  •	Revised: February 6, 2017  •	Accepted: February 21, 2017 •		Address for Correspondence: Jeong-Sook Seo, Division of Cardiology, Department of Internal Medicine, Busan Paik Hospital, Inje University, 75 Bokji-ro,  Busanjin-gu, Busan 47392, Korea   Tel: +82-51-890-6980, Fax: +82-51-898-4075, E-mail: orifilter@hanmail.net •	This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0)    which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.astolic volume.7) Increased body mass index (BMI) has also  been associated with worse LV diastolic function.1) However, it is uncertain whether similar relationships exist  in Asian populations, because Asians generally have a lower  BMI and a higher percentage of body fat at a given BMI com- pared to individuals from Western countries.",Non-OADS,/arxiv_data1/oa_pdf/5b/0a/jcu-25-5.PMC5385317.pdf
Contents lists available at ScienceDirect Annals of Medicine and Surgery journal homepage: www.annalsjournal.com http://dx.doi.org/10.1016/j.amsu.2017.01.025 2049-0801/ ©2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/26/02/main.PMC5385388.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/26/02/main.PMC5385388.pdf
"135 (2015) 795e803, http://dx.doi.org/10.1007/s00402-015-2217-7 .",Non-OADS,/arxiv_data1/oa_pdf/26/02/main.PMC5385388.pdf
"21 (2007) 357 e366, http://dx.doi.org/10.1007/ s00464-006-9072-0 .",Non-OADS,/arxiv_data1/oa_pdf/26/02/main.PMC5385388.pdf
"255 (2012) 30 e37,http://dx.doi.org/10.1097/SLA.0b013e318220ef31 .",Non-OADS,/arxiv_data1/oa_pdf/26/02/main.PMC5385388.pdf
"2015 (2015) 463987, http://dx.doi.org/10.1155/2015/463987 .",Non-OADS,/arxiv_data1/oa_pdf/26/02/main.PMC5385388.pdf
"154 (2009) 163 e166, http://dx.doi.org/10.1016/j.jss.2008.06.009 .",OADS,/arxiv_data1/oa_pdf/26/02/main.PMC5385388.pdf
"26 (2012) 3207 e3214, http://dx.doi.org/ 10.1007/s00464-012-2326-0 .",Non-OADS,/arxiv_data1/oa_pdf/26/02/main.PMC5385388.pdf
"(2016) 1 e7, http://dx.doi.org/10.1080/08941939.2016.1220652 .",Non-OADS,/arxiv_data1/oa_pdf/26/02/main.PMC5385388.pdf
"7 (2015) 17 e21, http://dx.doi.org/10.5539/gjhs.v7n7p17 .",Non-OADS,/arxiv_data1/oa_pdf/26/02/main.PMC5385388.pdf
"Herrick, et al., Psychometric evaluation of a direct observation of procedural skills assessment tool forultrasound-guided regional anaesthesia, Anaesthesia 69 (2014) 604 e612, http://dx.doi.org/10.1111/anae.12625 .",OADS,/arxiv_data1/oa_pdf/26/02/main.PMC5385388.pdf
"35 (2013) 231 e236, http://dx.doi.org/10.3109/ 0142159x.2012.737967 .",Non-OADS,/arxiv_data1/oa_pdf/26/02/main.PMC5385388.pdf
"75 (2012) 591 e597,http://dx.doi.org/10.1016/j.gie.2011.09.053 .",Non-OADS,/arxiv_data1/oa_pdf/26/02/main.PMC5385388.pdf
"32 (2015), http://dx.doi.org/ 10.3205/zma000987 .",Non-OADS,/arxiv_data1/oa_pdf/26/02/main.PMC5385388.pdf
"23 (2013) 77 e82,http://dx.doi.org/10.2013/jcpsp.7782 .",Non-OADS,/arxiv_data1/oa_pdf/26/02/main.PMC5385388.pdf
"35 (2013)e1230 e1234, http://dx.doi.org/10.3109/0142159x.2012.746447 .",Non-OADS,/arxiv_data1/oa_pdf/26/02/main.PMC5385388.pdf
"17 (2012), http://dx.doi.org/10.3402/ meo.v17i0.18398 .",Non-OADS,/arxiv_data1/oa_pdf/26/02/main.PMC5385388.pdf
"9 (2012) 228 e232, http://dx.doi.org/ 10.1111/j.1743-498X.2012.00582.x .",Non-OADS,/arxiv_data1/oa_pdf/26/02/main.PMC5385388.pdf
"25 (2011) 1192 e1198, http://dx.doi.org/10.1007/ s00464-010-1343-0 .",Non-OADS,/arxiv_data1/oa_pdf/26/02/main.PMC5385388.pdf
"30 (2016) 3007 e3013, http://dx.doi.org/10.1007/s00464-015-4591-1 .",Non-OADS,/arxiv_data1/oa_pdf/26/02/main.PMC5385388.pdf
"70 (2013) 443 e450, http://dx.doi.org/10.1016/ j.jsurg.2013.02.004 .",OADS,/arxiv_data1/oa_pdf/26/02/main.PMC5385388.pdf
"87 (2015) 425 e428, http://dx.doi.org/10.1515/pjs-2015-0083 .",Non-OADS,/arxiv_data1/oa_pdf/26/02/main.PMC5385388.pdf
645. http://dx.doi.org/10.1016/j.surg.2010.01.007 .,OADS,/arxiv_data1/oa_pdf/26/02/main.PMC5385388.pdf
"21 (1999) 15 e22,http://dx.doi.org/10.1080/01421599979978 .",Non-OADS,/arxiv_data1/oa_pdf/26/02/main.PMC5385388.pdf
176. http://dx.doi.org/10.1016/j.surg.2012.06.025 .,OADS,/arxiv_data1/oa_pdf/26/02/main.PMC5385388.pdf
"12 (2016) 8 e17,http://dx.doi.org/10.1016/j.amsu.2016.10.004 .P.",OADS,/arxiv_data1/oa_pdf/26/02/main.PMC5385388.pdf
"See: http://creativecommons.org/ licenses/by-nc/4.0/ Manuscript source:  Invited manuscript Correspondence to: Mario Morino, MD,  Professor,  Department  of Surgical Sciences, University of Torino, Corso A. M. Dogliotti,  14 - 10126 Torino, Italy.",Non-OADS,/arxiv_data1/oa_pdf/3f/9f/WJG-23-2269.PMC5385393.pdf
"In conclusion, the recent publication of pH monitoring  data and the new insights in the association between  sleeve morphology and GERD control have led to a  wider acceptance of LSG as bariatric procedure also  in obese patients with GERD, as recently stated in  EDITORIAL 2269 April 7, 2017 |Volume 23 |Issue 13 | WJG|www.wjgnet.comSubmit a Manuscript: http://www.f6publishing.com DOI: 10.3748/wjg.v23.i13.2269World J Gastroenterol   2017 April 7; 23(13): 2269-2275  ISSN 1007-9327 (print)  ISSN 2219-2840 (online)",Non-OADS,/arxiv_data1/oa_pdf/3f/9f/WJG-23-2269.PMC5385393.pdf
World J Gastroenterol  2017; 23(13): 2269-2275   Available from: URL: http://www.wjgnet.com/1007-9327/full/ v23/i13/2269.htm   DOI: http://dx.doi.org/10.3748/wjg.v23.,Non-OADS,/arxiv_data1/oa_pdf/3f/9f/WJG-23-2269.PMC5385393.pdf
"All rights reserved.Published by Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.f6publishing.com/helpdesk http://www.wjgnet.com I S S N  1 0  0 7  -   9  3 2  7 9    7 7 1 0  07   9 3 2 0 451  3",Non-OADS,/arxiv_data1/oa_pdf/3f/9f/WJG-23-2269.PMC5385393.pdf
"See: http://creativecommons.org/ licenses/by-nc/4.0/ Manuscript source:  Invited manuscript correspondence to: chandra Diwakarla, BSc(Hons), MBBS,  Oncology Fellow,  Department of Medical Oncology, The  Canberra Hospital, Yamba Drive, Woden ACT 2605,  Australia.",Non-OADS,/arxiv_data1/oa_pdf/8c/4d/WJG-23-2276.PMC5385394.pdf
"chandra.diwakarla@anu.edu.au  Telephone:  +61-2-62442220 Fax:  +61-2-62444266 received:  November 23, 2016 Peer­review started:  November 25, 2016 First decision:  December 19, 2016 revised:  January 18, 2017 Accepted:  March 15, 2017 Article in press:  March 15, 2017 Published online: April 7, 2017REVIEW 2276 April 7, 2017 |Volume 23 |Issue 13 | WJG|www.wjgnet.comSubmit a Manuscript: http://www.f6publishing.com DOI: 10.3748/wjg.v23.i13.2276World J Gastroenterol   2017 April 7; 23(13): 2276-2285  ISSN 1007-9327 (print)  ISSN 2219-2840 (online)",Non-OADS,/arxiv_data1/oa_pdf/8c/4d/WJG-23-2276.PMC5385394.pdf
World J Gastroenterol  2017;  23(13): 2276-2285  Available from: URL: http://www.wjgnet.,OADS,/arxiv_data1/oa_pdf/8c/4d/WJG-23-2276.PMC5385394.pdf
com/1007-9327/full/v23/i13/2276.htm   DOI: http://dx.doi.,OADS,/arxiv_data1/oa_pdf/8c/4d/WJG-23-2276.PMC5385394.pdf
"cited  2016-10-24 Available from: URL: https://seer.cancer.gov/ 16 Hidalgo M , Cascinu S, Kleeff J, Labianca R, Löhr JM,  Neoptolemos J, Real FX, Van Laethem JL, Heinemann V.  Addressing the challenges of pancreatic cancer: future directions  for improving outcomes.",Non-OADS,/arxiv_data1/oa_pdf/8c/4d/WJG-23-2276.PMC5385394.pdf
"Available from: URL: http://www.businesswire.com/ news/home/20160211005321/en/Incyte-Announces-Decision- Discontinue-JANUS-Studies-Ruxolitinib 41 Chang DK , Grimmond SM, Evans TR, Biankin AV.",Non-OADS,/arxiv_data1/oa_pdf/8c/4d/WJG-23-2276.PMC5385394.pdf
"All rights reserved.Published by Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.f6publishing.com/helpdesk http://www.wjgnet.com I S S N  1 0  0 7  -   9  3 2  7 9    7 7 1 0  07   9 3 2 0 451  3",Non-OADS,/arxiv_data1/oa_pdf/8c/4d/WJG-23-2276.PMC5385394.pdf
"See: http://creativecommons.org/ licenses/by-nc/4.0/ Manuscript source:  Invited manuscript  Correspondence to: Dr. Kashif Asghar,  Department of Basic  Sciences Research, Shaukat Khanum Memorial Cancer Hospital  and Research Centre, 7-A Block R-3, Johar Town, Lahore 54000,  Pakistan.",Non-OADS,/arxiv_data1/oa_pdf/c7/9e/WJG-23-2286.PMC5385395.pdf
"kashifasghar @skm.org.p k Telephone:  +92-42-3590500 0 Fax:  +92-42-3594520 6 Received:  December 29, 2016 Peer­review started:  January 3, 2017 First decision:  February 10, 2017MINIREVIEWS 2286 April 7, 2017 |Volume 23 |Issue 13 | WJG|www.wjgnet.comSubmit a Manuscript: http://www.f6publishing.com DOI: 10.3748/wjg.v23.i13.2286World J Gastroenterol   2017 April 7; 23(13): 2286-2293  ISSN 1007-9327 (print)  ISSN 2219-2840 (online)",Non-OADS,/arxiv_data1/oa_pdf/c7/9e/WJG-23-2286.PMC5385395.pdf
"World J  Gastroenterol  2017; 23(13): 2286-2293  Available from: URL:  http://www.wjgnet.com/1007-9327/full/v23/i13/2286.htm   DOI:  http://dx.doi.org/10.3748/wjg.v23.i13.2286 INTRODUCTION Hepatocellular carcinoma (HCC) is one of the top five  malignancies and the second leading cause of cancer  associated deaths worldwide[1,2].",Non-OADS,/arxiv_data1/oa_pdf/c7/9e/WJG-23-2286.PMC5385395.pdf
"All rights reserved.Published by Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.f6publishing.com/helpdesk http://www.wjgnet.com I S S N  1 0  0 7  -   9  3 2  7 9    7 7 1 0  07   9 3 2 0 451  3",Non-OADS,/arxiv_data1/oa_pdf/c7/9e/WJG-23-2286.PMC5385395.pdf
"See: http://creativecommons.org/ licenses/by-nc/4.0/ Manuscript source:  Invited manuscript Correspondence to: Dr. Taeko Dohi, Director,  Department of  Gastroenterology, Research Center for Hepatitis and Immunology,  Research Institute, National Center for Global Health and  Medicine, 1-7-1 Kohnodai, Ichikawa, Chiba 272-8516,  Japan.",Non-OADS,/arxiv_data1/oa_pdf/51/dc/WJG-23-2294.PMC5385396.pdf
"dohi@ri.ncgm.go.jp Telephone:  +81-4-73754754 Fax:  +81-4-73754766  Received:  November 28, 2016 Peer-review started:  November 29, 2016 First decision:  January 10, 2017 Revised:  February 6, 2017 Accepted:  March 2, 2017 Article in press:  March 2, 2017 Published online: April 7, 2017 2294 April 7, 2017 |Volume 23 |Issue 13 | WJG|www.wjgnet.comORIGINAL ARTICLE Disruption of the TWEAK/Fn14 pathway prevents  5-fluorouracil-induced diarrhea in miceBasic Study Takuhito Sezaki, Yuki Hirata, Teruki Hagiwara, Yuki I Kawamura, Tadashi Okamura, Rieko Takanashi,  Kenta Nakano, Miwa Tamura-Nakano, Linda C Burkly, Taeko DohiSubmit a Manuscript: http://www.f6publishing.com DOI: 10.3748/wjg.v23.i13.2294World J Gastroenterol   2017 April 7; 23(13): 2294-2307  ISSN 1007-9327 (print)  ISSN 2219-2840 (online)",Non-OADS,/arxiv_data1/oa_pdf/51/dc/WJG-23-2294.PMC5385396.pdf
wjgnet.com/1007-9327/full/v23/i13/2294.htm   DOI: http://dx.doi.,OADS,/arxiv_data1/oa_pdf/51/dc/WJG-23-2294.PMC5385396.pdf
"All rights reserved.Published by Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.f6publishing.com/helpdesk http://www.wjgnet.com I S S N  1 0  0 7  -   9  3 2  7 9    7 7 1 0  07   9 3 2 0 451  3",Non-OADS,/arxiv_data1/oa_pdf/51/dc/WJG-23-2294.PMC5385396.pdf
"See: http://creativecommons.org/ licenses/by-nc/4.0/ Manuscript source:  Unsolicited manuscript Correspondence to: Dr. Zhi- Yong Yuan, Professor,  Tianjin  Medical University Cancer Institute and Hospital, National  Clinical Research Center for Cancer, Key Laboratory of Cancer  Prevention and Therapy, Tianjin, Tianjin’s Clinical Research  Center for Cancer, Huanhu West Road, Tianjin 300000,  China.",Non-OADS,/arxiv_data1/oa_pdf/e8/6e/WJG-23-2308.PMC5385397.pdf
"METHODS Firstly, we detected expression of lysosome-associated  2308 April 7, 2017 |Volume 23 |Issue 13 | WJG|www.wjgnet.comORIGINAL ARTICLE CMA down-regulates p53 expression through degradation  of HMGB1 protein to inhibit irradiation-triggered apoptosis  in hepatocellular carcinomaBasic Study Jing-Hua Wu, Jia-Pei Guo, Jun Shi, Hui Wang, Lei-Lei Li, Bin Guo, Dian-Xing Liu, Qing Cao, Zhi-Yong YuanSubmit a Manuscript: http://www.f6publishing.com DOI: 10.3748/wjg.v23.i13.2308World J Gastroenterol   2017 April 7; 23(13): 2308-2317  ISSN 1007-9327 (print)  ISSN 2219-2840 (online)",Non-OADS,/arxiv_data1/oa_pdf/e8/6e/WJG-23-2308.PMC5385397.pdf
wjgnet.com/1007-9327/full/v23/i13/2308.htm   DOI: http://dx.doi.,OADS,/arxiv_data1/oa_pdf/e8/6e/WJG-23-2308.PMC5385397.pdf
"All rights reserved.Published by Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.f6publishing.com/helpdesk http://www.wjgnet.com I S S N  1 0  0 7  -   9  3 2  7 9    7 7 1 0  07   9 3 2 0 451  3",Non-OADS,/arxiv_data1/oa_pdf/e8/6e/WJG-23-2308.PMC5385397.pdf
"See: http://creativecommons.org/ licenses/by ­nc/4.0/ Manuscript source:  Unsolicited manuscript Correspondence to: Dong Xue, MD, PhD,  Department of  General Surgery, The People’s Hospital of Binzhou, No.",Non-OADS,/arxiv_data1/oa_pdf/ec/6f/WJG-23-2318.PMC5385398.pdf
"Finally, the  role of ZEB1 in regulating CUL4A mediated PHCC was  detected by IHC, Western blot, Transwell and Matrigel  2318 April 7, 2017 |Volume 23 |Issue 13 | WJG|www.wjgnet.comORIGINAL ARTICLE Cullin 4A is associated with epithelial to mesenchymal  transition and poor prognosis in perihilar  cholangiocarcinomaBasic Study Tong-Jun Zhang, Dong Xue, Cheng-De Zhang, Ze-Dong Zhang, Qing-Ran Liu, Jian-Qiang WangSubmit a Manuscript: http://www.f6publishing.com DOI: 10.3748/wjg.v23.i13.2318World J Gastroenterol   2017 April 7; 23(13): 2318-2329  ISSN 1007-9327 (print)  ISSN 2219-2840 (online)",Non-OADS,/arxiv_data1/oa_pdf/ec/6f/WJG-23-2318.PMC5385398.pdf
"World J  Gastroenterol  2017; 23(13): 2318­2329  Available from: URL:  http://www.wjgnet.com/1007 ­9327/full/v23/i13/2318.htm   DOI:  http://dx.doi.org/10.3748/wjg.v23.i13.2318 INTRODUCTION Cholangiocarcinoma (CCA), a primary epithelial cancer originating from the hepatobiliary tract and exhibiting  characteristics of cholangiocyte differentiation, is  classified into intrahepatic CCA, perihilar CCA (PHCC)  and distal CCA based on its anatomical location[1].",Non-OADS,/arxiv_data1/oa_pdf/ec/6f/WJG-23-2318.PMC5385398.pdf
"All rights reserved.Published by Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.f6publishing.com/helpdesk http://www.wjgnet.com I S S N  1 0  0 7  -   9  3 2  7 9    7 7 1 0  07   9 3 2 0 451  3",Non-OADS,/arxiv_data1/oa_pdf/ec/6f/WJG-23-2318.PMC5385398.pdf
"See: http://creativecommons.org/ licenses/by-nc/4.0/Manuscript source:  Unsolicited manuscript Correspondence to: Dr. Bei Zhang,  Department of  Immunology, Medical College of Qingdao University, 308  Ningxia Road, Qingdao 266071, Shandong Province,  China.",Non-OADS,/arxiv_data1/oa_pdf/9d/dd/WJG-23-2330.PMC5385399.pdf
"TGF- β inhibitor  2330 April 7, 2017 |Volume 23 |Issue 13 | WJG|www.wjgnet.comORIGINAL ARTICLE Notch signaling mediated by TGF- β/Smad pathway in  concanavalin A-induced liver fibrosis in ratsBasic Study Yi Wang, Ruo-Wu Shen, Bing Han, Zhen Li, Le Xiong, Feng-Yu Zhang, Bei-Bei Cong, Bei ZhangSubmit a Manuscript: http://www.f6publishing.com DOI: 10.3748/wjg.v23.i13.2330World J Gastroenterol   2017 April 7; 23(13): 2330-2336  ISSN 1007-9327 (print)  ISSN 2219-2840 (online)",Non-OADS,/arxiv_data1/oa_pdf/9d/dd/WJG-23-2330.PMC5385399.pdf
World  J Gastroenterol  2017; 23(13): 2330-2336  Available from: URL:  http://www.wjgnet.com/1007-9327/full/v23/i13/2330.htm   DOI:  http://dx.doi.org/10.3748/wjg.v23.i13.2330 INTRODUCTION Liver fibrosis occurs as a result of chronic liver disease  and is associated with severe morbidity and mortality.,Non-OADS,/arxiv_data1/oa_pdf/9d/dd/WJG-23-2330.PMC5385399.pdf
"All rights reserved.Published by Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.f6publishing.com/helpdesk http://www.wjgnet.com I S S N  1 0  0 7  -   9  3 2  7 9    7 7 1 0  07   9 3 2 0 451  3",Non-OADS,/arxiv_data1/oa_pdf/9d/dd/WJG-23-2330.PMC5385399.pdf
"See: http://creativecommons.org/ licenses/by-nc/4.0/ Manuscript source:  Unsolicited manuscript Correspondence to: Dr. Wei Wang,  Department of General  Surgery, The Second Affiliated Hospital of Fujian Medical  University, Zhongshanbei Road 34, Quanzhou 362000, Fujian  Province, China.",Non-OADS,/arxiv_data1/oa_pdf/85/b1/WJG-23-2337.PMC5385400.pdf
"In addition, miR-145  inhibition stimulated CD44 3’-UTR activity and disruption  2337 April 7, 2017 |Volume 23 |Issue 13 | WJG|www.wjgnet.comORIGINAL ARTICLE MicroRNA-145 exerts tumor-suppressive and chemo- resistance lowering effects by targeting CD44 in gastric  cancerBasic Study Jian-Feng Zeng, Xiao-Qiu Ma, Lin-Pei Wang, Wei WangSubmit a Manuscript: http://www.f6publishing.com DOI: 10.3748/wjg.v23.i13.2337World J Gastroenterol   2017 April 7; 23(13): 2337-2345  ISSN 1007-9327 (print)  ISSN 2219-2840 (online)",Non-OADS,/arxiv_data1/oa_pdf/85/b1/WJG-23-2337.PMC5385400.pdf
World J Gastroenterol  2017;  23(13): 2337-2345  Available from: URL: http://www.wjgnet.,Non-OADS,/arxiv_data1/oa_pdf/85/b1/WJG-23-2337.PMC5385400.pdf
com/1007-9327/full/v23/i13/2337.htm   DOI: http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/85/b1/WJG-23-2337.PMC5385400.pdf
"Cell cultures The human gastric cancer cell line, MGC-803, was  purchased from the Institute of Cell Biology (Shanghai,  China, http://www.cellbank.org.c n).",Non-OADS,/arxiv_data1/oa_pdf/85/b1/WJG-23-2337.PMC5385400.pdf
The  prediction of miRNA-recognition element (MRE) sites  for miR-145 on the CD44-3’ UTR was performed  using the TargetScan ( http://www.targetscan.,OADS,/arxiv_data1/oa_pdf/85/b1/WJG-23-2337.PMC5385400.pdf
"All rights reserved.Published by Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.f6publishing.com/helpdesk http://www.wjgnet.com I S S N  1 0  0 7  -   9  3 2  7 9    7 7 1 0  07   9 3 2 0 451  3",Non-OADS,/arxiv_data1/oa_pdf/85/b1/WJG-23-2337.PMC5385400.pdf
"See: http://creativecommons.org/ licenses/by-nc/4.0/ Manuscript source:  Unsolicited manuscript Correspondence to: Byung Chang Kim, MD,  Center for  Colorectal Cancer, Research Institute and Hospital, National  Cancer Center, 111 Jungbalsan-ro, Ilsandong-gu, Goyang-si,  Gyeonggi-do 10408, South Korea.",Non-OADS,/arxiv_data1/oa_pdf/64/20/WJG-23-2346.PMC5385401.pdf
"Age, gender, obesity indices [body mass  index (BMI), waist-to-hip circumference ratio (WHR),  waist circumference (WC), visceral adipose tissue (VAT)  2346 April 7, 2017 |Volume 23 |Issue 13 | WJG|www.wjgnet.comORIGINAL ARTICLE Predictors for difficult cecal insertion in colonoscopy: The  impact of obesity indicesCase Control Study Soo Yun Moon, Byung Chang Kim, Dae Kyung Sohn, Kyung Su Han, Bun Kim, Chang Won Hong,  Bum Joon Park, Kum Hei Ryu, Ji Hyung NamSubmit a Manuscript: http://www.f6publishing.com DOI: 10.3748/wjg.v23.i13.2346World J Gastroenterol   2017 April 7; 23(13): 2346-2354  ISSN 1007-9327 (print)  ISSN 2219-2840 (online)",Non-OADS,/arxiv_data1/oa_pdf/64/20/WJG-23-2346.PMC5385401.pdf
World J  Gastroenterol  2017; 23(13): 2346-2354  Available from: URL:  http://www.wjgnet.com/1007-9327/full/v23/i13/2346.htm   DOI:  http://dx.doi.org/10.3748/wjg.v23.i13.2346 INTRODUCTION Colonoscopy is widely used for the diagnosis and  treatment of colon disorders and is one of the reco­ mmended options for colorectal cancer screening[1].,Non-OADS,/arxiv_data1/oa_pdf/64/20/WJG-23-2346.PMC5385401.pdf
"All rights reserved.Published by Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.f6publishing.com/helpdesk http://www.wjgnet.com I S S N  1 0  0 7  -   9  3 2  7 9    7 7 1 0  07   9 3 2 0 451  3",Non-OADS,/arxiv_data1/oa_pdf/64/20/WJG-23-2346.PMC5385401.pdf
"See: http://creativecommons.org/ licenses/by-nc/4.0/ Manuscript source:  Invited manuscript Correspondence to: Daisuke Endo, MD,  Department  of Gastroenterology and Hepatology, Internal Medicine of  Jikei University Katsushika Medical Center, 6-41-2 Aoto,  Katsushikaku, Tokyo 125-8506, Japan.",Non-OADS,/arxiv_data1/oa_pdf/cc/72/WJG-23-2355.PMC5385402.pdf
"RESULTS Serum leve ls of TC, LDL-C, and HDL-C were significantly  increased throughout the observation period in both Submit a Manuscript: http://www.f6publishing.com DOI: 10.3748/wjg.v23.i13.2355 2355 April 7, 2017 |Volume 23 |Issue 13 | WJG|www.wjgnet.comWorld J Gastroenterol   2017 April 7; 23(13): 2355-2364  ISSN 1007-9327 (print)  ISSN 2219-2840 (online) ORIGINAL ARTICLE Impact of interferon-free antivirus therapy on lipid profiles  in patients with chronic hepatitis C genotype 1bRetrospective Cohort Study Daisuke Endo, Kenichi Satoh, Noritomo Shimada, Atsushi Hokari, Yoshio Aizawa",Non-OADS,/arxiv_data1/oa_pdf/cc/72/WJG-23-2355.PMC5385402.pdf
World J Gastroenterol  2017;  23(13): 2355-2364  Available from: URL: http://www.wjgnet.,OADS,/arxiv_data1/oa_pdf/cc/72/WJG-23-2355.PMC5385402.pdf
com/1007-9327/full/v23/i13/2355.htm   DOI: http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/cc/72/WJG-23-2355.PMC5385402.pdf
"All rights reserved.Published by Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.f6publishing.com/helpdesk http://www.wjgnet.com I S S N  1 0  0 7  -   9  3 2  7 9    7 7 1 0  07   9 3 2 0 451  3",Non-OADS,/arxiv_data1/oa_pdf/cc/72/WJG-23-2355.PMC5385402.pdf
"See: http://creativecommons.org/ licenses/by-nc/4.0/ Manuscript source:  Invited manuscript Correspondence to: Norman Junge, MD,  Department of  Pediatric Gastroenterology and Hepatology, Hannover Medical  School, Carl- Neuberg-Str 1, 30625 Hannover,  Germany.",Non-OADS,/arxiv_data1/oa_pdf/4f/54/WJG-23-2365.PMC5385403.pdf
"Included  in our study were all pre-transfer liver transplant and  combined liver-kidney transplant recipients aged 11-19  currently under our care and their parents, as well as  all post-transfer liver transplant and combined liver- kidney transplant recipients aged ≥ 17 years who had  received a liver transplant and were treated at our  center during childhood.Submit a Manuscript: http://www.f6publishing.com DOI: 10.3748/wjg.v23.i13.2365 2365 April 7, 2017 |Volume 23 |Issue 13 | WJG|www.wjgnet.comWorld J Gastroenterol   2017 April 7; 23(13): 2365-2375  ISSN 1007-9327 (print)  ISSN 2219-2840 (online) ORIGINAL ARTICLE Transition after pediatric liver transplantation - Perceptions  of adults, adolescents and parentsRetrospective Study Norman Junge, Katarina Migal, Imeke Goldschmidt, Ulrich Baumann",Non-OADS,/arxiv_data1/oa_pdf/4f/54/WJG-23-2365.PMC5385403.pdf
World J Gastroenterol  2017; 23(13): 2365-2375   Available from: URL: http://www.wjgnet.com/1007-9327/full/ v23/i13/2365.htm   DOI: http://dx.doi.org/10.3748/wjg.v23.,Non-OADS,/arxiv_data1/oa_pdf/4f/54/WJG-23-2365.PMC5385403.pdf
"All rights reserved.Published by Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.f6publishing.com/helpdesk http://www.wjgnet.com I S S N  1 0  0 7  -   9  3 2  7 9    7 7 1 0  07   9 3 2 0 451  3",Non-OADS,/arxiv_data1/oa_pdf/4f/54/WJG-23-2365.PMC5385403.pdf
"Morgagni Hospital, 47121  Forlì, ItalyOrhan Alimoglu, Metin Leblebici,  Department of General  Surgery, School of Medicine, Istanbul Medeniyet University,  34000 Istanbul, Turkey Johan Gagnière, Denis Pezet,  Department of Digestive and  Hepatobiliary Surgery, Estaing University Hospital, 63000  Clermont-Ferrand, France Graziano Pernazza,  Department of Surgery, Robotic General  Surgery Unit, San Giovanni Addolorata Hospital, 00184 Rome,  Italy Simone D’Imporzano,  Esophageal Surgery Unit, Tuscany  Regional Referral Center for the Diagnosis and Treatment of  Esophageal Disease, Medical University of Pisa, 56124 Pisa,  Italy Yan-Bing Zhou, Shou- Gen Cao,  Department of General  Surgery, The Affiliated Hospital of Qingdao University, Qingdao  266003, Shandong Province, China Juan-Santiago Azagra, Martine Goergen,  Unité des Maladies  de l’Appareil Digestif et Endocrine, Centre Hospitalier de  Luxembourg, 1210 Luxembourg, Luxembourg Olivier Facy,  Service de Chirurgie Digestive et Cancérologique  CHU Bocage, 21000 Dijon, France Steven T Brower,  Department of Surgical Oncology and HPB  Surgery, Englewood Hospital and Medical Center, Englewood,  NJ 07631, United States Zhi-Wei Jiang, Shu Zhang,  Department of General Surgery,  Jinling Hospital, Medical School, Nanjing University, Nanjing  210002, Jiangsu Province, China 2376 April 7, 2017 |Volume 23 |Issue 13 | WJG|www.wjgnet.comORIGINAL ARTICLE Minimally invasive surgery for gastric cancer: A comparison  between robotic, laparoscopic and open surgeryRetrospective Study Amilcare Parisi, Daniel Reim, Felice Borghi, Ninh T Nguyen, Feng Qi, Andrea Coratti, Fabio Cianchi,  Maurizio Cesari, Francesca Bazzocchi, Orhan Alimoglu, Johan Gagnière, Graziano Pernazza,  Simone D’Imporzano, Yan-Bing Zhou, Juan-Santiago Azagra, Olivier Facy, Steven T Brower, Zhi-Wei Jiang,  Lu Zang, Arda Isik, Alessandro Gemini, Stefano Trastulli, Alexander Novotny, Alessandra Marano, Tong Liu,  Mario Annecchiarico, Benedetta Badii, Giacomo Arcuri, Andrea Avanzolini, Metin Leblebici, Denis Pezet,  Shou-Gen Cao, Martine Goergen, Shu Zhang, Giorgio Palazzini, Vito D’Andrea, Jacopo DesiderioSubmit a Manuscript: http://www.f6publishing.com DOI: 10.3748/wjg.v23.i13.2376World J Gastroenterol   2017 April 7; 23(13): 2376-2384  ISSN 1007-9327 (print)  ISSN 2219-2840 (online)",Non-OADS,/arxiv_data1/oa_pdf/c5/a4/WJG-23-2376.PMC5385404.pdf
"See: http://creativecommons.org/ licenses/by-nc/4.0/ Manuscript source:  Invited manuscript Correspondence to: Jacopo Desiderio, MD,  Department of  Digestive Surgery, St. Mary’s Hospital of Terni - University of  Perugia, Via Tristano di Joannuccio 1, 05100 Terni,  Italy.",Non-OADS,/arxiv_data1/oa_pdf/c5/a4/WJG-23-2376.PMC5385404.pdf
World J Gastroenterol  2017; 23(13): 2376-2384   Available from: URL: http://www.wjgnet.com/1007-9327/full/ v23/i13/2376.htm   DOI: http://dx.doi.org/10.3748/wjg.v23.,Non-OADS,/arxiv_data1/oa_pdf/c5/a4/WJG-23-2376.PMC5385404.pdf
Source of data analyzed Investigators collected data through a web-based  system ( https://imigastric.logix-software.it /).,OADS,/arxiv_data1/oa_pdf/c5/a4/WJG-23-2376.PMC5385404.pdf
"All rights reserved.Published by Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.f6publishing.com/helpdesk http://www.wjgnet.com I S S N  1 0  0 7  -   9  3 2  7 9    7 7 1 0  07   9 3 2 0 451  3",Non-OADS,/arxiv_data1/oa_pdf/c5/a4/WJG-23-2376.PMC5385404.pdf
"See: http://creativecommons.org/ licenses/by-nc/4.0/ Manuscript source:  Invited manuscript Correspondence to: Sang Mi Lee, MD, PhD, Assistant  Professor,  Department of Nuclear Medicine, Soonchunhyang  University Hospital, 23-20 Byeongmyeong-dong, Dongnam-gu,  Cheonan, Chuncheongnam-do 330-721,  South Korea.",Non-OADS,/arxiv_data1/oa_pdf/d6/30/WJG-23-2385.PMC5385405.pdf
"Mean FDG uptake of BM (BM SUV) and BM-to-liver  2385 April 7, 2017 |Volume 23 |Issue 13 | WJG|www.wjgnet.comORIGINAL ARTICLE Clinical implication of FDG uptake of bone marrow on  PET/CT in gastric cancer patients with surgical resectionRetrospective Study Jeong Won Lee, Moon-Soo Lee, Il Kwon Chung, Myoung Won Son, Young Sin Cho, Sang Mi LeeSubmit a Manuscript: http://www.f6publishing.com DOI: 10.3748/wjg.v23.i13.2385World J Gastroenterol   2017 April 7; 23(13): 2385-2395  ISSN 1007-9327 (print)  ISSN 2219-2840 (online)",Non-OADS,/arxiv_data1/oa_pdf/d6/30/WJG-23-2385.PMC5385405.pdf
wjgnet.com/1007-9327/full/v23/i13/ 2385 .htm  DOI: http://dx.doi.,OADS,/arxiv_data1/oa_pdf/d6/30/WJG-23-2385.PMC5385405.pdf
"All rights reserved.Published by Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.f6publishing.com/helpdesk http://www.wjgnet.com I S S N  1 0  0 7  -   9  3 2  7 9    7 7 1 0  07   9 3 2 0 451  3",Non-OADS,/arxiv_data1/oa_pdf/d6/30/WJG-23-2385.PMC5385405.pdf
"See: http://creativecommons.org/ licenses/by-nc/4.0/ Manuscript source:  Invited manuscript Correspondence to: Myeong Jun Song, MD, PhD,  Division  of Hepatology, Department of Internal Medicine, Daejeon St.  Mary’s Hospital, College of Medicine, The Catholic University  of Korea, Daeheung-ro 64, Jung-gu, Daejeon 34943,  South Korea.",Non-OADS,/arxiv_data1/oa_pdf/e3/cf/WJG-23-2396.PMC5385406.pdf
"mjsong95@gmail.com Telephone:  +82-42-2209291 Received:  January 4, 2017 Peer-review started:  January 7, 2017 First decision:  February 9, 2017 Revised:  February 20, 2017 Accepted:  March 15, 2017   Article in press:  March 15, 2017 Published online: April 7, 2017 Abstract AIM To evaluate the safety and efficacy of tenofovir  disoproxil fumarate (TDF) as a first-line therapy in Submit a Manuscript: http://www.f6publishing.com DOI: 10.3748/wjg.v23.i13.2396 2396 April 7, 2017 |Volume 23 |Issue 13 | WJG|www.wjgnet.comWorld J Gastroenterol   2017 April 7; 23(13): 2396-2403  ISSN 1007-9327 (print)  ISSN 2219-2840 (online) ORIGINAL ARTICLE Safety and efficacy of tenofovir in chronic hepatitis  B-related decompensated cirrhosisObservational Study Soon Kyu Lee, Myeong Jun Song, Seok Hyun Kim, Byung Seok Lee, Tae Hee Lee, Young Woo Kang,  Suk Bae Kim, Il Han Song, Hee Bok Chae, Soon Young Ko, Jae Dong Lee",Non-OADS,/arxiv_data1/oa_pdf/e3/cf/WJG-23-2396.PMC5385406.pdf
"World J Gastroenterol  2017; 23(13): 2396-2403  Available from:  URL: http://www.wjgnet.com/1007-9327/full/v23/i13/2396.htm    DOI: http://dx.doi.org/10.3748/wjg.v23.i13.2396 INTRODUCTION Chronic hepatitis B virus (CHB) infection is a the  major public health problem because of its worldwide  distribution and its substantial morbidity, and mortality  due to complications of cirrhosis and hepatocellular  carcinoma (HCC)[1].",Non-OADS,/arxiv_data1/oa_pdf/e3/cf/WJG-23-2396.PMC5385406.pdf
"All rights reserved.Published by Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.f6publishing.com/helpdesk http://www.wjgnet.com I S S N  1 0  0 7  -   9  3 2  7 9    7 7 1 0  07   9 3 2 0 451  3",Non-OADS,/arxiv_data1/oa_pdf/e3/cf/WJG-23-2396.PMC5385406.pdf
"See: http://creativecommons.org/ licenses/by-nc/4.0/ Manuscript source:  Unsolicited manuscript Correspondence to: Dr. Chun-Fang Xu, Professor,   Department of Gastroenterology, The First Affiliated Hospital of Soochow University, 188 Shizi Street, Suzhou 215006, Jiangsu  Province, China.",Non-OADS,/arxiv_data1/oa_pdf/f7/be/WJG-23-2404.PMC5385407.pdf
"2404 April 7, 2017 |Volume 23 |Issue 13 | WJG|www.wjgnet.comORIGINAL ARTICLE Can mean platelet volume play a role in evaluating the  severity of acute pancreatitis?Observational Study Jing-Jing Lei, Li Zhou, Qi Liu, Can Xiong, Chun-Fang XuSubmit a Manuscript: http://www.f6publishing.com DOI: 10.3748/wjg.v23.i13.2404World J Gastroenterol   2017 April 7; 23(13): 2404-2413  ISSN 1007-9327 (print)  ISSN 2219-2840 (online)",Non-OADS,/arxiv_data1/oa_pdf/f7/be/WJG-23-2404.PMC5385407.pdf
World J Gastroenterol  2017; 23(13): 2404-2413  Available from:  URL: http://www.wjgnet.com/1007-9327/full/v23/i13/2404.htm    DOI: http://dx.doi.org/10.3748/wjg.v23.i13.2404 INTRODUCTION Severe acute pancreatitis (SAP) is a critical illness in which both the inflammatory and coagulation sys­ tems are considered ticking time bombs.,Non-OADS,/arxiv_data1/oa_pdf/f7/be/WJG-23-2404.PMC5385407.pdf
"All rights reserved.Published by Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.f6publishing.com/helpdesk http://www.wjgnet.com I S S N  1 0  0 7  -   9  3 2  7 9    7 7 1 0  07   9 3 2 0 451  3",Non-OADS,/arxiv_data1/oa_pdf/f7/be/WJG-23-2404.PMC5385407.pdf
"See: http://creativecommons.org/ licenses/by-nc/4.0/ Manuscript source:  Invited manuscript Correspondence to: Hiroki Sato, MD, PhD,  Division of  Gastroenterology and Hepatology, Niigata University Medical  and Dental Hospital, 757-1, Asahimachidori, Chuo-ku, Niigata  City, Niigata 951-8510, Japan.",Non-OADS,/arxiv_data1/oa_pdf/05/c1/WJG-23-2414.PMC5385408.pdf
"Using  manometry, failed peristalsis was observed in patients  with EoE and sEoE with some variation, while EoEM  was associated with hypercontractile or hypertensive  2414 April 7, 2017 |Volume 23 |Issue 13 | WJG|www.wjgnet.comORIGINAL ARTICLE Proposed criteria to differentiate heterogeneous  eosinophilic gastrointestinal disorders of the esophagus,  including eosinophilic esophageal myositisProspective Study Hiroki Sato, Nao Nakajima, Kazuya Takahashi, Go Hasegawa, Ken-ichi Mizuno, Satoru Hashimoto,  Satoshi Ikarashi, Kazunao Hayashi, Yutaka Honda, Junji Yokoyama, Yuichi Sato, Shuji TeraiSubmit a Manuscript: http://www.f6publishing.com DOI: 10.3748/wjg.v23.i13.2414World J Gastroenterol   2017 April 7; 23(13): 2414-2423  ISSN 1007-9327 (print)  ISSN 2219-2840 (online)",Non-OADS,/arxiv_data1/oa_pdf/05/c1/WJG-23-2414.PMC5385408.pdf
World J Gastroenterol  2017;  23(13): 2414-2423  Available from: URL: http://www.wjgnet.,OADS,/arxiv_data1/oa_pdf/05/c1/WJG-23-2414.PMC5385408.pdf
com/1007-9327/full/v23/i13/2414.htm   DOI: http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/05/c1/WJG-23-2414.PMC5385408.pdf
"All rights reserved.Published by Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.f6publishing.com/helpdesk http://www.wjgnet.com I S S N  1 0  0 7  -   9  3 2  7 9    7 7 1 0  07   9 3 2 0 451  3",Non-OADS,/arxiv_data1/oa_pdf/05/c1/WJG-23-2414.PMC5385408.pdf
Details can be found at http://www.researchregistry.,Non-OADS,/arxiv_data1/oa_pdf/c3/36/WJG-23-2424.PMC5385409.pdf
"See: http://creativecommons.org/ licenses/by-nc/4.0/ Manuscript source:  Unsolicited manuscript Correspondence to: Zong-Ming Zhang, MD, PhD, Professor,   Department of General Surgery, Beijing Electric Power Hospital,  State Grid Corporation of China, Capital Medical University, No.",Non-OADS,/arxiv_data1/oa_pdf/c3/36/WJG-23-2424.PMC5385409.pdf
"RESULTS The average age of the 289 patients with biliary diseases  2424 April 7, 2017 |Volume 23 |Issue 13 | WJG|www.wjgnet.comORIGINAL ARTICLE Therapeutic experience of 289 elderly patients with biliary  diseasesProspective Study Zong-Ming Zhang, Zhuo Liu, Li-Min Liu, Chong Zhang, Hong-Wei Yu, Bai-Jiang Wan, Hai Deng,  Ming-Wen Zhu, Zi-Xu Liu, Wen-Ping Wei, Meng-Meng Song, Yue ZhaoSubmit a Manuscript: http://www.f6publishing.com DOI: 10.3748/wjg.v23.i13.2424World J Gastroenterol   2017 April 7; 23(13): 2424-2434  ISSN 1007-9327 (print)  ISSN 2219-2840 (online)",Non-OADS,/arxiv_data1/oa_pdf/c3/36/WJG-23-2424.PMC5385409.pdf
"World J  Gastroenterol  2017; 23(13): 2424-2434  Available from: URL:  http://www.wjgnet.com/1007-9327/full/v23/i13/2424.htm   DOI:  http://dx.doi.org/10.3748/wjg.v23.i13.2424 INTRODUCTION With global prolongation of life expectancy, the incidence of diseases in the aging population has  increased.",Non-OADS,/arxiv_data1/oa_pdf/c3/36/WJG-23-2424.PMC5385409.pdf
"All rights reserved.Published by Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.f6publishing.com/helpdesk http://www.wjgnet.com I S S N  1 0  0 7  -   9  3 2  7 9    7 7 1 0  07   9 3 2 0 451  3",Non-OADS,/arxiv_data1/oa_pdf/c3/36/WJG-23-2424.PMC5385409.pdf
"See: http://creativecommons.org/ licenses/by-nc/4.0/ Manuscript source:  Invited manuscript Correspondence to: Mohammad Yaghoobi, MD, MSc,  AFS, FRCPC,  Division of Gastroenterology, Division of  Gastroenterology, McMaster University, Hamilton, ON L8S 4K1,  Canada.",Non-OADS,/arxiv_data1/oa_pdf/d9/d0/WJG-23-2435.PMC5385410.pdf
"The result was not different among  Asian studies as compared to others and remained META-ANALYSISSubmit a Manuscript: http://www.f6publishing.com DOI: 10.3748/wjg.v23.i13.2435 2435 April 7, 2017 |Volume 23 |Issue 13 | WJG|www.wjgnet.comWorld J Gastroenterol   2017 April 7; 23(13): 2435-2442  ISSN 1007-9327 (print)  ISSN 2219-2840 (online)",Non-OADS,/arxiv_data1/oa_pdf/d9/d0/WJG-23-2435.PMC5385410.pdf
World J Gastroenterol  2017;  23(13): 2435-2442  Available from: URL: http://www.wjgnet.,OADS,/arxiv_data1/oa_pdf/d9/d0/WJG-23-2435.PMC5385410.pdf
com/1007-9327/full/v23/i13/2435.htm   DOI: http://dx.doi.,OADS,/arxiv_data1/oa_pdf/d9/d0/WJG-23-2435.PMC5385410.pdf
"Available from: URL:  http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp 11 Higgins JP , Thompson SG, Deeks JJ, Altman DG.",Non-OADS,/arxiv_data1/oa_pdf/d9/d0/WJG-23-2435.PMC5385410.pdf
"All rights reserved.Published by Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.f6publishing.com/helpdesk http://www.wjgnet.com I S S N  1 0  0 7  -   9  3 2  7 9    7 7 1 0  07   9 3 2 0 451  3",Non-OADS,/arxiv_data1/oa_pdf/d9/d0/WJG-23-2435.PMC5385410.pdf
"See: http://creativecommons.org/ licenses/by-nc/4.0/ Manuscript source:  Unsolicited manuscriptCorrespondence to: Takeshi Saito, MD, PhD,  Department   of Medicine, Molecular Microbiology and Immunology, and  Pathology, Division of Gastrointestinal and Liver Diseases, Keck  School of Medicine of USC, University of Southern California,  2011 Zonal Avenue, HMR 801A, Los Angeles, CA 9003,  United States.",Non-OADS,/arxiv_data1/oa_pdf/57/65/WJG-23-2443.PMC5385411.pdf
"Key words:  Hepatic angiosarcoma; Kasabach-Merritt  syndrome; Vascular tumorCASE REPORT 2443 April 7, 2017 |Volume 23 |Issue 13 | WJG|www.wjgnet.comSubmit a Manuscript: http://www.f6publishing.com DOI: 10.3748/wjg.v23.i13.2443World J Gastroenterol   2017 April 7; 23(13): 2443-2447  ISSN 1007-9327 (print)  ISSN 2219-2840 (online)",Non-OADS,/arxiv_data1/oa_pdf/57/65/WJG-23-2443.PMC5385411.pdf
World J Gastroenterol  2017;  23(13): 2443-2447  Available from: URL: http://www.wjgnet.,OADS,/arxiv_data1/oa_pdf/57/65/WJG-23-2443.PMC5385411.pdf
com/1007-9327/full/v23/i13/2443.htm   DOI: http://dx.doi.,OADS,/arxiv_data1/oa_pdf/57/65/WJG-23-2443.PMC5385411.pdf
"All rights reserved.Published by Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.f6publishing.com/helpdesk http://www.wjgnet.com I S S N  1 0  0 7  -   9  3 2  7 9    7 7 1 0  07   9 3 2 0 451  3",Non-OADS,/arxiv_data1/oa_pdf/57/65/WJG-23-2443.PMC5385411.pdf
"See: http://creativecommons.org/ licenses/by-nc/4.0/ Manuscript source:  Unsolicited manuscript Correspondence to: Dr. Lorenza Rimassa, Deputy Director,   Medical Oncology and Hematology Unit, Humanitas Cancer  Center, Humanitas Clinical and Research Center, Via Manzoni  56, 20089 Rozzano,  Italy.",Non-OADS,/arxiv_data1/oa_pdf/92/fb/WJG-23-2448.PMC5385412.pdf
"lorenza.rimassa@cancercenter.humanitas.i t Telephone:  +39-2-82244573 Fax:  +39-2-82244590 Received:  January 20, 2017 Peer-review started:  January 22, 2017 First decision:  February 10, 2017 Revised:  February 24, 2017LETTERS TO THE EDITOR 2448 April 7, 2017 |Volume 23 |Issue 13 | WJG|www.wjgnet.comSubmit a Manuscript: http://www.f6publishing.com DOI: 10.3748/wjg.v23.i13.2448World J Gastroenterol   2017 April 7; 23(13): 2448-2452  ISSN 1007-9327 (print)  ISSN 2219-2840 (online)",Non-OADS,/arxiv_data1/oa_pdf/92/fb/WJG-23-2448.PMC5385412.pdf
"World J  Gastroenterol  2017; 23(13): 2448-2452  Available from: URL:  http://www.wjgnet.com/1007-9327/full/v23/i13/2448.htm   DOI:  http://dx.doi.org/10.3748/wjg.v23.i13.2448TO THE EDITOR Liver cancer was estimated to be responsible for  almost 746000 deaths worldwide in 2012 (WHO),  with hepatocellular carcinoma (HCC) being the most  common type[1].",Non-OADS,/arxiv_data1/oa_pdf/92/fb/WJG-23-2448.PMC5385412.pdf
"Available from: http://investors.arqule.com/ releasedetail.cfm?ReleaseID=1012374 25 Reig M , Rimola J, Torres F, Darnell A, Rodriguez-Lope C, Forner  A, Llarch N, Ríos J, Ayuso C, Bruix J. Postprogression survival  of patients with advanced hepatocellular carcinoma: rationale for  second-line trial design.",Non-OADS,/arxiv_data1/oa_pdf/92/fb/WJG-23-2448.PMC5385412.pdf
"Available from: http://www.eisai.com/news/ enews201706pdf.pdf P- Reviewer : Gkretsi V , Varona MA    S- Editor : Qi Y    L- Editor : A     E- Editor : Zhang FFRimassa L et al.",Non-OADS,/arxiv_data1/oa_pdf/92/fb/WJG-23-2448.PMC5385412.pdf
"All rights reserved.Published by Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.f6publishing.com/helpdesk http://www.wjgnet.com I S S N  1 0  0 7  -   9  3 2  7 9    7 7 1 0  07   9 3 2 0 451  3",Non-OADS,/arxiv_data1/oa_pdf/92/fb/WJG-23-2448.PMC5385412.pdf
"This Open Access article is distributed under the terms of the Creative Commons Attribution Noncommercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS Volume 33, Number 3, 2017Mary Ann Liebert, Inc.DOI: 10.1089/jop.2016.0093 149",Non-OADS,/arxiv_data1/oa_pdf/71/92/jop.2016.0093.PMC5385417.pdf
"This Open Access article is distributed under the terms of the Creative Commons Attribution Noncommercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits any non-commercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.",Non-OADS,/arxiv_data1/oa_pdf/87/38/jpm.2016.0540.PMC5385420.pdf
"‘‘Plenary 3: Elements and models of end-of-life care; Cicely Saun- ders trigger tape.’’ http://bioethics.northwestern.edu/programs/ epec/ (Last accessed November 20, 2016).",Non-OADS,/arxiv_data1/oa_pdf/87/38/jpm.2016.0540.PMC5385420.pdf
"This Open Access article is distributed under the terms of the Creative Commons Attribution Noncommercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits any noncom-mercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.JOURNAL OF PALLIATIVE MEDICINE Volume 20, Number 4, 2017Mary Ann Liebert, Inc.DOI: 10.1089/jpm.2016.0228 415",Non-OADS,/arxiv_data1/oa_pdf/97/cd/jpm.2016.0228.PMC5385423.pdf
http://hpna.advancingexpertcare.org/wp- content/uploads/2015/08/Value-of-the-Advanced-Practice- Registered-Nurse-in-Palliat ive-Care.pdf.,Non-OADS,/arxiv_data1/oa_pdf/97/cd/jpm.2016.0228.PMC5385423.pdf
"http://onlinelibrary.wiley.com/doi/10.1002/0471440264.pst256.pub2/abstract; jsessionid=D851C72B9A16B85582D64CD42DEAC CE3.f02t01 (last accessed Nov. 1, 2016).7.",Non-OADS,/arxiv_data1/oa_pdf/c6/f0/wound.2016.0705.PMC5385427.pdf
"See: http://creativecommons.org/ licenses/by-nc/4.0/ Manuscript source: Invited manuscript Correspondence to: Enrique Grande, MD, PhD, Medical  Oncology Department, Ramón y Cajal University Hospital, Ctra.",Non-OADS,/arxiv_data1/oa_pdf/25/60/WJCO-8-100.PMC5385431.pdf
"Today, at least  6 agents are approved after failure with cytokines, World Journal of Clinical Oncology WJCO Submit a Manuscript: http://www.f6publishing.com DOI: 10.5306/wjco.v8.i2.100World J Clin Oncol  2017 April 10; 8(2): 100-105 ISSN 2218-4333 (online)",Non-OADS,/arxiv_data1/oa_pdf/25/60/WJCO-8-100.PMC5385431.pdf
wjgnet.com/ 2218-4333 /full/v8/i2/100.htm  DOI: http://dx.doi.,OADS,/arxiv_data1/oa_pdf/25/60/WJCO-8-100.PMC5385431.pdf
"All rights reserved.Published by Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.f6publishing.com/helpdesk http://www.wjgnet.com",Non-OADS,/arxiv_data1/oa_pdf/25/60/WJCO-8-100.PMC5385431.pdf
"See: http://creativecommons.org/ licenses/by-nc/4.0/ Manuscript source:  Invited manuscript Correspondence to: Ruben R Gonzalez-Perez, PhD, Professor ,  Department of Microbiology, Biochemistry and Immunology,  Morehouse School of Medicine, 720 Westview Drive SW, Hugh  Gloster Bldg., Room 329, Atlanta, GA 30310,  United States.",Non-OADS,/arxiv_data1/oa_pdf/a2/34/WJCO-8-106.PMC5385432.pdf
"Core tip:  Obesity and its main mediator leptin, are  implicated in many protumorigenic processes, with World Journal of Clinical Oncology WJCO Submit a Manuscript: http://www.f6publishing.com DOI: 10.5306/wjco.v8.i2.106World J Clin Oncol  2017 April 10; 8(2): 106-119 ISSN 2218-4333 (online)",Non-OADS,/arxiv_data1/oa_pdf/a2/34/WJCO-8-106.PMC5385432.pdf
"World J Clin Oncol  2017; 8(2): 106-119  Available from: URL:   http://www.wjgnet.com/ 2218 ­4333 /full/v8/i2/106.htm  DOI:  http://dx.doi.org/10.5306/wjco.v8.i2.106 INTRODUCTION Obesity is the state of having excessive adipose tissue  reserves, commonly defined as having a body mass index  (BMI) of 30 or more.",Non-OADS,/arxiv_data1/oa_pdf/a2/34/WJCO-8-106.PMC5385432.pdf
"All rights reserved.Published by Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.f6publishing.com/helpdesk http://www.wjgnet.com",Non-OADS,/arxiv_data1/oa_pdf/a2/34/WJCO-8-106.PMC5385432.pdf
"See: http://creativecommons.org/ licenses/by-nc/4.0/ Manuscript source:  Unsolicited manuscript Correspondence to: Gilles Pagès, PhD, Director  of Research  INSERM, University Nice Sophia Antipolis, Institute for Research  on Cancer and Aging of Nice CNRS UMR7284/INSERM U 1081,  Centre Antoine Lacassagne 33 Avenue de V alombrose, 06189 Nice,  France.",Non-OADS,/arxiv_data1/oa_pdf/d6/d6/WJCO-8-120.PMC5385433.pdf
Our manuscript represents a  working document for researchers/oncologists in the field  of breast cancers.World Journal of Clinical Oncology WJCO Submit a Manuscript: http://www.f6publishing.com DOI: 10.5306/wjco.v8.i2.120World J Clin Oncol  2017 April 10; 8(2): 120-134 ISSN 2218-4333 (online),Non-OADS,/arxiv_data1/oa_pdf/d6/d6/WJCO-8-120.PMC5385433.pdf
World J Clin Oncol  2017;  8(2): 120-134  Available from: URL:  http://www.wjgnet.com/  2218-4333 /full/v8/i2/120.htm  DOI: http://dx.doi.org/10.5306/wjco.,OADS,/arxiv_data1/oa_pdf/d6/d6/WJCO-8-120.PMC5385433.pdf
"Table 2  Some of the current clinical trials in breast cancer targeted immunotherapy (http://www.cancerresearch.org./cancer- immunotherapy/impacting-all-cancers/breast-cancer) Title of clinical trial Type of breast cancer Phase Ⅲ clinical trial: NEUVAX: nelipepimut-S or  E75NCT01479244HER1+ HER2+ Phase Ⅱ clinical trial: NEUVAX NCTO1570036 Node positive or TNBC Phase Ⅰ clinical trial: Pembrolizumab PD1 antibody + dendritic  cell vaccine NCTO2479230Metastatic breast cancer Phase Ⅱ trial: Pembrolizumab PD1 antibody + HDAC inhibitor  and anti-estrogen therapy NCT02395627Breast cancer Phase Ⅱ first line neo adjuvant trial: Atezolizumab +  chemotherapy NCTO2530489TNBC Phase Ⅰ clinical trial: Atezolizumab and HER2 inhibitors  NCTO2605915HER2+  Phase Ⅰ/Ⅱ clinical trial: PDR001(PD1 antibody) Advanced breast cancer, TNBC Phase Ⅰ/Ⅱ clinical trial: MEDI6469 anti OX40 antibody  NCTO1642290Stage 4 breast cancer (patients with prior failure of hormone or chemotherapy) Pilot study of QBX258 targeting IL-4 and IL-13 NTCO2494206 Advanced TNBC whose cancer cells make a protein called glycoprotein NMB to  which CDX-011 binds IL: Interleukin; HER2: Human epidermal growth factor receptor 2; TNBC: Triple negative breast cancer.Masoud V  et al.",Non-OADS,/arxiv_data1/oa_pdf/d6/d6/WJCO-8-120.PMC5385433.pdf
"Resistance mechanisms in breast cancer targeted  therapies represent the main challenge to current research;  the combination of different molecules used to target Table 3  Some of the current clinical trials in breast cancer targeted therapy (http://www.breastcancertrials.org) Title of clinical trial Type of cancer Randomized open label Phase Ⅱ trial: Kadcyla, tykerb and abraxane vs herceptin, tykerb and  taxol before Surgery for HER2+ tumors NCT02073487HER2+ Phase Ⅲ randomised, placebo controlled clinical trial: Chemotherapy and a PARP-inhibitor  for BRCA1/2+, HER2- advanced breast cancer NCTO2163694HER2-, BRCA1/2+ metastatic or locally advanced  unresectable breast cancer  Phase Ⅱ, multicenter, randomized clinical trial: Alisertib with taxol for advanced ER+/ HER2- or TNBC NCTO2187991ER+/HER2- TNBC Phase Ⅱ Clinical trial: Gemzar, herceptin and perjeta for HER2+ metastatic breast cancer  NCTO2252887HER2+ metastatic breast cancer Phase Ⅰ clinical trial: CD-839 for advanced breast tumors NCTO2071862 Advanced breast cancer and solid tumors Phase Ⅰ clinical trial: Saracatinib and anastrozole for ER-positive disease  NCTO1216176ER+ Randomised Phase Ⅲ clinical trial: Hormone therapy with or without ibrance for HR+, HER2- stage Ⅱ-Ⅲ breast cancer  NCTO2513394HR+, HER2- Phase Ⅱ clinical trial: CDK-inhibitor for previously treated metastatic disease NCTO1037790 Previously treated metastatic breast cancer Phase Ⅰ clinical trial: GS-5745 in metastatic HER2- breast cancer and other solid tumors  NCTO1813282Metastatic HER2- breast cancer not responding to  other treatmentsMasoud V  et al.",Non-OADS,/arxiv_data1/oa_pdf/d6/d6/WJCO-8-120.PMC5385433.pdf
"All rights reserved.Published by Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.f6publishing.com/helpdesk http://www.wjgnet.com",Non-OADS,/arxiv_data1/oa_pdf/d6/d6/WJCO-8-120.PMC5385433.pdf
"See: http://creativecommons.org/ licenses/by-nc/4.0/ Manuscript source: Invited manuscript Correspondence to: Jeffrey H Lee, MD, MPH, FASGE, FACG,  AGAF, President-Elect (Texas Society for Gastroenterology  and Endoscopy), Professor (Department of Gastroenterology,  Hepatology, and Nutrition), Director (Advanced Therapeutic  Endoscopy Fellowship), Department of Gastroenterology,  Hepatology and Nutrition, University of Texas MD Anderson  Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030,  United States.",Non-OADS,/arxiv_data1/oa_pdf/e9/4e/WJCO-8-135.PMC5385434.pdf
"World J Clin Oncol  2017; 8(2): 135-144  Available from:  URL:  http://www.wjgnet.com/ 2218-4333 /full/v8/i2/135.htm   DOI: http://dx.doi.org/10.5306/wjco.v8.i2.135 INTRODUCTION Gastrointestinal stromal tumors (GISTs) are the most  common mesenchymal (sub epithelial) tumor , and are World Journal of Clinical Oncology WJCO Submit a Manuscript: http://www.f6publishing.com DOI: 10.5306/wjco.v8.i2.135World J Clin Oncol  2017 April 10; 8(2): 135-144 ISSN 2218-4333 (online)",Non-OADS,/arxiv_data1/oa_pdf/e9/4e/WJCO-8-135.PMC5385434.pdf
"All rights reserved.Published by Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.f6publishing.com/helpdesk http://www.wjgnet.com",Non-OADS,/arxiv_data1/oa_pdf/e9/4e/WJCO-8-135.PMC5385434.pdf
"See: http://creativecommons.org/ licenses/by-nc/4.0/ Manuscript source:  Invited manuscript Correspondence to: Elie El Rassy, MD, Department of Oncology,  Hotel Dieu de France University Hospital, Faculty of Medicine,  Saint Joseph University, Monot St, Beirut, PO Box 166830, Beirut  2038 3054, Lebanon.",Non-OADS,/arxiv_data1/oa_pdf/5a/ab/WJCO-8-145.PMC5385435.pdf
"World J Clin Oncol  2017; 8(2):  145-150  Available from: URL:  http://www.wjgnet.com/ 2218-4333 / full/v8/i2/145.htm  DOI: http://dx.doi.org/10.5306/wjco.v8.i2.145 INTRODUCTION Sarcomas are malignant tumors that derive from  embryonic mesodermic tissues including fat, muscles,  bones, nerves and blood vessels[1].",Non-OADS,/arxiv_data1/oa_pdf/5a/ab/WJCO-8-145.PMC5385435.pdf
Sarcomas are World Journal of Clinical Oncology WJCO Submit a Manuscript: http://www.f6publishing.com DOI: 10.5306/wjco.v8.i2.145World J Clin Oncol  2017 April 10; 8(2): 145-150 ISSN 2218-4333 (online),Non-OADS,/arxiv_data1/oa_pdf/5a/ab/WJCO-8-145.PMC5385435.pdf
"Available  from: URL: http://www.cancer.gov/aboutnci/servingpeople/cancer- statistics/snapshots 4 Mulder RL , Paulides M, Langer T, Kremer LC, van Dalen EC.",Non-OADS,/arxiv_data1/oa_pdf/5a/ab/WJCO-8-145.PMC5385435.pdf
"All rights reserved.Published by Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.f6publishing.com/helpdesk http://www.wjgnet.com",Non-OADS,/arxiv_data1/oa_pdf/5a/ab/WJCO-8-145.PMC5385435.pdf
"See: http://creativecommons.org/ licenses/by-nc/4.0/Manuscript source:  Unsolicited manuscript Correspondence to:  Dr. Mohamed Abdulaziz Al Dawish, MD,  Department of Endocrinology, Prince Sultan Military Medical  City, Alrabwa, P.O.",Non-OADS,/arxiv_data1/oa_pdf/d3/e4/WJCO-8-151.PMC5385436.pdf
World Journal of Clinical Oncology WJCO Submit a Manuscript: http://www.f6publishing.com DOI: 10.5306/wjco.v8.i2.151World J Clin Oncol  2017 April 10; 8(2): 151-157 ISSN 2218-4333 (online) Retrospective Study,Non-OADS,/arxiv_data1/oa_pdf/d3/e4/WJCO-8-151.PMC5385436.pdf
"World J Clin Oncol  2017; 8(2): 151-157   Available from: URL:  http://www.wjgnet.com/ 2218-4333 /full/v8/ i2/151.htm  DOI: http://dx.doi.org/10.5306/wjco.v8.i2.151 INTRODUCTION According to epidemiological and clinical studies thyroid  nodules are commonly encountered in clinical exams,  palpable in 5% of the population on thyroid examination  and detectable in nearly 60% of those subjected to thyroid  ultrasound.",Non-OADS,/arxiv_data1/oa_pdf/d3/e4/WJCO-8-151.PMC5385436.pdf
Available from: URL: http://www.iacr.com.fr/index.php?option=com_ comprofiler&task=userprofile&user=1215&Itemid=498 7 Mazzaferri EL .,Non-OADS,/arxiv_data1/oa_pdf/d3/e4/WJCO-8-151.PMC5385436.pdf
"All rights reserved.Published by Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.f6publishing.com/helpdesk http://www.wjgnet.com",Non-OADS,/arxiv_data1/oa_pdf/d3/e4/WJCO-8-151.PMC5385436.pdf
"See: http://creativecommons.org/ licenses/by ­nc/4.0/ Manuscript source: Invited manuscript Correspondence to:  Dr. Yi-Shan Wang, Center for Tumor  Treatment, People’s Liberation Army 107th Hospital, 7 Zhichu  South Road, Yantai 264002, Shandong Province,  China.",Non-OADS,/arxiv_data1/oa_pdf/c5/90/WJCO-8-158.PMC5385437.pdf
The 50 subjects in the treatment group  were furth er divided into five subgroups and intervened World Journal of Clinical Oncology WJCO Submit a Manuscript: http://www.f6publishing.com DOI: 10.5306/wjco.v8.i2.158World J Clin Oncol  2017 April 10; 8(2): 158-167 ISSN 2218-4333 (online) Clinical Trials Study,Non-OADS,/arxiv_data1/oa_pdf/c5/90/WJCO-8-158.PMC5385437.pdf
"World J Clin Oncol  2017; 8(2): 158 ­167   Available from: URL:  http://www.wjgnet.com/ 2218 ­4333 /full/ v8/i2/158.htm  DOI: http://dx.doi.org/10.5306/wjco.v8.i2.158 INTRODUCTION Interleukin-12 (IL-12) is an immunoregulatory protein  produced by macrophages, B cells, mononuclear cells,  keratinocytes and dendritic cells, and its target point lies  in early undifferentiated pluripotent hematopoietic stem  cells.",Non-OADS,/arxiv_data1/oa_pdf/c5/90/WJCO-8-158.PMC5385437.pdf
"All rights reserved.Published by Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.f6publishing.com/helpdesk http://www.wjgnet.com",Non-OADS,/arxiv_data1/oa_pdf/c5/90/WJCO-8-158.PMC5385437.pdf
"See: http://creativecommons.org/ licenses/by-nc/4.0/ Manuscript source:  Invited manuscript Correspondence to: Simone Polvani, PhD,  Gastroenterology  Research Unit, Department of Experimental and Clinical  Biomedical Sciences “Mario Serio”, University of Florence, viale  Pieraccini 6, 50139 Florence, Italy.",Non-OADS,/arxiv_data1/oa_pdf/c8/83/WJCO-8-168.PMC5385438.pdf
"simone.polvani@unifi.it Telephone: +39-055-2758115 Received: August 26, 2016 Peer-review started:  August 27, 2016 First decision:  November 19, 2016  Revised:  February 22, 2017 Accepted:  February 25, 2017 Article in press:  February 26, 2017 Published online:  April 10, 2017 Abstract   AIM To test the fujinon intelligent color enhancement (FICE)  in identifying dysplastic or adenomatous polyps in familial  adenomatous polyposis (FAP) patients.World Journal of Clinical Oncology WJCO Submit a Manuscript: http://www.f6publishing.com DOI: 10.5306/wjco.v8.i2.168World J Clin Oncol  2017 April 10; 8(2): 168-177 ISSN 2218-4333 (online) Observational Study",Non-OADS,/arxiv_data1/oa_pdf/c8/83/WJCO-8-168.PMC5385438.pdf
"All rights reserved.Published by Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.f6publishing.com/helpdesk http://www.wjgnet.com",Non-OADS,/arxiv_data1/oa_pdf/c8/83/WJCO-8-168.PMC5385438.pdf
"See: http://creativecommons.org/ licenses/by-nc/4.0/ Manuscript source:  Invited manuscript Correspondence to: Nicola Fazio, MD, PhD, Unit of Gastro - intestinal Medical Oncology and Neuroendocrine Tumors, European  Institute of Oncology, Via Ripamonti 435, 20141 Milan,  Italy.",Non-OADS,/arxiv_data1/oa_pdf/bb/d6/WJCO-8-96.PMC5385439.pdf
Therefore its application World Journal of Clinical Oncology WJCO Submit a Manuscript: http://www.f6publishing.com DOI: 10.5306/wjco.v8.i2.96World J Clin Oncol  2017 April 10; 8(2): 96-99 ISSN 2218-4333 (online),Non-OADS,/arxiv_data1/oa_pdf/bb/d6/WJCO-8-96.PMC5385439.pdf
"World J Clin Oncol  2017; 8(2): 96-99   Available from: URL:  http://www.wjgnet.com/ 2218-4333 /full/v8/ i2/96.htm  DOI: http://dx.doi.org/10.5306/wjco.v8.i2.96 INTRODUCTION Neuroendocrine neoplasms (NENs) represent a group  of rare and heterogeneous malignancies, which can  develop in various organ.",Non-OADS,/arxiv_data1/oa_pdf/bb/d6/WJCO-8-96.PMC5385439.pdf
"All rights reserved.Published by Baishideng Publishing Group Inc 8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.f6publishing.com/helpdesk http://www.wjgnet.com",Non-OADS,/arxiv_data1/oa_pdf/bb/d6/WJCO-8-96.PMC5385439.pdf
"This Open Access article is distributed under the terms of the Creative Commons Attribution Noncommercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits any noncommercial use,distribution, and reproduction in any medium, provided the original author(s) and the source are credited.THYROID Volume 27, Number 4, 2017Mary Ann Liebert, Inc.DOI: 10.1089/thy.2016.0426 484",Non-OADS,/arxiv_data1/oa_pdf/e6/85/thy.2016.0426.PMC5385443.pdf
"This Open Access article is distributed under the terms of the Creative Commons Attribution Noncommercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits any noncommercial use,distribution, and reproduction in any medium, provided the original author(s) and the source are credited.DNA AND CELL BIOLOGY Volume 36, Number 4, 2017Mary Ann Liebert, Inc.Pp.",Non-OADS,/arxiv_data1/oa_pdf/78/6e/dna.2016.3505.PMC5385449.pdf
"   Case Rep Oncol 2016;9:815 –825  DOI: 10.1159/000450939   Published online: November 29, 2016  © 2016 The Author(s)   Published by S. Karger AG, Basel   www.karger.com/cro   This article is licensed under the Creative Commons Attribution -NonCommercial 4.0  Intern ational License (CC BY -NC) (http://www.karger.com/Services/OpenAccessLicense).",Non-OADS,/arxiv_data1/oa_pdf/0b/62/cro-0009-0815.PMC5385453.pdf
"https://doi.org/10.1177/1179544116688899Clinical Medicine Insights: Arthritis and  Musculoskeletal Disorders  1–7 © The Author(s) 2017 Reprints and permissions:  sagepub.co.uk/journalsPermissions.nav DOI: 10.1177/1179544116688899 Creative Commons Non Commercial CC-BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial   3.0 License (http://www.creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use, reproduction and distribution of the work without  further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).Introduction Osteoarthritis (OA) is one of the most prevalent joint diseases  due to progressive c artilage degradation.",Non-OADS,/arxiv_data1/oa_pdf/c7/c1/10.1177_1179544116688899.PMC5385469.pdf
"Contemp Oncol (Pozn) 2017; 21 (1): 21–29   DOI: https://doi.org/10.5114/wo.2017.65157Review The role of mast cells in oral  squamous cell carcinoma  Swetha Gudiseva1, Arvind Babu Rajendra Santosh2, Raviteja Chitturi3,  Vamsikrishna Anumula4, Chandrashekar Poosarla1,   Venkat Ramana Reddy Baddam1 1Department of Oral Pathology and Microbiology, SIBAR Institute of Dental Sciences,   Guntur, Andhra Pradesh, India  2Dentistry Programme, Faculty of Medical Sciences, The University of the West Indies,   Mona campus, Kingston, Jamaica, West Indies  3School of Dentistry, University of the West Indies, St. Augustine, Trinidad and Tobago,   West Indies  4Department of Pedodontics and Preventive dentistry, Krishna devaraya Institute of   Dental Sciences, Bangalore, Karnataka, India  Introduction  Mast cells form a component of the immune system playing an important  role in host defence.",Non-OADS,/arxiv_data1/oa_pdf/66/d3/WO-21-29107.PMC5385471.pdf
"Contemp Oncol (Pozn) 2017; 21 (1): 77–82  DOI: https://doi.org/105114/wo.2017.66497Original paper Comparative analysis of the  incidence of head and neck cancer  in south-eastern Poland and   in Poland in the years 1990–2012 Jan Gawełko1, Marek Cierpiał-Wolan2, Andrzej Kawecki1, Konrad Wilk3,  Danuta B. Pięciak-Kotlarz4, Damian Sikorski5 1University of Rzeszow, Rzeszow, Poland  2Provincial Statistical Office, Rzeszow, Poland  3Regional Clinical Hospital No.",Non-OADS,/arxiv_data1/oa_pdf/c3/47/WO-21-29623.PMC5385472.pdf
Available at: http://stat.gov.pl (3.11.2015).,OADS,/arxiv_data1/oa_pdf/c3/47/WO-21-29623.PMC5385472.pdf
"Contemp Oncol (Pozn) 2017; 21 (1): 1–5  DOI: https://doi.org/10.5114/wo.2017.66651Review Programmed cell death 1  checkpoint inhibitors in the  treatment of patients with  advanced melanoma Jacek Mackiewicz1-3, Andrzej Mackiewicz3,4 1Department of Medical and Experimental Oncology, Heliodor Swiecicki Clinical   Hospital, Poznan University of Medical Sciences, Poland  2Department of Biology and Environmental Studies, University of Medical Sciences,   Poznan, Poland  3Department of Diagnostics and Cancer Immunology, Greater Poland Cancer Centre,   Poznan, Poland  4Chair of Medical Biotechnology, University of Medical Sciences, Poznan, Poland Introduction The treatment landscape of advanced melanoma has been changing  significantly with the approval of new medicinal products.",Non-OADS,/arxiv_data1/oa_pdf/58/41/WO-21-29656.PMC5385473.pdf
27. https://clinicaltrials.gov/ct2/show/NCT02631447?term=secom- bit&rank=1 28. https://clinicaltrials.gov/ct2/show/NCT02224781?term= ea6134&rank=1 29.,Non-OADS,/arxiv_data1/oa_pdf/58/41/WO-21-29656.PMC5385473.pdf
30. https://clinicaltrials.gov/ct2/show/study/NCT02908672?term=a-tezolizumab%2C+melanoma&rank=2&show_locs=Y#locn.,Non-OADS,/arxiv_data1/oa_pdf/58/41/WO-21-29656.PMC5385473.pdf
"Contemp Oncol (Pozn) 2017; 21 (1): 6–15 DOI: https://doi.org/10.5114/wo.2017.66652Review A systemic literature review   of neuroimaging studies in women  with breast cancer treated with  adjuvant chemotherapy Paulina Andryszak1, Monika Wiłkość1,2, Paweł Izdebski1, Bogdan Żurawski3 1Institute of Psychology, Kazimierz Wielki University in Bydgoszcz, Poland  2Department of Psychiatry, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus   University in Torun, Bydgoszcz, Poland  3The Franciszek Lukaszczyk Oncology Center, Bydgoszcz, Poland Introduction The results of neuropsychological examinations carried out over the last  two decades indicate the occurrence of cognitive impairments in patients  with breast cancer who received chemotherapy [1].",Non-OADS,/arxiv_data1/oa_pdf/02/76/WO-21-29657.PMC5385474.pdf
"Contemp Oncol (Pozn) 2017; 21 (1): 16–20  DOI: https://doi.org/10.5114/wo.2017.66653Review paper S-1 for treatment of advanced  hepatocellular carcinoma:  a systematic review of the literature Wu-kui Huang1*, Li-na You2*, Shu-fa Yang1*, Deng-yao Liu1, Mo Liu1,   Xi-wen Fan1 1Department of Intervention Radiology, The Affiliated Tumour Hospital of Xinjiang   Medical University, Urumqi, Xinjiang, People’s Republic of China  2Department of Traditional Chinese Medicine, The Fifth Affiliated Hospital of Xinjiang   Medical University, Urumqi, Xinjiang, People’s Republic of China *Contributed equally Introduction Worldwide, hepatocellular carcinoma (HCC) is one of the most usual can- cers.",Non-OADS,/arxiv_data1/oa_pdf/af/3f/WO-21-29658.PMC5385475.pdf
"Contemp Oncol (Pozn) 2017; 21 (1): 35–41  DOI: https://doi.org/10.5114/wo.2017.66654Original paper Lentivirus-mediated knockdown   of P27RF-Rho inhibits hepatocellular  carcinoma cell growth Shuli Xie1, Guangyi Wang1, Guofu Chen2, Mingguang Zhu3, Guoyue Lv1 1Department of General Surgery, The First Hospital of Jilin University, Jilin, China  2Department of General Surgery, Daqing City People’s Hospital, Daqing City,   Heilongjiang Province, China  3Department of Immunology, School of Basic Medical Sciences, Jilin University,   Changchun, Jilin, China Introduction Hepatocellular carcinoma (HCC) is ranked as the third cause of cancer-re- lated fatality worldwide.",Non-OADS,/arxiv_data1/oa_pdf/ad/90/WO-21-29659.PMC5385476.pdf
"Contemp Oncol (Pozn) 2017; 21 (1): 42–47 DOI: https://doi.org/10.5114/wo.2017.66655Original paper Leptin receptor Q223R  polymorphism in Egyptian female  patients with breast cancer Mona Abo-Bakr El-Hussiny1, Mohmed Ali Atwa1, Waleed Elnahas Rashad2,  Dalia A. Shaheen3, Nora Marzouk Elkady1 1Department of Clinical Pathology, Faculty of Medicine, Mansoura University, Mansoura,   Egypt  2Department of Surgical Oncology, Faculty of Medicine, Mansoura University, Mansoura,   Egypt  3Department of Medical Biochemistry, Faculty of Medicine, Mansoura University,    Mansoura, Egypt Introduction  Breast cancer is the most common cause of death in women worldwide.",Non-OADS,/arxiv_data1/oa_pdf/db/60/WO-21-29660.PMC5385477.pdf
"Contemp Oncol (Pozn) 2017; 21 (1): 48–53  DOI: https://doi.org/10.5114/wo.2017.66656Original paper The changes of tumour vascular  endothelial growth factor  expression after neoadjuvant  chemoradiation in patients with rectal adenocarcinoma David Buka1, Josef Dvorak2, Veronika Sitorova3, Igor Sirak1, Rene Voboril4,  Bohuslav Melichar5, Igor Richter6 1Department of Oncology and Radiotherapy, Charles University, Medical School and   Teaching Hospital, Hradec Kralove, Czech Republic  2Department of Oncology, First Faculty of Medicine, Charles University and Thomayer   Hospital, Prague, Czech Republic  3Department of Pathology, Charles University, Medical School and Teaching Hospital,   Hradec Kralove, Czech Republic  4Department of Surgery, First Faculty of Medicine, Charles University in Prague and Na   Bulovce Hospital, Prague, Czech Republic  5Department of Oncology, Palacky University Medical School and Teaching Hospital,   Olomouc, Czech Republic  6Department of Oncology, Regional Hospital Liberec, Liberec, Czech Republic Introduction Total mesorectal excision preceded by a neoadjuvant chemoradiothera- py is the current standard of care for patients with locally advanced rectal  cancer [1].",Non-OADS,/arxiv_data1/oa_pdf/40/7b/WO-21-29661.PMC5385478.pdf
"Contemp Oncol (Pozn) 2017; 21 (1): 54–59 DOI: https://doi.org/10.5114/wo.2017.66657Original paper Serum atrial natriuretic peptide:  a suspected biomarker of breast  cancer  Maha E. Houssen1, Hayam F. Ghazy2, Kamel Farag2,   Mona Abo Bakr El-Hussiny3, Mohamed A. El Ghaffar4,   Sahar Alsayed Mohamed Alsayed3, Omar Farouk4 1Department of Biochemistry, Faculty of Pharmacy, Damanhour University, Egypt  2Department of Medical Oncology, Faculty of Medicine, Mansoura University, Egypt  3Department of Clinical Pathology, Faculty of Medicine, Mansoura University, Egypt  4Department of Surgical Oncology, Faculty of Medicine, Mansoura University, Egypt Introduction Breast cancer is still one of the main causes of mortality in women  worldwide.",Non-OADS,/arxiv_data1/oa_pdf/9d/17/WO-21-29662.PMC5385479.pdf
"Contemp Oncol (Pozn) 2017; 21 (1): 60–65 DOI: https://doi.org/10.5114/wo.2017.66658Original paper Neoadjuvant sequential  chemoradiotherapy versus  radiotherapy alone for treatment  of high-risk extremity soft tissue sarcoma: a single-institution  experience Leyla Kılıç1, Meltem Ekenel1, Senem Karabulut1, Fulya Ağaoğlu2,   Emin Darendeliler2 1Department of Medical Oncology, Institute of Oncology, Istanbul University, Istanbul,   Turkey  2Department of Radiation Oncology, Institute of Oncology, Istanbul University, Istanbul,   Turkey Introduction Soft tissue sarcomas (STS) are neoplasms that can originate in any tissue  of mesenchymal origin, and they are localised to limbs in approximately half of the cases [1].",Non-OADS,/arxiv_data1/oa_pdf/6b/ee/WO-21-29663.PMC5385480.pdf
"Contemp Oncol (Pozn) 2017; 21 (1): 66–69  DOI: https://doi.org/10.5114/wo.2017.66659Original paper Head and neck lymphomas  – a retrospective ten-year  observation Marcelina Niemiec1, Grażyna Stryjewska-Makuch1, Małgorzata Janik2,  Bogdan Kolebacz1, Grażyna Lisowska3, Wojciech Ścierski3 1Department of Laryngology and Laryngological Oncology, Silesian Medical University    in Katowice, Poland  2Department of Biomedical Computer System, Institute of Informatics, University   of Silesia, Katowice, Poland  3Department of Otorhinolaryngology and Oncology in Zabrze, Silesian Medical   University in Katowice, Poland Introduction In recent decades, there has been a steady increase in the incidence of  non-Hodgkin’s lymphomas (NHL) of 2–4% per year [1, 2].",Non-OADS,/arxiv_data1/oa_pdf/4a/66/WO-21-29664.PMC5385481.pdf
"University of the Witwatersrand, Johannesburg 2016. http://wiredspace.wits.ac.za/bitstream/handle/10539/21400/Final%20submission%20pdf.pdf?sequence=1 (access 2.02.2017).",Non-OADS,/arxiv_data1/oa_pdf/4a/66/WO-21-29664.PMC5385481.pdf
"Contemp Oncol (Pozn) 2017; 21 (1): 70–76 DOI: https://doi.org/10.5114/wo.2017.66660Original paper Synchronous bilateral testis  cancer: clinical and oncological  management Davide Campobasso1, Stefania Ferretti2, Antonio Frattini1 1Urology OU, Civil Hospital of Guastalla, AUSL of Reggio Emilia, Guastalla (RE), Italy  2Urology OU, Surgical Department, University Hospital of Parma, Parma, Italy Introduction Testicular cancer is the most common solid malignancy in men between  the ages of 15 and 40 years, representing 2–3% of all male cancers, with  3–6 new cases occurring per 100,000 males/per year in Western countries.",Non-OADS,/arxiv_data1/oa_pdf/60/d3/WO-21-29665.PMC5385482.pdf
"Contemp Oncol (Pozn) 2017; 21 (1): 83–89  DOI: https://doi.org/10.5114/wo.2017.66661Original paper Phase II study of adjuvant  docetaxel and carboplatin  with/without doxorubicin and  cyclophosphamide in triple negative  breast cancer: a randomised  controlled clinical trial Safa Najafi1, Mehrdad Payandeh2, Masoud Sadeghi3, Vahideh Shafaei1,  Fateme Shojaiyan1, Fereshte Abbasvandi1 1Breast Cancer Research Center, ACECR, Tehran, Iran  2Department of Hematology and Medical Oncology, Kermanshah University of Medical   Sciences, Kermanshah, Iran  3Medical Biology Research Center, Kermanshah University of Medical Sciences,   Kermanshah, Iran Introduction Breast cancer (BC) is a chemosensitive tumour, and anthracyclines are  among the most active cytotoxic agents in chemotherapy treatment [1].",Non-OADS,/arxiv_data1/oa_pdf/b6/1e/WO-21-29666.PMC5385483.pdf
"Material and methods Participants This randomised phase II clinical trial was approved by the Ethics Commit- tee of Kermanshah University of Medical Sciences, Kermanshah, Iran, and reg- istered at http://www.irct.ir (registration number: IRCT2016070325791N2).",Non-OADS,/arxiv_data1/oa_pdf/b6/1e/WO-21-29666.PMC5385483.pdf
http://www.nccn.org/ professionals/physician_gls/PDF/breast.pdf.,Non-OADS,/arxiv_data1/oa_pdf/b6/1e/WO-21-29666.PMC5385483.pdf
"http://www.nccn.org/   professionals/physician_gls/PDF/breast.pdf, Accessed May 1, 2009.",Non-OADS,/arxiv_data1/oa_pdf/b6/1e/WO-21-29666.PMC5385483.pdf
"https://doi.org/10.1177/1179544117701724 Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial   4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without  further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).Clinical Medicine Insights: Arthritis and  Musculoskeletal Disorders Volume 10: 1–7 © The Author(s) 2017 Reprints and permissions:  sagepub.co.uk/journalsPermissions.nav DOI: 10.1177/1179544117701724 Introduction Distal tibial fractures are usually high-energy injuries, often  associated with extensive soft tissue damage.",Non-OADS,/arxiv_data1/oa_pdf/4e/fa/10.1177_1179544117701724.PMC5385485.pdf
"https://doi.org/10.1177/1177390116684686Analytical Chemistry Insights  1–10 © The Author(s) 2017 Reprints and permissions:  sagepub.co.uk/journalsPermissions.nav DOI: 10.1177/1177390116684686 Creative Commons Non Commercial CC-BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial   3.0 License (http://www.creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use, reproduction and distribution of the work without  further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).Introduction Noble metal nanomaterials, such as gold and silver, have attracted  the attention of researchers because of their distinctive proper-ties, such as large surface energies, unusual optical properties, chemical stability, good conductivity, and catalytic and antibacte-rial activity.",Non-OADS,/arxiv_data1/oa_pdf/f3/95/10.1177_1177390116684686.PMC5385488.pdf
"Keywords Hanging; Strangulation; Subarachnoid hemorrhage; SuicideClin Exp Emerg Med 2017;4(1):56-59 http://dx.doi.org/10.15441/ceem.15.115 eISSN: 2383-4625Case Report Received: 26 November 2016 Revised: 30 November 2016 Accepted: 28 December 2016  Correspondence to: Soo Hoon Lee Department of Emergency Medicine,  Gyeongsang National University  Hospital, Gyeongsang National  University School of Medicine, 79  Gangnam-ro, Jinju 52727, Korea  E-mail: ssoon0702@naver.com How to cite this article: Kim TH, Lee SH, Kim DH, Kim SC, Jin W,   Kim SY, Shin SH, Lee SB.",Non-OADS,/arxiv_data1/oa_pdf/e7/d1/ceem-15-115.PMC5385506.pdf
"Keywords Ultrasonography; Joints; Hemarthrosis; WarfarinClin Exp Emerg Med 2017;4(1):60-63 http://dx.doi.org/10.15441/ceem.16.137 eISSN: 2383-4625Case Report Received: 20 February 2016 Revised: 20 April 2016 Accepted: 10 May 2016  Correspondence to: David C. Mackenzie Department of Emergency Medicine,  Maine Medical Center, 22 Bramhall  Street, Portland, ME 04102, USA  E-mail: DMackenzie@mmc.org How to cite this article: Mackenzie DC, McCorvey S. Spontaneous  elbow hemarthrosis identified by point-of- care ultrasound.",Non-OADS,/arxiv_data1/oa_pdf/ed/2f/ceem-16-137.PMC5385507.pdf
"Keywords Vital signs; Tachypnea; Tachycardia; Mortality; TriageClin Exp Emerg Med 2017;4(1):2-9 https://doi.org/10.15441/ceem.16.144 eISSN: 2383-4625Original Article Received: 4 October 2016 Revised: 5 December 2016 Accepted: 16 December 2016  Correspondence to: Alan E Jones  Department of Emergency Medicine,  University of Mississippi Medical  Center, 2500 N State Street, Jackson,  MS 39216, USA E-mail: aejones@umc.edu How to cite this article: Puskarich MA, Nandi U, Long BG, Jones AE.",Non-OADS,/arxiv_data1/oa_pdf/8f/82/ceem-16-144.PMC5385508.pdf
Available form:  http://www.cdc.gov/nchs/fastats/emergency-department.htm.,OADS,/arxiv_data1/oa_pdf/8f/82/ceem-16-144.PMC5385508.pdf
"Keywords Heart arrest; Lactic acid; Prognosis; Induced hypothermiaClin Exp Emerg Med 2017;4(1):10-18 https://doi.org/10.15441/ceem.16.149 eISSN: 2383-4625Original Article Received: 24 October 2016 Revised: 30 December 2016 Accepted: 4 January 2017  Correspondence to: Byung Kook Lee Department of Emergency Medicine,  Chonnam National University Hospital,  42 Jebong-ro, Dong-gu, Gwangju  61469, Korea E-mail: bbukkuk@hanmail.net How to cite this article: Kim JC, Lee BK, Lee DH, Jung YH, Cho YS,  Lee SM, Lee SJ, Park CH, Jeung KW.",Non-OADS,/arxiv_data1/oa_pdf/aa/64/ceem-16-149.PMC5385509.pdf
"Keywords Neutrophils; Neutrophil-to-lymphocyte ratio; C-reactive protein; Central nervous sys - tem infectionClin Exp Emerg Med 2017;4(1):25-31 https://doi.org/10.15441/ceem.16.152 eISSN: 2383-4625Original Article Received: 2 November 2016  Revised: 21 December 2016 Accepted: 25 December 2016  Correspondence to: Dong Hyuk Shin Department of Emergency Medicine,  Kangbuk Samsung Hospital,  Sungkyunkwan University School of  Medicine, 29 Saemunan-ro, Jongno- gu, Seoul 03181, Korea E-mail: shindhk@daum.net *These two authors contributed equally  to this study.",Non-OADS,/arxiv_data1/oa_pdf/ad/19/ceem-16-152.PMC5385510.pdf
"Keywords Orbital fractures; Pediatric; Facial injuries; Computed tomography; Emergency medi - cal servicesClin Exp Emerg Med 2017;4(1):32-37 https://doi.org/10.15441/ceem.16.153 eISSN: 2383-4625Original Article Received: 2 November 2016 Revised: 28 December 2016 Accepted: 1 February 2017  Correspondence to: Dong-Woo Seo Department of Emergency Medicine,  Asan Medical Center, University of  Ulsan College of Medicine, 88 Olympic- ro 43-gil, Songpa-gu, Seoul 05505,  Korea E-mail: leiseo@gmail.com How to cite this article: Yang DJ, Kim YJ, Seo DW, Lee HJ, Park IJ,  Sohn CH, Ryoo JM, Lee JS, Kim WY, Lim KS.",Non-OADS,/arxiv_data1/oa_pdf/93/be/ceem-16-153.PMC5385511.pdf
"Keywords Electrocardiography; Pneumothorax; Tension pneumothoraxClin Exp Emerg Med 2017;4(1):38-47 http://dx.doi.org/10.15441/ceem.16.154 eISSN: 2383-4625Original Article Received: 8 October 2016 Revised: 26 November 2016 Accepted: 2 December 2016  Correspondence to: Yoonje Lee Department of Emergency Medicine,  Hanyang University Guri Hospital,   153 Gyeongchun-ro, Guri 11923, Korea  E-mail: yong0831@naver.com How to cite this article: Lee W, Lee Y, Kim C, Choi HJ, Kang B, Lim  TH, Oh J, Kang H, Shin J.",Non-OADS,/arxiv_data1/oa_pdf/18/44/ceem-16-154.PMC5385512.pdf
"Keywords Mortality; Aged; C-reactive protein; AlbuminsClin Exp Emerg Med 2017;4(1):19-24 http://dx.doi.org/10.15441/ceem.16.158 eISSN: 2383-4625Original Article Received: 21 November 2016 Revised: 15 December 2016 Accepted: 27 December 2016  Correspondence to: Chun Song Youn Department of Emergency Medicine,  Seoul St. Mary’s Hospital, 222 Banpo- daero, Seocho-gu, Seoul 06591, Korea E-mail: ycs1005@catholic.ac.kr How to cite this article: Oh J, Kim SH, Park KN, Oh SH, Kim YM,   Kim HJ, Youn CS.",Non-OADS,/arxiv_data1/oa_pdf/28/74/ceem-16-158.PMC5385513.pdf
"Keywords Sepsis; Emergency medical services; Knowledge; AttitudeClin Exp Emerg Med 2017;4(1):48-55 http://dx.doi.org/10.15441/ceem.16.159 eISSN: 2383-4625Original Article Received: 27 December 2016 Revised: 20 January 2017 Accepted: 25 January 2017  Correspondence to: Sung Yeon Hwang Department of Emergency Medicine,  Samsung Medical Center,  Sungkyunkwan University School of  Medicine, 81 Irwon-ro, Gangnam-gu,  Seoul 06351, Korea E-mail: gerup@hanmail.net How to cite this article: Park J, Hwang SY, Shin TG, Jo IJ, Yoon H,   Lee TR, Cha WC, Sim MS.",Non-OADS,/arxiv_data1/oa_pdf/aa/a2/ceem-16-159.PMC5385514.pdf
Available from: http://fire.seoul.,OADS,/arxiv_data1/oa_pdf/aa/a2/ceem-16-159.PMC5385514.pdf
"1 Copyright © 2017 The Korean Society of Emergency MedicinePubMed inclusion: Clinical and  Experimental Emergency  Medicine   joins the club Adam J Singer Department of Emergency Medicine, Stony Brook University, Stony Brook, NY, USAClin Exp Emerg Med 2017;4(1):1-1 https://doi.org/10.15441/ceem.17.215 eISSN: 2383-4625Editorial Received: 18 February 2017 Revised: 20 February 2017 Accepted: 20 February 2017  Correspondence to: Adam J Singer Department of Emergency Medicine,  Stony Brook University, HSC-L4-080,  Stony Brook, NY 11794, USA E-mail: adam.singer@stonybrook.edu How to cite this article: Singer AJ.",Non-OADS,/arxiv_data1/oa_pdf/87/44/ceem-17-215.PMC5385515.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/24/1a/main.PMC5385576.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/24/1a/main.PMC5385576.pdf
http://dx.doi.org/10.1016/j.eucr.2017.03.010Urology Case Reports 12 (2017) 81 e83,Non-OADS,/arxiv_data1/oa_pdf/24/1a/main.PMC5385576.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/08/ee/main.PMC5385577.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/08/ee/main.PMC5385577.pdf
http://dx.doi.org/10.1016/j.eucr.2016.11.024Urology Case Reports 12 (2017) 78 e80,Non-OADS,/arxiv_data1/oa_pdf/08/ee/main.PMC5385577.pdf
http://dx.doi.org/10.1016/j.pmedr.2017.03.0022211-3355/© 2017 Published by Elsevier Inc.,Non-OADS,/arxiv_data1/oa_pdf/05/4c/main.PMC5385579.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/05/4c/main.PMC5385579.pdf
Contents lists available at ScienceDirect Preventive Medicine Reports journal homepage: http://ees.elsevier.com/pmedr,Non-OADS,/arxiv_data1/oa_pdf/05/4c/main.PMC5385579.pdf
AMA Adopts New Policies on Second Day of Voting at Annual Meet- ing.http://www.ama-assn.org/ama/pub/news/news/2013/2013-06-18-new-ama- policies-annual-meeting.page .P u b l i s h e d .,Non-OADS,/arxiv_data1/oa_pdf/05/4c/main.PMC5385579.pdf
http://dx.doi.org/10.1016/ j.jada.2010.10.008 .,OADS,/arxiv_data1/oa_pdf/05/4c/main.PMC5385579.pdf
http://dx.doi.org/10.1046/j.1463-1326.2002.00236.x .,Non-OADS,/arxiv_data1/oa_pdf/05/4c/main.PMC5385579.pdf
130 –138http://dx.doi.org/10.1370/afm.1768.INTRODUCTION .,Non-OADS,/arxiv_data1/oa_pdf/05/4c/main.PMC5385579.pdf
http://dx.doi.org/10.1016/S0140-6736(09)61794-3 .,OADS,/arxiv_data1/oa_pdf/05/4c/main.PMC5385579.pdf
http://dx.doi.org/10.1001/jama.2016.12858 .,OADS,/arxiv_data1/oa_pdf/05/4c/main.PMC5385579.pdf
http://dx.doi.org/10.1016/j.jand.2014.07.005 .,OADS,/arxiv_data1/oa_pdf/05/4c/main.PMC5385579.pdf
http://dx.doi.org/10.1016/j.pec.2014.07.026 .,OADS,/arxiv_data1/oa_pdf/05/4c/main.PMC5385579.pdf
http://dx.doi.org/10.5993/AJHB.38.1.9 .,Non-OADS,/arxiv_data1/oa_pdf/05/4c/main.PMC5385579.pdf
http://dx.doi.org/10.1016/j.jand.2013.04.001 .,OADS,/arxiv_data1/oa_pdf/05/4c/main.PMC5385579.pdf
14:9. http://dx.doi.org/10.1186/ 1472-6823-14-9 .,Non-OADS,/arxiv_data1/oa_pdf/05/4c/main.PMC5385579.pdf
http://dx.doi.org/10.1016/j.pmedr.2017.03.019 2211-3355/© 2017 Published by Elsevier Inc.,Non-OADS,/arxiv_data1/oa_pdf/b7/f5/main.PMC5385580.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/b7/f5/main.PMC5385580.pdf
Contents lists available at ScienceDirect Preventive Medicine Reports journal homepage: http://ees.elsevier.com/pmedr,Non-OADS,/arxiv_data1/oa_pdf/b7/f5/main.PMC5385580.pdf
http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/b7/f5/main.PMC5385580.pdf
http://dx.doi.org/10.1016/j.atmosenv.2008.05.026 .,OADS,/arxiv_data1/oa_pdf/b7/f5/main.PMC5385580.pdf
71 (4):807 –814 http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/b7/f5/main.PMC5385580.pdf
https://old.kuopio.,Non-OADS,/arxiv_data1/oa_pdf/b7/f5/main.PMC5385580.pdf
Cities 32 (Supplement 1):S21 –S28http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/b7/f5/main.PMC5385580.pdf
http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/b7/f5/main.PMC5385580.pdf
http://dx.doi.org/10.3310/hta19950 .,Non-OADS,/arxiv_data1/oa_pdf/b7/f5/main.PMC5385580.pdf
19 (1):37 –46.http://dx.doi.org/10.1007/s11136-009-9571-2 .,Non-OADS,/arxiv_data1/oa_pdf/b7/f5/main.PMC5385580.pdf
http://www.eurofound.europa.eu/surveys/eqls/index.htm .,Non-OADS,/arxiv_data1/oa_pdf/b7/f5/main.PMC5385580.pdf
http://dx.doi.org/10.1136/jech.54.,Non-OADS,/arxiv_data1/oa_pdf/b7/f5/main.PMC5385580.pdf
Lancet 374 (9707):2104 –2114 http://dx.doi.org/10.1016/S0140- 6736(09)61759-1.,Non-OADS,/arxiv_data1/oa_pdf/b7/f5/main.PMC5385580.pdf
http://dx.doi.org/10.1007/s10902-013-9441-z .,Non-OADS,/arxiv_data1/oa_pdf/b7/f5/main.PMC5385580.pdf
13 (2):95 –111http://dx.doi.org/10.1016/j.trd.2007.12.003 .,OADS,/arxiv_data1/oa_pdf/b7/f5/main.PMC5385580.pdf
http://dx.doi.org/10.1007/s11109-010- 9149-2 .,Non-OADS,/arxiv_data1/oa_pdf/b7/f5/main.PMC5385580.pdf
http://dx.doi.org/10.1080/02673039608720856 .,Non-OADS,/arxiv_data1/oa_pdf/b7/f5/main.PMC5385580.pdf
http://dx.doi.org/10.1016/0277- 9536(90)90336-q .,OADS,/arxiv_data1/oa_pdf/b7/f5/main.PMC5385580.pdf
35 (5):508 –516 http://dx.doi.org/10.1016/j.amepre.2008.08.022 .,OADS,/arxiv_data1/oa_pdf/b7/f5/main.PMC5385580.pdf
http://dx.doi.org/10.1016/j.atmosenv.2008.04.049 .,OADS,/arxiv_data1/oa_pdf/b7/f5/main.PMC5385580.pdf
"Health 63 (1):27 –33.http://dx.doi.org/10.3200/aeoh.63.1.27-33 .L im, Y.-H., Kim, H., Kim, J.H., Bae, S., Park, H.Y., Hong, Y.-C., 2012.",Non-OADS,/arxiv_data1/oa_pdf/b7/f5/main.PMC5385580.pdf
http://dx.doi.org/10.1289/ehp.1104100 .,Non-OADS,/arxiv_data1/oa_pdf/b7/f5/main.PMC5385580.pdf
http://dx.doi.org/10.3390/ijerph13030344 .,Non-OADS,/arxiv_data1/oa_pdf/b7/f5/main.PMC5385580.pdf
Health Place 17 (3):727 –737 http://dx.doi.org/10.1016/j.,Non-OADS,/arxiv_data1/oa_pdf/b7/f5/main.PMC5385580.pdf
http://dx.doi.org/10.1016/j.ecolecon.2011.09.,OADS,/arxiv_data1/oa_pdf/b7/f5/main.PMC5385580.pdf
http://dx.doi.org/10.1068/b35120 .,Non-OADS,/arxiv_data1/oa_pdf/b7/f5/main.PMC5385580.pdf
56 (4): 594 –609http://dx.doi.org/10.1016/j.ecolecon.2005.03.015 .,OADS,/arxiv_data1/oa_pdf/b7/f5/main.PMC5385580.pdf
http://dx.doi.org/10.1136/jech.48.6.555 .,Non-OADS,/arxiv_data1/oa_pdf/b7/f5/main.PMC5385580.pdf
63 (11):2835 –2846 http://dx.doi.org/10.1016/j.socscimed.2006.07.018 .,OADS,/arxiv_data1/oa_pdf/b7/f5/main.PMC5385580.pdf
http://www.who-5.,Non-OADS,/arxiv_data1/oa_pdf/b7/f5/main.PMC5385580.pdf
http://www.phac-aspc.gc.ca/hp-ps/hl-mvs/pa-ap/at-ta-eng.,Non-OADS,/arxiv_data1/oa_pdf/b7/f5/main.PMC5385580.pdf
24 (1):46 –57.http://dx.doi.org/10.1093/ heapro/dan039 .,Non-OADS,/arxiv_data1/oa_pdf/b7/f5/main.PMC5385580.pdf
http://dx.doi.org/10.1007/s11482-010-9132-4 .,Non-OADS,/arxiv_data1/oa_pdf/b7/f5/main.PMC5385580.pdf
Health 8 (15 (Suppl 1)):25. http://dx.doi.org/10.1186/s12940-016-0097-0 .,Non-OADS,/arxiv_data1/oa_pdf/b7/f5/main.PMC5385580.pdf
Noise Health 12 (46):7 –16  .http://dx.doi.org/10.4103/1463-1741.59995 .,Non-OADS,/arxiv_data1/oa_pdf/b7/f5/main.PMC5385580.pdf
http://dx.doi.org/10.2105/ajph.2006.093773 .,Non-OADS,/arxiv_data1/oa_pdf/b7/f5/main.PMC5385580.pdf
14 (8):1028 –1040 http://dx.doi.org/ 10.1016/j.envsci.2011.07.011 .,OADS,/arxiv_data1/oa_pdf/b7/f5/main.PMC5385580.pdf
"50 (2), 77 –86 http://dx.doi.org/10.1016/S0022-3999(00)00216-6.",Non-OADS,/arxiv_data1/oa_pdf/b7/f5/main.PMC5385580.pdf
http://dx.doi.org/10.1080/ 00420980701426665 .,Non-OADS,/arxiv_data1/oa_pdf/b7/f5/main.PMC5385580.pdf
Health 14 (1):1–13.http://dx.doi.org/10.1186/s12940-015-0082-z .,Non-OADS,/arxiv_data1/oa_pdf/b7/f5/main.PMC5385580.pdf
http://www.unep.org/sbci/pdfs/SBCI-BCCSummary.pdf .,Non-OADS,/arxiv_data1/oa_pdf/b7/f5/main.PMC5385580.pdf
http://dx.doi.org/10.1016/j.ecolecon.2005.,OADS,/arxiv_data1/oa_pdf/b7/f5/main.PMC5385580.pdf
http://dx.doi.org/10.1177/0956797612464659 .269 R. Hiscock et al.,OADS,/arxiv_data1/oa_pdf/b7/f5/main.PMC5385580.pdf
http://www.euro.,Non-OADS,/arxiv_data1/oa_pdf/b7/f5/main.PMC5385580.pdf
http://dx.doi.org/10.1177/ 0013916511402058 .,Non-OADS,/arxiv_data1/oa_pdf/b7/f5/main.PMC5385580.pdf
136 (3):882 –888 http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/b7/f5/main.PMC5385580.pdf
70 (9):1381 –1390 http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/b7/f5/main.PMC5385580.pdf
205 (4):517 –522 http://dx.doi.org/10.1006/jsvi.1997.1020 .,Non-OADS,/arxiv_data1/oa_pdf/b7/f5/main.PMC5385580.pdf
112 (Part 5):3605 –3615 http://dx.doi.org/10.1016/j.jclepro.2015.09.046 .270 R. Hiscock et al.,OADS,/arxiv_data1/oa_pdf/b7/f5/main.PMC5385580.pdf
This  is  an  open  access  article  under  the  CC  BY-NC-ND license  (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/7d/1a/main.PMC5385582.pdf
http://dx.doi.org/10.1016/j.idcr.2017.03.007 2214-2509/©  2017  The  Authors.,Non-OADS,/arxiv_data1/oa_pdf/7d/1a/main.PMC5385582.pdf
This  is  an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/ ).IDCases  8  (2017)  48–49 Contents  lists  available  at  ScienceDirect IDCases journal  homepage:  www.elsevier.com/locat  e/idcr,Non-OADS,/arxiv_data1/oa_pdf/7d/1a/main.PMC5385582.pdf
<https://www.uptodate.com/contents/ infections-due-to-the-streptococcus-anginosus-streptococcus-milleri- group#H1 >.,Non-OADS,/arxiv_data1/oa_pdf/7d/1a/main.PMC5385582.pdf
Contents lists available at ScienceDirect Epilepsy & Behavior Case Reports journal homepage: www.elsevier.com/locate/ebcr http://dx.doi.org/10.1016/j.ebcr.2017.03.003 2213-3232/© 2017 The Authors.,Non-OADS,/arxiv_data1/oa_pdf/d4/92/main.PMC5385583.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/d4/92/main.PMC5385583.pdf
J Med Genet 1988;25(1):41 –3.http://dx.doi.org/10.1136/jmg.25.1.41 .,Non-OADS,/arxiv_data1/oa_pdf/d4/92/main.PMC5385583.pdf
Nat Genet 2012;44(4):440 –4.http://dx.doi.org/10.1038/ng.1091 .,Non-OADS,/arxiv_data1/oa_pdf/d4/92/main.PMC5385583.pdf
Am J Med Genet 2016;9999A:1 –8.http://dx.doi.org/10.1002/ajmg.a.37771 .,Non-OADS,/arxiv_data1/oa_pdf/d4/92/main.PMC5385583.pdf
http://dx.doi.org/10.1038/ejhg.,OADS,/arxiv_data1/oa_pdf/d4/92/main.PMC5385583.pdf
Epilepsia 2010;51(4):676 –85.http://dx.doi.org/10.1111/j.1528-1167.2010.02522.x .,Non-OADS,/arxiv_data1/oa_pdf/d4/92/main.PMC5385583.pdf
Eur J Hum Genet 2014;22(2):179 –83.http://dx.doi.org/10.1038/ ejhg.2013.130 .,Non-OADS,/arxiv_data1/oa_pdf/d4/92/main.PMC5385583.pdf
J Med Genet 2000;37(6):460 –2.http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/d4/92/main.PMC5385583.pdf
Eur J Med Genet 2015;58(8): 416 –8.http://dx.doi.org/10.1016/j.ejmg.2015.06.006 .,OADS,/arxiv_data1/oa_pdf/d4/92/main.PMC5385583.pdf
Am J Med Genet 1995;57(3):403 –9.http://dx.doi.org/10.1002/ajmg.1320570308 .,Non-OADS,/arxiv_data1/oa_pdf/d4/92/main.PMC5385583.pdf
"Brain Dev Jpn 2010; 32(6):502 –5.http://dx.doi.org/10.1016/j.braindev.2009.04.015 .Table 1 Comparing clinical, MRI, and EEG features in previously-reported cases of BWCS.",OADS,/arxiv_data1/oa_pdf/d4/92/main.PMC5385583.pdf
(3) Can the test be applied to this patient who is right now sitting in front of http://dx.doi.org/10.1016/j.bbacli.2017.03.003 Received 18 December 2016; Received in revised form 5 March 2017; Accepted 17 March 2017⁎Corresponding author.,Non-OADS,/arxiv_data1/oa_pdf/0c/73/main.PMC5385584.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/BY-NC-ND/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/0c/73/main.PMC5385584.pdf
"Alexander, et al., 2016 guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and the postpar-tum, Thyroid (2017), http://dx.doi.org/10.1089/thy.2016.0457 (PM:28056690).",Non-OADS,/arxiv_data1/oa_pdf/0c/73/main.PMC5385584.pdf
"Oliver, Conceptualizing fraudulent studies as viruses: new models for handling retractions, Minerva (2016), http://dx.doi.org/10.1007/ s11024-016-9311-z .",Non-OADS,/arxiv_data1/oa_pdf/0c/73/main.PMC5385584.pdf
"Neuroimaging studies of healthy young adults indicate that recollectionof spatial contextual details relies on the activation of a distributed http://dx.doi.org/10.1016/j.nicl.2017.03.016 Received 21 November 2016; Received in revised form 29 March 2017; Accepted 30 March 2017⁎Corresponding author at: Room 2114 CIC Pavilion, Douglas Mental Health University Institute, 6875 LaSalle Blvd, Montreal H4H 1R3, QC, Canada.",Non-OADS,/arxiv_data1/oa_pdf/f5/60/main.PMC5385589.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/BY-NC-ND/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/f5/60/main.PMC5385589.pdf
Spatio-temporal Partial LeastSquares (PLS) was used to conduct event-related fMRI data analysis using PLSGUI software ( https://www.rotman-baycrest.on.ca/index.,OADS,/arxiv_data1/oa_pdf/f5/60/main.PMC5385589.pdf
Activations are presented on template images of the lateral and medial surfaces of the left and right hemispheres of the brain using Caret software ( http://brainvis.wustl.edu/wiki/index.php/Caret:Download ).,OADS,/arxiv_data1/oa_pdf/f5/60/main.PMC5385589.pdf
"Previous studies of IGD or Internet addiction disorder (IAD) have revealed neural alterations underlying reward/outcome proces- sing including ones involving the medial prefrontal cortex (MPFC), http://dx.doi.org/10.1016/j.nicl.2017.03.010 Received 25 November 2016; Received in revised form 5 March 2017; Accepted 24 March 2017☆The address where the data were collected: 3.0 T Siemens Trio scanner at State Key Laboratory of Cognitive Neuroscience and Learning, Beijing Normal University.",OADS,/arxiv_data1/oa_pdf/7d/6f/main.PMC5385591.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/BY-NC-ND/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/7d/6f/main.PMC5385591.pdf
The results were visualized using DPABI ( http://rfmri.org/dpabi ).,OADS,/arxiv_data1/oa_pdf/7d/6f/main.PMC5385591.pdf
"For exploratory purpose, regions of interests (ROIs) analyses were also conducted including the vmPFC, VS, and OFC using bilateral masks derived from the Harvard- Oxford atlas ( http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/Atlases ; we applied the Harvard-Oxford atlas to MNI space with DPABI).",OADS,/arxiv_data1/oa_pdf/7d/6f/main.PMC5385591.pdf
"http://dx.doi.org/10.1016/j.nicl.2017.03.015 Received 28 February 2017; Received in revised form 20 March 2017; Accepted 30 March 2017⁎Corresponding author at: Connecticut Mental Health Center, S112, Department of Psychiatry, Yale University School of Medicine, 34 Park Street, New Haven, CT 06519, United States.",Non-OADS,/arxiv_data1/oa_pdf/93/44/main.PMC5385596.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/BY-NC-ND/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/93/44/main.PMC5385596.pdf
"VBM was performed using the Computational Anatomy Toolbox (CAT 12 r933, http://dbm.neuro.uni-jena.de/cat/ ) packaged in Statistical Parametric Mapping 12 (Wellcome Department of ImagingNeuroscience, University College London, U.K.).",OADS,/arxiv_data1/oa_pdf/93/44/main.PMC5385596.pdf
"We used the standard DARTEL template in MNI space, constructed from 555 healthy subjects of the IXI-database ( http://www.brain-development.org/ ), to drive the DARTEL normalization.",Non-OADS,/arxiv_data1/oa_pdf/93/44/main.PMC5385596.pdf
"We performed mediation analyses ( MacKinnon et al., 2007 ), using the toolbox M3, developed by Tor Wager and Martin A. Lindquist ( http://wagerlab.colorado.edu/tools ).",OADS,/arxiv_data1/oa_pdf/93/44/main.PMC5385596.pdf
http://dx.doi.org/10.,Non-OADS,/arxiv_data1/oa_pdf/93/44/main.PMC5385596.pdf
"Artemisinin, a sesquiterpene lactone, was originally isolated from http://dx.doi.org/10.1016/j.redox.2017.04.003 Received 8 February 2017; Received in revised form 8 March 2017; Accepted 2 April 2017⁎Correspondence to: Faculty of Health Sciences, University of Macau, Room 4021, Building E12, Avenida de Universidade, Taipa, Macau, China.",Non-OADS,/arxiv_data1/oa_pdf/46/d6/main.PMC5385605.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/BY-NC-ND/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/46/d6/main.PMC5385605.pdf
"This Open Access article is distributed under the terms of the Creative Commons Attribution Noncommercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits any noncommercial use, distribution, and re- production in any medium, provided the original author(s) and the source are credited.JOURNAL OF NEUROTRAUMA 34:1364–1381 (April 1, 2017) Mary Ann Liebert, Inc.DOI: 10.1089/neu.2016.4569 1364",Non-OADS,/arxiv_data1/oa_pdf/cb/f9/neu.2016.4569.PMC5385606.pdf
1) (see online supplementary material at http://www.liebertpub .com) for direct comparison of assessment techniques with the novel r-mTBI model through 6 weeks post-injury.,Non-OADS,/arxiv_data1/oa_pdf/cb/f9/neu.2016.4569.PMC5385606.pdf
2 and 3) (see online supplementary material at http://www.liebert pub.com).,Non-OADS,/arxiv_data1/oa_pdf/cb/f9/neu.2016.4569.PMC5385606.pdf
"3F,G) (see online supplementary material at http://www.liebertpub.com) or GFAP (Supplementary Fig.",Non-OADS,/arxiv_data1/oa_pdf/cb/f9/neu.2016.4569.PMC5385606.pdf
3H) (see onlinesupplementary material at http://www.liebertpub.com) and did not have cortical abnormalities for DTI or DKI analysis (Sup- plementary Fig.,Non-OADS,/arxiv_data1/oa_pdf/cb/f9/neu.2016.4569.PMC5385606.pdf
2) (see online supplementary material at http://www.liebertpub.com).,Non-OADS,/arxiv_data1/oa_pdf/cb/f9/neu.2016.4569.PMC5385606.pdf
"4) (see online supplementary material at http://www.liebertpub.com), consistent with demyelination ob- served by electron microscopy in this model at 6 weeks post-TBI.",Non-OADS,/arxiv_data1/oa_pdf/cb/f9/neu.2016.4569.PMC5385606.pdf
"5A,B) (see online supple-mentary material at http://www.liebertpub.com), compared to the r-mTBI mice (Fig.",Non-OADS,/arxiv_data1/oa_pdf/cb/f9/neu.2016.4569.PMC5385606.pdf
5C) (see online supplementary material at http://www.liebertpub.com) models.,Non-OADS,/arxiv_data1/oa_pdf/cb/f9/neu.2016.4569.PMC5385606.pdf
2 and 3) (see online supplementarymaterial at http://www.liebertpub.com) did not result in behavioral changes in either wheel running or social interaction (Supple- mentary Fig.,Non-OADS,/arxiv_data1/oa_pdf/cb/f9/neu.2016.4569.PMC5385606.pdf
6) (see online supplementary material at http://www.liebertpub.com) and serves as a negative control comparison.,Non-OADS,/arxiv_data1/oa_pdf/cb/f9/neu.2016.4569.PMC5385606.pdf
3) (see online supplementary material at http://www.liebertpub.com) detectable by DTI (Supplementary Fig.,Non-OADS,/arxiv_data1/oa_pdf/cb/f9/neu.2016.4569.PMC5385606.pdf
"2) (see online supplementary material at http://www.liebertpub.com), to more accurately interpret the mainly negative ﬁndings for DTIand DKI in the corpus callosum of r-mTBI mice (Fig.",Non-OADS,/arxiv_data1/oa_pdf/cb/f9/neu.2016.4569.PMC5385606.pdf
"5) (see online supplementary material at http://www.liebertpub .com) Yet, cortical regions showed signiﬁcantly reduced AD and increased K a, which typically corresponds to axon damage.",Non-OADS,/arxiv_data1/oa_pdf/cb/f9/neu.2016.4569.PMC5385606.pdf
6A) (see online sup- plementary material at http://www.liebertpub.com).,Non-OADS,/arxiv_data1/oa_pdf/cb/f9/neu.2016.4569.PMC5385606.pdf
2) (see online supplementary material at http://www.liebertpub.com).,Non-OADS,/arxiv_data1/oa_pdf/cb/f9/neu.2016.4569.PMC5385606.pdf
"http://dvbic.dcoe.mil/ resources/clinical-tools ( last accessed April 12, 2016).",OADS,/arxiv_data1/oa_pdf/cb/f9/neu.2016.4569.PMC5385606.pdf
"http://dvbic.dcoe.mil/ dod-worldwide-numbers-tbi (last accessed April 12, 2016).",OADS,/arxiv_data1/oa_pdf/cb/f9/neu.2016.4569.PMC5385606.pdf
"To view a copy of this  license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/ © The Author(s) 2016",Non-OADS,/arxiv_data1/oa_pdf/4a/48/cr2016150a.PMC5385607.pdf
"It http://dx.doi.org/10.1016/j.redox.2017.03.025 Received 20 December 2016; Received in revised form 23 March 2017; Accepted 24 March 2017⁎Correspondence to: Departamento de Morfología y Biología Celular, Facultad de Medicina, C/Julián Clavería 6, 33006 Oviedo, Spain.",Non-OADS,/arxiv_data1/oa_pdf/c8/40/main.PMC5385622.pdf
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/BY-NC-ND/4.0/).,Non-OADS,/arxiv_data1/oa_pdf/c8/40/main.PMC5385622.pdf
J Clin Imaging Sci 2017;7:13.Available FREE in open access from: http://www.clinicalimagingscience.org/text.asp?2017/7/1/13/203164 Radiologic-Pathologic Correlation Aൻඌඍඋൺർඍ Received :  27-01-2017 Accepted :   17-02-2017 Published :   28-03-2017,Non-OADS,/arxiv_data1/oa_pdf/90/88/JCIS-7-13.PMC5385699.pdf
J Clin Imaging Sci 2017;7:14.Available FREE in open access from: http://www.clinicalimagingscience.org/text.asp?2017/7/1/14/203163 Pictorial Essay,Non-OADS,/arxiv_data1/oa_pdf/34/25/JCIS-7-14.PMC5385700.pdf
Available from:  http://www.amar.sci.org.ir/PlanList.aspx.,Non-OADS,/arxiv_data1/oa_pdf/59/5b/ABR-6-36.PMC5385701.pdf
Available from: http://www.euroqol.org/eq‑5d‑products/ eq‑5d‑3l.html.,Non-OADS,/arxiv_data1/oa_pdf/ab/b2/SJG-23-112.PMC5385713.pdf
Available from: http://www.euroqol.,Non-OADS,/arxiv_data1/oa_pdf/ab/b2/SJG-23-112.PMC5385713.pdf
Surveillance Epidemiology and End Results (SEER) 18 2004‑2010 [cited  2015 April 21st]; Available from: http://www.seer.cancer.gov 8.,Non-OADS,/arxiv_data1/oa_pdf/35/54/SJG-23-75.PMC5385721.pdf
http://www.amar.org.ir/Portals/1/Iran/census-2.pdf  (2012).,OADS,/arxiv_data1/oa_pdf/0f/ed/RPS-12-144.PMC5385729.pdf
http://www.cbi.ir/NonRefExRatesRSS.aspx?cid=1  (2015).,OADS,/arxiv_data1/oa_pdf/0f/ed/RPS-12-144.PMC5385729.pdf
http://rvu.behdasht.gov.ir/ index.aspx?fkeyid=&siteid=431&pageid=54142  (2014).,OADS,/arxiv_data1/oa_pdf/0f/ed/RPS-12-144.PMC5385729.pdf
"World Bank Group, GDP per capita,  http://data.worldbank.org/indicator/ .NY.GDP.PCAP.",OADS,/arxiv_data1/oa_pdf/0f/ed/RPS-12-144.PMC5385729.pdf
The software used for codon optimization  (20 first codons) was an online codon  adaptation tool (http://www.jcat.de/).,OADS,/arxiv_data1/oa_pdf/ec/05/RPS-12-168.PMC5385732.pdf
Alignment results of the first 20 codons of the two N-terminally modified cDNAs of hGH versus intact  cDNA of hGH using Cell Biology Unit Web Server tool  (http://xylian.igh.cnrs.fr/bin/align-guess.cgi).,OADS,/arxiv_data1/oa_pdf/ec/05/RPS-12-168.PMC5385732.pdf
Available  from: http://www.psychiatryonline.org/pb/assets/raw/ sitewide/practice_guidelines/guidelines/bpd.pdf.,Non-OADS,/arxiv_data1/oa_pdf/a4/54/IJPsyM-39-105.PMC5385735.pdf
Start a QR-code reading software (see list of free applications from http://tinyurl.com/ yzlh2tc) and point the camera to the QR-code printed in the journal.,Non-OADS,/arxiv_data1/oa_pdf/45/b5/IJPsyM-39-122.PMC5385738.pdf
See http://tinyurl.com/2bw7fn3 or http://tinyurl.com/3ysr3me for the free  applications.,Non-OADS,/arxiv_data1/oa_pdf/45/b5/IJPsyM-39-122.PMC5385738.pdf
Available from: http://www.who.int/whr/2002.,OADS,/arxiv_data1/oa_pdf/25/0e/IJPsyM-39-131.PMC5385739.pdf
Available from: http://mohfw.nic.in/WriteReadData/l892s/1455618937GATS%20 India.pdf.,Non-OADS,/arxiv_data1/oa_pdf/25/0e/IJPsyM-39-131.PMC5385739.pdf
Available  from: http://www.rchiips.org/nfhs/nfhs3.shtml.,Non-OADS,/arxiv_data1/oa_pdf/25/0e/IJPsyM-39-131.PMC5385739.pdf
"New Delhi: Ministry of Health and Family Welfare,  Government of India; 2004. http://www.mohfw.nic.",Non-OADS,/arxiv_data1/oa_pdf/25/0e/IJPsyM-39-131.PMC5385739.pdf
Author Help: Online submission of the manuscripts Articles can be submitted online from http://www.journalonweb.com.,Non-OADS,/arxiv_data1/oa_pdf/25/0e/IJPsyM-39-131.PMC5385739.pdf
Available  from: http://www.dget.nic.in/upload/uploadfiles/files/ publication/Code%20Structure.pdf.,OADS,/arxiv_data1/oa_pdf/bd/b0/IJPsyM-39-157.PMC5385744.pdf
Available from: http://www.ncbi.nlm.,Non-OADS,/arxiv_data1/oa_pdf/04/04/IJPsyM-39-202.PMC5385754.pdf
Available from: http://www.appliedradiology.com.,Non-OADS,/arxiv_data1/oa_pdf/e3/86/IJRI-27-23.PMC5385769.pdf
2014;  Available from: http://www.areyoudenseadvocacy.org/dense/.,Non-OADS,/arxiv_data1/oa_pdf/58/70/IJRI-27-52.PMC5385776.pdf
Available from: http://www.acr.org/About‑Us/Media‑Center/ Position‑Statements/Position‑Statements‑Folder/Statement‑on‑ Reporting‑Breast‑Density‑in‑Mammography‑Reports‑and‑Patie nt‑Summaries.,Non-OADS,/arxiv_data1/oa_pdf/58/70/IJRI-27-52.PMC5385776.pdf
Available from: https://esa.un.org/ unpd/wpp/DVD/Files/3_Indicators%20(Special%20Aggregates)/ EXCEL_FILES/2_Political/Population/WPP2015_SA2_POP_F08_1_ TOTAL_POPULATION_BY_BROAD_AGE_GROUP_BOTH_ SEXES.XLSX.2.,Non-OADS,/arxiv_data1/oa_pdf/57/cc/IJRI-27-73.PMC5385782.pdf
http://economictimes.indiatimes.com//articleshow/45190294.,Non-OADS,/arxiv_data1/oa_pdf/57/cc/IJRI-27-73.PMC5385782.pdf
Available from: http://economictimes.indiatimes.,Non-OADS,/arxiv_data1/oa_pdf/57/cc/IJRI-27-73.PMC5385782.pdf
Available from: http://apps.who.int/nha/database/Key_Indicators/ Index/en.,OADS,/arxiv_data1/oa_pdf/57/cc/IJRI-27-73.PMC5385782.pdf
Available from:  http://www.rsna.org/NewsDetail.aspx?id = 10112 10.,Non-OADS,/arxiv_data1/oa_pdf/57/cc/IJRI-27-73.PMC5385782.pdf
Available  from: http://www.cancer.gov/about‑cancer/causes‑prevention/ risk/radiation/pediatric‑ct‑scans.,Non-OADS,/arxiv_data1/oa_pdf/57/cc/IJRI-27-73.PMC5385782.pdf
Available  from: https://www.advisory.com/‑/media/ABI/Research/CII/ Research‑Briefs/2015/Emerging‑Trends‑and‑Technology‑in‑Paed iatric‑Radiology.pdf.,Non-OADS,/arxiv_data1/oa_pdf/57/cc/IJRI-27-73.PMC5385782.pdf
Available from: https://www.rsna.org/Derek_ Harwood‑Nash_International_Fellowship.aspx.23.,Non-OADS,/arxiv_data1/oa_pdf/57/cc/IJRI-27-73.PMC5385782.pdf
Available from: http://www.esor.org/ cms/website.php?id=/en/programmes/paediatric_radiology.htm.,Non-OADS,/arxiv_data1/oa_pdf/57/cc/IJRI-27-73.PMC5385782.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/96/79/srep06217.PMC5385804.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/aa/e2/srep06203.PMC5385805.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/ www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 6203 | DOI: 10.1038/srep06203 6",Non-OADS,/arxiv_data1/oa_pdf/aa/e2/srep06203.PMC5385805.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/72/66/srep05767.PMC5385818.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/a3/b3/srep05751.PMC5385819.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/ www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 5751 | DOI: 10.1038/srep05751 7",Non-OADS,/arxiv_data1/oa_pdf/a3/b3/srep05751.PMC5385819.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests : The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/ea/96/srep06269.PMC5385820.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/ www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 6269 | DOI: 10.1038/srep06269 7",Non-OADS,/arxiv_data1/oa_pdf/ea/96/srep06269.PMC5385820.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/26/60/srep05757.PMC5385822.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/ www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 5757 | DOI: 10.1038/srep05757 7",Non-OADS,/arxiv_data1/oa_pdf/26/60/srep05757.PMC5385822.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/ www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 6243 | DOI: 10.1038/srep06243 4",Non-OADS,/arxiv_data1/oa_pdf/22/e4/srep06243.PMC5385825.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/ www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 6283 | DOI: 10.1038/srep06283 7",Non-OADS,/arxiv_data1/oa_pdf/b1/2f/srep06283.PMC5385826.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreportsCompeting financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/92/5b/srep05768.PMC5385827.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/88/5c/srep06130.PMC5385828.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/57/4d/srep06196.PMC5385829.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/b5/44/srep06222.PMC5385830.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/ www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 6222 | DOI: 10.1038/srep06222 12",Non-OADS,/arxiv_data1/oa_pdf/b5/44/srep06222.PMC5385830.pdf
"Methods Case history .The affected animal was a juvenile Asian elephant, Vijay ( =; barn name; official name Ganesh), which was born at Twycross Zoo, UK, within a herd of four adult, female Asian elephants on 6 August 2009 (http://www.elephant.se/database2.php?elephant_id 54826).",Non-OADS,/arxiv_data1/oa_pdf/b1/5b/srep06299.PMC5385831.pdf
Sequence comparisons .Overall percentages of sequence identity between EEHV genomes were assessed using Stretcher (http://emboss.bioinformatics.nl).,OADS,/arxiv_data1/oa_pdf/b1/5b/srep06299.PMC5385831.pdf
Similarity among imputed amino acid sequences was investigated by using Needle (http://emboss.bioinformatics.nl).,OADS,/arxiv_data1/oa_pdf/b1/5b/srep06299.PMC5385831.pdf
"Phylogenetic trees were constructed by using Neighbor- Joining and Poisson model implemented in the MEGA v. 5.03 software 24with confidence values calculated from 2000 replicates, having obtained sequences fromNCBI RefSeq (http://www.ncbi.nlm.nih.gov/genomes/GenomesGroup.",OADS,/arxiv_data1/oa_pdf/b1/5b/srep06299.PMC5385831.pdf
cConserved proteins are named according to the nomenclature employed in NCBI Reference Sequence files (http://www.ncbi.nlm.nih.gov/genomes/Gen omesGroup.cgi?taxid 510292).,Non-OADS,/arxiv_data1/oa_pdf/b1/5b/srep06299.PMC5385831.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/e6/3a/srep06221.PMC5385832.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/ www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 6221 | DOI: 10.1038/srep06221 9",Non-OADS,/arxiv_data1/oa_pdf/e6/3a/srep06221.PMC5385832.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/71/b9/srep06145.PMC5385833.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/ www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 6145 | DOI: 10.1038/srep06145 10",Non-OADS,/arxiv_data1/oa_pdf/71/b9/srep06145.PMC5385833.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/cc/81/srep06218.PMC5385834.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/6c/a9/srep05769.PMC5385835.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/ www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 5769 | DOI: 10.1038/srep05769 8",Non-OADS,/arxiv_data1/oa_pdf/6c/a9/srep05769.PMC5385835.pdf
"unpublished) using the qTeller public database (Schnable and Freeling 2013, http://qteller.com/) and con-firmed by qPCR (Supplement Figure 1).",OADS,/arxiv_data1/oa_pdf/25/40/srep06194.PMC5385836.pdf
A maximum likelihood analysis was performed using PHYML (http://www.atgc-montpellier.fr/phyml/) with 100 boot- strap replicates.,OADS,/arxiv_data1/oa_pdf/25/40/srep06194.PMC5385836.pdf
RT-PCR primers were designed using Primer3 (http://frodo.wi.mit.edu/) based on Musa basjoo andCostus spicatus transcripts.,OADS,/arxiv_data1/oa_pdf/25/40/srep06194.PMC5385836.pdf
http://qteller.com/ Date of access: 22/03/2014.,Non-OADS,/arxiv_data1/oa_pdf/25/40/srep06194.PMC5385836.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/25/40/srep06194.PMC5385836.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/ www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 6194 | DOI: 10.1038/srep06194 9",Non-OADS,/arxiv_data1/oa_pdf/25/40/srep06194.PMC5385836.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/f0/e2/srep06266.PMC5385837.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/ www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 6266 | DOI: 10.1038/srep06266 11",Non-OADS,/arxiv_data1/oa_pdf/f0/e2/srep06266.PMC5385837.pdf
"   Case Rep Oncol   DOI: 10.1159/000455092    © 2017 The Author(s)   Published by S. Karger AG, Basel   www.karger.com/cro   This article is licensed under the Creative Commons Attribution -NonCommercial 4.0  International License (CC BY -NC) (http://www.karger.com/Services/OpenAccessLicense).",Non-OADS,/arxiv_data1/oa_pdf/6e/f5/cro-0010-0008.PMC5385863.pdf
"http://seer.cancer.gov/csr/1975_2012/, based on November 2014 SEER d ata submission,  posted to the SEER web site, April 2015.",Non-OADS,/arxiv_data1/oa_pdf/6e/f5/cro-0010-0008.PMC5385863.pdf
"   Case Rep Ophthalmol 2017;8:40 –48  DOI: 10.1159/000456027   Published online: January 24, 2017  © 2017 The Author(s)   Published by S. Karger AG, Basel   www.karger.com/cop   This article is licensed under the Creative Commons Attribution -NonCommercial 4.0  International License (CC BY -NC) (http://www.karger.com/Services/OpenAccessLicense).",Non-OADS,/arxiv_data1/oa_pdf/84/1f/cop-0008-0040.PMC5385865.pdf
All authors contributed to the manuscript preparation.Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/83/51/srep06335.PMC5385871.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/ www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 6335 | DOI: 10.1038/srep06335 8",Non-OADS,/arxiv_data1/oa_pdf/83/51/srep06335.PMC5385871.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/54/5a/srep06329.PMC5385874.pdf
Additional information Supplementary information accompanies this paper at http://www.nature.com/ scientificreports Competing financial interests: The authors declare no competing financial interests.,Non-OADS,/arxiv_data1/oa_pdf/63/eb/srep06341.PMC5385886.pdf
"To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/ www.nature.com/ scientificreports SCIENTIFIC REPORTS | 4 : 6341 | DOI: 10.1038/srep06341 7",Non-OADS,/arxiv_data1/oa_pdf/63/eb/srep06341.PMC5385886.pdf
We also thank the members of the Program of Complex Trait Genomics at the Institute for Molecular Bioscience for theirsupport (a list of members of this centre can be found at http://cnsgenomics.com/index.html).,Non-OADS,/arxiv_data1/oa_pdf/3d/80/bjporcpsych004077.PMC5385921.pdf
(https://cran.r-project.org/web/packages/mix/ mix.pdf).,OADS,/arxiv_data1/oa_pdf/3d/80/bjporcpsych004077.PMC5385921.pdf
Two months after publication it is available  to the public under an Attribution–Noncommercial–Share Alike 3.0 Unported  Creative Commons License (http://creativecommons.org/licenses/by-nc-sa/3.0).,Non-OADS,/arxiv_data1/oa_pdf/b1/f4/843.PMC5385932.pdf
Two months after publication it is available to  the public under an Attribution–Noncommercial–Share Alike 3.0 Unported Cre - ative Commons License (http://creativecommons.org/licenses/by-nc-sa/3.0).,Non-OADS,/arxiv_data1/oa_pdf/4e/0c/848.PMC5385933.pdf
Two months after publication it is available  to the public under an Attribution–Noncommercial–Share Alike 3.0 Unported  Creative Commons License (http://creativecommons.org/licenses/by-nc-sa/3.0).,Non-OADS,/arxiv_data1/oa_pdf/c7/20/858.PMC5385934.pdf
Two months after publication it is avail - able to the public under an Attribution–Noncommercial–Share Alike 3.0 Unported  Creative Commons License (http://creativecommons.org/licenses/by-nc-sa/3.0).,Non-OADS,/arxiv_data1/oa_pdf/c8/d0/865.PMC5385935.pdf
Two months after publication it is avail - able to the public under an Attribution–Noncommercial–Share Alike 3.0 Unported  Creative Commons License (http://creativecommons.org/licenses/by-nc-sa/3.0).,Non-OADS,/arxiv_data1/oa_pdf/6d/2d/875.PMC5385936.pdf
Available at https://zfin.org/ZDB-PUB-010810-1 (accessed 13 February  2013).,Non-OADS,/arxiv_data1/oa_pdf/6d/2d/875.PMC5385936.pdf
Available at https://zfin.org/ZDB   -PUB-040907-1 (accessed 13 February 2013).,Non-OADS,/arxiv_data1/oa_pdf/6d/2d/875.PMC5385936.pdf
Two months after publication it  is available to the public under an Attribution–Noncommercial–Share Alike 3.0  Unported Creative Commons License (http://creativecommons.org/licenses/by   -nc-sa/3.0).,Non-OADS,/arxiv_data1/oa_pdf/70/a0/883.PMC5385937.pdf
Two months after publication it is  available to the public under an Attribution–Noncommercial–Share Alike 3.0 Un - ported Creative Commons License (http://creativecommons.org/licenses/by-nc   -sa/3.0).,Non-OADS,/arxiv_data1/oa_pdf/22/1e/890.PMC5385938.pdf
Two months after publication it is available  to the public under an Attribution–Noncommercial–Share Alike 3.0 Unported  Creative Commons License (http://creativecommons.org/licenses/by-nc-sa/3.0).,Non-OADS,/arxiv_data1/oa_pdf/c9/ae/898.PMC5385939.pdf
Two months after publication it is avail - able to the public under an Attribution–Noncommercial–Share Alike 3.0 Unported  Creative Commons License (http://creativecommons.org/licenses/by-nc-sa/3.0).,Non-OADS,/arxiv_data1/oa_pdf/a9/1a/907.PMC5385940.pdf
Two months after publication it is available  to the public under an Attribution–Noncommercial–Share Alike 3.0 Unported Cre - ative Commons License (http://creativecommons.org/licenses/by-nc-sa/3.0).,Non-OADS,/arxiv_data1/oa_pdf/e2/58/922.PMC5385941.pdf
Two months after publication it is  available to the public under an Attribution–Noncommercial–Share Alike 3.0  Unported Creative Commons License (http://creativecommons.org/licenses/by   -nc-sa/3.0).,Non-OADS,/arxiv_data1/oa_pdf/0d/98/935.PMC5385942.pdf
Two months after publication it is avail - able to the public under an Attribution–Noncommercial–Share Alike 3.0 Unported  Creative Commons License (http://creativecommons.org/licenses/by-nc-sa/3.0).,Non-OADS,/arxiv_data1/oa_pdf/eb/4d/947.PMC5385943.pdf
Two months after publication it is avail - able to the public under an Attribution–Noncommercial–Share Alike 3.0 Unport - ed Creative Commons License (http://creativecommons.org/licenses/by-nc   -sa/3.0).,Non-OADS,/arxiv_data1/oa_pdf/8e/f2/962.PMC5385944.pdf
Two months after publication it is available  to the public under an Attribution–Noncommercial–Share Alike 3.0 Unported  Creative Commons License (http://creativecommons.org/licenses/by-nc-sa/3.0).,Non-OADS,/arxiv_data1/oa_pdf/84/30/975.PMC5385945.pdf
Two months after publication it is avail - able to the public under an Attribution–Noncommercial–Share Alike 3.0 Unported  Creative Commons License (http://creativecommons.org/licenses/by-nc-sa/3.0).,Non-OADS,/arxiv_data1/oa_pdf/a0/7e/984.PMC5385946.pdf
"In silico analysis of nuclear export and import sequences In silico prediction of NLS in C3G was done using the PSORT II Pre - diction server (http://psort.hgc.jp/form2.html; Horton and Nakai,  1997), the NucPred tool (www.sbc.su.se/~maccallr/nucpred/cgi-bin/ single.cgi; Brameier et al.",OADS,/arxiv_data1/oa_pdf/a0/7e/984.PMC5385946.pdf
This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ).,Non-OADS,/arxiv_data1/oa_pdf/c3/a3/nihms854566.PMC5386003.pdf
"Validations were performed according to the Guidance for Industry: Bioanalytical Methods  Validation issued (May 2001) by the U.S. Department of Health and Human Services, the  Food and Drug Administration, and the Centers for Drug Evaluation and Research and for  Veterinary Medicine ( http://www.fda.gov/downloads/Drugs/Guidance/ucm070107.pdf ).",OADS,/arxiv_data1/oa_pdf/c3/a3/nihms854566.PMC5386003.pdf
Supplementary data Supplementary data related to this article can be found at http://dx.doi.org/10.1016/j.canlet.,OADS,/arxiv_data1/oa_pdf/c3/a3/nihms854566.PMC5386003.pdf
2014; 3:25922. http://dx.doi.org/10.3402/jev.v3.25922 .,OADS,/arxiv_data1/oa_pdf/c3/a3/nihms854566.PMC5386003.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution- NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited.",Non-OADS,/arxiv_data1/oa_pdf/c6/11/afw204.PMC5386006.pdf
"2014 Oct 16. https://www.gov.uk/government/ uploads/system/uploads/attachment_data/ ﬁle/364440/CQC_ StateOfSocial_20 14.pdf (28 December 2015, date last accessed) .",Non-OADS,/arxiv_data1/oa_pdf/c6/11/afw204.PMC5386006.pdf
"2009 Sept. http://www.twocanassociates.co.uk/ perch/resources/ ﬁles/Sally%202009.pdf (28 December 2015, date last accessed) .",Non-OADS,/arxiv_data1/oa_pdf/c6/11/afw204.PMC5386006.pdf
http://www.jla.nihr.,Non-OADS,/arxiv_data1/oa_pdf/c6/11/afw204.PMC5386006.pdf
London: Alzheimer ’s Society 2013. http://www.alzheimers.org.uk/site/scripts/download_ info.php?,Non-OADS,/arxiv_data1/oa_pdf/c6/11/afw204.PMC5386006.pdf
"17.Splisbury K, Hanratty B, McCaughan D. Supporting Nursing in Care Homes: Project Report for the RCN Foundation.London: RCN Foundation 2015. http://www.rcnfoundation.",Non-OADS,/arxiv_data1/oa_pdf/c6/11/afw204.PMC5386006.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered , transformed, or built upon in any way.DERMATO-ENDOCRINOLOGY 2017, VOL.",Non-OADS,/arxiv_data1/oa_pdf/98/55/kder-09-01-1270485.PMC5386099.pdf
"1, e1270485 (2 pages)http://dx.doi.org/10.1080/19381980.2016.1270485",Non-OADS,/arxiv_data1/oa_pdf/98/55/kder-09-01-1270485.PMC5386099.pdf
"Int JCancer 2006; 120:1116-22; http://dx.doi.org/10.1002/ijc.22453 [2] Boniol M, Autier P, Boyle P, Gandini S. Cutaneous mela- noma attributable to sunbed use: systematic review andmeta-analysis.",OADS,/arxiv_data1/oa_pdf/98/55/kder-09-01-1270485.PMC5386099.pdf
"J Am Acad Dermatol 2014; 70:847-57;PMID:24629998; http://dx.doi.org/10.1016/j.jaad.2013.11.050 [4] Clough-Gorr KM, Titus-Ernstoff L, Perry AE, Spencer SK, Ernstoff MS.",OADS,/arxiv_data1/oa_pdf/98/55/kder-09-01-1270485.PMC5386099.pdf
"Cancer Causes Control 2008; 19:659-69; PMID:18273687; http://dx.doi.org/10.1007/s10552-008- 9129-6 [5] Chen YT, Dubrow R, Zheng T, Barnhill RL, Fine J, Berwick M. Sunlamp use and the risk of cutaneousmalignant melanoma: a population-based case-controlstudy in Connecticut, USA.",Non-OADS,/arxiv_data1/oa_pdf/98/55/kder-09-01-1270485.PMC5386099.pdf
"Int J Epidemiol 1999; 28:418-27; PMID:10405843; http://dx.doi.org/10.1093/ ije/28.3.418 [8] Papas MA, Chappelle AH, Grant WB.",Non-OADS,/arxiv_data1/oa_pdf/98/55/kder-09-01-1270485.PMC5386099.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License ( http://creativecommons.org/licenses/by-nc-nd/ 4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not alter ed, transformed, or built upon in any way.DERMATO-ENDOCRINOLOGY 2017, VOL.",Non-OADS,/arxiv_data1/oa_pdf/11/75/kder-09-01-1267078.PMC5386100.pdf
"1, e1267078 (12 pages)http://dx.doi.org/10.1080/19381980.2016.1267078",Non-OADS,/arxiv_data1/oa_pdf/11/75/kder-09-01-1267078.PMC5386100.pdf
"Funding ALR was supported as post doctoral fellow by the Research Institute for Disease of Old Age.ORCID Alberto Leguina-Ruzzi http://orcid.org/0000-0002-4761- 3491Juan P. Valderas http://orcid.org/0000-0001-8508-3340 References [1] World Health Statistics, WHO.",Non-OADS,/arxiv_data1/oa_pdf/11/75/kder-09-01-1267078.PMC5386100.pdf
"Diabetes Care 2009; 32(Suppl 2):S151- 6; PMID:19875543; http://dx.doi.org/10.2337/dc09-S301 [4] Muller IS, de Grauw WJ, van Gerwen WH, Bartelink ML, van Den Hoogen HJ, Rutten GE.",Non-OADS,/arxiv_data1/oa_pdf/11/75/kder-09-01-1267078.PMC5386100.pdf
"Diabetes Care 2002; 25(3):570-4;PMID:11874949; http://dx.doi.org/10.2337/diacare.25.3.570 [5] Kamohara M, Takasaki J, Matsumoto M, Saito T, Ohishi T, Ishii H, Furuichi K. Molecular cloning and characteri- zation of another leukotriene B4 receptor.",Non-OADS,/arxiv_data1/oa_pdf/11/75/kder-09-01-1267078.PMC5386100.pdf
"J Biol Chem 2001; 276(15):12454-9; PMID:11278893; http://dx.doi.org/10.1074/jbc.M011361200 [7] Liu M, Saeki K, Matsunobu T, Okuno T, Koga T, Sugi- moto Y, Yokoyama C, Nakamizo S, Kabashima K, Naru-miya S, et al.",OADS,/arxiv_data1/oa_pdf/11/75/kder-09-01-1267078.PMC5386100.pdf
"J Exp Med2014; 211(6):1063-78; PMID:24821912; http://dx.doi.org/10.1084/jem.20132063 [8] Iizuka Y, Yokomizo T, Tera waki K, Komine M, Tamaki K, Shimizu T. Characterization of a mouse second leukotriene B4 receptor, mBLT2: BLT2-dependent ERK activation andcell migration of primary mouse keratinocytes.",OADS,/arxiv_data1/oa_pdf/11/75/kder-09-01-1267078.PMC5386100.pdf
"J Biol Chem2005; 280(26):24816-23; PMID:15866883; http://dx.doi.org/10.1074/jbc.M413257200 [9] Yoo MH, Song H, Woo CH, Kim H, Kim JH.",OADS,/arxiv_data1/oa_pdf/11/75/kder-09-01-1267078.PMC5386100.pdf
"Br J Can-cer 2008; 99(7):1064-73; PMID:18781173; http://dx.doi.org/10.1038/sj.bjc.6604655 [11] Shao WH, Del Prete A, Bock CB, Haribabu B.",Non-OADS,/arxiv_data1/oa_pdf/11/75/kder-09-01-1267078.PMC5386100.pdf
"FASEB J 2013; 27(8):3306-14;PMID:23603839; http://dx.doi.org/10.1096/fj.12-217000 [14] Iizuka Y, Okuno T, Saeki K, Uozaki H, Okada S, Misaka T, Sato T, Toh H, Fukayama M, Takeda N, et al.",OADS,/arxiv_data1/oa_pdf/11/75/kder-09-01-1267078.PMC5386100.pdf
"FASEB J 2010; 24(12):4678-90; PMID:20667973; http://dx.doi.org/10.1096/fj.10-165050 [15] Ishii Y, Saeki K, Liu M, Sasaki F, Koga T, Kitajima K, Meno C, Okuno T, Yokomizo T. Leukotriene B4 receptortype 2 (BLT2) enhances skin barrier function by regulat-ing tight junction proteins.",Non-OADS,/arxiv_data1/oa_pdf/11/75/kder-09-01-1267078.PMC5386100.pdf
"FASEB J 2016; 30(2):933-47;PMID:26527063; http://dx.doi.org/10.1096/fj.15-279653 [16] Chiba T, Nakahara T, Hashimoto-Hachiya A, Yokomizo T, Uchi H, Furue M. The leukotriene B4 receptor BLT2protects barrier function via actin polymerization withphosphorylation of myosin phosphatase target subunit 1in human keratinocytes.",OADS,/arxiv_data1/oa_pdf/11/75/kder-09-01-1267078.PMC5386100.pdf
"Exp Dermatol 2016; 25(7):532-6; PMID:26896822; http://dx.doi.org/10.1111/exd.12976 [17] Luo L, Tanaka R, Kanazawa S, Lu F, Hayashi A, Yokomizo T, Mizuno H. A synthetic leukotriene B4 receptor type 2 agonist accelerates the cutaneous wound healing process in diabetic rats by indirect stimulation ofﬁbroblasts and direct stimulation of keratinocytes.",Non-OADS,/arxiv_data1/oa_pdf/11/75/kder-09-01-1267078.PMC5386100.pdf
"Adv Wound Care (New Rochelle) 2014;3(3):272-280; PMID:24669361; http://dx.doi.org/ 10.1089/wound.2013.0503 [19] Kabashima K, Murata T, Tanaka H, Matsuoka T, Sakata D, Yoshida N, Katagiri K, Kinashi T, Tanaka T, MiyasakaM, et al.",Non-OADS,/arxiv_data1/oa_pdf/11/75/kder-09-01-1267078.PMC5386100.pdf
"Thromboxane A2 modulates interaction of den-dritic cells and T cells and regulates acquired immunity.Nat Immunol 2003; 4(7):694-701; PMID:12778172;http://dx.doi.org/10.1038/ni943 [20] Terawaki K, Yokomizo T, Nagase T, Toda A, Taniguchi M, Hashizume K, Yagi T, Shimizu T. Absence of leukotri- ene B4 receptor 1 confers resistance to airway hyperres-ponsiveness and Th2-type immune responses.",Non-OADS,/arxiv_data1/oa_pdf/11/75/kder-09-01-1267078.PMC5386100.pdf
"JImmunol 2005; 175(7):4217-25; PMID:16177061; http://dx.doi.org/10.4049/jimmunol.175.7.4217 [21] Matsunobu T, Okuno T, Yokoyama C, Yokomizo T. Thromboxane A synthase-independent production of12-hydroxyheptadecatrienoic acid, a BLT2 ligand.",Non-OADS,/arxiv_data1/oa_pdf/11/75/kder-09-01-1267078.PMC5386100.pdf
J Lipid Res 2013; 54(11):2979-87; PMID:24009185; http://dx.doi.,OADS,/arxiv_data1/oa_pdf/11/75/kder-09-01-1267078.PMC5386100.pdf
"Anal Bioch em 2012; 425(2):157-65; PMID:22465329; http://dx.doi.org/10.1016/j.ab.2012.03.014 [23] Kuo IH, Carpenter-Mendini A, Yoshida T, McGirt LY, Ivanov AI, Barnes KC, Gallo RL, Borkowski AW, Yamasaki K, Leung DY, et al.",OADS,/arxiv_data1/oa_pdf/11/75/kder-09-01-1267078.PMC5386100.pdf
"Activation of epidermal toll-like receptor 2 enhances tight junction function:implications for atopic dermatitis and skin barrier repair.J Invest Dermatol 2013; 133(4):988-98; PMID:23223142;http://dx.doi.org/10.1038/jid.2012.437 [24] Winzell MS, Ahr /C19en B.",Non-OADS,/arxiv_data1/oa_pdf/11/75/kder-09-01-1267078.PMC5386100.pdf
Diabetes 2004; 53(Suppl 3):S215-9; PMID:15561913; http://dx.doi.,Non-OADS,/arxiv_data1/oa_pdf/11/75/kder-09-01-1267078.PMC5386100.pdf
"Br J Pharmacol 2012; 166(3):877-94; PMID:22352879;http://dx.doi.org/10.1111/j.1476-5381.2012.01911.x [26] Gilbert ER, Fu Z, Liu D. Development of a nongenetic mouse model of type 2 diabetes.",Non-OADS,/arxiv_data1/oa_pdf/11/75/kder-09-01-1267078.PMC5386100.pdf
"Exp Diabetes Res 2011;2011:416254; PMID:22164157; http://dx.doi.org/10.1155/ 2011/416254 [27] Li P, Oh DY, Bandyopadhyay G, Lagakos WS, Talukdar S, Osborn O, Johnson A, Chung H, Mayoral R, Maris M,et al.",Non-OADS,/arxiv_data1/oa_pdf/11/75/kder-09-01-1267078.PMC5386100.pdf
"Int J Biol Macromol2016; 89:582-91; PMID:27174907; http://dx.doi.org/10.1016/j.ijbiomac.2016.05.021 [29] Desposito D, Chollet C1, Taveau C, Descamps V, Alhenc-Gelas F, Roussel R, Bouby N, Waeckel L. Improve-ment of skin wound healing in diabetic mice by kinin B2 receptor blockade.",OADS,/arxiv_data1/oa_pdf/11/75/kder-09-01-1267078.PMC5386100.pdf
"Clin Sci ( Lond) 2016; 130(1):45-56; PMID:26443866; http://dx.doi.org/10.1042/CS20150295 [30] K €ampfer H, Schmidt R, Geisslinger G, Pfeilschifter J, Frank S. Wound in ﬂammation in diabetic ob/ob mice: functional coupling of prostaglandin biosynthesis to cyclooxygenase-1activity in diabetes-impaired wound healing.",Non-OADS,/arxiv_data1/oa_pdf/11/75/kder-09-01-1267078.PMC5386100.pdf
Diabetes 2005;54(5):1543-51; http://dx.doi.org/10.2337/diabetes.54.5.1543 [31] Brownlee M. Advanced protein glycosylation in diabetes and aging.,Non-OADS,/arxiv_data1/oa_pdf/11/75/kder-09-01-1267078.PMC5386100.pdf
"Annu Rev Med 1995; 46:223-34; PMID:7598459; http://dx.doi.org/10.114 6/annurev.med.46.1.223 [32] List EO, Berryman DE, Palmer AJ, Qiu L, Sankaran S, Kohn D T ,K e l d e rB ,O k a d aS ,K o p c h i c kJ J .A n a l y s i so fm o u s es k i nreveals proteins that are altered in a diet-induced diabeticstate: a new method for detection of type 2 diabetes.",Non-OADS,/arxiv_data1/oa_pdf/11/75/kder-09-01-1267078.PMC5386100.pdf
"Proteo-mics 2007; 7(7):1140-9; PMID:17390296; http://dx.doi.org/10.1002/pmic.200600641 [33] Spravchikov N, Sizyakov G, Gartsbein M, Accili D, Tennenbaum T, Wertheimer E. Glucose effects on skinDERMATO-ENDOCRINOLOGY e1267078-11",Non-OADS,/arxiv_data1/oa_pdf/11/75/kder-09-01-1267078.PMC5386100.pdf
"Diabetes 2001; 50(7):1627-35; PMID:11423485;http://dx.doi.org/10.2337/diabetes.50.7.1627 [34] Terashi H, Izumi K, Deveci M, Rhodes LM, Marcelo CL.",Non-OADS,/arxiv_data1/oa_pdf/11/75/kder-09-01-1267078.PMC5386100.pdf
"Diabetes2013; 62(7):2530-8; PMID:23423570; http://dx.doi.org/10.2337/db12-1714 [36] Reed MJ, Scribner KA.",Non-OADS,/arxiv_data1/oa_pdf/11/75/kder-09-01-1267078.PMC5386100.pdf
"Diabe- tes Obes Metab 1999; 1(2):75-86; PMID:11220515;http://dx.doi.org/10.1046/j.1463-1326.1999.00014.x [37] Salpea KD, Maubaret CG, Kathagen A, Ken-Dror G, Gilroy D W ,H u m p h r i e sS E .T h ee f f e c to fp r o - i n ﬂammatory condi- tioning and/or high glucose on telomere shortening of agingﬁbroblasts.",Non-OADS,/arxiv_data1/oa_pdf/11/75/kder-09-01-1267078.PMC5386100.pdf
"PLoS One 2013; 8(9):e73756; PMID:24086293; http://dx.doi.org/10.1371/journal.pone.0073756 [38] Rozlomiy VL, Markov AG.",OADS,/arxiv_data1/oa_pdf/11/75/kder-09-01-1267078.PMC5386100.pdf
"Bull Exp Biol Med 2010; 149(3):280-3; PMID:21246082; http://dx.doi.org/10.1007/s10517-010-0927-y [39] Tsai WC, Liang FC, Cheng JW, Lin LP, Chang SC, Chen HH, Pang JH.",OADS,/arxiv_data1/oa_pdf/11/75/kder-09-01-1267078.PMC5386100.pdf
"BMC Musculoskelet Disord 2013; 14:255; PMID:23981230; http://dx.doi.org/10.1186/1471-2474-14-255 [40] Lan CC, Liu IH, Fang AH, Wen CH, Wu CS.",OADS,/arxiv_data1/oa_pdf/11/75/kder-09-01-1267078.PMC5386100.pdf
Exp Eye Res 2014; 120:50-4; PMID:24345371; http://dx.doi.org/10.1016/j.,OADS,/arxiv_data1/oa_pdf/11/75/kder-09-01-1267078.PMC5386100.pdf
"J Cell Mol Med 2015; 19(6):1366-74; PMID:25702768; http://dx.doi.org/10.1111/jcmm.12523 [44] Breton J, Woolf D, Young P, Chabot-Fletcher M. Human keratinocytes lack the components to produce leukotrieneB4.",Non-OADS,/arxiv_data1/oa_pdf/11/75/kder-09-01-1267078.PMC5386100.pdf
"J Invest Dermatol 1996; 106(1):162-7; PMID:8592068; http://dx.doi.org/10.1111/1523-1747.ep12329890 [45] Allombert-Blaise C, Tamiji S, Mortier L, Fauvel H, Tual M, Delaporte E, Piette F, DeLassale EM, Formstecher P, Mar-chetti P, et al.",Non-OADS,/arxiv_data1/oa_pdf/11/75/kder-09-01-1267078.PMC5386100.pdf
"Cell Death Differ 2003; 10(7):850-2;PMID:12815468; http://dx.doi.org/10.1038/sj.cdd.4401245 [46] Wikramanayake TC, Stojadinovic O, Tomic-Canic M. Epidermal differentiation in barrier maintenance and wound healing.",Non-OADS,/arxiv_data1/oa_pdf/11/75/kder-09-01-1267078.PMC5386100.pdf
"Adv Wound Care (New Rochelle) 2014;3(3):272-280; PMID:24669361; http://dx.doi.org/10.1089/wound.2013.0503 [47] Thyssen JP, Linneberg A, Carlsen BC, Johansen JD, Engkilde K, Hansen T, Pociot F, Pedersen O, MeldgaardM, Szecsi PB, et al.",Non-OADS,/arxiv_data1/oa_pdf/11/75/kder-09-01-1267078.PMC5386100.pdf
"Exp Cell Res 2001; 270(2):199-213; PMID:11640884; http://dx.doi.org/10.1006/excr.2001.5348 [51] Leguina-Ruzzi A, Pereira J, Pereira-Flores K, Valderas JP, Mezzano D, Velarde V, S /C19aez CG.",OADS,/arxiv_data1/oa_pdf/11/75/kder-09-01-1267078.PMC5386100.pdf
MetabSyndr Relat Disord 2015; 13(9):373-80; PMID:26512756;http://dx.doi.org/10.1089/met.2015.0061e1267078-12 A. LEGUINA-RUZZI AND J. P. VALDERAS,OADS,/arxiv_data1/oa_pdf/11/75/kder-09-01-1267078.PMC5386100.pdf
"This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered , transformed, or built upon in any way.DERMATO-ENDOCRINOLOGY 2017, VOL.",Non-OADS,/arxiv_data1/oa_pdf/da/75/kder-09-01-1267080.PMC5386101.pdf
"1, e1267080 (17 pages)http://dx.doi.org/10.1080/19381980.2016.1267080",Non-OADS,/arxiv_data1/oa_pdf/da/75/kder-09-01-1267080.PMC5386101.pdf
"Psychother Psychosom Med Psychol2006; 56(11):445-9; PMID:17091447; http://dx.doi.org/10.1055/s-2006-951817 [2] Brown KM, Perlmutter P, McDermott RJ.",Non-OADS,/arxiv_data1/oa_pdf/da/75/kder-09-01-1267080.PMC5386101.pdf
J SchHealth 2000; 70(9):355-60; PMID:11126997; http://dx.doi.org/10.1111/j.1746-1561.2000.tb07273.x [3] Goldstein N. Tattoos de ﬁned.,Non-OADS,/arxiv_data1/oa_pdf/da/75/kder-09-01-1267080.PMC5386101.pdf
Clin Dermatol 2007; 25 (4):417-20; PMID:17697927; http://dx.doi.org/10.1016/j.clindermatol.2007.05.015 [4] Sperry K. Tattoos and tattooing.,Non-OADS,/arxiv_data1/oa_pdf/da/75/kder-09-01-1267080.PMC5386101.pdf
"Am J Forensic Med Pathol 1991; 12 (4):313-9; PMID:1807141; http://dx.doi.org/10.1097/00000433-199112000-00008 [5] Lozano AT, Morgan RD, Murray DD, Varghese F. Prison tattoos as a re ﬂection of the criminal lifestyle.",Non-OADS,/arxiv_data1/oa_pdf/da/75/kder-09-01-1267080.PMC5386101.pdf
"Int J Offender Ther Comp Criminol 2011; 55(4):509-29; PMID:20508085;http://dx.doi.org/10.1177/0306624X10370829 [6] Cruz FA, Lage D, Frig /C19erio RM, Zaniboni MC, Arruda LH.",OADS,/arxiv_data1/oa_pdf/da/75/kder-09-01-1267080.PMC5386101.pdf
"An Bras Dermatol 2010; 85(5):708-11; PMID:21152800; http://dx.doi.org/10.1590/S0365-05962010000500019 [7] Kaur RR, Kirby W, Maibach H. Cutaneous allergic reac- tions to tattoo ink.",Non-OADS,/arxiv_data1/oa_pdf/da/75/kder-09-01-1267080.PMC5386101.pdf
"J Cosmet Dermatol 2009; 8(4):295-300; PMID:19958434; http://dx.doi.org/10.1111/j.1473-2165.2009.00469.x [8] Kluger N, Cohen-Valensi R, Nezri M. Black lymph nodes –and a colourful skin.",Non-OADS,/arxiv_data1/oa_pdf/da/75/kder-09-01-1267080.PMC5386101.pdf
"Lancet 2008; 371 (9619):1214; PMID:18395584; http://dx.doi.org/10.1016/S0140-6736(08)60529-2 [9] Mataix J, Silvestre JF.",OADS,/arxiv_data1/oa_pdf/da/75/kder-09-01-1267080.PMC5386101.pdf
"Actas Dermosi ﬁliogr 2009; 100 (8):643-56; PMID:19775542; http://dx.doi.org/10.1016/S0001-7310(09)72277-X [10] Kluger N, Koljonen V. Tattoos, inks, and cancer.",OADS,/arxiv_data1/oa_pdf/da/75/kder-09-01-1267080.PMC5386101.pdf
"Lancet Oncol 2012; 13(4):e161-8; PMID:22469126; http://dx.doi.org/10.1016/S1470-2045(11)70340-0 [11] Regensburger J, Lehner K, Maisch T, Vasold R, Santarelli F, Engel E, Gollmer A, K €onig B, Landthaler M, B €aumler W. Tattoo inks contain polycyclic aromatic hydrocarbonsthat additionally generate deleterious singlet oxygen.",Non-OADS,/arxiv_data1/oa_pdf/da/75/kder-09-01-1267080.PMC5386101.pdf
"J Dtsch Der-matol Ges 2004; 2(5):350-3; PMID:16281523; http://dx.doi.org/10.1046/j.1439-0353.2004.04755.x [13] Vasold R, Engel E, K €onig B, Landthaler M, B €aumler W. Health risks of tattoo colors.",OADS,/arxiv_data1/oa_pdf/da/75/kder-09-01-1267080.PMC5386101.pdf
"Anal Bioanal Chem 2008;391(1):9-13; PMID:18327571; http://dx.doi.org/10.1007/ s00216-008-1978-z [14] Brady BG, Gold H, Leger EA, Leger MC.",Non-OADS,/arxiv_data1/oa_pdf/da/75/kder-09-01-1267080.PMC5386101.pdf
Contact Dermatitis 2015; 73(2):91-9;PMID:26016445; http://dx.doi.org/10.1111/cod.12425 [15] Risikobewertung BF.,Non-OADS,/arxiv_data1/oa_pdf/da/75/kder-09-01-1267080.PMC5386101.pdf
"Exp Dermatol 2010; 19(1):54-60; PMID:19703227;http://dx.doi.org/10.1111/j.1600-0625.2009.00925.x [17] Gopee NV, Cui Y, Olson G, Warbritton AR, Miller BJ, Couch LH, Wamer WG, Howard PC.",OADS,/arxiv_data1/oa_pdf/da/75/kder-09-01-1267080.PMC5386101.pdf
"Toxicol Appl Pharmacol 2005; 209(2):145-58; PMID:15913690; http://dx.doi.org/10.1016/j.taap.2005.04.003 [18] Braithwaite R, Robillard A, Woodring T, Stephens T, Arriola KJ.",OADS,/arxiv_data1/oa_pdf/da/75/kder-09-01-1267080.PMC5386101.pdf
"J Subst Abuse 2001; 13(1-2):5-16; PMID:11547624; http://dx.doi.org/10.1016/S0899-3289(01)00061-X [19] Drews DR, Allison CK, Probst JR. Behavioral and self-con- cept differences in tattooed and nontattooed college students.Psychol Rep 2000; 86(2):475-81; PMID:10840898; http://dx.doi.org/10.2466/pr0.2000.86.2.475 [20] Heywood W, Patrick K, Smith AM, Simpson JM, Pitts MK, Richters J, Shelley JM.",Non-OADS,/arxiv_data1/oa_pdf/da/75/kder-09-01-1267080.PMC5386101.pdf
"Ann Epi- demiol 2012; 22(1):51-6; PMID:22153289; http://dx.doi.org/10.1016/j.annepidem.2011.10.005 [21] Pajor AJ, Broniarczyk-Dyla G, Switalska J.",OADS,/arxiv_data1/oa_pdf/da/75/kder-09-01-1267080.PMC5386101.pdf
"Psychiatr Pol 2015; 49(3):559-73; PMID:26276922; http://dx.doi.org/10.12740/PP/27266 [22] Ekinci O, et al.",Non-OADS,/arxiv_data1/oa_pdf/da/75/kder-09-01-1267080.PMC5386101.pdf
"Community Ment Health J 2012; 48(6):798-803; PMID:22438142; http://dx.doi.org/10.1007/s10597-012-9509-y [23] Kertzman S, Topcuoglu V, Sabuncuoglu O, Berkem M, Akin E, Gumustas FO.",Non-OADS,/arxiv_data1/oa_pdf/da/75/kder-09-01-1267080.PMC5386101.pdf
BMC Psychiatry 2013; 13:278; PMID:24180254; http://dx.doi.org/10.1186/1471-244X-13-278e1267080-16 C. S. L. M €ULLER ET AL.,Non-OADS,/arxiv_data1/oa_pdf/da/75/kder-09-01-1267080.PMC5386101.pdf
"J Psychosom Res 2006; 60(5):531-4; PMID:16650594; http://dx.doi.org/10.1016/j.jpsychores.2005.09.002 [25] Andreeva VA, Salanave B, Castetbon K, Deschamps V, Vernay M, Kesse-Guyot E, Hercberg S. Comparison of the sociodemographic characteristics of the large Nutri-Net-Sante e-cohort with French Census data: the issue ofvolunteer bias revisited.",OADS,/arxiv_data1/oa_pdf/da/75/kder-09-01-1267080.PMC5386101.pdf
"J Epidemiol Community Health2015; 69(9):893-8; PMID:25832451; http://dx.doi.org/10.1136/jech-2014-205263[26] Eysenbach G, Wyatt J.",Non-OADS,/arxiv_data1/oa_pdf/da/75/kder-09-01-1267080.PMC5386101.pdf
"J Med Internet Res 2002; 4(2):E13; PMID:12554560; http://dx.doi.org/10.2196/jmir.4.2.e13 [27] Hutton Carlsen K, Køcks M, Sepehri M, Serup J. Allergic reactions in red tattoos: Raman spectroscopy for ‘ﬁnger- print ’detection of chemical risk spectra in tattooed skin and culprit tattoo inks.",OADS,/arxiv_data1/oa_pdf/da/75/kder-09-01-1267080.PMC5386101.pdf
